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 The four dengue viruses (DENV) are mosquito-borne flaviviruses and are 
considered the world’s most significant arboviruses in terms of worldwide disease 
burden. Symptoms of dengue disease are classified into dengue fever, a mild, febrile 
illness, and the potentially fatal severe dengue, which can include hemorrhaging and 
shock. Antibody protection against DENV correlates with the production of neutralizing 
antibodies against the envelope (E) glycoprotein.  
To understand the role of antibodies in DENV infection, we sought to dissect the 
relationship between epitope and function. Virologic studies had identified that the most 
potently neutralizing antibodies are against domain III (DIII) of the E protein. We have 
identified five epitopes within DENV DIII. Our data suggests that the most potently 
neutralizing antibodies are specific for a single serotype, while cross-reactive antibodies 
are relatively poorly neutralizing. Additionally, we were surprised to define neutralizing 
epitopes that were shown to be inaccessible on the surface of the virion in cryo-electron 
microscopy studies. 
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Fine epitope mapping was used to define the epitopes of a panel of existing 
DENV-2 antibodies. Antibodies against the lateral ridge were the most potently 
neutralizing antibodies and reacted only with the DENV-2 serotype. The second epitope 
was centered on the DIII A-strand, and antibodies against this epitope reacted with 
several serotypes of DENV. Several poorly neutralizing antibodies reacted to all four 
DENV serotypes, as well as West Nile virus, a related flavivirus, mapped to the highly 
conserved AB loop of DIII.  
We expanded our studies of DIII-specific antibodies to the DENV-1 serotype. 
One antibody, E106, potently neutralized the five DENV-1 strains representing the five 
genotypes, and bound a composite epitope of the lateral ridge and A-strand epitopes. 
Despite the potency of E106-mediated neutralization, a combination of structural, 
biophysical, virologic data suggest that potent DENV-1 neutralization by E106 is 
coincident with bivalent engagement of the virus. 
Additionally, we determined the crystal structures of E111 bound to a novel fifth 
CC' loop epitope on domain III (DIII) of the E protein from two different DENV-1 
genotypes. The available atomic models of DENV virions revealed that the E111 epitope 
was inaccessible, suggesting that it recognizes an uncharacterized virus conformation. 
While the affinity of binding between E111 and DIII varied by genotype, we observed 
limited correlation with inhibitory activity. Instead, our results support the conclusion 
that potent neutralization depends on genotype-dependent exposure of the CC’ loop 
epitope. These findings establish new structural complexity of the DENV virion, which 
may be relevant for the choice of DENV strain for induction or analysis of neutralizing 
antibodies in the context of vaccine development. 
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1.1 Overview of the dengue viruses 
 The dengue viruses (DENV) are mosquito-transmitted members of the Flavivirus 
genus of viruses.  Other flaviviruses with a significant impact on human disease include 
West Nile virus (WNV), Yellow Fever virus (YFV), and tick-borne encephalitis virus 
(TBEV) 1 (Figure 1A). It is estimated that there are approximately 50 million dengue 
infections annually worldwide, with approximately 2.5 billion people living in dengue 
endemic areas 2.  Although the majority of infections are asymptomatic 3,4, infection with 
DENV is capable of causing a range of symptoms from a mild febrile disease (dengue 
fever) to more severe pathologies including dengue hemorrhagic fever and dengue shock 
syndrome (DHS and DSS) and death 5. Due to a lack of specific antiviral therapies or 
vaccines, DENV remains a significant threat to human health and an economic burden 6–
10. The dengue serocomplex is comprised of four genetically related, but antigenically 
distinct viruses: DENV-1, -2, 3, and -4 11–13. Classification of the four serotypes is based 
upon serology 14 as well as genetic sequencing 15. Most antibody reactivity is against the 
Envelope (E) protein that can vary from 35-40% at the amino acid level.  Each serotype 
is further diversified into a genotypes based upon the E protein amino acid sequence, 
which diverges up to 3% within a serotype 16,17 (Figure 1A).   
 
1.2 DENV Clinical Disease 
 Most dengue infections are asymptomatic 3,4. Symptomatic dengue infection 
generally manifests 4-7 days after a bite from an infected mosquito, and lasts between 3-
10 days 18. In general, disease symptoms follow three phases: a febrile phase, a critical 
phase, and a recovery phase 19. The initial febrile phase (also known as dengue fever or 
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break-bone fever 20) is characterized by a high fever (104°F) and may include headache, 
muscle and joint pain, vomiting, and rash 21,22. Laboratory sampling may include 
thrombocytopenia and leukopenia. Most patients recover within 2-7 days after presenting 
symptoms.  A small population of patients will progress into the next phase of infection, 
the critical phase of severe dengue. Around 3-7 days after the onset of symptoms, the 
fever may ablate (< 100°F), but severe abdominal pain, vomiting and blood in the vomit, 
mucosal bleeding, bleeding gums, trouble breathing, and lethargy or restlessness may 
begin 22. During the next 24-48 hours, the critical stage may be lethal, as systemic 
vascular leak syndrome (DSS) can lead to a drop in blood pressure and shock 22,23. While 
there are no specific treatments for dengue infection, it is essential to maintain body fluid 
volume for proper organ perfusion. Proper medical care can reduce patient mortality from 
20%, to less than 1%.  The vascular permeability syndrome lasts ~48-72 hours followed 
by amelioration of symptoms in the recovery phase. While recovering, a secondary rash 
may appear, and fatigue may last for weeks after recovery. The development of dengue 
fever is indiscriminate of age, though children are more likely to develop severe dengue 
disease 24,25.  
 
1.3 Diagnosis of DENV infection 
 There are several means for accurate diagnosis of DENV infection, direct and 
indirect, that depend on the duration between inoculation and diagnosis. During the 
febrile phase, viral nucleic acids in serum may be detected by reverse-transcriptase 
polymerase chain reaction (RT-PCR) 26 or by detection of the soluble nonstructural 
protein 1 (NS1) using enzyme-linked immunosorbent assay (ELISA) 27. Serological 
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assays have also been developed to identify a particular DENV serotype based upon 
reactivity with monoclonal antibodies 28 with viral isolates. Alternatively, serologic 
diagnosis of DENV can be used after viremia is no longer detectable.  In dengue-naïve 
patients, the early antibody response will consist of DENV-specific IgM in a primary 
response, and a later DENV-specific IgG response 29,30.  In secondary DENV infections, 
the DENV-specific IgG response may be detected within a week of the onset of 
symptoms 22,30–32. An important consideration for DENV diagnosis using serology is the 
presence of cross-reactive antibodies, due to previous infection or immunization with a 
related flavivirus 33.  
 
1.4 Virology of DENV 
 Genome organization of DENV. Flaviviruses have a positive, single-stranded 
RNA genome approximately 11 kilobases in length.  The genome is translated as a single 
polyprotein and cleaved by host and viral proteases.  A total of ten proteins are encoded: 
three structural proteins and seven non-structural proteins (Figure 1B).  
DENV proteome. The three structural proteins, capsid (C), membrane (M, 
translated as precursor to membrane (prM)), and envelope (E), compose the viral particle 
along with a lipid bilayer and the virus genome.  Capsid binds the viral genome to form a 
nucleocapsid 34, prM prevents premature fusion of newly assembled virus during 
exocytosis 35, and E is responsible for mediating cellular attachment and fusion (see 
section 1.5). The non-structural proteins are NS1, NS2A, NS2B, NS3, NS4A, NS4B, and 
NS5.  The NS1 glycoprotein is the only secreted protein of the Flavivirus family, though 
the role of the secreted form is poorly understood. NS1 has been implicated in diverse 
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functions in the viral life cycle, including: participation in the viral replication machinery 
36, complement modulation 37–39, virulence 40, and lipid binding 41. NS2A contributes to 
viral assembly 42,43 and inhibits interferon-driven transcription 44. NS3 is a dual-function 
protease/RNA-helicase 45, and NS2B is a co-factor for NS3 protease activity 46,47. NS4A 
has been implicated in autophagy modulation 48, as well as influencing the interferon 
response 49 with NS4B. NS5 is a methyltransferase and RNA-polymerase 50, and may 
serve as an interferon antagonist in some flaviviruses 51.  
DENV infection of mammalian cells. Details of DENV infection is a composite 
of studies from DENV as well as inference from related flaviviruses (Figure 2). 
Currently, the mechanisms of cellular entry are incompletely understood. While there 
have been several proposed receptors for flaviviruses, none have been shown to be both 
necessary and sufficient for infection. (Potential receptor candidates are discussed in 
more detail in section 1.5 DENV receptors.) DENV enters the cell through clathrin-
dependent endocytosis 52,53 and trafficks to Rab5-positive and/or Rab7-postive 
endosomes 54,55. Upon acidifcation of the endosome, the anti-parallel E homodimers 
dissociate and then irreversibly re-associate into trimeric spikes 56–59. This pH-dependent 
rearrangement is required to expose the fusion loop, which inserts into the endosomal 
lipid bilayer. Virus-cellular membrane fusion is thought to occur upon repositioning of 
the stem regions of E along a groove in the trimeric spikes of E, allowing the release of 
the viral genome into the cytoplasm. Replication of the genome and the assembly of 
virions is thought to occur proximal to the endoplasmic reticulum (ER) membrane 60. 
Immature virions bud from the ER, to transit through the secretory pathway. While 
passing through the trans-Golgi network (TGN), cellular furin-like proteases cleave the 
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prM protein, into the mature M protein 61. The pr peptide remains associated with the 
virion in this mildly acidic environment (~pH 6.0), but upon exposure to the extracellular 
neutral pH, the pr peptide dissociates 62. Cleavage of the pr peptide dramatically increases 
the fusion efficacy, and infectivity, of DENV 63–66.  However, in vitro approximately 40% 
of the virus produced possesses some amount of prM 63,67–69. 
 
1.5 The Flavivirus E protein  
 The E protein is the major structural protein on the surface of DENV virions and 
is the major antibody antigen of flaviviruses. The E protein is responsible for both 
receptor binding and facilitating endosomal fusion. 
 Structure of the Flavivirus ectodomain. The first 395 residues of the E protein is 
termed the ectodomain. Crystal structures of the soluble ectodomain of TBEV 70, WNV 
71, Japanese Encephalitis virus (JEV) 72, and the four DENV serotypes 59,73–75 have been 
determined. While the Flavivirus E protein consists of three conserved domains, they 
share only 37% sequence identity. Six conserved disulfide bonds stabilize the overall E 
protein architecture. Centrally located, Domain I (DI) has a β-barrel fold and contains the 
conserved N-linked glycan (ASN 153 in DENV). Domain II (DII) protrudes out of DI as 
two discontinuous loops. This domain possesses a DENV-specific N-linked glycan (ASN 
67) that has been shown to be essential for virus secretion 76,77. Additionally, DII contains 
the highly conserved hydrophobic fusion loop at its distal tip 78,79. Connected by a 
flexible linker to DI, DIII has an immunoglobulin-like fold that is thought to be involved 
in attachment to the host cell receptor. 
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 DENV receptors. An essential Flavivirus receptor has not been identified. Several 
candidates have been proposed to mediate entry of DENV into cells (laminin receptor 80 
and heat shock proteins 70 and 90 81), though specific mechanisms of interaction are 
lacking. DC-SIGN 82–85 and Mannose Receptor are two C-type lectin-like domain 
(CTLD)-containing proteins that have been shown to increase the infectivity of cells in 
vitro. Additionally, heparin sulfate has been shown to assist in viral attachment on cell 
surface 86–90. However, these are not “true” receptors as they primarily aggregate virus on 
the surface of the cell 91,92, increasing the likelihood of a secondary receptor ligation 
event. Several reports suggest a role for DIII of E as the receptor binding partner 93,94. A 
multitude of potential receptors have been described, but remain unidentified (reviewed 
in 95). That there are a diverse range of attachment factors and putative receptors reported 
opens the possibility of a multicomponent receptor complex or that different viruses use 
different receptors for entry 96. 
 DENV stem loop and transmembrane region. The C-terminal portion of the 
Flavivirus E protein is composed of two regions: the stem anchor region (residues 396-
449) and the transmembrane region (residues 450-496).  Currently, there is no 
crystallographic structure of these regions, but cryo-electron microscopy (cryo-EM) 
reconstructions provide molecular details of their relative orientations in the virus particle 
97. Cryo-EM atomic models show that both the stem anchor and the transmembrane 
regions consist of two anti-parallel helices each and embed solely in the outer leaflet of 
the viral lipid bilayer.  While the helices of the stem anchor are amphipathic, allowing 
interaction between the negatively-charged phospholipid head groups, those of the 
transmembrane region are hydrophobic and embed in the lipid bilayer. The 
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transmembrane helices were observed in association with the two bilayer-embedded 
helices of the M protein.  The stem anchor and transmembrane helices play a critical role 
in the fusion of the virus to the endosomal membrane 56,58.  
 Structural flexibility of the Ectodomain. The respective orientation of the 
domains of the E proteins is known to vary according to the stage of the virus lifecycle. 
Crystal structures of prM bound E of the immature virus 98, the pre-fusion dimer 73, and 
the post-fusion trimer 57 reveal the flexibility of the DI-DII and DI-DIII hinges. As the 
newly assembled virion traverses the TGN, the prM caps the fusion loop to prevent 
adventitious fusion during virus egress 99.  The prM-E heterodimer possesses a rather 
linear conformation from DII through DI, while DIII is slightly offset, but within the 
same plane (Figure 3A). The prM-E heterodimers are arranged in a trimeric spike on the 
surface of the immature virion. Once cleaved, the pr peptide dissociates from the particle 
and the E homotrimers relax into flat anti-parallel dimers on the surface of the virion 
(Figure 3B).  In this pre-fusion arrangement on the surface of the mature virion, the E 
domain arrangements are relatively similar to those of the prM-E immature conformation, 
though they differ in local stoichiometry. With the formation of the E homodimer, the 
fusion loop is secured by packing into a pocket of the adjacent E. It is the transition from 
the pre-fusion dimer to the post-fusion trimer that shows the greatest movement about the 
hinges. Upon acidification of the endosome, the once-flat E homodimers dissociate to 
form homotrimers 100.  The structures of the post-fusion trimer reveals that DI rotates 
approximately 30 degrees relative to DII 56,57,59 (Figure 3C). This movement occurs 
about the hinge around residue 191 (in DENV) and the kl hairpin.  However, it is the 
movement of DIII that is most dramatic.  Acidification results in DIII rotating ~70° 
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degrees to settle adjacent to DI.  With this movement DIII is repositioned approximately 
40 Å closer to the fusion loop and shortens the overall length of the E protein.  It has been 
proposed, the movement of the DIII brings the C-terminus closer to the membrane where 
the stem anchor region could be capable of binding a groove formed between DII-DII 
interfaces 56.  The final rearrangement in the flavivirus lifecycle has been shown to be 
irreversible, presumably due to the induction of fusion with neighboring membranes. 
 
1.6 Structure of the Flavivirus Virion  
 Throughout the flavivirus lifecycle, the virion undergoes dramatic structural 
changes that are essential for functional aspects of virus replication and pathogenesis. As 
these viruses undergo fusion in a pH-dependent manner, it is no surprise that the 
macromolecular organization changes based upon the pH of its environment. Antibodies 
have also proven to be a useful tool in probing the conformational flexibility of these 
viruses. 
The Mature Virion. The mature DENV virion is approximately 500 Å in 
diameter, characterized by a relatively smooth, spherical surface as shown by cryoEM at 
9.5 Å resolution 97 (Figure 4A), and is similar to the structure of the mature WNV virion 
101.  The viral surface is tiled with E proteins forming 90 antiparallel homodimers. The 
arrangement of E on the surface has icosahedral symmetry, but lacks the expected T=3 
quasiequivalence. The E proteins are divided into 2-, 3-, and 5-fold axes of symmetry. 
The lipid bilayer is approximately 65 Å in diameter, surrounding a poorly organized 
nuclocapsid of 200 Å in diameter. 
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 The Immature Virion. Once viral RNA and proteins have been synthesized, they 
assemble on the ER membrane and bud into the lumen. These immature particles consist 
of 60 prM-E heterotrimeric spikes on the surface as they migrate through the secretory 
pathway (Figure 4B). The recently determined cryo-EM atomic model shows that the 
acidification of the TGN compartment engenders the first known morphological change 
of the young virus 62,99. The heterotrimeric spikes found in the neutral pH of the ER 
lumen, lay flat on the surface in the low pH of the TGN, giving it a relative smooth 
surface with knobs of prM decorating the surface (62 and Figure 4C). The lower pH of 
the TGN has been proposed to increase the exposure of a furin-like protease site that 
cleaves prM to the pr peptide and M 61, an event required for maturation 102. The pr 
peptide remains non-covalently associated with the virion at low pH, but upon exiting the 
cell, the peptide is thought to rapidly dissociate from the particle at neutral pH. Thus, the 
mature particle advances to the next stage of the viral lifecycle.  
 The Partially Mature Virion. While virions containing prM are less infectious 
than fully mature particles, the efficiency of prM cleavage varies by cell type. Indeed, for 
DENV, up to 40% of extracellular particles contain some amount of uncleaved prM 63,67–
69. Cryo-EM and cryo-electron tomography of partially mature particles suggests that 
there are mismatched symmetries over the surface of the virus 103. The authors conclude 
that the DENV glycoprotein organization is not synchronized over the surface of the 
virus, but is described as occurring from independent nucleation sites. 
 Alternate Virion Conformations.  There is one example of an antibody-bound 
DENV conformation that is described as a conformational intermediate.  Studies have 
shown that in addition to being pH-sensitive, virus conformations may also be sensitive 
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to temperature 104–107. The cryo-EM reconstruction of DENV bound by the 1A1D-2 Fab 
suggests that while virus particles show a relatively smooth surface at 4°C, an increase in 
temperature causes a radial expansion of the particle 108 (Figure 4D). This expansion is 
due to dissociation of the E protein homodimers on the surface of the virus into alternate 
conformations. The full conformational flexibility and heterogeneity of the virus 
population is uncharacterized. Additional, ultrastructural and functional studies are 
needed to explore the conformational potential of the virus. 
 
1.7 Prevention and Treatment of DENV 
 Currently, there are no specific antiviral therapies to prevent or treat dengue virus 
infection and disease. The most effective DENV prevention efforts have focused on 
vector control 109. DENV is primarily transmitted by the bite of female Aedes egypti 
mosquitos. These mosquitos breed mainly in man-made containers in urban environments 
110. A contributing factor in dengue transmission is that these mosquitos feed during the 
daytime, when humans are more active. Aedes albopictus is another vector for DENV 
spread. This mosquito is relatively tolerant to cooler temperatures, facilitating its spread 
from Asia to Europe and North America through international trade. As vector control 
initiatives declined, global dissemination of these vectors enabled the spread of DENV 
worldwide. The use of insecticides and elimination of open water containers suitable for 
laying eggs has been shown effective in reducing the mosquito population 111. Recently, 
several reports shown that mosquitos infected with the Wolbachia species bacterium do 
not transmit DENV 112. Preliminary studies suggest that the bacterium primes the 
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mosquito immune response, preventing DENV infection of the mosquito 113. Large-scale 
trials are needed to show efficacy in controlling DENV infection in endemic areas. 
 While vector control has proven to reduce the burden of DENV infections when 
properly implemented, induction of immunity by a DENV vaccine has been investigated 
since the 1940s. However, a significant challenge for vaccine development is that there 
are four dengue viruses that cause disease. A DENV vaccine must induce a protective 
immune response against all four serotypes. Infection with one serotype of DENV is 
thought to provide life-long immunity against that serotype, and only transient protection 
from the other serotypes. Furthermore, secondary infection with a heterologous serotype 
has been shown to increase the risk of developing severe dengue. The mechanisms 
responsible for the increase in disease pathology are incompletely understood (see section 
1.10).  
Currently, there are multiple DENV vaccine candidates in clinical trials. 
Universities, governments, militaries, and pharmaceutical companies have independently 
or in collaboration been involved in the development of DENV vaccines. There are 
several recombinant subunit vaccines using combinations of E protein, DIII, and NS1 in 
different combinations and adjuvants 114–116. Similarly, there are virus-like particle (VLP) 
vaccines that use only the structural DENV proteins, which form particles without 
genomes 117. Tetravalent DNA vaccines usually encode for DIII or prM/E 118–120. Several 
virus-vectored vaccines use other viral genomes to carry DENV structural genes 121,122. 
There are also preparations of purified inactivated virus 123,124 and a range of live 
attenuated virus vaccines 123,125. The ChimeriVax-DEN1-4 vaccine by Sanofi-Pasteur is 
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currently in Phase III clinical trials and if successful, could enter the market within five 
years 126. 
 
1.8 Antibody-mediated protection against enveloped viruses 
 Antibodies play a crucial role in the host immune response to many viruses. There 
are many mechanisms of neutralization used by antibodies, though an antibody may use 
more than one mechanism for neutralization 127. The potential mechanisms of virus 
neutralization are virus specific and dependent on the particulars of the virus lifecycle. 
Before a virus attaches to a cell, an antibody may bind two virus particles (one virus per 
arm), resulting in aggregation. Aggregation is thought to interfere with the normal virus 
entry processes, effectively resulting in neutralization. Another possible mechanism is the 
blockade of virus attachment to cell surface receptors or attachment factors. Inhibition 
may occur by directly binding the site of receptor engagement, by sterically hindering 
access by binding an adjacent epitope, or by inferring with the cooperative effort of 
multiple viral proteins required for cell entry. Fusion of the virus and host membrane is 
an essential stage in virus infection, and can be prevented by antibody binding. Fusion 
inhibition may occur in endosomal compartments after the antibody-virus complex has 
entered the cell. 
 An additional complexity of antibody-mediated neutralization of virus concerns 
the number of antibodies required to neutralize a single virus particle 128. First, there is 
the single-hit hypothesis. This hypothesis proposes as few as one or two antibodies are 
capable of neutralizing a virus. According to the single-hit hypothesis, a single antibody 
may neutralize a virus by binding to a critical site. Several mechanisms of inactivation of 
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the antibody-bound virus have been proposed, primarily a forced conformational change 
of the surface capsid proteins, though exceptions have been found and a single 
mechanism remains elusive. The multiple-hit hypothesis proposes that neutralization 
occurs as a function of a number of antibodies occupying a repeated epitope on the 
virion. Indeed, antibody neutralization of flaviviruses requires multiple antibodies 
molecules to bind to a single virion before a neutralization threshold is reached 129. It 
should also be noted that there appears to be a relationship between the epitope and the 
required occupancy for neutralization. Highly exposed epitopes appear to have a lower 
occupancy requirement than less accessible epitopes 130.  Complement fixation also plays 
a role in governing the occupancy requirement of neutralization by cross-linking multiple 
antibodies on the virus surface 131. 
 
1.9 Antibody-mediated protection against DENV  
 The role of antibody-mediated protection has been recognized since at least the 
mid-twentieth century. Albert Sabin showed that serum from convalescent patients was 
able to prevent skin lesions from appearing in naïve humans inoculated subcutaneously 
with DENV 12. As stated above, the E protein is the immunodominant antigen of DENV 
and a key correlate for protection in DENV is the presence of neutralizing antibodies 
against the E protein 132,133. However, protective antibodies against NS1 134 and M 135 
have also been described.  
Nomenclature of Flavivirus Antibody Reactivity 
 The scope of this thesis is focuses on the antibody response against DENV. 
Relationships between flaviviruses were based upon serology 14,33 before genetic 
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sequencing became commonplace. These studies determined the serocomplexes for the 
Flavivirus genus (Figure 1). Technological advances resulted in the isolation of 
monoclonal antibodies. Reactivity of these monoclonal antibodies was used to define the 
antigenic structure of the E protein and shared common elements of flaviviruses. 
Monoclonal antibodies are classified into one of the following groups: cross- (or group)-
reactive, complex-specific, subcomplex-specific, or (sero)type-specific. Cross-reactive 
antibodies react with viruses found in multiple serocomplexes. For example, a fusion 
loop monoclonal antibody, 4G2, was raised against DENV, but reacts with viruses in the 
dengue and Japanese encephalitis serocomplexes, as well as Yellow Fever virus 136. 
Complex-specific antibodies are restricted to a single serocomplex, such as the dengue 
serocomplex. The MAb 4E11 is an example of a complex-specific MAb. 4E11 was 
generated from a mouse infected with DENV-1, but was shown to neutralize all four 
DENV of the dengue serocomplex 137. There are also examples of antibodies that react 
with select members of a serocomplex. 1A1D-2 neutralizes DENV-1, -2, and -3, but does 
not react with DENV-4 138. Finally, there are antibodies that are reactive with only a 
single serotype of virus. MAb 3H5-1 reacts with only DENV-2 strains 138, while WNV 
E16 is restricted to only WNV strains 139,140.  
 It is important to remember that while an antibody may be reactive to a virus, it 
may not necessarily neutralize that virus or neutralize related viruses equivalently.  
Lessons from WNV 
Significant advances in understanding antibody-mediated neutralization of 
flaviviruses has emerged using WNV as a model. Two of the most extensively 
characterized flavivirus epitopes described are the cross-reactive DII fusion loop (DII-
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FL) epitope and the serotype-specific DIII lateral ridge (DIII-LR) epitope 139,141. 
Generally, the most potent neutralizing antibodies are type-specific (i.e. only bind and 
neutralize one serotype of virus). Antibodies mapping to the DIII-LR are type-specific 
due to serotype-specific sequence variation found in the loops that compose this epitope. 
Antibodies that bind this epitope have been shown to inhibit virus infection primary 
through a post-attachment stage of infection (Figure 5). WNV E16, a potently 
neutralizing DIII-LR-specific antibody, has been shown to enter cells bound to virus, 
preventing the pH-dependent rearrangements necessary for fusion 142,143. Antibodies that 
react with the DII-FL have also been characterized extensively functionally and 
structurally. The fusion loop is a hydrophobic loop that is completely conserved between 
the DENV and JEV serocomplexes. While antibodies that interact with the fusion loop 
may cross-reactively bind multiple viruses, they do not neutralize viruses equivalently 144. 
Functionally, these antibodies primarily inhibit virus attachment to the cell surface 139,145 
(Figure 5). Due to the inaccessibility of the fusion loop in the mature virus conformation, 
the DII-FL epitope is poorly accessible on the mature virus. The cryo-EM model of 
mature WNV bound by WNV E53, a DII-FL-reactive antibody, suggests that the fusion 
loop is transiently exposed 141.  
DENV-specific Neutralizing Antibodies  
The last five years have produced a wealth of knowledge concerning DENV 
antibody responses. Neutralizing epitopes have been mapped to all three domains of the 
DENV E protein ectodomain 138,145–152 (Figure 6A). In addition, the structures of 
antibody Fab fragments or single chain variable fragments in complex with DENV E 
antigens have been determined 75,107,153,154. The extensive epitope mapping data and 
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structural studies in conjunction with functional assays have facilitated the understanding 
of the relationship between epitopes and the mechanism of DENV neutralization. Many 
of the most potently inhibitory mouse MAbs localize to DIII 146. To date, five epitopes 
have been established on DIII 138,151,153,155,156 (Figure 6B). MAbs binding the lateral 
ridge, A-strand, or a composite of the two epitopes are relatively inhibitory, whereas 
those recognizing the AB loop neutralize infection less efficiently or not at all 107, 
presumably due to poor epitope accessibility on the virion. The CC’ epitope appears to be 
differentially exposed in DENV-1 strains in a genotype-dependent manner 153.   
Role of Epitope Acessibility in Antibody-Mediated Neutralization 
While 180 copies of the E protein are present on all flavivirus virions, the 
different environments imposed by the quasi-icosahedral symmetry make some epitopes 
unequally accessible. Epitope exposure also may be affected by neighboring E proteins in 
adjacent symmetry units, or by the presence or absence of prM in the case of immature, 
partially mature, and mature virions 139,144,157–160. The arrangement of the E proteins on 
the surface of the virion can be further modulated over time and across a range of 
temperatures due to the intrinsic conformational heterogeneity of virons 105,108  
Consequently, the accessibility of epitopes can vary across structurally distinct epitopes, 
ultimately affecting the number of sites available for antibody binding and neutralization. 
The Human Antibody Response to DENV E 
Historically, the majority of DENV-specific antibodies characterized come from 
non-human sources, and the study of the human antibody response to DENV was limited 
to serum. Studies with serum from convalescent WNV patients showed few DIII-specific 
antibodies and the bulk of the response appeared to be directed towards the DII-FL 161. 
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These results are in contrast with the mouse immune response for which the major 
neutralizating epitope is the DIII-LR 140. Serum from DENV patients have shown a 
similar skewing effect away from DIII-specific reactivity towards of cross-reactive 
epitopes 162–165. However, there are conflicting reports in the literature as to the role of 
DIII antibodies in natural infection. Investigation of the antibody population using E 
protein mutants or depletion studies has shown little evidence for the role of DIII 
antibodies in human immunity 166–170. However, another study found that while the DIII-
specific antibodies were variable across patients and generally low in number, there was a 
correlation with DIII antibodies and protection 171. Recent advances in the development 
of human B-cell clones has expanded our understanding of the human antibody response 
during DENV infection 172.  Immortalization of B-cells from DENV patients has been 
used successfully to create human monoclonal antibodies 149,173. Characterization of these 
antibodies has found a similar pattern as studies with serum: these DENV antibodies 
tended to be cross-reactive and all could enhance DENV infection. Future studies are 
needed to define the role of DIII-specific antibodies in natural DENV infection. 
 
1.10 Antibody-dependent enhancement of DENV infection 
 While antibodies play an important role in neutralization of DENV, they also 
have been implicated in DENV disease pathogenesis. Infection with DENV is believed to 
induce a life-long protective neutralizing antibody response to the strains belonging to 
that serotype 12.  However, subsequent infection with a DENV of a different serotype has 
been correlated with an increase in the risk of the more severe forms of DENV 
pathogenesis (i.e. DHF/DSS) 174,175.  Epidemiological observations have suggested that 
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the increasing occurrence of severe dengue (DHF/DSS) is due to this phenomenon, 
termed antibody-dependent enhancement (ADE). ADE occurs when antibodies bind a 
virus particle, but do not inhibit infection and instead facilitate entry into Fc-γ-bearing 
cells (Figure 5). Recent studies in non-human primates and immunocompromised mice 
have confirmed that passive transfer of anti-DENV monoclonal or polyclonal antibodies 
can augment replication of a heterologous DENV in challenge models, and in some cases 
cause a lethal vascular leakage syndrome that resembles DSS 155,176,177. While the 
mechanistic details of ADE in disease are still under investigation, it is thought that entry 
into the cell through Fc-mediated endocytosis alters the inflammatory signaling response 
or the additional entry pathway increases the viral burden 178.  
Populations at Risk for Severe Dengue 
Two populations are most at risk from ADE: people with prior DENV exposure 
and infants. Natural infection with DENV is thought to provide lifelong-immunity to the 
homologous serotype, and transient protection against other serotypes (≤ 6 months). It is 
thought that once the protective cross-reactive antibody response diminishes, the 
remaining cross-reactive antibody population can facilitate ADE. A similar, yet indirect, 
phenomenon is thought to occur in infants whose mother has had prior DENV exposure 
179. Infants acquire passive immunity through maternal antibodies crossing the placenta. 
However, as this population of antibodies diminishes in the months after birth, the 
concentration of antibodies required for protection falls below the neutralization 
threshold. ADE in babies that are breast-fed from mothers with prior DENV exposure is 
thought to experience a similar phenomenom from maternal antibodies in breast milk 180. 
A sub-neutralizing concentration of antibodies may result in ADE upon DENV infection. 
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Epitope and enhancement.  
Studies with monoclonal antibodies and sera have shown there is a correlation 
between epitope-specificity and the risk of ADE. Antibodies against any epitope have the 
possibility to enhance infection if occupancy of the epitope is below the threshold 
required for neutralization. However, due to the structure-function relationship of the E 
protein domains and their relative occupancies on mature, immature, or partially mature 
viruses, as well as sequence conservation, antibodies against certain epitopes have been 
shown to have a higher propensity for enhancement. In a mouse model of DENV disease, 
serotype-specific antibodies did not enhance disease until reaching sub-neutralizing 
concentrations, although cross-reactive and polyclonal sera resulted in enhanced DENV 
disease 176. Modifying the requisite N-linked glycosylation site (N297) for Fc-γ receptor 
engagement ablated the observed disease enhancement in this model 176, and other 
systems 149. Additional studies are needed to investigate the potential therapeutic 
applications in DENV treatment with antibodies that do not engage Fc-receptors. 
 
1.11 Summary 
Antibodies play a paradoxical role in DENV infection, assisting in both protection from 
and enhancement of disease. Defining the epitopes of the humoral response to DENV 
would assist in understanding vaccine correlates of protection and developing 
therapeutics used to treat or prevent DENV disease. Using a combination of structural 
modeling and crystallography, I defined characteristics of five DIII epitopes with 
different neutralization potencies. My contributions to defining the immunological 
landscape of DENV DIII have increased perception of unique issues related to DENV 
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neutralization. Application of these studies should aid in the assessment and evaluation of 
DENV-specific vaccines and therapeutics. 
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Figure 1: Phylogenetic tree of the Flavivirus genus and their genome. A. The 
relationship between select pathogenic Flavivirus members is shown in the dendrogram. 
These relationships are based upon the full amino acid sequences of their respective viral 
genomes. The serocomplex of the viruses is shown on the left. The strains representing 
the five DENV-1 genotypes are shown on the right. B. The genomes of these viruses are 
translated as a single polypeptide. Viral and host proteases cleave the product into the 10 
Flavivirus proteins. 





Figure 2: The Flavivirus life cycle. Virions attach to the cell surface via poorly 
understood receptors. The virus is endocytosed in a catherin-dependent fashion before 
trafficking through the Rab5/7+ endosomes. Acidification of the late endosome induces a 
conformation rearrangement of the virus envelope glycoprotein, promoting fusion of the 
viral and endosomal membranes and releasing the viral RNA into the cytoplasm. 
Replication and particle assembly occurs on the endoplasmic reticulum. The assembled 
immature particles enter the secretory pathway and transverse the trans-Golgi network 
(TGN). The pr peptide is cleaved from the prM-E homodimers by furin-like proteases. 
Due to low pH of the TGN, the pr peptide remains associated with the viral particle until 
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Figure 3. Structural conformations of the DENV E glycoprotein. A. The pr peptide 
(purple) caps the DII fusion loop (green) in the structure of the prM-E heterodimer at 
neutral pH (PDB 3C6E). DI, DII, and DIII are colored in red, yellow, and blue, 
respectively; disulfides are shown in orange and the fusion loop in green. B. The structure 
of the pre-fusion DENV (PDB 1OAN) dimer. Domains of one chain are colored as 
above; the other chain in shown in grey. C. The structure of the post-fusion DENV trimer 

























Figure 4. Atomic models of DENV virions. Cartoon representations of available 
cryoEM reconstructions progressing through the flavivirus lifecycle in a 
counterclockwise fashion. For each model, the axes of symmetry are labeled. A. The 
infectious mature virus attaches to the DENV receptor to enter the cell through 
endocytosis. B. The surface of the newly assembled immature particle consists of trimeric 
spikes of prM-E heterodimers. C. As these particles transition from the neutral pH of the 
ER to the lower pH of the TGN, the trimeric spikes relax form flattened prM-E 
heterodimers. This conformation facilitates cleavage of the pr peptide by furin-like 
proteases. Upon exposure to the neutral pH of the extracellular space, the cleaved pr 
peptide will dissociate from the viral surface, returning the virus to the mature virion 
conformation (A). D. The model of DENV bound by the 1A1D-2 Fab shows a viral 
conformation that was trapped by the Fab. Increasing the temperature to 37°C, increasing 
the rate at which these Fab fragments bound, suggesting that temperature, as well as pH 
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Figure 5. Mechanisms of Antibody Neutralization and Enhancement in DENV 
infection. Two mechanisms of neutralization have been identified for DENV. The first 
class of antibodies blocks attachment of the virus to the host receptor or prevents entry of 
the virus into the cell Antibodies that bind the highly conserved fusion loop tend to block 
cellular attachment. The second class of antibody does not block attachment or entry into 
the cell, but instead enters the cell as a complex with the virus. Upon acidification in the 
late endosome, these antibodies prevent the pH-dependent structural rearrangements 
necessary for fusion and release of the viral RNA. Antibodies against the DIII lateral 
ridge and DI hinge regions are capable of blocking fusion. Finally, antibodies may also 
enhance virus infection by binding virions at sub-neutralizing concentrations and 






















Figure 6. Neutralizing Antibody Epitopes in the DENV E protein. A. Sites of 
neutralizing antibody epitopes in the DENV E protein are colored in magenta. The 
DENV dimer is colored as in Figure 3. B. Face view of the five epitopes in DIII of the E 
protein. Residues corresponding to the lateral ridge (blue), A-strand (magenta), the 
overlapping residues of the composite lateral ridge/A-strand (LRA; red), the AB loop 
(orange), and CC’ loop (green) epitopes are mapped on the surface model of DIII. C. 
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2.1 Abstract 
 
Neutralization of flaviviruses in vivo correlates with the development of an 
antibody response against the viral envelope (E) protein. Previous studies demonstrated 
that monoclonal antibodies (MAbs) against an epitope on the lateral ridge of domain III 
(DIII) of the West Nile virus (WNV) E protein strongly protect against infection in 
animals. Based on X-ray crystallography and sequence analysis, an analogous type-
specific neutralizing epitope for individual serotypes of the related flavivirus dengue virus 
(DENV) was hypothesized. Using yeast surface display of DIII variants, we defined 
contact residues of a panel of type-specific, subcomplex-specific, and cross-reactive 
MAbs that recognize DIII of DENV type 2 (DENV-2) and have different neutralizing 
potentials. Type-specific MAbs with neutralizing activity against DENV-2 localized to a 
sequence-unique epitope on the lateral ridge of DIII, centered at the FG loop near 
residues E383 and P384, analogous in position to that observed with WNV-specific 
strongly neutralizing MAbs. Subcomplex-specific MAbs that bound some but not all 
DENV serotypes and neutralized DENV-2 infection recognized an adjacent epitope 
centered on the connecting A-strand of DIII at residues K305, K307, and K310. In 
contrast, several MAbs that had poor neutralizing activity against DENV-2 and cross-
reacted with all DENV serotypes and other flaviviruses recognized an epitope with 
residues in the AB loop of DIII, a conserved region that is predicted to have limited 
accessibility on the mature virion. Overall, our experiments define adjacent and 
structurally distinct epitopes on DIII of DENV-2 which elicit type-specific, subcomplex-
specific, and cross-reactive antibodies with different neutralizing potentials.  
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2.3 Introduction 
Dengue fever (DF), the most prevalent arthropod-borne viral illness in humans, is 
caused by dengue virus (DENV). The four serotypes of DENV are transmitted to humans 
primarily by the mosquitoes Aedes aegypti and Aedes albopictus. DENV is a member of 
the Flaviviridae family and is related to the viruses that cause yellow fever and the 
Japanese, St. Louis, and West Nile encephalitides 1. Infection by DENV causes a 
spectrum of clinical disease, ranging from an acute, debilitating, self-limited febrile 
illness (DF) to a life-threatening hemorrhagic and capillary leak syndrome (dengue 
hemorrhagic fever/dengue shock syndrome). At present, no approved antiviral treatment 
or vaccine is available, and therapy is supportive in nature. DENV causes an estimated 25 
to 100 million cases of DF and 250,000 cases of dengue hemorrhagic fever per year 
worldwide, with 2.5 billion people at risk for infection 2,3.  
DENV is an enveloped virus with a single-stranded, positive-sense RNA genome 
4. The 10.7-kilobase genome is translated as a single polyprotein, which is then cleaved 
into three structural proteins (C, prM/M, and E) and seven nonstructural (NS) proteins 
(NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) by virus-and host-encoded proteases. 
The 500-Å DENV mature virion has a well-organized outer protein shell, a 50Å-thick 
lipid membrane bilayer, and a less-defined inner nucleocapsid core 5,6. The icosahedral 
scaffold consists of 180 E and 180 M protein monomers arranged in a repeating pattern 
that lacks the predicted T=3 quasisymmetry 5,6. The immature virion, which lacks 
cleavage of the prM protein, has a rough surface with 60 spikes 7, whereas the mature 
virion has a smooth surface. X-ray crystallographic analyses of the soluble ectodomains 
of the E proteins from tick-borne encephalitis virus and DENV demonstrated a dimeric 
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assembly, with each subunit containing three domains 8–10. Domain III (DIII), which 
adopts an immunoglobulin-like fold, is believed by some to contain a cell surface 
receptor recognition site 8,11–13. Recent structural results detailing the postfusion trimeric 
conformation of DENV type 2 (DENV-2) and tick-borne encephalitis virus E proteins has 
prompted a new model for type II viral fusion 14,15. In the postfusion trimer, there is a 
reorganized E protein domain structure, with significant exposure of the hydrophobic 
fusion peptide in DII 15.  
The majority of flavivirus-neutralizing antibodies recognize the structural E 
protein, although some also bind to the prM/M protein 16–19. Serotype-specific epitopes 
elicit antibodies with the strongest neutralizing activities 20,21, and protection in animals 
by antibodies correlates with neutralizing activity in vitro 21–26. Based on epitope 
mapping data, many type-specific neutralizing antibodies against individual flaviviruses 
localize to DIII 26–35, whereas neutralizing monoclonal antibodies (MAbs) that cross-react 
with other flaviviruses localize primarily to DII, near the fusion peptide 32,36–40. Alteration 
of specific residues in DIII results in the loss of binding of neutralizing MAbs 28,35,41–44. 
Recently, our group, along with others, localized individual contact residues of a large 
panel of anti-West Nile virus (anti-WNV) MAbs and defined a dominant neutralizing 
epitope on the lateral ridge of DIII 26,35,45. Crystallographic analysis indicated that a 
strongly neutralizing, DIII-specific anti-WNV MAb engaged four discontinuous 
segments, including the N-terminal linker region (residues 302 to 309) and three strand-
connecting loops, namely, BC (residues 330 to 333), DE (residues 365 to 368), and FG 
(residues 389 to 391), which together form a single concave surface patch 46. Comparison 
of available WNV sequences revealed nearly complete conservation of the structurally 
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defined epitope. However, sequence analysis of other flaviviruses revealed diversity in 
the four segments, with notable variation even between DENV serotypes. Interestingly, 
other groups have also identified individual flavivirus-specific neutralizing antibodies that 
localize to an analogous DIII binding region 12,31,41. Based on the coincident mapping of 
our and other neutralizing MAbs, we predicted that this structural epitope, although 
specific for individual flaviviruses, would have a dominant role in neutralization of all 
flaviviruses 46,47.  
In this study, we mapped the contact residues of a panel of anti-DENV-2, DIII-
specific MAbs with distinct neutralizing potentials. Type-specific MAbs with the 
strongest neutralizing activities against DENV-2 localized to an epitope on the lateral 
ridge of DIII that was analogous in location to that seen with neutralizing WNV MAbs. 
Subcomplex-specific neutralizing MAbs that recognized several serotypes of DENV 
bound an adjacent epitope centered on the A-strand of DIII. In contrast, several poorly 
neutralizing MAbs recognized conserved flavivirus residues within the AB loop that 
appear to have limited accessibility on the mature virion. Overall, in contrast to previous 
studies with WNV DIII, our data suggest the existence of two structurally distinct 
neutralizing epitopes on DIII of DENV-2 E protein, with a type-specific epitope on the 
lateral ridge of DIII centered at the unique FG loop and a subcomplex-specific epitope 
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2.4 Results 
Strongly neutralizing MAbs against WNV localize to an epitope (see Fig 2A) 
composed of the loops from three β-strands and an N-terminal region on the lateral ridge 
of DIII. 12,26,35,45,46,48. Sequence analysis indicated that this neutralizing epitope is highly 
conserved among WNV strains but divergent from those of other flaviviruses 46,49. To test 
whether the analogous epitope on DIII of DENV-2 elicited strongly neutralizing 
antibodies, we screened a panel of 40 MAbs obtained from colleagues for 
immunoreactivity with DENV-2 strain 16681. Twenty-one of 40 MAbs exhibited sig-
nificant reactivity with DENV-2-infected cells or purified recombinant soluble DENV-2 
E protein derived from insect cells (data not shown). Of the MAbs that recognized 
DENV-2 infected cells, 14 bound strongly to yeast cells displaying DENV-2 DIII (data 
not shown). Of these, four had moderate (50% PRNT [PRNT50], 1 to 100 μg/ml) and six 
had strong (PRNT50 <1 μg/ml) neutralizing activities against strain 16681 in a standard 
PRNT assay (Table 1). Four others had weak or no appreciable inhibitory activity 
(PRNT50, >100 μg/ml). Notably, five of the six strongly neutralizing MAbs were type 
specific and showed no significant cross-reactivity with DENV1-, DENV-3-, or DENV-4-
infected cells (Table 2).  
To map the amino acid contact residues of the DIII-specific DENV-2 MAbs with 
distinct neutralizing properties, we applied a high-throughput strategy that previously 
mapped 167 WNV E protein-specific MAbs 26,39. Error-prone PCR mutagenesis 
introduced random point mutations within DIII of DENV-2 E. A library of ~3.5 X 105 
variants was pooled and used to create a mutant yeast expression library. Individual 
screens were performed to identify DIII mutants that lost binding selectively to strongly 
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neutralizing MAbs. To eliminate mutants that abolished surface expression of DIII, yeast 
cells were stained sequentially with an Alexa Fluor 647-conjugated individual MAb and 
an Alexa Fluor 488-conjugated oligoclonal antibody derived from a pool of individual 
MAbs. After several rounds of cell sorting, yeast cells that selectively lost expression of 
an individual MAb epitope but retained expression of DIII on the surface were identified. 
Multiple independent yeast clones that selectively lost binding of individual MAbs were 
subjected to plasmid recovery and sequencing. Subsequently, mutant DIII expressed on 
the yeast surface was tested for MAb reactivity against the remainder of the panel of 
MAbs by flow cytometry (Fig 1 and data not shown).  
From each screen, we recovered 6 to 20 independent mutants that lost binding for 
an individual MAb. After sequencing them, we discovered that some of these mutants 
contained multiple mutations within the DIII region. In such cases, single mutations were 
engineered separately by site-directed mutagenesis to identify the change that caused the 
phenotype. Type-specific MAbs that localized to DIII and neutralized DENV-2 strongly 
(1F1, 3H5-1, 6B6-10, 9A3D-8, and 9F16) showed markedly reduced binding (>80% 
reduction) when residues G304 (five of five MAbs), E383 (three of five MAbs), and P384 
(four of five MAbs) were altered (Fig 1 and Table 3). Similarly, type-specific MAbs that 
neutralized moderately (PRNT50 of 2 to 5 μg/ml; M8051122, 9F11, and 2Q1899) also 
showed decreased binding when these three residues were changed. G304, E383, and 
P384 are located on adjacent loops and form a contiguous patch on the solvent-exposed 
surface at the lateral ridge of DIII (Fig 2). As observed for DIII-specific neutralizing 
MAbs against WNV 26, the type-specific neutralizing DENV-2 MAbs bound overlapping 
epitopes. Consistent with this, the following additional point mutations caused significant 
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loss of binding of individual type-specific neutralizing MAbs tested: T303Y (1F1), 
K307E (9A3D-8), E327R (9A3D-8), D329R (6B6-10), G330D (1F1 and 6B6-10), and 
S331Y (6B6-10). Mutation of G304, which appears to comprise part of a type-specific 
neutralizing epitope on DENV-2 DIII, also affected binding of both subcomplex-specific 
MAbs (9D12 and 1A1D-2) and one non-or weakly neutralizing MAb (E114). Because 
binding of several MAbs of different classes was affected by the G304 mutation, we 
cannot absolutely exclude perturbations of the structure of this mutant DIII. Against this, 
we did observe relatively wild-type levels of binding of two other nonneutralizing MAbs 
(13D4-1 and E111) to this mutant.  
In our panel of MAbs, we also identified two neutralizing MAbs (9D12 and 
1A1D-2) that reacted with additional DENV serotypes. These subcomplex-specific MAbs 
showed moderate and strong inhibitory activities against DENV-2 infection, respectively 
(Tables 1 and 2). These MAbs, however, bound DIII somewhat distinctly. 1A1D-2, 
which binds DENV-1, DENV-2, and DENV-3, retained relatively normal binding with 
E383G and P384N mutations but showed markedly reduced binding with mutations in 
residues K305, K307, and K310. In comparison, 9D12, which binds DENV-2 and 
DENV-4 and weakly binds DENV-1, retained binding with the E383G and P384A 
mutations but had markedly reduced binding with K305E, K307E, K310E, and P384N 
mutations (Table 3).  
 Also in our panel were four MAbs (5A2-7, 13D4-1, E111, and E114) that had 
little or no neutralizing activity (2). This group of MAbs recognized all four serotypes of 
DENV (Table 2). Two of them, E111 and E114, were cross-reactive and also recognized 
yeast expressing WNV DIII (data not shown). Independent yeast sorting for loss-of-
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binding mutations was performed with three of the four MAbs. Several mutations that 
specifically reduced binding of the poorly neutralizing MAbs but had little effect on most 
strongly neutralizing MAbs were identified. For example, H317Y mutation specifically 
reduced binding of the 5A2-7, 13D4-1, and E111 MAbs (Table 3), and a DIII variant 
with two mutations (T315G and S331Y) also diminished binding of these MAbs but did 
not affect any neutralizing MAbs, with the exception of 6B6-10. Interestingly, the T315G 
single mutant only modestly decreased 5A2-7 (71% reduction) binding, and the S331Y 
single mutant had no effect on binding of 5A2-7, 13D4-1, or E111.  
To visualize spatially the different recognition patterns of MAbs that strongly, 
moderately, and weakly neutralized DENV-2 infection, we docked the loss-of-binding 
mutations (<20% of wild-type binding) defined by the yeast assay onto the existing 
crystallographic structure of DENV-2 DIII, the prefusion DENV-2 E protein dimer 
structure 9, and the pseudoatomic model of the mature DENV-2 virion 5. The DIII 
structures were compared to the previously defined crystallographic epitope (16 contact 
residues) of E16 on the lateral ridge of DIII of WNV 46 (Fig 2A and B). Type-specific 
MAbs with the strongest neutralizing activities (3H5-1, 6B6-10, and 1F1) localized to 
amino acids on the analogous lateral ridge of DIII (Fig 2D, E, and F). Nonetheless, the 
yeast mapping did suggest some subtle differences. Whereas the lateral ridge epitope of 
the strongly neutralizing anti-WNV MAb E16 was centered on the N-terminal region and 
the BC loop (K307, T330, and T332 of WNV), strongly neutralizing type-specific anti-
DENV-2 MAbs localized more to the FG loop (E383 and P384 of DENV-2). The E383 
and P384 residues in the FG loop are highly conserved among DENV-2 isolates but are 
not present in DENV-1, DENV-3, or DENV-4 strains (Fig 3). The epitope of type-
	   	   49	  
specific neutralizing MAbs against DENV-2 followed the same exposure pattern on the 
virion as that previously identified for E16 46,50: two of the three DIIIs per icosahedral 
asymmetric unit were exposed, with steric hindrance noted at the fivefold clustered DIII 
(Fig 2C).  
Subcomplex-specific MAbs (1A1D-2 and 9D12) that strongly and moderately 
neutralized DENV-2 infection recognized a flanking epitope (Fig 4A and B). This 
epitope was centered on amino acids K305, K307, and K310 on the A-strand. Consistent 
with the limited cross-reactivity of these subcomplex-specific MAbs, K310 is completely 
conserved among all four DENV serotypes, whereas K305 and K307 are conserved in 
DENV-4 and DENV-1 strains, respectively (Fig 3). Although the 1A1D-2 and 9D12 
MAb epitopes are reasonably exposed in all three symmetry environments on the mature 
virion (Fig 4C and data not shown), some differences with the type-specific lateral ridge 
epitope were apparent, as follows: the 9D12 epitope appears predominantly exposed on 
the fivefold clustered DIII, and thus, one could speculate that a full complement of 180 
Fabs could bind DENV-2 at saturation.  
Several of the poorly neutralizing, cross-reactive MAbs (5A2-7, 13D4-1, and 
E111) mapped to an amino acid residue (e.g., H317) that was localized to the back side of 
DIII in the AB loop (Fig 5A and B). Consistent with the cross-reactive nature of these 
MAbs, the entire AB loop sequence (E314, T315, Q316, H317, G318, and T319) is 
completely conserved among all four DENV serotypes. Moreover, the H317, G318, and 
T319 residues are present in virtually all WNV isolates and the H317 and T319 amino 
acids are conserved among flaviviruses (Fig 3 and data not shown). Structurally, the AB 
loop has limited exposure on the surface of the E protein dimer and faces inward toward 
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2.5 Discussion 
The goal of this study was to characterize epitopes on DIII recognized by potent 
neutralizing antibodies against DENV-2. Previous studies had established a dominant 
type-specific epitope for eliciting protective antibodies in vitro and in vivo against the 
related flavivirus WNV. Here we tested a panel of MAbs against DIII of the DENV-2 E 
protein. Type-specific strongly neutralizing MAbs mapped to an analogous epitope 
centered on the FG loop of the lateral ridge region on DIII of DENV-2. Subcomplex-
specific strongly neutralizing MAbs localized to a flanking epitope that was centered on 
three lysine residues in the A-strand of DIII. 
Extensive MAb competition binding studies have been performed by several 
groups to identify distinct antigenic and functional determinants on DENV-2 32,34,51–53. 
Potently inhibitory type-specific MAbs were localized to domain B, which is now called 
DIII, based on structural analysis of the domain organization of flavivirus E proteins 8,9. 
Nonetheless, amino acid contact residues of few neutralizing MAbs that react with 
DENV-2 have been established. For these (3H5-1, 4E11, G8D11, and 4G2), precise 
mapping data were obtained by analyzing neutralization escape mutants 28 and by 
differential recognition of chimeric DENV variants 41, site-specific DENV-2 mutants 
36,54, and E protein peptide sequences 55–57. We used a forward genetic strategy, error-
prone PCR mutagenesis of DIII of DENV-2 E protein, and expression on yeast cells to 
map antibody contact residues in a nonbiased manner. By having a panel of DIII MAbs 
with differing neutralization potentials, we minimized the possibility that mutations 
would grossly affect folding. The validity of the yeast approach for identifying critical 
contact residues was confirmed by X-ray crystallographic studies that resolved the 
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structural interface between DIII and a neutralizing anti-WNV Fab fragment 46. Of the 
DENV-2 MAbs that have been reported to contact specific amino acid residues in DIII, 
only the type-specific MAb 3H5-1 was available for our analysis. Prior fine mapping 
studies suggested that 3H5-1 recognized either a Glu-Pro-Gly motif centered at amino 
acids 383, 384, and 385 41 or a linear peptide encompassing amino acids 386 to 397 41,56. 
Our yeast mapping experiments confirmed an essential role for residues E383 and P384 
but also suggested an additional important contact residue (G304) located on an adjacent 
strand. DIII of the E protein adopts an immunoglobulin-like fold 8,9 that is significantly 
exposed on the surface of the mature virion 6,58. The lateral ridge epitope on DIII was 
previously defined by X-ray crystallographic and nuclear magnetic resonance studies of 
Fab-DIII complexes of WNV and Japanese encephalitis virus and encompasses four 
discontinuous loops 12,31,46. In our study, we found six different strongly neutralizing 
MAbs against DENV-2 that localized to two overlapping structural epitopes on the lateral 
ridge and adjacent A-strand of DIII. 
For flaviviruses, virus type-specific epitopes generally elicit the most potent 
neutralizing antibodies 21,26,35,45,59–61. Of the DIII-specific MAbs against DENV-2 in our 
panel, in general, the ones with the strongest neutralizing activities were type specific and 
localized to the lateral ridge of DIII centered at the FG loop, near residues E383 and 
P384. Nonetheless, some of the type-specific neutralizing MAbs inhibited virus 
infectivity less strongly, although they recognized similar residues. Although further 
biophysical studies are needed, the affinities of binding of MAbs for a given DENV-2 
DIII epitope may correlate with relative occupancy and may predict the strength of 
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neutralization. Such a result was observed with less strongly neutralizing MAbs that 
recognized the lateral ridge epitope of DIII of WNV 62.  
 The two subcomplex-specific (1A1D-2 [PRNT50, 0.3 μg/ml] and 9D12 
[PRNT50, 2 μg/ml]) MAbs that we tested had strong and moderate neutralizing activities, 
respectively, consistent with prior studies with the group-specific MAb 4E11 (PRNT50 
values of 0.3 to 2.4 μg/ml for DENV-1 to DENV-4) 63. 1A1D-2 and 9D12 bind a more 
conserved epitope among DENV serotypes that partially overlaps with the type-specific 
lateral ridge neutralizing epitope but is centered on the A-strand at residues K305, K307, 
and K310. Notably, several of these amino acids were recently identified as contact 
residues for the MAb 4E11, which neutralizes all four DENV serotypes 57,64. Such 
broadly neutralizing subcomplex-or group-specific MAbs may have potential for 
development as antibody-based therapeutics against all serotypes of DENV. 
 An epitope map analysis of the different DENV-2 MAbs at the amino acid 
sequence level begins to explain their serotype-specific properties. Type-specific 
neutralizing MAbs against DENV-2 are centered on amino acids E383 and P384 in the 
FG loop, which are conserved among DENV-2 isolates but divergent in all other DENV 
serotypes. Subcomplex-specific neutralizing MAbs that bind some but not all DENV 
serotypes recognize a distinct epitope centered on three A-strand lysines of DIII. K310 is 
completely conserved among all four DENV serotypes, whereas K305 and K307 are 
conserved in DENV-4 and DENV-1 strains, respectively. The distinct binding speci-
ficities of 9D12 and 1A1D-2 for other DENV serotypes likely reflect differences in 
interactions with specific lysines on the A-strand and the divergence of other additional 
contact residues in the FG loop and the G-strand. Cross-reactive poorly neutralizing 
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MAbs localized to the AB loop on DIII. Their lack of neutralizing activity is probably 
explained by the limited surface exposure of the AB loop. As seen for the DIII-specific 
poorly neutralizing anti-WNV MAb E9, a relative lack of accessibility directly affects the 
stoichiometry of binding, such that a threshold for antibody neutralization is rarely 
reached 62. The cross-reactivity of these AB loop MAbs with all DENV serotypes and 
distantly related flaviviruses is reasonably explained by sequence conservation: amino 
acids 314 to 319 are completely conserved among all four DENV serotypes, and residues 
317 and 319 (which include the critical H317 amino acid) are conserved in virtually all 
flaviviruses. This analysis has implications for the development of novel DIII epitope-
based diagnostic reagents for polyclonal antibodies, as mutation of AB loop sequences 
could abolish serotype and flavivirus nonneutralizing cross-reactive epitopes, making 
DIII-based immunologic assays more predictive of serotype-specific neutralizing 
antibodies.  
Although the sequence of the lateral ridge epitope of DIII is variable among 
flaviviruses, the majority of mutations that abolish binding of virus-specific strongly 
neutralizing antibodies map there 21,26,27,31,32,34,35,42,45,54, suggesting the existence of a 
type-specific neutralizing epitope for flaviviruses on DIII. It is important, however, that 
these epitope maps were derived using murine MAbs. Whether the human antibody 
response recognizes the same or different epitopes has not yet been determined in detail. 
Only 8% (4 of 51 antibodies) and 0% (0 of 11 antibodies) of human single-chain 
antibodies that were isolated from phage display libraries of WNV-infected or naïve 
patients reacted with DIII 65,66. These results suggest that the human antibody repertoire 
against flaviviruses may actually be directed away from these DIII neutralizing epitopes 
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and toward the inherently less neutralizing immunodominant epitopes on DI and DII 67. 
Since our results suggest that strongly neutralizing antibodies against DIII of DENV-2 
map to the lateral ridge and A-strand epitopes, flavivirus DIII-based vaccines 68–70 that 
intentionally skew the humoral response to these epitopes and away from the cross-
reactive, poorly accessible epitope in the AB loop could elicit a greater protective 
response.  
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2.6 Discussion Addendum 
 Since the completion and publication of this work almost five years ago, several 
advancements have been made in understanding the atomic structure and functional 
behavior of antibodies described in this work. Contemporaneous manuscripts were 
published using alanine scanning of DENV-2 DIII to map several of the same antibodies 
used in the above work to similar residues 71,72. Antibodies against the analogous lateral 
ridge epitope have been described for DENV-1 73 and DENV-3 74–76. While the A-strand 
antibodies mapped in our study were produced from mice, antibodies against the A-
strand epitope have also been discovered humans 77.  
The crystal structure of the sub-complex, A-strand reactive 1A1D-2 Fab in 
complex with DENV-2 confirmed the validity of our non-biased mapping of this 
antibody 78. The loss-of-binding DIII mutants identified 27% (3 of 11) of the residues 
involved in 1A1D-2 binding. In our structural analysis of the 1A1D-2 residues mapped 
onto the surface of the virion, we had predicted the possibility of 100% occupancy of the 
180 DIII epitopes by 1A1D-2. However, the 1A1D-2 epitope is not fully accessible on 
the surface of the mature virion, requiring a structural rearrangement of the E protein for 
binding, a conformation that is temperature-sensitive. The cryo-EM atomic model of 
1A1D-2 demonstrated that the DENV-2 particles appear to present a different ensemble 
of structures from that of the mature DENV-2 particle we used in our analysis 78. 
Mapping of the 1A1D-2 footprint failed to identify the contributions of residues 388 and 
390 on the G-strand, the strand that is inaccessible in the mature virion structure. So 
while our approach provides details of specific residues involved in antibody-DIII 
interactions, contacts that provide relatively lower energy to binding may not be 
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identified. Additionally, the structure of a single-chain variable fragment (scFv) of the 
complex-specific (i.e. reacts with all four DENV serotypes) antibody 4E11 in complex 
with each of the DENV DIII serotypes was also determined 79 by x-ray crystallography. 
The 4E11 structures reveal that residues 307 and 310 play an essential role in recognizing 
the four DENV DIII. Unlike 1A1D-2, 4E11 can neutralize all four DENV serotypes 
despite recognizing similar A-strand epitopes. A change of a glutamate in 1A1D-2 to a 
glycine in 4E11 changes the electrostatic potential of the CDR3 loop of the heavy chain. 
The authors reason that this difference facilitates binding to DENV-4 DIII, which lacks 
the basic residues found in the A- and B-strands found in other serotypes. Taken as a 
whole, the structures validate the identification of the A-strand in playing a critical role in 
cross-serotype reactivity as shown by our mapping studies. 
Recently, the structures of the 2H2 AB loop binding antibody Fab fragment in 
complex with DENV-1, -3, and -4 were determined 80.  The 2H2 antibody reacts with all 
four DENV serotypes, yet neutralizes only DENV-1, -3, and -4. As with antibodies 
specific for the A-strand epitope, 2H2 showed increased reactivity with virus particles at 
37°C compared to 4°C or 30°C. While there is no cryo-EM model of 2H2 or any AB loop 
reactive antibody bound to DENV, the temperature-sensitive nature of 2H2 binding 
suggests that antibodies against this epitope may require an alternate virus conformation 
from those currently described. As with the 1A1D-2 epitope, the AB loop epitope does 
not appear to be exposed on the surface of the mature virion. The potential for structural 
rearrangements of the E glycoprotein may explain why these AB loop antibodies can 
neutralize virus, albeit relatively poorly compared to antibodies against other DIII-
specific epitopes. 
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Overall, the more recent structural characterizations of DENV DIII antibodies 
support the original descriptions of the lateral ridge, A-strand, and AB loop antibodies. 
To date, only the A-strand epitope antibodies have been identified from human sera and 
further studies are needed to address the possibility of human lateral ridge and AB loop 
reactive antibodies. The structural information of non-murine antibodies against 
flaviviruses is limited. There is currently only one human Fab-WNV cryo-EM model 81 
and one chimpanzee Fab-DENV-4 x-ray crystallography-determined 82 structure 
available, neither of which are DIII-specific.  Increasingly there is evidence that there are 
potently DENV neutralizing epitopes in DI and DII of the E protein, and the human 
antibody response is skewed towards these epitopes, and away from those in DIII 83–86. 
Identification and characterization of the immunodominant epitope in humans during 
natural infection and vaccination are needed to assess whether the DIII epitopes play a 
significant role in human immunity to DENV.    
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2.7 Methods and Materials 
Cells and viruses. Vero, BHK21-15, and Raji-DC-SIGN-R cells were maintained 
at 37°C in a 5% CO2 incubator in Dulbecco’s modified essential medium or RPMI 1640 
supplemented with 10% fetal bovine serum (Omega Scientific Inc., Tarzana, CA), 1% 
penicillin G, and 1% streptomycin. The DENV strains used were 16007 (DENV-1), 
16681 (DENV-2), 16652 (DENV-3), and H241 (DENV-4). The viruses were amplified in 
C6/36 cells according to established protocols 87. Plaque reduction neutralization titer 
(PRNT) assays were performed on BHK21-15 cells with individual MAbs and 
quantitated as previously described 26.  
MAbs. The MAbs used in this study are presented in Table 1 and were purified 
from hybridoma culture supernatants or mouse ascites fluid by using an NAB protein A 
spin purification kit (Pierce, Rockford, IL). For sorting experiments, MAbs were labeled 
with Alexa Fluor 647 or Alexa Fluor 488, using a MAb labeling kit (Molecular Probes, 
Invitrogen, Carlsbad, CA). 
Expression of DENV-2 E protein DIII in yeast. The DNA fragment encoding 
amino acid residues 294 to 409 (DIII) of the DENV-2 E protein was amplified from a 
DENV-2 strain 16681 infectious cDNA clone 88 by PCR, with BamHI and XhoI sites 
added at the 5' and 3' ends, respectively. The PCR products were digested and cloned as 
downstream fusions to Aga2 and Xpress epitope tag genes in the yeast surface display 
vector pYD1 (Invitrogen, Carlsbad, CA), under the control of an upstream GAL1 
promoter. These constructs were transformed into Saccharomyces cerevisiae strain 
EBY100 89,90, using an S.c. EasyComp transformation kit (Invitrogen, Carlsbad, CA), to 
generate yeast that expressed DENV-2 DIII. Individual yeast colonies were grown to 
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logarithmic phase at 30°C in tryptophan-free yeast medium containing 2% glucose. 
Fusion protein expression was induced on the surface by growing yeast cells for an 
additional 48 h in tryptophan-free medium containing 2% galactose at 20°C. Yeast cells 
were harvested, washed with phosphate-buffered saline (PBS) supplemented with bovine 
serum albumin (1 mg/ml), and stained with 50 μl of diluted MAbs. Purified antibodies 
were used at a concentration of 50 μg /ml, and MAbs from ascites fluid were used at a 
1:100 dilution. After a 30-min incubation on ice, yeast cells were washed in PBS with 
bovine serum albumin and then stained with a goat anti-mouse immunoglobulin G (IgG) 
secondary antibody conjugated to Alexa Fluor 647 (Molecular Probes, Invitrogen, 
Carlsbad, CA). After fixation with 1% paraformaldehyde in PBS, yeast cells were 
analyzed on a FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ).  
Library construction and screening. To generate a random mutant library, 
DENV-2 DIII was mutated by error-prone PCR, using a GeneMorph II random 
mutagenesis kit (Stratagene). The mutant library was ligated into the pYD1 vector and 
transformed into XL2-Blue ultracompetent cells (Stratagene, La Jolla, CA). The colonies 
were pooled and transformed into yeast cells as described above.  
For each individual MAb, the DENV-2 DIII mutant library was screened 
according to a previously described protocol 26. To identify yeasts that had selectively 
lost binding to a given MAb, the library was initially stained with this antibody 
conjugated to Alexa Fluor 647 for 30 min on ice. To control for the surface expression of 
DENV-2 DIII, yeast cells were subsequently stained for 30 min on ice with an Alexa 
Fluor 488-conjugated oligoclonal antibody that was derived from a pool of individual 
MAbs (1F1, 1A1D-2, 6B6-10, 9A3D-8, 13D4-1, and 5A2-7). After being stained, yeast 
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cells were subjected to flow cytometry, and the population that was single MAb negative 
but oligoclonal antibody positive was identified. After three or four rounds of sorting, 
yeast cells were plated and individual colonies were tested for binding to individual 
MAbs by flow cytometry. For individual clones that had lost only the desired MAb 
binding epitope, the pYD1-DV2 DIII plasmid was recovered using a Zymoprep yeast 
miniprep kit (Zymo Research, Orange, CA). The plasmid was transformed into XL1-Blue 
competent cells (Stratagene, La Jolla, CA), purified using a QIAprep spin mini-prep kit 
(QIAGEN), and sequenced. In some cases, DENV-2 DIII variants with multiple 
mutations were isolated. To determine which mutation conferred the phenotype, single 
independent mutations were engineered by site-directed mutagenesis, using a 
QuikChange II mutagenesis kit (Stratagene, La Jolla, CA), or by using splice-overlap 
PCR 91.  
MAb staining of DENV-infected cells. Raji-DC-SIGN-R cells were infected 
with DENV-1, DENV-2, DENV-3, or DENV-4 at a multiplicity of infection of 0.5 or 1. 
Depending on the strain, cells were harvested at 72 or 96 h, washed three times in PBS, 
and fixed in PBS with 1% paraformaldehyde. Cells were then washed twice in PBS and 
permeabilized in Hanks’ balanced salt solution (Cellgro, Herndon, VA) containing 10 
mM HEPES (pH 7.3), 0.1% saponin (Sigma, St. Louis, MO), and 0.02% NaN3 (HHSN). 
MAbs were bound to permeabilized virus-infected cells for 30 min on ice, washed three 
times in HHSN, and resuspended in 50 μl of a 1/500 dilution of Alexa Fluor-conjugated 
anti-mouse IgG (Molecular Probes, Invitrogen, Carlsbad, CA). After 15 min, cells were 
again washed in HHSN three times, fixed in PBS with 1% paraformaldehyde, and 
processed by flow cytometry. 
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Mapping of mutations onto the DENV-2 DIII crystal structure and virion. 
Figures were prepared using the atomic coordinates of DENV-2 E (Research 
Collaboratory for Structural Bioinformatics [RCSB] accession number 1OAN) and the 
WNV E DIII/E16 Fab complex (RCSB accession number 1ZTX), using the programs 
Ribbons 92, MOLEMAN2 93, Insight II (Accelrys, San Diego, CA), and PyMol 
(http://www.pymol.org). The representations of the DENV-2 virion were generated using 
the atomic coordinates and transformation matrices found in RCSB entry 1THD. 
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1F1 IgG2a 0.01 Megret	  et	  al.	  1992 
3H5-1 IgG1 0.18 Gentry	  et	  al	  1982 
6B6-10 IgG2a 0.07 Kaufman	  et	  al.	  1987 
9A3D-8 IgG2a 0.03 Roehrig	  et	  al.	  1998 
M8051122 IgG1 2 Unpublished data 
9F16 IgG1 0.8 Unpublished data 
9F11 IgG1 2 Unpublished data 
2Q1899 IgG1 5 Unpublished data 
9D12 IgG1 2 Henchal et al. 1982 
1A1D-2 IgG1 0.3 Roehrig	  et	  al.	  1998 
5A2-7 IgG2a >100 Megret	  et	  al.	  1992 
13D4-1 IgG2a >100 Mason	  et	  al.	  1990 
E111 IgG2a >100 Oliphant et al. 2006 
E114 IgG1 >100 Oliphant et al. 2006 
a Determined by PRNT assay on BHK21 cells with 102 PFU of DENV-2.  
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1F1 Strong Type − +++ − − 
3H5-1 Strong Type − +++ − − 
6B6-10 Strong Type − +++ − − 
9A3D-8 Strong Type − +++ − − 
M8051122 Moderate Type − +++ − − 
9F16 Strong Type − +++ − − 
9F11 Moderate Type − +++ − − 
2Q1899 Moderate Type − +++ − − 
9D12 Moderate Subcomplex + +++ − +++ 
1A1D-2 Strong Subcomplex +++ +++ +++ − 
5A2-7 Weak/none Complex +++ +++ +++ +++ 
13D4-1 Weak/none Complex +++ +++ +++ +++ 
E111 Weak/none Cross-
reactive 
+++ +++ +++ +++ 
E114 Weak/none Cross-
reactive 
+++ +++ +++ +++ 
a+++, strong binding (40 to 100% compared to control) to infected cells; +, weak binding 
(15 to 40% compared to control) to infected cells; −, no appreciable binding detected.  
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Figure 1: Flow cytometry histograms of loss-of-function DIII variants (G304Y, 
K307N, D329G, and P384N) selected by yeast surface display after being sorted with 
MAbs. Representative histograms are shown for MAbs 1F1, 3H5-1, and 13D4-1 with 
wild-type DIII (WT) and each of the DIII mutants. Data shown are representative of three 
independent experiments. 
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Figure 2: DIII lateral ridge antibody epitope. The structures of WNV and DENV-2 
DIIIs are shown, with identification of binding sites of type-specific neutralizing 
antibodies. (A) Structure of WNV E16 neutralizing epitope determined by X-ray 
crystallography (16 residues in blue) or by using yeast display mapping (4 residues in 
orange). (B) Structure of DENV-2 DIII, with the corresponding 16 amino acids of the 
WNV E16 neutralizing antibody epitope highlighted. (C) Yeast display epitope residues 
(red) for the 1F1 MAb were mapped onto the pseudoatomic model of the mature DENV-
2 virion 5. Virions are depicted as 2.0-Å-radius C-α atoms and are colored according to 
their E protein symmetry relationships, i.e., twofold (cyan), threefold (green), or fivefold 
(yellow) symmetry. (D to F) Structure of DENV DIII, with amino acid residues that 
significantly affect binding of type-specific neutralizing MAbs 3H5-1 (D), 6B6-10 (E), 
and 1F1 (F) marked in orange. The DIII disulfide bond is depicted in yellow. 	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Figure 3: DIII amino acid sequence alignment. The sequence and secondary structure 
of DIII from the DENV-2 (strain 16681) E protein are aligned with those for DENV-1 
(strain 16007), DENV-3 (strain 16652), DENV-4 (strain 1036), and WNV (New York 
1999). The secondary structure of DENV-2 E DIII residues 294 to 395 (RCSB entry 
1OAN) was predicted by DSSP 94. The results of yeast surface display epitope mapping 
are highlighted, with DENV-2 residues recognized primarily by type-specific MAbs 
colored magenta, subcomplex-specific residues colored green, and cross-reactive residues 
colored orange. The residues contacted by E16 on WNV DIII, as determined by 
crystallography, are colored blue 46, with black asterisks denoting residues identified by 
yeast display 26. Colored asterisks denote DENV-2 residues that are recognized by 
multiple classes of antibodies. For example, G304Y mutation resulted in a loss of binding 
of all type- and subcomplex-specific MAbs and a single cross-reactive MAb. 	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Figure 4: DIII A-strand epitope. The structure of DENV-2 DIII is shown, with 
identification of binding sites of subcomplex-specific neutralizing antibodies. (A and B) 
Structure of DENV DIII, with amino acid residues that significantly affect binding of 
subcomplex-specific neutralizing MAbs 1A1D-2 (A) and 9D12 (B) marked in orange. 
(C) Yeast display epitope residues (red) for the 9D12 MAb were mapped onto the 
pseudoatomic model of the mature DENV-2 virion. Virions are depicted as described in 
the legend to Fig. 2. 	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Figure 5: DIII AB loop epitope. The structure of DENV-2 DIII is shown, with 
identification of binding sites of poorly neutralizing antibodies. (A and B) Structure of 
DENV DIII, with amino acid residues that significantly affect binding of the poorly 
neutralizing MAbs E111 (A) and 13D4-1 (B) marked in orange. (C) Yeast display 
epitope residues (red) for the 13D4-1 MAb were mapped onto the pseudoatomic model of 
the mature DENV-2 virion. Virions are depicted as described in the legend to Fig. 2. Note 
that the 13D4-1 epitope is poorly accessible on the virion compared to the 1F1 (Fig. 2C) 
and 9D12 (Fig. 4C) epitopes. 	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Figure 6: Mapping of MAb epitopes onto the DENV-2 E protein dimer. The yeast 
display epitope residues (in red) for the type-specific 1F1 (A), subcomplex-specific 9D12 
(B), and cross-reactive 13D4-1 (C) MAbs were rendered on the crystal structure of the 
DENV-2 E protein dimer 9 and are shown in side view, with the bottom side facing the 
viral lipid membrane. 	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3.1 Abstract 
 We recently described a therapeutic monoclonal antibody (MAb E106) that maps 
to domain III (DIII) on the viral envelope (E) protein and potently neutralizes infection of 
strains corresponding to all five Dengue virus type 1 (DENV-1) genotypes. Here, to 
acquire a more complete molecular understanding of the potency and specificity of this 
MAb, we solved the crystal structure of E106 Fab in complex with DIII to 2.6 Å 
resolution. Structural analysis of this complex revealed a novel epitope that overlaps two 
previously identified binding sites for neutralizing anti-DENV MAbs along an interface 
of the lateral ridge and A-strand of DIII. Despite its strong inhibitory activity in vitro and 
in vivo, surface plasmon resonance and isothermal calorimetry established a micromolar 
monovalent affinity of E106 Fab for DENV-1 DIII or E ectodomain. Consistent with 
biophysical studies, Fab fragments of E106 bound poorly to DENV-1 virions and failed 
to neutralize infection efficiently. As E106 MAb binding and neutralization was largely 
temperature-independent, the composite lateral ridge and A-strand epitope on DIII is 
likely readily accessible, a conclusion supported by docking models of E106 Fab 
fragment bound to the DENV virion. Unexpectedly, our structural, biophysical, and 
virological data suggest that our most inhibitory DENV-1 MAb requires bivalent binding 
to neutralize infection. 
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3.3 Author Summary 
Dengue virus (DENV) is an important human pathogen that is transmitted by 
mosquitoes. In recent years, the number and severity of DENV human infections have 
increased. At present, there is no approved vaccine or therapy. Neutralizing antibodies 
have the potential to protect against DENV infection in humans. One recently described 
antibody (E106) protects mice against infection of DENV-1 when administered before or 
after virus infection. Because of these results, we investigated the mechanism of action of 
E106 using a combination of structural and functional approaches. E106 engaged a novel 
epitope on domain III of the viral envelope protein, which was a composite of the 
adjacent lateral ridge and A-strand epitopes. Somewhat surprisingly, E106 Fab fragments 
were ineffective at neutralizing virus; this was explained by an inability of E106 Fab 
fragments to bind virus particles with adequate affinity. Based on these and other studies, 
our results suggest that neutralization by E106, our most potently inhibitory and 
protective anti-DENV-1 MAb, requires bivalent binding of both arms of the antibody to 
DENV-1 virions. Thus, strategies that favor the selection of neutralizing antibodies that 
neutralize by bivalent binding mechanisms could augment the potency of inhibitory 
humoral responses against DENV and other flaviviruses. 
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3.4 Introduction 
 Dengue virus (DENV) infection in humans can cause symptoms in humans 
ranging from a mild febrile illness (Dengue Fever, DF) to a more severe hemorrhagic 
fever (DHF) and life-threatening dengue shock syndrome (DSS). Currently, it is 
estimated that DENV infects ~50 to 100 million people per year resulting in ~250,000 to 
500,000 cases of DHF/DSS, with over 2.5 billion people are at risk for DENV infection 1, 
with approximately 50 million cases of DF and 250,000 cases of DHF annually. 
Currently, there is no antiviral therapy or vaccine approved for use in humans. DENV 
belongs to the Flaviviridae family of medically important postitive stranded RNA 
viruses, which include other human pathogens such as yellow fever (YFV), West Nile 
(WNV) Japanese encephalitis (JEV), and tick-borne encephalitis (TBEV) viruses. Within 
the DENV serocomplex, there is significant diversity, including four serotypes (DENV-1, 
DENV-2, DENV-3, and DENV-4) that differ at the amino acid level of the envelope (E) 
protein by 25 to 40 percent and multiple genotypes within a serotype that vary up to ~3% 
2,3. 
 The 10.7-kb RNA genome of DENV encodes for three structural proteins (capsid 
(C), precursor membrane or membrane (prM/M), and E protein) and seven nonstructural 
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5). The mature DENV virion is 
an ~500 Å particle composed of a nucleocapsid (RNA + capsid) associated with the 
positive-sense RNA genome that is surrounded by a lipid bilayer with 180 copies of the 
M and E proteins inserted. DENV enters cells via clathrin-dependent, receptor-mediated 
endocytosis involving an unknown surface receptor and partially characterized 
attachment and entry factors including DC-SIGN, and the mannose receptor 4–6. The 
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acidic environment of the early endosome triggers a conformational rearrangement in the 
E protein, exposing the fusion peptide, which inserts into endosomal membranes 
allowing for release of the infectious RNA genome into the cytosol. Viral RNA is 
translated, replicated and then packaged on ER-derived membranes into immature 
particles that display 180 prM-E heterodimers arranged into 60 trimeric spikes of ~ 600 Å 
diameter 7. During transit through the trans-Golgi network (TGN), the acidic pH of this 
compartment induces a rearrangement of the prM-E heterodimers into 90 E protein 
homodimers, which exposes a furin-like protease cleavage site on prM 8. Although 
cleavage occurs in the TGN, the pr peptide remains associated with E until secretion into 
the extracellular space, where the mildly alkaline pH promotes its release and formation 
of the fusion competent mature virion 9.  
 A humoral response against DENV infection is believed to contribute to lifelong 
immunity against challenge by the homologous serotype. In comparison, protection 
against heterologous DENV serotype infection is transient (< 6 months) 10 allowing re-
infection to occur with a distinct serotype in hyper-endemic areas of the world. Recent 
estimates suggest that greater than 90% of DHF/DSS cases occur during secondary 
DENV infection with a heterologous DENV serotype, possibly because sub-neutralizing 
amounts of cross-reactive antibody facilitate viral entry in myeloid cells expressing Fc-γ 
receptors, a phenomenon termed antibody-dependent enhancement of infection (ADE) 11. 
Antibody-mediated protection against homologous DENV infection correlates with a 
neutralizing antibody response directed predominantly against the viral E protein 12. The 
ectodomain of the viral E protein is comprised of three domains: domain I (DI), a central 
eight-stranded β-barrel (domain I) that connects domain II (DII), which contains the 
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fusion peptide at its distal end, and domain III (DIII), an immunoglobulin-like fold that 
putatively mediates virus attachment to the cell surface 11–14. Although neutralizing 
antibodies have been mapped to all three domains of the E protein, many potently 
inhibitory anti-DENV mouse MAbs map to DIII 15–22, specifically to the lateral ridge and 
A-strand epitopes, respectively. The most potently inhibitory MAbs that block flavivirus 
infection, function at a post-attachment state, by likely preventing E protein dimer-to-
trimer transitions that are required for viral fusion 12,18,23,24.  
 We recently described a therapeutic MAb DENV1-E106 (hereafter termed E106), 
which neutralized infection efficiently of strains corresponding to all five DENV-1 
genotypes. To better understand the basis for the potency and specificity of this MAb, we 
solved the crystal structure of the complex consisting of E106 Fab in complex with 
DENV-1 E DIII. Our analysis reveals a novel epitope that is a composite of two 
previously identified DIII epitopes with a surprisingly small buried interface compared to 
typical antibody-antigen interactions, including other neutralizing anti-flavivirus 
antibodies. Biophysical studies showed an unexpectedly weak micromolar monovalent 
affinity of E106 Fab fragment binding to E proteins, which was confirmed in virological 
experiments. Our structural results are most consistent with a model in which a potently 
inhibitory and therapeutic DENV-1 MAb requires bivalent binding to the surface of an 
individual virion to neutralize infection. 
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3.5 Results 
Crystal structure of E106 Fab fragment in complex with DENV-1 E DIII. 
E106 is a sub-complex specific therapeutic MAb that binds to both DENV-1 and DENV-
4 and neutralizes infection of all five DENV-1 genotypes efficiently (EC50 ranging from 
1 to 50 ng/ml) 20. To elucidate the basis for the potency and specificity of this MAb we 
solved the co-crystal structure of E106 Fab fragments bound to DIII to 2.6 Å resolution 
(Table 1). The crystal structure revealed contact residues from the A-strand (K307, E309, 
K310), the end of the B-strand (K325, Y326), and the connecting BC (E327, T329, 
D330) and DE (K361, E362) loops (Figure 1A and Table 2); these results were 
consistent with prior functional mapping data by yeast surface display, which implicated 
several of these residues (K310, T329, D330, K361 and E362) as potential contact sites 
20. Overall, the contact residues contributed 20 van der Waal interactions, 16 hydrogen 
bonds, and 6 electrostatic interactions to the interface (Table 2). The E106 structural 
footprint thus represents a unique composite of previously identified DIII-specific 
neutralizing epitopes on flaviviruses including the lateral ridge (N-terminal region, BC, 
DE and FG loops) 15,25 and A-strand epitopes 24,25. DENV-1 DIII was engaged by 10 
heavy chain residues from CDR1 (I30, G31, and Y33), CDR2 (N52, E50, and R54), and 
CDR3 (R99, I100, W102, and N101) loops through 17 van der Waal interactions, 11 
hydrogen bonds, and one electrostatic interaction (Figure 1B and Table 2). In addition, 
residues from the light chain CDR1 (D30 and D32), CDR2 (E50), and CDR3 (S91, D92, 
and L94) loops contributed 3 van der Waal interactions, 5 hydrogen bonds and, 5 
electrostatic interactions (Table 2).  
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 A comparison of the DIII structure in complex with Fab versus unbound DIII 
reveals small conformational changes, consistent with a root mean square displacement 
of 0.9 Å in the α−carbons over 98 residues. Of the DIII residues that directly interact with 
E106 Fab, the greatest movements in a-carbon positions involved residue T329 (1.1 Å); 
this was significant because a recently identified E106 MAb neutralization escape mutant 
showed a TA amino acid change at position 329 (Figure 1B) 26. Smaller amino acid 
transitions were observed for the other nine contact residues, K310 (0.7 Å), E309 (0.6 Å), 
E327 (0.6 Å) and Y326 (0.5 Å), K307 (0.4 Å), D330 (0.4 Å), K361 (0.4 Å), E362 (0.4 
Å), and K325 (0.2 Å). Residues in the FG loop, although they did not directly interacting 
with Fab in the crystal structure showed relatively large conformational changes in the 
complex, specifically, E384 (1.6 Å), G383 (1.3 Å), and K385 (0.8 Å); this finding is 
consistent with our yeast epitope mapping data, which suggested these amino acids 
contributed functionally to E106 binding to DIII 20. 
 The E106 structural epitope on DIII was characterized by a high shape 
complementarity score (Sc = 0.79, with a perfect fit being 1) 27, which is greater than 
typical antibody-antigen interactions (Sc = 0.64-0.68) 27 and most anti-flavivirus MAb-E 
protein interactions (Table 3). The combined surface area buried by the DIII-E106 Fab 
complex was  ~1,264 Å2 (Figure 1C and Table 3) 28 which is less than most antibody-
antigen (1,400 – 2,300 Å2) 29,30 and anti-flavivirus MAb-E protein interactions (Table 3). 
Much (~ 70%) of the DIII-E106 Fab interface was contributed by the heavy chain 
(Figure 1C), with a combined buried surface of 879 Å2 (404 Å2 of the heavy chain and 
475 Å2 of domain III). The light chain contributed the remaining buried surface (186 Å2 
of the light chain, 199 Å2 of domain III).  
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 All ten crystallographic contact residues were conserved in the five DENV-1 
genotypes (K361 is replaced by the conservative substitution R361 in genotype 5 strains); 
this likely explains why E106 neutralized infection of all five DENV-1 genotypes 
efficiently (Figure 2A and 2B), and 20. In comparison, only one of the ten contact 
residues (Y326) was conserved in DENV-2, DENV-3, DENV-4, or WNV, a finding that 
is consistent with virological data showing that E106 MAb neutralizes infection in a 
serotype-specific manner 20.  
E106 binds DIII with micromolar monovalent affinity. To determine the 
significance of the small buried interface of our E106-DIII complex, we investigated the 
dynamics of E106 Fab binding to DENV-1 DIII by surface plasmon resonance (SPR). 
Increasing concentrations of purified, recombinant DENV-1 DIII monomer were flowed 
over immobilized E106 Fab fragments (Figure 3A). Equilibrium analysis surprisingly 
revealed a micromolar affinity (28.7 μM ± 1.2) for this interaction. The low monovalent 
affinity also was observed after binding of the ectodomain of DENV-1 E (DI-DII-DIII) to 
E106 Fab fragments; thus, DI and DII of E did not contribute additional contacts that 
strengthen binding in this assay (data not shown). A similar result was observed with 
binding by SPR in which increasing concentrations of DENV-1-DIII monomer was 
flowed over immobilized E106 MAb in the solid phase (42.0 μM ± 2.8), Figure 3B). As 
an independent measurement of affinity, we performed isothermal titration calorimetry. 
Regardless of the experimental sequence (whether DENV-1 DIII (Figure 3C) or E106 
Fab (data not shown) was injected into the cell), a micromolar affinity interaction was 
calculated.  
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E106 Fab fragments bind to and neutralize DENV-1 poorly. The micromolar 
monovalent affinity of the highly therapeutic E106 antibody was unanticipated 29; in 
comparison, our therapeutic DIII-specific anti-WNV MAb E16 had a monovalent affinity 
of 3.4 nM 31. Because of this, we hypothesized that while E106 MAb potently inhibited 
DENV-1 infection, Fab fragments should lack this activity. To assess this, we compared 
the ability of Fab and intact IgG from three different DIII-specific DENV-1 neutralizing 
MAbs (DENV1-E99 (E99), DENV1-E103 (E103), and E106) to inhibit infection. While 
monovalent Fab fragments of E99 and E103, which respectively map to the A-strand and 
lateral ridge epitopes, showed moderate and expected reductions (588- and 114-fold 
increase in PRNT50) in neutralization potency compared to the intact bivalent IgG, Fab 
fragments of E106 Fab showed a remarkable loss of inhibitory activity (18,150-fold 
increase in PRNT50) when compared to intact IgG (Figure 4A and B and Table 4).  
 To confirm this observation, we performed a direct virion-binding assay by 
ELISA. DENV-1 virions (strain 16007, 2.5 x 105 PFU) were captured with the anti-fusion 
loop antibody WNV E60 and then detected with biotinylated Fab fragments or intact IgG 
of E99, E103, or E106. Notably, the amount of virus detected with E106 IgG was 
indistinguishable from E99 or E103 IgG (Figure 4C). In comparison, Fab fragments of 
E106 bound virions to a significantly lower level than those derived from E99 and E103 
(Figure 4D). Thus, the virus binding results recapitulates the neutralization data and are 
consistent with the biophysical measurements: monovalent binding by E106 Fab 
fragments are surprisingly inefficient given the potent inhibitory and protective activity 
of intact IgG. 
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Neutralization by E106 MAb is largely time- and temperature-independent. 
A previously described DENV-2 neutralizing MAb (1A1D-2) that mapped to the A-
strand epitope of DIII required higher temperatures for binding because the epitope was 
partially inaccessible under steady-state conditions and required a conformational 
rearrangement of the E glycoproteins for exposure 25. This concept of different 
conformational ensembles of the virion affecting MAb neutralization has been 
corroborated independently for WNV, DENV, and Hepatitis C virus in studies that varied 
the temperature and time of pre-incubation and determined their effects on neutralization 
32,33. To assess whether the E106 epitope was readily accessible, time and temperature of 
incubation studies were performed using DENV-1 reporter virus particles (RVP) and Raji 
cells that ectopically express the DENV attachment receptor, DC-SIGN 34. Serial 
dilutions of E106 MAb were incubated with DENV-1 RVP for one hour at 4°C, 37°C, or 
40°C prior to infection. To ensure that only the pre-incubation temperature was being 
evaluated, virus-MAb mixtures subsequently were bound to cells at 4°C, and unbound 
virus and MAb were washed away prior to raising the temperature to 37°C for infection. 
Notably, neutralization by E106 MAb was unaffected by a one-hour incubation at 
different temperatures (Figure 5A).  
 Increasing the pre-incubation period also can enhance MAb potency, possibly due 
to changes in epitope accessibility as the virus samples alternate ensembles of 
conformations over time 32. To assess whether longer incubation times augmented E106 
neutralization, serial dilutions of MAb were incubated for five hours at 4°C, 37°C, or 
40°C prior to infection. In this case, a relatively small increase in neutralization was 
observed in samples incubated for five hours at 37°C or 40°C (Figure 5B). These 
	    90 
experiments suggest that the E106 MAb epitope is largely accessible under steady-state 
conditions and does not require alternative conformational ensembles to expose its 
epitope and facilitate antibody binding and neutralization. 
E106 MAb neutralizes infection at a post-attachment state. Inhibitory MAbs 
may neutralize DENV infection by preventing virus attachment, internalization and/or 
fusion. To begin to define the mechanism by which E106 blocks infection, we performed 
pre- and post-attachment neutralization assays 18,35,36. E106 MAb was incubated with 
DENV-1 before or after virus binding to BHK21-15 cells, and infection was measured by 
the plaque reduction assay. Notably, E106 neutralized infection when premixed with the 
virus before cell attachment or when added after the virus had attached to the cell surface 
(Figure 5C). Thus, E106 has the capacity to neutralize infection after virus attachment, 
which is consistent with data from several other potently neutralizing DIII-specific 
antibodies against flaviviruses 18,23,36,37. 
Modeling of E106 binding to E protein and virus. To gain further insight into 
the structural basis of neutralization, we docked our E106 Fab–DIII complex onto the 
structures of the pre-fusion DENV E protein dimer (Figure 6A) and post-fusion trimer 
(Figure 6B), and assessed the potential for bivalent binding. The E106 epitope was 
readily accessible on each of the individual E monomers within the pre-fusion dimer or 
post-fusion trimer. Adjacent epitopes were separated by ~140 Å in the pre-fusion dimer 
and ~163 Å in the post-fusion trimer, however intact E106 antibody is unlikely to 
recognize the isolated oligomers within a single dimeric or trimeric unit bivalently 
because the CH1 Fab termini spatially were too far apart (~ 224 Å and 182 Å, 
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respectively), and beyond the reach of antibodies of the IgG subclass (117 to 134 ± 40 Å) 
38. 
 To understand how E106 recognizes DIII in the context of the mature virus, we 
docked our structure onto the cryo-electron-microscopy-derived pseudo-atomic model of 
the intact DENV virion 38,39 (Figure 6C and D). The 180 E protein monomers form 
head-to-tail dimers on the mature DENV virion surface, and are arranged in three distinct 
chemical environments around two-, three- and five-fold axes of symmetry 39. The E106 
structural epitope was readily accessible on each of the 30 two-fold symmetry axes. 
Docking of E106 Fab fragment on the two-fold axis of the mature virion showed that the 
closest pairs of Fab fragments were 85 Å and 137 Å apart, and thus, within the reach of a 
single IgG molecule 39. Of the 30 two-fold dimers on the mature virion, up to 24 may be 
occupied by intact IgG molecules. Similarly, the E106 structural epitope was readily 
accessible on each of the 20 three-fold symmetry axes of the mature virion. Despite their 
sufficient proximity (51.9 Å), the angle of modeled Fab interaction likely occludes 
bivalent binding by IgG. However, bivalent binding across the two- and three-fold axes 
of symmetry (to E proteins in adjacent symmetry groups) may be accommodated, as both 
the distance (61 to 116 Å) and the angle of engagement appear favorable for bivalent 
binding. At the five-fold axes, as seen with other anti-flavivirus DIII neutralizing MAbs 
15, in silico docking showed that the obtuse angle of E106 Fab engagement creates light 
chain clashes between adjacent DIII, likely making these 60 sites unavailable for either 
monovalent or bivalent binding (Figure 6D). Our modeling data predicts a maximum 
occupancy on the mature virion of 120 E106 Fab binding sites. However, since DENV1 
E106 Fab binding inefficiently inhibits infection, we propose that neutralization by 
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DENV1 E106 MAb occurs largely through bivalent binding on single virions. In one 
possible arrangement, a single virion may be bound at all 60 two-fold symmetry axes by 
30 bivalent MAbs (Figure 6E).   
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3.6 Discussion 
 Structural analyses of Fab-antigen complexes have contributed greatly to our 
understanding of the mechanistic correlates of virus neutralization. Such studies have 
identified epitopes on the E protein of flaviviruses as the target of neutralizing antibodies 
including the lateral ridge of WNV and JEV (WNV E16 37 JEV E3.3 40, the A-strand of 
DENV (DENV-2 1A1D-2 25 and 4E11 22) , the conserved AB loop of DENV 41, the 
fusion loop of WNV and DENV (WNV E53) 42, a DI epitope of DENV-4 (5H2) 24, and a 
complex epitope present only in the intact WNV virion (WNV CR4354) 43. Here, we 
described a composite epitope, comprised of regions of the lateral ridge and A-strand of 
DIII that is the targeted by the therapeutic MAb E106. DIII residues contacted by E106 
were highly conserved among DENV-1 genotypes but variable in other DENV serotypes.  
Consistent with this, E106 potently neutralized all five DENV-1 genotypes, but not other 
DENV serotypes nor WNV, another flavivirus 20. Thus, our structural analysis provides 
an explanation for the type-specific pattern of neutralization by E106. These results are 
consistent with the observation that the DIII lateral ridge epitope is relatively poorly 
conserved among flaviviruses, and that antibodies mapping to this region are largely 
type-specific 37.  
 The E106-DIII complex was characterized by a surprisingly small buried 
interface, which correlated with an unexpectedly weak micromolar affinity, as 
determined both by SPR and ITC. We found no evidence for E106 binding to residues 
outside of DIII; consistent with this, neutralization escape studies only identified residues 
in DIII 26. Monovalent E106 Fab fragments poorly neutralized DENV-1 compared to 
intact E106 IgG, and this finding correlated with poor binding of Fab to whole virus. 
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Although our structural models suggest that E106 can readily bind the isolated pre-fusion 
dimer and post-fusion trimer and possibly prevent the 70° transition of DIII that is 
required for membrane fusion 31,43, the inability of E106 Fab fragments to effectively 
neutralize virus efficiently suggests against such a mechanism of neutralization. Rather, 
our data are more consistent with a mechanism of E106 neutralization that requires 
bivalent binding of E106 to a single virion, and cross-linking of E protein monomers in 
adjacent symmetry groups to prevent requisite E protein rearrangements during infection.  
 The measurement of micromolar monovalent affinity initially was surprising 
given that E106 is our most potently neutralizing anti-DENV-1 MAb or even anti-
flavivirus MAB  (EC50 of 0.6 ng/ml against parent DENV-1 strain 16007), which is at 
least 10-fold more potent than our well-characterized DIII-lateral ridge-specific 
therapeutic MAb (E16) against WNV 31,37. Is there a correlation between neutralization 
potency and E106 bivalent binding to single virions? The icosahedral arrangement of the 
E protein on the mature DENV virion displays 180 copies of the envelope protein, 120 of 
which should be accessible to the E106 MAb. Our in silico modelling studies predict that 
up to 60 of these sites are available for bivalent engagement by 30 intact E106 IgG. Since 
monovalent binding is insufficient for neutralization, bivalent binding to single virions 
could neutralize infection by inhibiting an essential stage of the virus lifecycle 
(attachment, entry, or fusion). Alternatively, bivalent binding across virions could 
neutralize DENV infection by aggregating virus. Our post-attachment studies suggest that 
E106 MAb is capable of neutralizing infection even after virus attaches to the cell 
surface. Aggregation appears less likely because the neutralization curves did not show a 
characteristic triphasic dose-response curve that is reported in inhibition studies 
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describing antibody-virus aggregation 44. We favor a model in which bivalent binding of 
E106 stabilizes and/or crosslinks one or more E protein monomers in different symmetry 
groups, and thus prevents radial expansion and rearrangement that is requisite for fusion 
of viral and host endosomal membranes 45,46.  
 E106 is one of very few MAbs that have been suggested to or shown to require 
bivalent binding for virus neutralization 47–49, and the first one directed against a 
flavivirus. While antibodies are multivalent, with the potential to bind to virus particles 
with high avidity, the relatively small number of bivalent binding MAbs described to date 
may be attributed to the following: (i) the limited number of epitopes displayed on a 
single virion; (ii) the position and orientation of epitopes that are beyond the reach of a 
bivalent MAb as limited by torsional flexibility of its hinge; (iii) post-translational 
modification (e.g. N-linked glycans) of virions that may sterically hinder bivalent MAb 
engagement; (iv) immunization protocols that rely on isolated recombinant envelope 
proteins, rather than envelope proteins in the structurally unique form of the whole virus; 
and (v) assays that do not screen for bivalent neutralizing MAbs. While some antibodies 
against HIV have been described as bivalent, many actually are bispecific, with each arm 
having the ability to binding distinct epitopes 50. This is likely due to the paucity of 
trimeric spikes on the surface of the virus (~14) and their irregular spacing 51. The 
isolation of a bivalent, neutralizing anti-flavivirus MAb in general may be favored by the 
regular icosahedral arrangement of the 180 copies of the E protein, which is preserved as 
it undergoes ensembles of conformations during dynamic motion 25. Together, these 
factors may create an ideal landscape for facilitating bivalent MAb engagement.   
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 Bivalent engagement of the virion by antibodies could be an important concept 
for DENV vaccine development. Immunity against DENV may not be optimally 
achieved using a subunit vaccine approach. For example, individual E proteins are 
unlikely to induce an antibody response that requires bivalent binding. Analogously, the 
human MAb WNV-CR4354, which isolated from a convalescent patient after WNV 
infection 36,52, binds a complex epitope at two independent positions on adjacent E 
protein monomers in different symmetry groups, which is only present on an intact WNV 
particle 43. Given that DENV-1 E106 MAb was our most potent and therapeutic anti-
DENV-1 MAb of more than 100 isolated, strategies that enhance the likelihood of 
generating neutralizing antibodies that function via bivalent binding mechanisms could 
improve the potency of inhibitory humoral responses against DENV and other 
flaviviruses.  
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3.7 Materials and Methods 
E106 Fab-DIII crystal structure determination. DENV-1 DIII (residues 293 to 
399 of the E protein of strain 16007) was expressed in bacteria and re-folded oxidatively 
from isolated inclusion bodies as described previously 20. Antibody–antigen complexes 
were formed by mixing papain-generated E106 Fab fragments with DIII, and purified by 
gel filtration chromatography. The complex of DENV1 DIII and E106 Fab at a ratio of 
1:1.2 was crystallized by the hanging drop vapor diffusion method at a total protein 
concentration of 14 mg/mL in a solution of 22% PEG 6,000, and 0.1 M MES pH 5.0 
(final pH 5.7). Crystals (in 1 mL crystallization drops) were slowly cryoprotected by the 
addition of 0.2 μL aliquots of cryobuffer (in 23.5% PEG 6,000, 0.1 M MES pH 5.0, final 
pH 5.7, and 20% glycerol), then transferred to a fresh drop of cryobuffer and rapidly 
cooled in liquid nitrogen. X-ray diffraction data were collected at ALS beamline 4.2.2 
(Lawrence Berkeley Laboratories) at a wavelength of 0.976 Å at 100K with a CCD 
detector, and indexed and scaled in HKL2000 53. The crystals diffracted to 2.6 Å 
resolution and belonged to the space group P212121 with unit cell dimensions of a = 82.7 
Å, b = 91.8 Å, c = 92.6 Å, with one E106 Fab-DIII complex per asymmetric unit. 
Crystallographic phasing was obtained by molecular replacement using the program 
PHASER 54 and the coordinates of DENV1 DIII (Protein Data Bank (PDB) 3EGP) and 
the Fab fragment of CTM01 IgG (PDB 1AD9). Iterative model building and refinement 
was performed using COOT 55 and Refmac [50]. The final structure was refined to  Rcryst 
= 20.4 % and Rfree = 25.3%. The final model includes DENV-1 DIII amino acid residues 
297 to 394, E106 heavy chain residues 1 to 218 (excluding residues 133 to 136 due to 
poor electron density), and light chain residues 1 to 213.  
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Fab fragmentation and neutralization analysis.  Fab fragments of DENV1-
E99, DENV1-E103, and E106 were prepared using immobilized papain resin according 
to the manufacturer’s instructions (Pierce). MAb (5 to 10 mg) was digested for 18 hours 
at 37°C, and passed over a protein A agarose resin to remove Fc fragments and 
undigested MAb. Fab fragments were purified subsequently on a S-75 size exclusion 
chromatography column equilibrated in 20mM HEPES pH 7.4 and 150mM NaCl. Plaque 
reduction neutralization titer (PRNT) and pre- and post-attachment neutralization assays 
were performed with DENV-1 strain 16007 on Vero cells as previously described 18,36 
For the pre-attachment assay, 100 PFU of DENV-1 16007 virus and serial dilutions of 
MAbs were mixed in pre-chilled DMEM and incubated at 4ºC for one hour. Virion-MAb 
complexes were added to pre-chilled Vero cells for and incubated for one hour. Cells 
were then washed three times with chilled medium and warmed to 37ºC before 
measurement of PRNT determination. In the post-attachment assay, cells were pre-chilled 
at 4ºC and infected with 100 PFU of DENV-1 16007 virus at 4ºC for one hour. Cells 
were then washed three times with pre-chilled medium and serial dilutions of MAbs were 
added. Virion-MAb complexes on the surface of the cell were allowed to form for one 
hour at 4ºC, followed by three washes with chilled medium. Cells were then warmed to 
37ºC before infection proceeded and PRNT were determined. 
Surface plasmon resonance and isothermal titration calorimetry. Monovalent 
antibody affinity analysis was performed using SPR (BIAcore T100, GE Company) or 
isothermal titration calorimetry (ITC). For SPR, binding curves and kinetic analyses were 
obtained as follows: E106 MAb or Fab was immobilized at low concentrations (~500 
Response Units) to a CM5 chip (GE) using amine-coupling chemistry. Bacterially-
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expressed DIII (residues 293-399 of strain 16007) or insect cell-expressed E ectodomain 
(amino acids 1-397) of DENV1 (strain 16007) were injected at a flow rate of 65 ml/min 
at concentrations ranging from 0.5 μM to 600 μM for three minutes to saturate binding 
and then allowed to dissociate for seven minutes. The half-life of the monovalent 
interaction was short and did not require additional regeneration of the chip surface in 
preparation for the next DIII injection. Curves were analyzed by a steady-state fit for a 
1:1 interaction. Alternatively, 500 response units (RU) of DIII was immobilized onto a 
CM5 chip and E106 Fab fragments were injected to saturation. ITC experiments were 
performed on a VP-ITC instrument (Microcal) at 10°C in 50 mM HEPES, pH 7.5 and 
100 mM NaCl.  4 to 8 mL of DENV1-DIII (90 to 110 mM ) was injected into 1.4 mL of 
E106 Fab (6 to 7 mM) over a total of 36 injections In an alternative setup, 58 mM of 
E106 Fab was injected into 6 mM of DENV1-DIII in the sample cell. The titration data 
were integrated and normalized in Origin (Microcal) to determine the reaction 
stoichiometry, n, and equilibrium constant Ka (=K-1d). 
DENV-1 capture ELISA. Binding of intact MAbs of Fab fragments (DENV1-
E99, DENV1-E103, and E106) to DENV-1 virions (strain 16007) was detected by 
capture ELISA as previously described 20,36 with slight modifications. Briefly, humanized 
anti-WNV E60 MAb (flavivirus cross-reactive neutralizing mouse IgG2a) was coated at 
2 mg/ml on MaxiSorp (Nunc) polystyrene 96-well microtiter plates in a sodium carbonate 
(pH 9.3) buffer. Plates were washed three times in wash buffer (PBS with 0.02% Tween 
20) and blocked for one hour at 37°C with blocking buffer (DMEM with 10% FBS). 
DENV-1 virions (2.5 × 105 PFU) diluted in DMEM with 10% heat-inactivated FBS were 
captured on plates coated with anti-DENV-1 MAb or Fab fragments for two hours at 
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37oC. Wells were washed thrice with blocking buffer and DENV-1 MAb or biotinylated 
Fab was then added at 100 mg/ml and 4-fold serial dilutions to duplicate wells and 
incubated for one hour at 37oC. Plates were washed again five times and then incubated 
sequentially with horseradish peroxidase (HRP) -conjugated streptavidin (Vector 
Laboratories) or goat anti-mouse IgG-HRP (Sigma, St Louis, MO) and 
tetramethylbenzidine substrate (Dako). The reaction was stopped with the addition of 2 N 
H2SO4 to the medium, and emission (450 nm) was read using an iMark microplate reader 
(Bio-Rad).   
Time- and temperature-dependent neutralization of DENV-1. DENV-1 RVP 
were produced by genetic complementation of a WNV subgenomic replicon with the 
structural genes of DENV1 in trans as described previously 32,34. Plasmids expressing the 
prM-E genes and the capsid (C) gene of DENV-1 (strain 16007) were transfected into 
BHK21-15 cells that stably propagate a WNV replicon expressing GFP. DENV-1 RVP 
were incubated with serial dilutions of MAb under conditions of antibody excess at 4oC, 
37oC, or 40oC for one or five hours. Subsequently, MAb-RVP mixtures were added to 
Raji-DCSIGNR cells and incubated at 37ºC for 48 hours. Infected cells were assayed for 
GFP expression using a BD FACSCalibur flow cytometer as described 32.  
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Table 1. Data collection and refinement statisticsa Wavelength	  (Å)	   	   	   	   0.976	  Resolution	  range	  	  (Å)	   	   	   20	  –	  2.45	  Temperature	  (K)	   	   	   100	  Number	  of	  observed	  reflections	   	   166	  322	  Unique	  reflections	   	   	   26	  014	  Redundancy	   	   	   	   6.4	  (4.8)	  I/σI	   	   	   	   	   19.8	  (2.1)	  
Rmergeb	   	   	   	   0.083	  (0.546)	  Completeness	  (%)	   	   	   99.5	  (95.9)	   	   	   	   	  Spacegroup	   	   	   	   P212121	  Cell	  dimensions	   	   	   	   a=82.7	  Å,	  b=	  91.8	  Å,	  c=92.6	  Å	  	   	   	   	   	   α=β=γ=90°	   	   	  
Refinement	  statistics	  High	  resolution	  limit	  (Å)	  	  	   2.6	  No.	  of	  reflections/No.	  in	  Rfree	   	   21052/1134	  Rcryst/Rfreec(%)	   	   	   	   20.4/	  25.3	  No.	  atoms	  protein/water	  	   4165/126	  <B>	  protein	  (Å2)	  	   	   50.6	  <B>	  solvent	  (Å2)	  	   	   48.8	   	   	   	  Rmsd	  bond	  lengths	  (Å)	   	   	   0.008	   	   	  Rmsd	  bond	  angles	  (°)	   	   	   1.13	  Ramachandran	  violations	  Most	  favoured	   	   	   	   97.5%	  Allowed	  	   	   	   2.3%	  Disallowed	   	   	   	   0.2%	  Molprobity	  scored	   	   	   1.8	  (99th	  percentile)	  Molprobity	  clash	  score	   	   	   6.6	  (99th	  percentile)	   	   	   	  
aNumbers	  in	  parentheses	  refer	  to	  the	  highest	  resolution	  shell	  (2.54	  -­‐	  2.45	  Å).	  
bRmerge	  =	  σ|I	  −	  <I>|/ σ	  <I>,	  where	  I	  is	  the	  intensity	  of	  each	  individual	  reflection.	  
cR	  =	  ∑(FP-­‐Fcalc)/	  ∑FP	  	  
dMolprobity	  score	  defined	  as	  0.42574	  *	  log(1+clashscore)	  +	  0.32996	  *	  log(1+max(0,pctRotOut-­‐1))	  +	  0.24979	  *	  log(1+max(0,100-­‐pctRamaFavored-­‐2))	  +	  0.5	  56	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Table 2. E106/DENV1-DIII interface 
 
Van der Waals contactsa Direct hydrogen bondsb 
DIII E106 Distance(Å) DIII E106 Distance(Å) 
LysE307   (Cβ)       TrpH102  (CH2)     3.54 LysE325 (Nζ)       GluL50   (Oε1)     2.70 
LysE307   (Cβ)      TrpH102 (Cζ3)     3.79 LysE325 (Nζ) GluL50   (Oε2) 3.12 
LysE310   (Cε)      AspL30  (Cγ) 3.57   GluE327 (Oε1)   AsnH101 (N)  2.99 
LysE325   (Cε)       TrpH102  (Cε2)     3.73 GluE327 (Oε2)   TrpH102  (N) 2.77 
LysE325   (Cε)      TrpH102  (Cδ1)     3.80 ThrE329 (O) AsnH52  (Nδ2) 2.85 
TyrE326   (C)        TrpH102  (Cζ2)     3.80 ThrE329 (Oγ1)     IleH30     (O)       2.63 
GluE327   (Cβ)      TrpH102  (Cε2)     3.84 ThrE329 (Oγ1)     ArgH54   
(NH2) 
2.93 
GluE327   (Cβ)       TrpH102  (Cζ2)     3.65 ThrE329 (Oγ1)     ArgH54    (Nε)  3.20 
GluE327   (Cδ)       IleH100   (Cα)      3.79 LysE361 (Nζ)      GluH50    (Oε2)     2.92 
ThrE329   (Cβ)       AsnH52  (Cγ)      3.67 LysE361  (Nζ)       GluH50    (Oε1)     3.12 
ThrE329   
(Cγ2)      
TyrH33   (Cε1)    3.72 Indirect (solvent mediated) hydrogen bondsb 
ThrE329   
(Cγ2)      
TyrH33   (Cδ1)   3.60 DIII E106  
ThrE329   
(Cγ2)     
TyrH32   (C)     3.72 GluE309 (Oε1) AspL32 (Oδ1)  
ThrE329   
(Cγ2)      
TyrH32   (Cα)     3.76 GluE309 (Oε1) AspL92 (Oδ2)  
ThrE329   
(Cγ2)      
GlyH31   (C)       3.62 LysE325 (Nζ) SerL91 (O)  
AspE330  (Cβ)       ArgH54   (Cζ)      3.88 ThrE329 (N) GlyH31 (O)  
LysE361   (Cε)       TyrH33   (Cζ)      3.82 GluE362 (Oε1) ArgH99 (NH1)  
LysE361   (Cε)       TyrH33   (Cε1)    3.86 GluE362 (Oε2) ArgH99 (NH1)  
GluE362   (Cδ)      LeuL94   (Cδ1)  3.62 Electrostatic interactionsc 
GluE362   (Cδ)      LeuL94   (Cγ)  3.71 DIII E106 Distance(Å) 
   LysE310 
(Nζ)     
AspL30 
(Oδ1)    
3.79 
   LysE310 
(Nζ)     
AspL30 
(Oδ2)    
3.64    
   LysE325 (Nζ)     AspL32 
(Oδ1)    
3.40  
   LysE325 
(Nζ)    
AspL32 
(Oδ2)    
3.78    
   LysE325 (Nζ)    GluL50 (Oε2)   3.12    
   GluE362 (Oε1) ArgH99 (NH1) 3.87 
aVan der Waals interactions defined in Ligplot 57,  
bhydrogen bonds as defined by HBPLUS 58 in Ligplot and celectrostatic interactions as 
defined by PISA 28. 
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Table 3.  Comparison of Flavivirus DIII-Fab structural interfaces 
 

















E106 – DENV-1 E DIII 674 590 1 264 0.79 
E16 – WNV E DIII 789 810 1 599 0.76 
1A1D-2 – DENV-2 E 
DIII 
914 936 1 850 0.44-0.54 
E53 – WNV E 596 581 1 177 0.66 
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Table 4. PRNT50 values of DENV-1 Fabs versus MAbs 
 E99 E103 E106 
Fab (ng/mL) 6 473 ± 1 079 80.35 ± 10 10 890 ± 509 
MAb (ng/mL) 11 ± 3.1 0.7 ± 0.3 0.6 ± 0.3 
Fold reduction 588 114 18 150 
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Figure 1. Crystal structure of E106 Fab in complex with DENV1 E DIII. (A) The 
E106 Fab epitope on DENV-1 E DIII is contributed by residues in the A-strand (K307, 
E309, and K310), the end of the B-strand (K325 and Y326), and the connecting BC 
(E327, T329, and D330) and DE (K361 and E362) loops. The IgG fold of DENV-1 E 
DIII is shown in blue, and the quartenary structure of E106 Fab in green (heavy chain) 
and cyan (light chain). (B) Heavy chain residue W102 binds in a deep pocket contributed 
by the aliphatic groups of side chain DENV1 E DIII residues K307, K325, E327 and 
main chain of Y326 (top panel). Ball and stick representation of the molecular 
interactions involving the (in vitro) escape mutant T329A, in stereo (bottom panel). (C) 
Surface representation of E106 Fab (left) and DENV1 E DIII (right) highlighting residues 
making direct contacts in the complex (see Table S2). 
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Figure 2.  The E106 structural epitope in DENV-1 DIII is conserved in DENV-1 
genotypes but not DENV serotypes or WNV. (A) Sequence of DIII of DENV-1 aligned 
with that of DENV-2, -3, -4 and WNV highlighting the E106 structural epitope. Residues 
previously identified by yeast surface display mapping are shown in magenta [16]. For 
comparison, previously published WNV E16 and DENV-2 1A1D-2 MAb contact 
residues are marked with black and grey asterisks, respectively 25,37.  (B) The structural 
epitope on DENV1 DIII is shown in ribbon representation. Residues previously identified 
by yeast surface display mapping are shown in magenta. 
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 Figure 3. E106 MAb binds to DENV-1 DIII with micromolar affinity. Equilibrium 
analysis of DENV-1 DIII binding to (A) E106 Fab and (B) E106 MAb, as measured by 
SPR. Results are representative of two independent experiments. (C) ITC confirms a 
micromolar affinity of E106 Fab for DENV-1 DIII. KD = ~ 0.7 ± 2 μM – 7.3 μM ± 3 μM 
for the two independent experiments where DENV-1 DIII, in the syringe was injected 
into E106 Fab, in the cell.  
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Figure 4. The poor neutralizing activity of E106 Fab correlates with poor binding to 
intact DENV-1 virions. DENV-1 neutralization by E99, E103 and E106 (A) Fab 
fragments and (B) intact E99, E103 and E106 MAbs. Results are representative of two 
independent experiments. (C) E106 MAb binds DENV-1 virions to a similar extent as 
E99 and E103 MAbs. (D) E106 Fab fragment binding to DENV-1 virions is significantly 
lower than E99 and E103 Fab fragments. 
  




Figure 5. Functional characteristics of neutralization by E106 MAb. A-B. Time and 
temperature dependence. DENV-1 RVPs were pre-incubated with E106 MAb for one (A) 
or five hours (B) at three different temperatures (4 °C, 37 °C and 40 °C). Results are 
representative of two independent experiments. (C) Neutralization stage. To determine 
whether E106 neutralized infection before or after cellular attachment, BHK21-15 cells 
were prechilled to 4°C, and 102 PFU of DENV-1 (16007) was added to each well for one 
hour at 4°C. After extensive washing at 4°C, increasing concentrations of E106 MAb 
were added for one hour at 4°C, and the PRNT protocol was then completed (dashed 
lines, Post). In comparison, a standard preincubation PRNT with all steps performed at 
4°C is shown for reference (solid lines, Pre). Data shown are representative from three 
experiments performed in duplicate.  
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Figure 6. In silico modeling of E106 binding to DENV E protein and virus. E106 Fab 
was docked onto the (A) pre-fusion envelope dimer or (B) post-fusion envelope trimer. 
(C) E106 Fab epitope is highlighted in magenta on a DENV-1 model of the DENV-2 
cryo-electron microscopic reconstruction (PDB code 1P58). All atoms of the model are 
displayed, and their van der Waal radii are represented by spheres. (D) E106 Fab crystal 
structure docked onto the 2- and 3-fold axes of symmetry of the same virion 
reconstruction outlined above. For clarity, the Fab is not docked on the 5-fold epitope 
(shown in magenta) which is structured in a way that precludes Fab binding due to the 
angle at which Fab engages its DIII epitope. (E) Schematic showing one possible 
arrangement of E106 MAb bivalent binding to the lateral ridge plus A-strand epitope on a 
single virion. E106 MAb is represented by green (heavy chain) and cyan (light chain) 
spheres and its epitope at the two-, three- and five-fold symmetry axes of the icosahedral 
virion is colored magenta. In this model, two MAbs bind on the two-fold symmetry axes 
(each ~ 85 Å apart, solid line), and a third MAb binds across a two and three fold axis (~ 
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 We previously developed a panel of neutralizing monoclonal antibodies against 
Dengue virus (DENV)-1, of which few exhibited inhibitory activity against all DENV-1 
genotypes. This finding is consistent with reports observing variable neutralization of 
different DENV strains and genotypes using serum from individuals that experienced 
natural infection or immunization. Herein, we describe the crystal structures of DENV1-
E111 bound to a novel CC' loop epitope on domain III (DIII) of the E protein from two 
different DENV-1 genotypes. Docking of our structure onto the available cryo-electron 
microscopy models of DENV virions revealed that the DENV1-E111 epitope was 
inaccessible, suggesting that it recognizes an uncharacterized virus conformation. While 
the affinity of binding between DENV1-E111 and DIII varied by genotype, we observed 
limited correlation with inhibitory activity. Instead, our results support the conclusion 
that potent neutralization depends on genotype-dependent exposure of the CC’ loop 
epitope. These findings establish new structural complexity of the DENV virion, which 
may be relevant for the choice of DENV strain for induction or analysis of neutralizing 
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4.3 Author Summary 
 DENV are mosquito-transmitted members of the Flavivirus family of viruses and 
the cause of dengue fever and dengue hemorrhagic fever. The dengue serocomplex is 
comprised of four genetically related, but antigenically distinct viruses: DENV-1, -2, 3, 
and -4. Within each serotype, additional diversity is observed resulting in further 
subdivision of serotypes into genotypes. Infection with a given serotype is believed to 
induce durable levels of neutralizing antibodies that provide long-term immunity against 
secondary infection by a strain of the same serotype. However, recent studies suggest that 
some classes of neutralizing monoclonal and polyclonal antibodies however, fail to 
inhibit infection equivalently of all DENV genotypes within a serotype. DENV-1 E111 is 
an example of a monoclonal antibody that differentially neutralizes infection of DENV-1 
strains corresponding to distinct genotypes. We used structural and molecular approaches 
to determine that DENV-E111 binds to an epitope centered on the CC' loop in domain III 
(DIII) of the envelope protein. Docking of our structures onto the available models of 
DENV virions revealed that the DENV1-E111 epitope was inaccessible, suggesting that 
it recognizes an uncharacterized virus conformation. Although this CC' loop epitope had 
amino acid residues that varied among DENV-1 genotypes, mutational analysis showed 
that exchange of amino acids within the epitope among genotypes could not explain the 
differential inhibitory activity of the antibody. Rather, our studies suggest that the 
conformational ensemble of DENV virion structures differs in a genotype-dependent 





 Dengue viruses (DENV) are mosquito-borne viruses of the Flavivirus genus, 
which include other significant human pathogens such as West Nile virus (WNV), 
Japanese encephalitis virus, and yellow fever virus. Infection with DENV can cause 
symptoms in humans ranging from a mild febrile illness (Dengue Fever, DF) to a more 
severe hemorrhagic fever (DHF) and life-threatening dengue shock syndrome (DSS). 
Currently, it is estimated that DENV infects ~50 to 100 million people per year resulting 
in ~250,000 to 500,000 cases of DHF/DSS. DENV is considered a re-emerging pathogen 
with ~40% of the world’s population at risk for infection 
(http://www.who.int/mediacentre/factsheets/fs117/en/index.html). The four serotypes of 
DENV (DENV-1, DENV-2, DENV-3, and DENV-4) comprise a genetically related yet 
antigenically distinct serocomplex, varying from one another by 25 to 40% at the amino 
acid level. Each DENV serotype is further divided into genotypes, which can vary up to 
3% 1,2. Currently, there are no specific antiviral therapies or vaccines approved for use in 
humans, and treatment of severe disease remains supportive in a tertiary care setting. 
 The humoral response to DENV contributes to protection and also, paradoxically 
to the pathogenesis of severe disease. Infection with a given serotype is believed to 
induce durable levels of neutralizing antibodies that provide life-long immunity against 
secondary challenge by a strain of the same serotype 3. However, secondary infection 
with a heterologous serotype increases the relative risk of developing DHF and DSS 4. A 
favored hypothesis for this effect is that during secondary infection poorly neutralizing 
cross-reactive antibodies from the primary infection enhance infection of the 
heterologous virus in cells bearing Fc-γ receptors 5. Recent studies in non-human 
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primates and immunocompromised mice have confirmed that passive transfer of anti-
DENV monoclonal or polyclonal antibodies can augment replication of a heterologous 
DENV in challenge models, and in some cases cause a lethal vascular leakage syndrome 
that resembles DSS 6–8. 
 Humoral protection against DENV correlates with the induction of a neutralizing 
antibody response against the envelope (E) protein on the surface of the virion 9 and 
reviewed in 10). The ectodomain of the DENV E protein is composed of three domains 11: 
DI is a central eight-stranded β-barrel domain, DII consists of two finger-like protrusions 
from DI and contains the hydrophobic peptide required for virus fusion, and DIII is an 
immunoglobulin-like domain on the other side of DI that has been proposed to interact 
with as yet uncharacterized host receptor(s). Neutralizing monoclonal antibodies (MAbs) 
against the different DENV serotypes have been mapped to all three domains 12–18, 
although many of the most potently inhibitory mouse MAbs localize to DIII 12. To date, 
three epitopes have been established on DIII 6,19,20: MAbs binding the lateral ridge or A-
strand epitope are relatively inhibitory, whereas those recognizing the AB loop neutralize 
infection less efficiently or not at all 21, presumably due to poor epitope accessibility on 
the virion.  
 Cryo-electron microscopy studies have revealed that the E proteins of mature 
flavivirus virions form anti-parallel dimers that lie flat against the surface of the virion 
and are arranged with T = 3 quasi-icosahedral symmetry 22,23. In this configuration, E 
proteins exist in three distinct chemical environments defined by their proximity to the 2-, 
3-, or 5-fold axis of symmetry 22,23. While 180 copies of the E protein are present on all 
flavivirus virions, the different environments imposed by the quasi-icosahedral symmetry 
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make some epitopes unequally accessible. Epitope exposure also may be affected by 
neighboring E proteins in adjacent symmetry units, or by the presence or absence of prM 
in the case of immature, partially mature, and mature virions 24–29. The arrangement of 
the E proteins on the surface of the virion can be further modulated over time and across 
a range of temperatures due to the intrinsic conformational heterogeneity of virons 30,31  
Consequently, the accessibility of epitopes can vary across structurally distinct epitopes, 
ultimately affecting the number of sites available for antibody binding and neutralization. 
 Recently, we generated a panel of 79 MAbs against DENV-1 to define how 
antibodies neutralized different DENV-1 genotypes 16. Within this panel, 15 MAbs were 
potently neutralizing, and most mapped to previously identified epitopes in DIII, 
although few retained strong inhibitory activity against heterologous DENV-1 genotypes.  
Consistent with this observation, prior studies have described disparate neutralization 
patterns with strains corresponding to different genotypes within a serotype after natural 
infection 32–34 or immunization with live-attenuated tetravalent vaccine candidates  33,35–
37. One such DIII-specific neutralizing MAb, DENV1-E111 (henceforth termed E111) 
remained unmapped at the amino acid level. E111 potently neutralized infection of a 
genotype 2 DENV-1 (strain 16007, EC50 of ~4 ng/ml), but inhibited infection of a 
genotype 4 virus poorly (strain Western Pacific-74 (West Pac-74), EC50 of ~15,200 
ng/ml). Consistent with this, E111 bound DENV-1 West Pac-74 poorly in a virus capture 
ELISA. Sequence analysis of the variation between residues 296-400 of DIII for 16007 or 
West Pac-74 revealed only two differences (amino acids 339 and 345), with amino acid 
345 as the only residue that varied in all five DENV-1 genotypes. 
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 To explore in greater detail why E111 neutralized infection in a genotype-
dependent manner, we determined the crystal structures of an E111 single chain variable 
fragment (scFv) in complex with DIII of 16007 and the E111 Fab fragment in complex 
with DIII from West Pac-74. E111 bound to a previously uncharacterized epitope 
centered on the CC' loop of DIII, which should not be exposed on the virion according to 
existing flavivirus atomic models; our structural data defining the CC' loop epitope of 
E111 was supported by extensive mutagenesis and binding analyses. While E111 showed 
a higher affinity and longer half-life of binding to DIII of 16007 (genotype 2) compared 
to DIII from several other DENV-1 genotypes, this did not explain the disparity in 
neutralization potency for viruses from all five genotypes. Mutation at position 345 of 
West Pac-74 DIII to the corresponding residue in 16007 resulted in increased E111 
binding, but only a small improvement in neutralization potency, suggesting that 
differences in amino acids within the epitope among genotypes could not account for the 
phenotype. However, neutralization of DENV-1 West Pac-74 with E111 was enhanced 
by incubating virus-antibody complexes at higher temperature or for longer times, 
whereas this treatment failed to equivalently impact inhibition of strain 16007 by E111. 
Our experiments suggest that the conformational ensemble of DENV virion structures 
differs in a genotype-dependent manner, which impacts the neutralizing activity of 
antibodies that recognize nominally cryptic epitopes. 
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4.5 Results 
 Structure of E111 in complex with DIII. To explore the basis for the genotype-
dependent neutralization of DENV-1 by the DIII-specific MAb E111 in greater detail, we 
undertook crystallographic studies. Initially, we complexed E111 Fab fragments purified 
from papain-cleaved IgG with soluble, bacterially expressed DENV-1 DIII (residues 293-
399) for crystallization (Fig 1A). We obtained crystals of DIII of West Pac-74 in 
complex with E111 Fab fragments that diffracted to 3.8 Å resolution. Several conditions 
yielded diffracting crystals of the 16007 DIII-E111 Fab complex but failed to diffract 
better than ~6.0 Å resolution. As an alternative, we cloned the heavy (VH) and light chain 
(VL) variable domain sequences from the E111 hybridoma to create an scFv. Two 
constructs of the E111 scFv were generated, with either the VL or VH sequence at the N-
terminus, separated with a (GGGGS)3 linker, and a C-terminal hexahistadine tag for 
affinity purification. These inserts were cloned into the pAK400 vector that contains a 
pelB leader sequence for targeting the polyprotein transcript to the oxidative environment 
of the bacterial periplasm 38. Sequential purification by nickel affinity and size exclusion 
chromatography revealed two species of scFv: a non-disulfide domain-swapped dimer 
and a monomer. For our structural analysis, we used the monomeric species with VL at 
the N-terminus (Fig 1B). 
 We determined the structure of E111 scFv in complex with DIII of DENV-1 
16007 to 2.5 Å resolution (model statistics are in Table 1). There were no major 
structural perturbations to the immunoglobulin-like β-sandwich topology of DIII found in 
other flavivirus E proteins, with a root mean squared displacement of 0.7 Å compared to 
unbound DIII. The E111 scFv adopted the predicted variable domain assembly (Fig 2A). 
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The binding interface had an average degree of shape complementarity (Sc = 0.68, with Sc 
= 1.0 a perfect score) for antibody-antigen interactions and 2,095 Å2 of combined surface 
area. The light and heavy chains engaged DIII equivalently, with a combined buried 
surface area of 1,017 Å2 (460 Å2 of DIII and 557 Å2 of the light chain) versus 1,078 Å2 
(550 Å2 of DIII and 528 Å2 of the heavy chain) (Fig 2C). The interaction between E111 
and DIII of strain 16007 was dominated by hydrophobic interactions, in addition to six 
direct hydrogen bonds and fourteen water-mediated networks at the interface of the 
complex (Table 2).  
 The complex of DIII of West Pac-74 bound to E111 Fab fragments diffracted to 
3.8 Å resolution. There were two complexes in the asymmetric unit, and non-
crystallographic symmetry restraints were applied in the refinement (model statistics are 
in Table 1). The two Fab fragments have essentially identical structures with the notable 
exception of the elbow angles between the variable and constant domains ((149.0° versus 
133.5° as calculated by the RBOW server 39). As with the co-crystal structure with the 
E111 scFv and DIII of 16007, there were limited conformational changes in the West 
Pac-74 DIII upon E111 Fab ligation (R.m.s.d = 0.8 Å). The E111 Fab-DIII interface also 
had a similar average degree of shape complementarity (Sc = 0.65) and total buried 
surface area (2,076.5 Å2). Overall, the E111 scFv and Fab structures (DIII and Fv 
domains) varied little from one another in terms of structure (R.m.s.d = 0.3 Å) or 
orientation of engagement of DIII (Fig 1C).  
 E111 engaged discontinuous segments of DIII of 16007 and West Pac-74 
including the N-terminal linker (residues 300-301), C-strand-CC' loop-C' strand (residues 
334-351), EF loop (372), and FG loop (residues 382-384) (Fig 2D), which together form 
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a single convex surface patch of 25 residues. A total of 20 residues of E111 contacted 
DIII: 8 from the light chain and 12 from the heavy chain. The heavy and light chains both 
formed contacts with three of the same amino acid residues (S338, G344, and A345). The 
E111 binding site was centered on the CC' loop (7 of 25 residues), a previously 
uncharacterized epitope for flavivirus neutralizing MAbs (Fig 2E). Analysis of the CC' 
loop sequences from other DENV serotypes revealed significant variation (Fig 2F), 
which likely explains the type-specificity (i.e., does not bind or neutralize other DENV 
serotypes) of E111 16.  
 We previously observed reduced binding of E111 to DENV-1 West Pac-74 strain 
(genotype 4) in a virus capture ELISA, which correlated with a ~4,100-fold decrease in 
neutralization efficiency 16. E111 contacted every residue in the CC’ loop of 16007 DIII, 
as well as residues on the adjacent C- and C'-strands. Sequence analysis of 16007 
(genotype 2) and West Pac-74 (genotype 4) showed variation at only two DIII positions, 
339 and 345, both of which are directly contacted by E111. Based on this, we 
hypothesized the genotypic variation within the CC' loop and surrounding regions would 
explain the differential binding and neutralization of E111 for different DENV-1 
genotypes. 
 Binding of mutant DIII to E111. To define the functional role of the CC' loop in 
E111 MAb binding, we generated a library of soluble DENV-1 DIII proteins based upon 
natural sequence variation of all five DENV-1 genotypes and tested their binding kinetics 
at 25°C to E111 by surface plasmon resonance (SPR) (Fig 3A, 3F, and Table 3). 
Whereas E111 had a KD of 18.0 ± 0.08 nM and a half-life of 194 seconds for DIII from 
16007, its interaction with West Pac-74 DIII was noticeably weaker with a KD of 415 ± 
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24 nM and half-life of 6.5 seconds (Fig 3B and 3C). Mutagenesis of a TS at position 
339 had a similar affinity as wild type 16007 DIII (KD of 16.6 ± 0.17 nM; t1/2 = 222.4 
seconds (Fig 3D)). The crystal structures show that the additional methyl group present in 
the 16007 Thr residue does not contact E111, whereas the Ser/Thr hydroxyl groups both 
make equivalent hydrogen bonds with TyrL30B in CDR1 of the E111 light chain, with 
(see Fig 2E). In contrast, an AV change at position 345 of 16007 DIII (to the residue 
in West Pac-74) decreased the affinity of binding such that kinetics became comparable 
to West Pac-74 DIII with a KD of 1143 ± 60 nM and half-life of 5.3 seconds (Fig 3E). 
The sidechain of Ala 345 of 16007 makes limited contact with E111, and the additional 
two methyl groups in Val 345 of West Pac-74 appear to be tolerated sterically at the E111 
interface with only minor structural perturbations. However, position 345 and the 
adjacent CC’ loop residues participate in an extensive network of hydrogen bonds with 
E111 (Fig 1D), and we speculate that Val 345 leads to a dramatically faster off-rate by 
subtle destabilization of this interface. Due to the low resolution of the E111 Fab-West 
Pac-74 DIII structure ordered water molecules could not be modeled, making precise 
comparison of the interfaces difficult.  
While the on-rates for E111-DIII interactions were relatively constant, the off-rate 
governed the differences in affinity for the DIII variants (Fig 3F). DIII from strain 3146 
SL varies in six positions from 16007, including a valine at position 345. Kinetic analysis 
with 3146 SL DIII revealed a decreased half-life (5.5 seconds) as compared to 16007. 
Substitution of individual amino acids corresponding to variation in strain 3146L (D341N 
(CC’ loop) or A369T (E-strand)) had little negative effect on the half-life of strain 16007 
(t1/2 of 173 seconds and 182 seconds, respectively). One amino acid difference (V380I (F-
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strand)) in 3146 SL caused a small increase in the half-life (t1/2 of 296 seconds) when 
inserted into DIII of 16007, despite its side chain location ~10 Å from DIII. An AI 
change at position 345 was the only difference in DIII sequence between strains 16007 
(genotype 2) and TVP-5175 (genotype 3); this single amino acid substitution reduced the 
half-life (t1/2 of 2.2 seconds) and affinity of binding (KD of 1981 ± 441 nM). Precise 
kinetic measurements with DIII from TVP-2130 (genotype 1) were limited by non-
specific interactions, and thus not analyzed (data not shown). However, a DIII variant of 
16007 that included the unique variation of strain TVP-2130 in the CC' loop (L351V) 
showed a decreased half-life with E111 (t1/2 of 32.9 seconds) likely due to the disruption 
of optimal hydrophobic contact with Tyr30B of the variable light chain CDR1 loop. As a 
control, insertion of a triple mutation of K310E/T329E/K361T into the 16007 DIII lateral 
ridge and A-strand epitopes did not alter significantly E111 binding affinity or half-life 
(t1/2 of 155 seconds). Importantly, SPR binding studies with the E111 scFv showed a 
similarly reduced half-life for West Pac-74 DIII compared to 16007 DIII (Table 3). Of 
note, a similar kinetic pattern of E111-DIII interactions also was observed at 37°C (data 
not shown). Overall, our genetic and biophysical studies support the crystallographic 
analysis and establish the CC' loop as important for recognition of DIII by E111.   
 Differential neutralization of DENV-1 genotypes by E111. While the structural 
and biophysical studies suggested the dominance of the CC' loop in E111 recognition, we 
assessed the impact of sequence variation in this region by testing the neutralization 
potential of E111 against strains corresponding to different DENV-1 genotypes. As 
mentioned, prior studies showed a 4,100-fold reduction in neutralizing activity of West 
Pac-74 (genotype 4) compared to 16007 (genotype 2) 16. To gain further insight, we 
 128 
determined the inhibitory activity of E111 against TVP-2130 (genotype 1), TVP-5175 
(genotype 3), and 3146 SL (genotype 5). Notably, only strains corresponding to 
genotypes 2 and 5 (16007 and 3146 SL) were neutralized potently by E111 with EC50 
values of 3.8 ± 2.0 ng/ml and 22 ± 10 ng/ml, respectively (Fig 4A and Table 4). In 
comparison, E111 neutralized strains of genotype 1, 3, and 4 poorly with EC50 values 
ranging from 9,700 ± 3,200 ng/ml to greater than 25,000 ng/ml. Although rather extreme 
differences in E111-mediated neutralization were observed with different genotypes, this 
pattern failed to correlate directly with the KD or half-life of binding with recombinant 
DIII by SPR (see Table 3). This suggests that DIII epitope sequence-independent factors 
(e.g., CC' epitope accessibility on the virion or secondary binding sites in other domains) 
likely contribute to the differential genotype neutralization by E111. 
 Substitution of V345A into the West Pac-74 strain only modestly enhances 
neutralizing activity of E111. Our SPR data suggested that substitution of a single 
residue (AV) at position 345 of 16007 DIII reduced the E111 binding half-life to that 
observed with DIII of West Pac-74. Given that E111 neutralized infection of 16007 more 
potently than West Pac-74, we hypothesized that the reciprocal VA change at position 
345 of 16007 into the West Pac-74 strain would enhance neutralization. To test this, we 
used a reverse genetic system: DENV-1 West Pac-74 reporter virus particles (RVP) 31,40 
incorporating a single V345A mutation were produced in HEK293T cells and analyzed 
for sensitivity to MAb neutralization. Whereas DENV1-E103 MAb (which maps to 
residues T303, G328, T329, D330, and P332 on the lateral ridge of DIII (Shrestha et al., 
2010)) neutralized both wild-type and V345A DENV-1 West Pac-74 RVP equivalently 
(Fig 4B), E111 showed only moderately enhanced neutralization of the V345A-
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containing RVP (3.6-fold, P < 0.05, Fig 4C). Although the V345A change improved 
neutralization of West Pac-74 by E111, it failed to restore the sensitivity seen with 
DENV-16007 RVP or the fully infectious virus. Thus, either additional amino acid 
residues accounted for the genotypic difference in neutralization or the epitope was not 
displayed equivalently on the two viruses.  
E111 epitope accessibility is not affected by the maturation state of the virus. 
The pr peptide is covalently linked to the M protein to prevent adventitious fusion during 
virion transit through the acidic environment of the trans Golgi network (TGN). Within 
the TGN, a furin-like protease cleaves pr, although it remains associated with the virion 
until neutral pH exposure in the extracellular space after virus secretion 41,42. The 
maturation process for flaviviruses, however, is inefficient, resulting in secretion of 
particles that are mature, immature, and partially mature 28,31,43–45. Because several anti-
flavivirius MAbs (e.g., DII fusion loop-specific) show differential neutralization of 
mature and partially mature virions, we hypothesized that intrinsic differences in particle 
maturation among different DENV-1 genotypes might impact neutralization by E111. To 
test this, we prepared a standard preparation of 16007 or West Pac-74 DENV-1 RVP 
containing a mixture of mature, partially mature, and immature particles or a preparation 
enriched for mature RVP made in cells over-expressing furin 28. As expected, we 
observed modest differences in neutralization potential of standard versus mature 
preparations of 16007 and West Pac-74 DENV-1 RVP with WNV E60, a fusion-loop 
reactive cross-reactive MAb (Fig 5A and B). In comparison, differences in the 
maturation state of 16007 and West Pac-74 DENV-1 RVP failed to impact neutralization 
by E111 (Fig 5C and D). Thus, the distinct neutralization profiles by E111 of strains 
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corresponding to genotypes 2 and 4 of DENV-1 were not explained by differential 
epitope accessibility due to variation in the maturation state of the viruses. 
The structural basis of E111 neutralization. Because of the differential 
neutralization of West Pac-74 and 16007 by E111, we evaluated its epitope in the context 
of full-length E protein structures. To begin to assess this, we docked our scFv–DIII 
complex onto the available structure of the pre-fusion DENV E protein dimer (PDB ID 
1OAN 11), and compared this to other characterized DIII-specific anti-flavivirus 
neutralizing MAbs (Fig 6A). E111 engaged the opposite face of DIII compared to that 
seen previously with 1A1D-2 and 4E11 (A-strand) 30,46 or WNV-E16 (lateral ridge) Fab-
DIII 24 structures. The E111 Fab was rotated in a downward orientation compared to the 
WNV E16 Fab (Fig 6A) or the A-strand DENV Fabs docked onto the same structure 
(data not shown). Based on this docking it appears that E111 does not bind the outer 
exposed surface of the DV1 E protein but rather a determinant that is localized to the 
interior of the virus. 
Antibody neutralization of flaviviruses can occur by blocking attachment, 
internalization, and/or endosomal fusion. Prior to viral fusion, the E proteins on the 
surface of the virus dissociate from their dimeric hairpin arrangement to form trimeric 
spikes upon acidification in the late endosome. This conformational rearrangement is 
essential to allow the newly exposed fusion loop to insert into the endosomal membrane. 
While the exact structural transitions of the E proteins from dimer to trimer remain 
unknown, DIII is displaced ~70° from the pre-fusion structure and settles adjacent to DI 
in the post-fusion state 47–49. We examined structurally how E111 could disrupt a post-
attachment step by docking our Fab-DIII complex onto the structure of the DENV-1 post-
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fusion trimer 49. While the Fab fragment does not clash with the adjacent E protein in the 
DENV-2 pre-fusion dimer structure (Fig 6A), the light chain of E111 sterically would 
inhibit formation of the post-fusion trimer (Fig 6B) by clashing with the neighboring DI 
of an adjacent E protein. Thus, from a structural perspective, E111 likely hinders the 
necessary conformational change from E protein homodomer to homotrimer, and limits 
viral fusion and infection. 
To begin to understand the mechanism of E111-mediated neutralization, we 
performed pre- and post-attachment neutralization assays 9,17,24,50. E111 MAb was 
incubated with DENV-1 16007 before or after virus binding to BHK21-15 cells, and 
infection was measured by the plaque reduction assay. E111 efficiently neutralized 
DENV-1 when premixed with the virus before cell attachment or when added after the 
virus had attached to the cell surface (Fig 6C). This result suggests that E111 has the 
capacity to neutralize infection after virus attachment has occurred, and is consistent with 
previously observed patterns of inhibition seen for potently neutralizing DIII-specific 
antibodies 17,24,50,51.  
 The E111 epitope is not accessible in the existing cryo-electron microscopy 
models of DENV. Based on our functional data, we hypothesized that the CC' loop 
epitope was preferentially exposed on the 16007 but not West Pac-74 virion. To gain 
more insight as to how E111 recognized DIII in the context of the mature virus, we 
docked our structure onto the cryo-electron-microscopy-derived model of the mature 
DENV virion 22. With three envelope glycoproteins in the asymmetric unit, there are 
three potential E111-binding environments. However, in the existing cryo-electron 
microscopy model for DENV, the E111 epitope was not accessible on the surface in any 
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of the three symmetry environments (Fig 7A). Instead, the E111 epitope was buried in E 
protein contacts on the virion surface (Fig 8A-E).  
Because some anti-flavivirius MAbs (e.g., DII fusion loop-specific) show 
differential neutralization of mature and partially mature virions, we hypothesized that 
intrinsic differences in particle maturation among different DENV-1 genotypes might 
impact neutralization by E111. However, the distinct neutralization profiles by E111 of 
DENV-1 16007 and West Pac-74 were not explained by differential epitope accessibility 
due to variation in the maturation state of the viruses (see Fig 5). As in the mature virion 
model, the E111 epitope also appeared inaccessible on the cryo-electron microscopy 
model of the immature DENV virion 52, due to the trimeric arrangement of prM-E, which 
positions the epitope farther into the virus interior (Fig 7B and Fig 8 F-H).  
 The cryo-electron microscopy model of DENV-2 in complex with the 1A1D-2 
Fab describes one conformational ensemble that is a consequence of “breathing” of a 
virus particle 30. The 1A1D-2 epitope is partially inaccessible in the unbound 
conformation of the mature virion, and an increase in temperature allows for dissociation 
of E protein homodimers and greater exposure of the A-strand of DIII, a major 
component of the 1A1D-2 epitope. Although there are major rearrangements of the E 
proteins in this structure, E111 binding still would be prohibited by steric clashes of 
adjacent E protein monomers (Fig 7C and Fig 8 I-K) at the 3- and 5-fold axes of 
symmetry. While access of the 2-fold axis is not hindered by contacts with neighboring E 
proteins, its orientation would inhibit an immunoglobulin from binding this site. Based on 
these models, it appears unlikely that E111 binds to DENV-1 in the conformations that 
have been described by cryo-electron microscopy to date. 
 133 
 Neutralization of DENV-1 by E111 varies with time and temperature in a 
genotype-dependent manner. Prior studies with WNV, DENV, and hepatitis C viruses 
suggested that changes in time and temperature of binding can expose cryptic epitopes 
and enhance neutralizing activity of some MAbs 30,31,53. Given our structural, biophysical, 
genetic, and virological data, we hypothesized that the CC' epitope on West Pac-74 
(genotype 4) was less well exposed compared to 16007 (genotype 2). Alternatively, a 
difference in the range of the ensemble structures sampled by the two viruses could 
contribute to the differential neutralization by E111. To begin to evaluate this, we 
compared the time- and temperature-dependence of neutralization of E111 with 16007. 
We observed little change in EC50 values after incubation of 16007 in the presence of 
antibody at 37°C or 40°C from 1 to 7 or 4.5 hours, respectively (Fig 9A and E); this 
suggests that the CC' loop epitope is generally accessible among the ensemble of 
conformations sampled by 16007 under steady-state conditions. Similarly, a modest 
change in the pattern of neutralization was observed with E111 and West Pac-74 RVP 
after incubation at 37°C up through 7 hours (Fig 9B). However, we observed a marked 
increase in neutralization when E111 and West Pac-74 RVP were incubated at 40°C for 
4.5 hours, with a 20-fold (P < 0.001) reduction in the EC50 value (Fig 9F). By 
comparison, 16007 exhibited only a 3.5-fold fold increase in potency over the same 
interval. A shift in EC50 was observed with both 16007 and West Pac-74 after 22 hours 
at 37°C suggesting that over time, a greater number of E111 epitopes become exposed for 
binding (Fig 9A and B).  
 Because our SPR binding and structural data (Fig 2 and 3) did not correlate with 
neutralization experiments in which amino acids of 16007 and West Pac-74 were 
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exchanged (Fig 4), we speculated that the interaction between E111 and amino acid 345 
on DIII might be modulated by epitope accessibility in a genotype-dependent manner. To 
evaluate this, we tested the effects on time and temperature on E111 neutralization of the 
reciprocal pair of DENV-1 RVP, V345A West Pac-74 and A345V 16007. Notably, we 
observed enhanced E111 neutralization of V345A West Pac-74 as a function of increased 
time and temperature (Fig 9C and G); by 22 hours at 37°C or 7 hours at 40°C, the EC50 
value of V345A West Pac-74 RVP neutralization approached that of the wild type 16007 
RVP (Fig 10). Neutralization of the A345V 16007 RVP by E111 also increased with time 
and temperature (Fig 9D and H), although there was no difference in EC50 value 
compared with wild type 16007 RVP. Overall, these experiments suggest that under 
steady-state conditions, the ensemble of structures with respect to exposure of the CC' 
loop epitope are different between strains 16007 and West Pac-74. Changes in 
temperature likely alter the virion conformations sampled by individual DENV-1 
genotypes, which may vary considerably from those described in existing cryo-electron 
microscopy models. 
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4.6 Discussion 
Antibody neutralization of flaviviruses requires multiple antibodies to bind a 
single virion until a neutralization threshold is reached. The ability of a MAb to bind a 
given viral epitope depends on its concentration, the affinity of its interaction with the 
infectious virus particle, and the accessibility of the epitope on the virion 10. While some 
epitopes are readily accessible on the surface of mature DENV, others are partially or 
completely inaccessible 26,28,30,43. However, antibodies that recognize partially or 
completely occluded sites on the mature virion can still neutralize flavivirus infection 
because of particle heterogeneity with respect to maturation 28,43 and/or by sampling of 
alternate ensemble structures or “breathing”, which allows for intermittent display of 
cryptic epitopes 30,31. Here, our structural studies show that E111 binds to a novel CC' 
loop epitope on DIII that does not appear to be affected by particle maturation. Although 
the CC' epitope is predicted to be inaccessible on both the mature and immature virion, 
E111 still potently neutralizes some but not all DENV-1 genotypes. While the amino acid 
sequence of DIII varies among genotypes in and around the CC' loop, which affects E111 
binding by SPR, there was a limited relationship between the kinetics of binding in vitro 
and the potency of genotypic neutralization in cell culture. Thus, some aspect of E111 
recognition and neutralization appears independent of the epitope sequence. While E111-
mediated neutralization of strain 16007 was less affected by changes in time or 
temperature of incubation, neutralization of West Pac-74 was enhanced substantially after 
incubation with E111 at higher temperatures and for longer times. These experiments 
suggest that at steady state, DENV-1 16007 has a unique ensemble of conformations 
compared to West Pac-74, allowing for enhanced exposure of particular DIII-specific 
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epitopes for MAb neutralization. This phenomenon could explain in part why so many 
(13 of 15) of our DIII-specific MAbs strongly neutralized infection of strain 16007 but 
not West Pac-74 despite the relatively few amino acid changes in DIII 16.  
  Within DIII of different DENV-1 genotypes, the greatest sequence variation 
occurs within and surrounding the CC' loop (4 of 9 sites), suggesting this may be a 
possible site of immune system pressure and selection. In comparison, the CC' loop 
residues of other DENV serotypes are highly conserved: for DENV-2 and DENV-3 
genotypes, only 2 of 8 and 1 of 11 sites, respectively, show amino acid variation within 
or proximal to the CC’ loop. Recent studies suggest that neutralizing antibodies that 
localize to the CC' loop may not be completely unique to DENV-1. We recently mapped 
the binding of four inhibitory DENV-2 MAbs to residues within the CC' loop by yeast 
surface display 17. Several of our DENV-2-specific CC' loop MAbs protected against 
DENV-2 challenge both as pre-exposure prophylaxis and post-exposure therapy in mice. 
Due to the lack of a reproducible mouse model for DENV-1 16007 infection, we have not 
directly assessed the therapeutic efficacy of E111 under conditions where it is highly 
neutralizing. Nonetheless, E111 did show protective activity as prophylaxis against 
DENV-1 West Pac-74 in an immunocompromised AG129 mouse model of infection 16, 
despite its relatively poor EC50 value in cell culture.  
 Flavivirus virions can undergo structural re-arrangements with an increase of 
temperature, which can facilitate binding of antibodies to epitopes with limited 
accessibility 30,31. Indeed, DENV-1 RVP showed markedly enhanced neutralization by 
E111 that was dependent on both time and temperature of incubation with antibody. 
While these pre-incubation conditions alone improved neutralization of West Pac-74 
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RVP by E111, insertion of the V345A substitution (from 16007 into West Pac-74) was 
required to shift the neutralization curve to achieve an EC50 value of wild type 16007. 
This observation is consistent with a role for amino acid 345 in E111 engagement and 
correlates with differences in the binding of V345A and wild type DIII of West Pac-74 
observed by SPR. Thus, while a lack of E111 epitope accessibility explains why West 
Pac-74 was not efficiently neutralized under steady-state conditions, prolonged time and 
higher temperature of incubation promoted sampling of a unique ensemble of structures 
that revealed the differential effect of residue 345 on neutralization of West Pac-74. 
Interestingly, the reciprocal mutation, A345V, when substituted into 16007 had 
essentially no impact on neutralization by E111, regardless of the time and temperature of 
incubation. While wild type DIII of 16007 binds E111 with a 37-fold longer half-life than 
the A345V variant, the on-rates were equivalent. Thus, E111 binding and neutralization 
may be preferentially determined by the on-rate kinetics of antibody attachment through 
stabilization of a potentially transient/infrequent conformation present in the 16007 
ensemble of structures. Consistent with this, we generated a mutant DIII of 16007 
(K343I), which showed a substantially enhanced half-life of binding interaction (~45 
minutes) with E111, but this did not affect neutralization potency (S. K. Austin, M. 
Diamond, and D. Fremont unpublished results). 
Currently, there are no cryo-electron microscopy models of DENV-1, whereas 
several models of DENV-2 have been described 22,30,41. These models were used as 
surrogates of DENV-1 in an attempt to understand how E111 engaged its epitope in the 
context of a virion.  Due to the packing of individual E protein monomers in the particle, 
there are limitations of accessibility of antibodies to portions of the E protein depending 
 138 
upon its particular symmetry environment. Examination of the available cryo-electron 
microscopy models of DENV failed to explain how E111 binds to the CC' loop on the 
virion, as it is completely inaccessible in all models, in all symmetry environments. 
DENV-2 particles are believed to sample ensemble of conformations 31, as shown in the 
captured intermediate of the cryo-electron microscopy reconstruction of DENV-2 with 
the 1A1D-2 Fab 30. Despite a sizable increase in the relative E protein surface area 
exposed in the 1A1D-2 captured intermediate, from a structural perspective there was 
still insufficient accessibility to allow engagement by E111. Our crystallographic, kinetic, 
and functional data all support a role for the CC' loop in E111 recognition yet the existing 
atomic models cannot explain how it engages the virion. We speculate that a unique 
structural ensemble allows exposure of the CC' loop and binding of E111 for certain 
DENV-1 genotypes. Indeed, we know little about the alternate conformational states 
sampled by flaviviruses, as only two cryo-electron microscopy models of transitional 
flavivirus states exist: a low pH model of WNV E16 Fab and WNV, and the 1A1D-2 Fab 
binding to DENV-2 at physiological pH 30,54. Further investigation using antibody 
captured virus conformations are needed to fully explore the breadth of structures 
sampled by flaviviruses.  
Our structural and functional characterization of E111 has implications for 
vaccine development and assessment. While natural infection with DENV is believed to 
confer durable protective immunity against homologous DENV serotypes, several papers 
have reported disparate neutralization titers of homotypic strains and genotypes after 
natural infection or immunization. The neutralization potency of patient sera during the 
course of an DENV-3 epidemic varied substantially for DENV-3 strains corresponding to 
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distinct genotypes 32. Similarly, a study of sera from individuals experiencing DENV-1 
infections also showed variable neutralizing activity against different DENV-1 strains 34. 
Consistent with this, pooled sera from monkeys immunized with a tetravalent chimeric 
live attenuated DENV vaccine revealed a range (e.g., ~12-fold for DENV-1 strains) of 
variability in EC50 neutralization titers against individual strains of a given DENV 
serotype 37. It remains possible that the differences are even larger, as full neutralization 
profiles or EC90 values were not reported in this latter study.   
Studies examining how genotypic variation affects neutralization with MAbs 15–
17,55,56 suggest that natural sequence variation among genotypes of a DENV serotype 
impacts the potency of antibody neutralization. While the cryptic nature of the CC' loop 
may be a unique case 16, we propose that disparate neutralization of DENV-1 strains by 
monoclonal or polyclonal antibodies could be due to or at least affected by differences in 
the ensemble of conformations sampled by the virion. Indeed, we observed that DENV1-
E103, a DIII lateral ridge antibody, also shows a time- and temperature-dependent 
increase in neutralization potency of West Pac-74 compared to strain 16007 (K. Dowd 
and T. Pierson, unpublished results). Selection of DENV strains that sample a greater 
diversity of conformations as vaccine candidates could broaden the repertoire of 
neutralizing antibodies against DENV. Such strains could better expose and present the 
spectrum of epitopes available, and thereby induce a more diverse neutralizing antibody 
repertoire. Alternatively, the use of DENV strains or formulations with a limited 
structural ensemble could focus the neutralizing antibody response on specific epitopes 
whose accessibility is independent of time and temperature, and thus, more effective at 
neutralizing a diverse range of strains, regardless of particle conformation. Although a 
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monovalent formalin-fixed DENV-2 vaccine induced strongly neutralizing antibodies 
against the parent strain in mice and monkeys, it was never evaluated for activity against 
a range of strains corresponding to different genotypes 57. Clearly, our work suggests that 
further empirical studies are necessary to assess directly how virion ensembles affect 
immunogenicity as well as pathogenesis. Finally, the conformational diversity of DENV 
strains used for diagnostic evaluation of polyclonal serum could affect the interpretation 
of its neutralizing potential; for example, the choice of a DENV strain that cycles through 
limited structural conformations at 37oC for neutralization assays could underestimate the 
quality of the inhibitory activity of the antibody response in human serum. 
 In summary, we have defined a novel structural epitope on the CC' loop of DIII of 
DENV, which is not accessible in the existing cryo-electron microscopy reconstruction 
models of DENV particles. Our experiments also suggest that the ensemble of 
conformations of the DENV virion structure differ in a genotype-dependent manner, 
which impacts the neutralizing activity of antibodies and has direct implications for the 
development and analysis of candidate DENV tetravalent vaccines.  
 141 
4.7 Methods and Materials 
 Protein production, purification, and crystallization. An untagged form of 
DENV-1 DIII (strain 16007, residues 293 to 399) was cloned into the pET21a vector 
(Novagen) and expressed by autoinduction 58 in BL21 bacterial cells (Agilent). Isolated 
inclusion bodies were solubilized and oxidatively re-folded, as previously described 59. 
Variants of the DENV-1 16007 strain (residues 293-399) were generated by site-directed 
mutagenesis (QuikChange, Agilent) using unique primer sets (Table 5). E111 scFv was 
engineered with a (GGGGS)3 linker between the VH and VL domains and a C-terminal 
hexahistadine tag, cloned into the pAK400 vector, and expressed in the periplasm of 
bacteria. The bacteria were lysed and the E111 scFv was purified by nickel affinity and 
size exclusion chromatography. The scFv was complexed with excess DIII and purified 
by size exclusion chromatography. The E111 scFv-DIII complexes were crystallized at 
10 mg/ml by sitting-drop vapor diffusion at 20°C using 20% polyethylene glycol (PEG) 
3350, 0.2 M potassium sulfate, and 5% glycerol. Crystals were cryo-protected in a 
solution containing 35% glycerol and cooled in liquid nitrogen.  
 After protein A affinity purification, the E111 IgG was cleaved with immobilized 
papain (Pierce Biotechnology), and Fab fragments were recovered, as the Fc and 
uncleaved IgG were removed by passage over a second protein A affinity column. West 
Pac-74 DIII and E111 Fab fragments were mixed and isolated by size exclusion 
chromatography on a S75 Superdex column. The E111 Fab-DIII complexes were 
crystallized at 15.8 mg/ml by sitting-drop vapor diffusion at 20°C using 0.1 M MES pH 
5.3, 20% PEG 6000 (final pH 6.0) with 1% glycerol. The crystals were cryo-protected in 
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the mother solution supplemented with 20% ethylene glycol and cooled in liquid 
nitrogen.  
 Structure determination and refinement. Data were collected at APS beamline 
19–ID (Argonne National Laboratories) at 293° K and at a wavelength of 1.007 Å using a 
CCD detector. Data were processed, scaled, and merged with HKL-2000 60. 
Crystallographic phasing for the E111 scFv-DIII complex was obtained by molecular 
replacement (PHENIX 61) using the predicted scFv model given by the PIGS server 62 
and the atomic structure of DENV-1 16007 DIII (PBD accession number 3IRC 16). The 
crystals belong to the space group P43212 with the unit cell dimensions of a = b = 
135.224 and c = 52.221, with one E111 scFv-DIII complex per asymmetric unit. An 
atomic model was iteratively built in COOT 63 and refined in PHENIX, and contained 
328 amino acids (residues 298-396 from DIII, 1-114 of the E111 VH, and 1-107 of the 
E111 VL, (Chothia numbering), 147 water molecules, four chloride ions and one sulfate 
and glycol molecule each. The final 2.5 Å resolution model was refined to an Rwork = 
19.6% and Rfree = 23.9% for all F > 0, with excellent geometry and Ramachandran angles 
(97.4% favored and 0.3% outliers).  
Data for the E111 Fab-West Pac-74 DIII complex were initially processed with 
centered orthorhombic symmetry with subsequent identification of pseudo-merohedral 
twinning. The crystals actually belong to space group P21 and suffer ~30% twinning with 
the operator h,-k,-h-l. The data was successfully phased by molecular replacement using 
the E111 scFv-DIII complex and the constant domains from PDB ID 4AEH with two 
molecules per asymmetric unit. The atomic model was iteratively build in COOT and 
refined in REFMAC 64 and PHENIX using jelly body and reference model restrains, 
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respectively. The structure contained 1060 amino acids (residues 299-395 from DIII, 1-
212 from the light chain, and 1-212 from the heavy chain (Chothia numbering). The final 
3.8 Å resolution model was refined to an Rwork = 23.7% and Rfree = 27.8% for all F > 0, 
with excellent geometry and Ramachandran angles (97.0% favored and 0.4% outliers). 
The atomic coordinates and structure factors have been deposited in the Protein Data 
Bank (www.rcsb.org) under accession number 4FFY and 4FFZ for the scFv and Fab 
complexes, respectively. 
 Surface plasmon resonance. Kinetic information on the interaction between 
E111 and DIII variants was obtained using a Biacore T100 instrument. Approximately 
500 response units (RU) of E111 or control MAb/scFv (WNV E16) was immobilized 
using amine coupling to a Series S CM5 chip. Once stabilized, a two-fold dilution series 
of the DENV DIII variants were injected over the chip at a flow rate of 65 ml/min for 180 
seconds and allowed to dissociate for 1,000 seconds. DIII had dissociated over this time 
period and additional regeneration was not necessary. Data was processed using the 
Biacore Evaluation Software (Version 1.1.1) by double referencing and a1:1 Langmuir fit 
of the curves. All curves were reference subtracted from a flow cell containing the 
negative control WNV E16 MAb/scFv. Maximum response units were plotted versus 
concentration and this curve was fitted to determine the KD. Results were generated from 
at least three independent experiments, with a minimum of six binding curves per 
experiment. 
 Plaque reduction neutralization tests (PRNT).  PRNT were performed with the 
five DENV-1 genotype strains with E111 on Vero cells as described previously 16. In 
some experiments, pre- or post-attachment studies were performed as a variation 17,50. 
 144 
Briefly, serially diluted MAbs were mixed 1:1 with 102 PFU of 16007 DENV-1 virus in 
DMEM containing 10% FBS and incubated for one hour at 4°C. The virus-MAb mixture 
was then added to the cells at 4°C, and after washing, incubated at 37ºC for one 
additional hour. Alternatively, cells and media were chilled to 4°C before 102 PFU of 
virus was added and incubated for one hour. Unbound virus was washed away with 
chilled media before the addition of E111 MAb. After one hour at 4°C, cells were washed 
with warm media and overlaid with 2% low-melt agarose (SeaPlaque) in modified Eagle 
medium and 4% FBS and incubated at 37ºC for 6 days. PRNT50 values were determined 
using non-linear regression analysis (Graph Pad Prism4).  
 MAb neutralization of DENV-1 using RVP. DENV-1 RVP were generated as 
described previously 31,40. Plasmids expressing the wild type or mutant capsid (C)-prM-E 
genes of DENV-1 (strain 16007 or West-Pac 74) were co-transfected into HEK293T cells 
with a plasmid encoding a sub-genomic WNV replicon expressing GFP. E protein 
variants were engineered by site-directed mutagenesis (QuikChange, Agilent) and 
confirmed by sequencing. Standard neutralization assays with RVP were performed by 
incubating serial dilutions of antibody with DENV-1 RVP for 1 hour at 37°C, followed 
by addition of Raji-DCSIGNR cells. Infection was carried out at 37°C and monitored by 
flow cytometry 48 hours later for GFP expression. To assess the role of temperature on 
MAb activity, neutralization assays were performed as above, and designated as 
“reference” neutralization profiles. Additional RVP-antibody complexes, following the 
initial 1 hour incubation at 37°C, were further incubated at 37°C or 40°C for incremental 
lengths of time, followed by infection of Raji-DCSIGNR cells. Relative infectivity was 
determined after comparison to infectivity of DENV-1 RVP incubated at the same 
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temperature in parallel in the absence of antibody.   
Effects of maturation on E111 MAb neutralization. RVP were produced from 
HEK293T cells to represent various stages of maturation (standard (containing a 
heterogeneous mixture of partially mature and mature) or mature (produced in the 
presence of an over-expression of furin)) according to published protocols 28. Standard 
neutralization assays with RVP were performed by incubating serial dilutions of antibody 
with DENV-1 RVP for 1 hour at 37°C, followed by addition of Raji-DCSIGNR cells. 
Infection was carried out at 37°C and monitored by flow cytometry 48 hours later for 
GFP expression. To assess the role of temperature on MAb activity, neutralization assays 
were performed as above, and designated as “reference” neutralization profiles. 
  Docking of E111 scFv onto structural models. (a) E protein dimer. Docking of 
the E111-DIII structure and the WNV E16 Fab-DIII (PDB 1ZTX) onto the pre-fusion 
dimer structure of DENV2 (PDB 1OAN) was based upon superimposition of DIII. (b) E 
protein trimer. The same procedure was used for docking of the E111 scFv onto the post-
fusion DENV-1 trimer structure (PDB 3G7T). (c) Virions. The coordinates for the full 
mature (PDB 1KR4), immature (PDB 3C6D), and 1A1D-2-bound (PDB 2R6P) DENV-2 
virus assemblies were downloaded from VIPERdb 65 (http://viperdb.scripps.edu/). The 
surface of the virus was clipped to reveal the interior of the virion models. All structural 
representations were colored and rendered using PyMOL (The PyMOL Molecular 
Graphics System, Version 1.4-1.5.1 Schrödinger, LLC., http://www.pymol.org).  
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Table 1. Data collection and refinement statistics.  
Data collection 
 16007 DIII  
–  
E111 scFv 
Western Pacific-74 DIII 
–  
E111 Fab 
Space group  P43212 P21 
Cell dimensions (Å) a= b=135.2, c=52.2 a= 82.9, b= 52.0, c=136.4 
Total reflections 105832 44787 
Unique reflections 17132 11029 
Resolution  50.0-2.5 Å (2.59-2.50) 50.0-3.8 Å (3.97-3.8) 
Completeness (%) 98.1% (94.3%) 97.4% (98.6%) 
Rsym (%)          9.2 (49.4%) 12.0 (51.4 %) 
I/σ (I)    18.78 (2.35) 9.74 (1.91) 
Refinement 
Resolution  41.36-2.50 Å (2.65-2.50) 43.45-3.79 Å (4.18-3.80) 
R-work  17.2% 23. 7% 
R-free   22.9% 27.8 % 
Ramachandran favored 97.4% 97.0 % 
Ramachandran outliers   0.3% 0.4% 
Rotamer outliers  0% 0.0% 
Protein residues  328 1060 
Water molecules 139 Not Placed 
Average B-factor 57.6 Å2 158.0 Å2 
R.m.s.d. bond angles 0.004° 0.003° 
R.m.s.d. bond lengths 0.883 Å 0.860 Å 
MolProbity score 100th percentile 100th percentile 
MolProbity clash score 99th percentile 97th percentile 
 
Values in parentheses are for the highest resolution shell.
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Table 2. E111-DIII interface  
16007 DIII – E111 scFv Western Pacific-74 DIII – E111 
Fab 
Van der Waals contactsa 
DIII E111 scFv  E111 Fab  
Val300 AsnL53    
Met301 AsnL53  AsnL53  
LeuL50 
 
Lys334 AsnL30D  AsnL30D  
Pro336 TrpH99  TrpH99  
Phe337 TyrL30B  TyrL30B  





















































Gln347 HisL30A  HisL30A  
Gly349 TyrL30B  TyrL30B  
Arg350 TryL30B  TyrL30B  
Leu351 TyrL30B  TyrL30B  
Pro372 TyrL30B  TyrL30B  
Val379 PheH97  PheH97  
Ala382 PheH96  
PheH97 
TrpH99 















     










TyrL30B (OH) 2.96 TyrL30B (OH) 2.71 
Ser339 (O)   HisL30A (NE2) 2.95 
Lys343(O) ArgH50 (NE) 2.93 ArgH50 (NE) 3.29 
Lys343(O) ArgH50 (NH1) 2.90 ArgH50 (NH1) 3.20 
Lys343(NZ) AsnH57 (O) 3.00 AsnH57 (O) 3.32 
Thr346 (OG1) AsnL91 (O) 2.77 AsnL91 (O) 2.81 
Gly383 (N) PheH97 (O) 2.59 PheH97 (O) 2.84 
     
E111/DIII water mediated hydrogen bondsb,c 
DIII E111    
Ile335 (O) AsnL53 (OD1)    
Phe337 (O) AsnL30D (OD1) 
HisL30A (O) 
   
Asp341 (OD2) LysH58 (NZ)    
Lys343 (NZ) AsnH57 (O) 
AsnH57 (OD1) 
   
Gly344 (O) TyrL96 (OH)    
Thr346 (O) AspL92 (O)    
Thr346 (OG1/N) AspL91 (O) 
AsnL92 (O) 
AsnL94 (OD1) 
   
Asn348 (OD1) HisL30A (ND1) 
AsnL92 (OD1) 
   
Asn348 (OD1) AsnL92 (O)    
Gly349 (O) TyrL30B (N)    
 
aVan der Waals contacts have interatomic distance ≤ 4.0 Å  
bPutative H-bonds defined by HBPlus (McDonald IK) 
cWater molecules were not placed in the E111 Fab-West Pac-74 DIII structure.
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Table 3. SPR results for binding of DENV-1 E111 to DIII variants. 
 
a Values for ka, kd, KD are means ± standard deviations. KD = kd/ka; t1/2 = ln(2)/kd. 
b  P-values were determined in comparison to the 16007 half-life value by t-test: * P < 
0.05, ** P < 0.01, *** P < 0.001. 
 
DIII variant 



















Western Pacific-74 2.56  ± 
0.18 
106.4 ± 





3146 SL 2.67 ± 
1.02 
141.6 ± 


















1.21 ± 0.4 
4.57 ± 
0.77 



























± 14 N.S. 


















± 11 ** 
16007 A369T 1.51 ± 
0.12 
3.83 ± 




± 25 N.S. 
16007 V380I 1.24 ± 
0.05 
2.36 ± 




± 34 * 
E111 scFv-16007 
DIII  2.88 ± 0.7  
6.95 ± 
0.7 






± 9.7  ** 
E111 scFv- 











± 0.2  
*** 
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Table 4. PRNT50 values of E111 against strains representing five DENV-1 
genotypes.  
 
DENV-1 strain Genotype PRNT50  
(ng/ml) ± SD 
16007  2 3.8 (± 2.0) 
3146 SL  5 21 (± 10) 
Western Pacific-74 4 9,720 (± 3,180) 
TVP-5175  3 >25,000 ng/ml 
TVP-2130 1 >25,000 ng/ml 
 
Neutralizing activity was determined by PRNT assay on Vero cells with increasing 
concentrations of purified DENV1-E111 and 102 PFU of the indicated DENV-1 
genotypes. The data was derived from three independent experiments performed in 
duplicate. PRNT50 values were calculated by non-linear regression analysis and SD 
indicates the standard deviations. 
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Table 5. DENV-1 DIII oligonucleotide primers.  
 







































6 16007 T339S 5’-GCAAGTTCCCTTTTCGAGCCAAGATGAGAAAGG-3’ 
7 16007 D341N 5’-GCAAGATTCCCTTTTCGACCCAAAATGAGAAAGGAGC
A-3’ 
 
8 16007 A345V 5’-CCAAGATGAGAAAGGAGTAACCCAGAATGGGAGAT -3’ 
 
9 16007 L351V  5’-GGAGCAACCCAGAATGGGAGAGTAATAACAGCCAACC
-3’ 
 
12 16007 A369T  5’-CCAGTCAATATTGAGACAGAACCACCCTTTGGTGAG- 




Figure 1: Expression and purification of proteins. (A) A scheme of the proteolytic 
cleavage of the E111 IgG2c molecule, purification, and complex purification with DIII of 
West Pac-74. (B) A scheme of E111 scFv construct design, expression, and purification 
with DIII of 16007. (C) Structural alignment of ribbon representations of the two 
structures. The chain colors are as follows: 16007 DIII (white), scFv light variable 
domain (cyan), scFv heavy variable domain (magenta), and the E111 Fab-West Pac-74 
structure is in light green. (D) Detailed hydrogen bonding interactions of 16007 DIII CC’ 
loop residues (yellow) with E111 light (cyan) and heavy (magenta) chains, with 




Figure 2. E111 in complex with DENV-1 DIII.  A ribbon diagram of the crystal 
structure of (A) E111 scFv in complex with DENV-1 strain 16007 DIII and (B) E111 Fab 
in complex with DENV-1 strain West Pac-74 DIII. The light chain is colored in cyan and 
the heavy chain in magenta. 16007 DIII is colored in light gray and West Pac-74 DIII is 
in gray. C. A surface model showing the contact residues in the scFv complex. Contacts 
in the scFv are highlighted by light chain (cyan) or heavy chain (magenta) contacts. DIII 
contacts are highlighted by heavy chain (magenta), light chain (cyan), or both chains 
(green).  D. A ribbon diagram showing the residues of DIII contacted by the E111 scFv in 
the crystal structure. E. A close-up of the contacts made by E111 in the CC’ loop of 
16007 DIII (yellow) or West Pac-74 DIII (white). F. Sequence of the four segments of 
16007 DIII contacted by E111 aligned with the analogous residues of the other four 




Figure 3. Kinetic analysis of E111 interaction with DENV-1 genotypes and single 
variants. A. Ribbon diagram of DENV-1 16007 DIII with amino acids highlighted 
corresponding to tested mutants. Lateral ridge mutants and A-strand mutants are shown 
in gray. Amino acids representing genotypic variation of DENV-1 are shown in green. B-
E. SPR curves of E111 MAb interacting with (B) 16007 DIII, (C) West Pac-74 DIII, (D) 
16007 DIII containing a T339S substitution or (E) 16007 DIII containing an A345V 
substitution. A single representative sensogram is shown for each DIII variant. The 
experimental curves (gray lines) were fit using a 1:1 Langmuir analysis (black lines), 
after double referencing, to determine the kinetic parameters presented in panel F and 
Table 3. Graphical representation of E111 binding to 16007 DIII mutants is presented 
according to the half-life (in seconds) of the interaction. The results are representative of 
a minimum of three independent experiments, with error bars showing standard 
deviation. Statistical significance was determined using a paired student t-test comparing 
the half-life of the E111 binding to 16007 DIII to that of another DIII variant. 
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Figure 4. E111 neutralization of different DENV-1 genotypes is only partially 
dependent on differences in epitope sequence. A. Plaque reduction and neutralization 
curves for five DENV-1 strains representing the five genotypes. The data is 
representative of three independent experiments performed in duplicate. PRNT50 values 
are shown in Table 4. B-C. Serial six-fold dilutions of (B) DENV1-E103 or (C) E111 
were incubated with wild type or V345A West Pac-74 RVPs for one hour at 37°C, and 
then added to Raji-DC-SIGNR cells. Infection was assessed by flow cytometry 48 hours 
later. One representative experiment of four is shown. The data is normalized relative to 
the infectivity of the RVPs in the absence of antibody. Error bars indicate standard error 




Figure 5. E111 neutralization occurs independently of the maturation state of 
DENV-1 particles. A-D. Serial dilutions of (A-B) E60 (DII-fusion loop) or (C-D) E111 
(DIII CC' loop) were added to the heterogeneous mixture of DENV-1 RVPs released 
from cells using standard production conditions (std, green triangles) or a more 
homogeneous mature population (mat, blue circles) of (A and C) DENV-1 West Pac-74 
or (B and D) DENV-1 16007 RVPs to determine the effect of the virus maturation state 
on MAb neutralization. MAb-RVP complexes were incubated for one hour at 37°C 
before being added to Raji-DC-SIGNR cells. Infectivity was determined by flow 
cytometry 48 hours later. One representative experiment of three is shown. The data is 
normalized relative to the infectivity of the RVPs in the absence of antibody. Error bars 





Figure 6. The structural basis of E111 neutralization. A. E111 Fab fragment docked 
onto the DENV-2 dimer (PDB 1OAN). Transparent gray space filled-ribbon model of 
DENV-2 dimer with N-linked glycans colored green. The E111 Fab light (cyan) and 
heavy (magenta) chains are shown bound to the equivalent DIII of the three dimensional 
structure within the DENV-2 dimer. The WNV E16 Fab (DIII lateral ridge antibody), in 
green and gold, (PDB 1ZTX) is docked onto the analogous DENV-2 residues for 
comparison. B. Surface representation of the DENV-1 post-fusion trimer structure. Upper 
panel: Each E protein in the trimer is colored independently (white, red and yellow), and 
the E111 epitope (colored as in Fig 2D) is mapped onto DIII. The red surface of DI was 
made transparent to show the ribbon structure. Lower panel: The E111 scFv complex was 
superimposed onto a monomer of the post-fusion trimer (white); The E111 scFv light 
chain (cyan) bound to DIII clashes with DI of the neighboring E monomer (red) 
suggesting that E111 likely would inhibit formation of the E homotrimer required for 
virus fusion. Clashing beta strands from DI are labeled. C. To determine whether E111 
neutralizes infection before or after cellular attachment, BHK21-15 cells were pre-chilled 
to 4°C, and 102 PFU of DENV-1 (16007) was added to each well for 1 h at 4°C. After 
extensive washing at 4°C, increasing concentrations of E111 were added for 1 h at 4°C, 
and the PRNT protocol was then completed (dashed lines, Post). In comparison, a 
standard pre-incubation PRNT with all steps performed at 4°C is shown for reference. In 
this case, virus and MAb were incubated together for 1 h at 4°C, prior to addition to cells 





Figure 7. Mapping of the E111 epitope on the DENV virion. The atomic structures of 
the (A) mature (PDB 1K4R), (B) immature (PDB 3C6D), and (C) 1A1D-2-bound 
DENV-2 (PDB 2R6P) are shown as determined by modeling of cryo electron-microscopy 
reconstructions. E proteins in each icosahedral symmetry axis are highlighted: yellow (5-
fold), blue (3-fold), or red (2-fold). The E111 epitope is colored in cyan in each 
symmetry group. To visualize the localization of the E111 epitope (on the interior of the 
viral surface in certain axes) a cross-section of each viral particle is shown. prM is 
colored in green on the immature virus model. In panel C, the 1A1D-2 Fab fragments 
were removed from the deposited cryo-electron microscopy structure to show only the 




Figure 8. The E111 epitope is occluded in the three existing cryo-electron 
microscopic models of DENV for different reasons. The equivalent residues were 
mapped onto the surface of the DENV-2 mature cryo-electron microscopy atomic 
reconstruction model (see Fig 7A; PDB 1K4R). The orientation of bound E111 places the 
Fab within the plane of the E protein arrangement on the viral surface (Fig 8A), DIII in 
gold at the 3-fold axis. The contacts made by the E111 scFv (Fig 8B, colored as in Fig 
2D) are shown in contrast to the contacts made by neighboring E proteins for the mature 
virus in the two-fold (C), three-fold (D), or five-fold (E) axes of symmetry. The DIII 
molecules are oriented and colored as in Fig 2D, while the contacts of the adjacent E 
proteins are shown in red. The immature form of DENV-2 (PDB 3C6D) shows a 
different impediment to E111 engagement. The formation of the prM-E heterotrimers on 
the surface of the virus pushes the E111 epitope towards the interior of the virus (see Fig 
7B). Individual chains from the 2-fold (red), 3-fold (blue), and 5-fold (yellow) associated 
with prM form the homotrimeric spikes on the surface of the immature virus (Fig 8F-H). 
While the E proteins from each chain contact at DIII (H), the repositioning of DIII 
towards the interior of the immature virus (F, side view, and G, bottom view) prevents its 
accessibility in this model. The final model of DENV complexed with the 1A1D-2 Fab 
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(PDB 2R6P) is shown in Fig 8C. The E111 epitope is surface accessible in all three axes 
of symmetry, in contrast to that of the immature virus.  However, steric hindrance at the 
3-fold (I) and 5-fold (J) axes due to the tight spatial arrangement of neighboring DIII 
prohibits E111 engagement. Adjacent E proteins do not contact DIII at the 2-fold axis. 
However, due to the orientation of the E111 epitope at this axis, there is insufficient 





Figure 9. Neutralization of DENV-1 by E111 varies with time and temperature in a 
genotype-dependent manner. Serial dilutions of E111 were incubated with (A and E) 
DENV-1 16007, (B and F) West Pac-74, (C and G) V345A West Pac-74, or (D and H) 
A345V 16007 RVP for 1 hour at 37ºC before the addition of Raji-DCSIGNR cells to 
establish reference neutralization curves. Additional DENV-1 RVP-E111 complexes 
were incubated for 2, 4.5, 7, and 22 hours at 37ºC (A-D) or 2 and 4.5 hours at 40ºC (E-H) 
before addition to Raji-DC-SIGNR cells. Infection was carried out at 37ºC and 
determined by flow cytometry 48 hours later. One representative experiment of three is 
shown. The data is normalized relative to the infectivity of the RVP in the absence of 
antibody at each time point for each temperature. Error bars indicate standard error of the 





Figure 10. Neutralization potency of DENV-1 by E111 for V345A West Pac-74 
RVPs approaches wild type 16007 RVP with an increase of time and temperature. 
Serial dilutions of E111 were incubated at (A) 37ºC or (B) 40ºC with DENV-1 16007, 
West Pac-74, and V345A West Pac-74 RVPs for 1 hour or 22 hours before the addition 
of Raji-DCSIGNR cells to establish reference neutralization curves. Infection was carried 
out at 37ºC and determined by flow cytometry 48 hours later. One representative 
experiment of three is shown. The data is normalized relative to the infectivity of the 
RVPs in the absence of antibody at each time point for each temperature. Error bars 
indicate standard error of the mean of replicate infections. 
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5.1 Abstract 
 The dengue viruses (DENV) are re-emerging, mosquito-transmitted viruses that 
cause dengue fever and severe dengue disease. This thesis has focused on the structural 
basis of antibody-mediated DENV neutralization. I have presented data concerning the 
initial identification and characterization of five epitopes found located within domain III 
(DIII) of the envelope (E) protein of DENV DIII. Epitope mapping of DENV-2 DIII 
reactive antibodies led to the classification of three DIII epitopes with varying 
neutralization potencies. Incorporation of structural modeling based upon the epitope 
mapping data allowed us to begin to explain how an epitope’s location within a virion 
correlates with its neutralization potential. There was a correlation between serotype 
specificity and surface accessibility on the virion with neutralization with antibodies that 
are more specific and accessibly being more potently neutralizing. Additionally, I 
presented data concerning the how the crystallographically determined structures of 
DENV-1 DIII bound by E106 and E111 led to new understanding of how bivalency and 
genotype-dependent conformations may contribute to neutralization. Based upon the 
above studies, I have included sections discussing the future directions for bivalency in 
neutralization of flaviviruses, the role alternate virion conformations may play in 
pathogenesis and antibody neutralization, future directions concerning vaccine design, 
development, and evaluation, and the possibility of antiviral DENV therapies. 
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5.2 Conclusions and Summary: DENV-2 DIII epitopes 
We initially fine epitope mapped a panel of DENV-2 DIII reactive antibodies with 
differing neutralization potency 1. These studies resulted in identification of three 
epitopes of DIII, two neutralizing and one non-neutralizing. 
Antibodies that mapped to DIII lateral ridge (DIII-LR) were type-specific and the 
most potently neutralizing, likely because the DIII-LR is completely accessible in the 
infectious DENV-2 virion structures. These results are consistent with other studies 
showing type-specific reactive antibodies are the most potently neutralizing 2–7. 
Antibodies against the A-strand reacted with and neutralized multiple DENV serotypes, 
likely due to higher sequence conservation in this region as compared to the DIII-LR 1,8. 
The AB loop antibodies were non-neutralizing in the strains we tested, though reacted 
with all four DENV serotypes and WNV. The AB loop is highly conserved in 
flaviviruses, though it does not appear to be readily accessible on the surface of the 
virion.  
Since the completion and publication of this work almost five years ago, several 
advancements have been made in understanding the atomic structure and functional 
behavior of antibodies against these epitopes. Our mapping analysis has been validated 
by other groups 9,10, and in serotypes other than DENV-2 11–14. The structures of Fab 
fragments bound to the A-strand 8,15 and AB loop have been determined, confirming the 
residues identified by yeast surface display. This structural work also explains why the A-
strand and AB loop epitopes are less potently neutralizing that the DIII-LR. The A-strand 
antibody 1A1D-2 and AB loop antibody 2H2 bind virions poorly when incubated at 4°C. 
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In fact, the cryo-EM atomic model of 1A1D-2 Fab bound to DENV-2 appears to capture 
a “breathing” conformation of the virus that is dependent on temperature 15.  
Overall, these more recent studies corroborate our classification of the lateral 
ridge, A-strand, and AB loop epitopes and their mechanistic correlates of protection. That 
A-strand and AB loop antibodies show a dependence on temperature for binding and 
neutralization suggests that their epitopes are not always available for binding. 
Conformational rearrangements of the E glycoproteins on the viral surface are necessary 
for binding and reaching the occupancy threshold for neutralization. While mapping 
studies did identify residues essential for antibody binding, modeling of these epitopes in 
the context of the virion allowed us to draw conclusions as to why each class of antibody 
has the functional properties it does.  
 
5.3 Conclusions and Summary: DENV1-E106  
Characterization of a panel of neutralizing antibodies raised against DENV-1 
strain 16007 yielded an interesting result. Unexpectedly, only 2 of 15 of these antibodies 
potently neutralized five strains of DENV-1 representing the five genotypes belonging to 
that serotype 14. These two potently neutralizing antibody antibodies DENV1-E105 and 
DENV1-E106 lost binding when residues on the BC, DE, and FG loops of the DIII-LR 
region were altered. Reduced binding DENV1-E106 binding was also seen upon the 
mutation of an A-strand residue (K310E). E105 and E106 were able to protect mice from 
lethal DENV-1 challenge before and after virus challenge. These results led us to explore 
additional structural and functional studies to explore how DENV1-E106 potently 
neutralizes DENV-1. 
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The most potently described DENV antibody, E106, binds a novel composite 
epitope consisting of residues of the DIII-LR and A-strand 14. To our surprise, the 
monovalent affinity of E106 to DIII was in the micromolar range, unlike most other 
neutralizing antibodies 5,8. Neutralization assays showed that the E106 Fab fragment 
neutralized virus >18,000-fold less potently than the intact IgG. A binding assay showed 
that the E106 MAb bound equivalent amounts of DENV-1 virus to other neutralizing 
antibodies while the E106 Fab fragment bound considerably less virus. These results 
suggest bivalent binding is requisite for potent inhibition for E106, making it unique 
among characterized flavivirus antibodies. 
Enveloped icosahedral viruses have ordered, repeating display of the virus 
glycoproteins on the virus surface. Yet, other flavivirus neutralizing antibodies have been 
shown to bind to viruses monovalently due to the arrangements of their epitopes on the 
viral surface 16–19. We speculate that while most antibodies may bind monovalently, a 
limited set of epitopes permit bivalent engagement facilitated by the array of repeating 
epitopes on the virus surface. 
 
5.4 Conclusions and Summary: DENV1-E111 
Another DIII-specific neutralizing MAb from our panel, E111 was not mapped to 
specific residues by yeast surface display. E111 potently neutralized infection of a 
genotype 2 DENV-1, but inhibited infection of a genotype 4 virus poorly (strain Western 
Pacific-74 14. Consistent with this, E111 bound DENV-1 West Pac-74 poorly in a virus 
capture ELISA. Sequence analysis of the variation between residues 296-400 of DIII for 
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16007 or West Pac-74 revealed only two differences (amino acids 339 and 345), with 
amino acid 345 as the only residue that varied in all five DENV-1 genotypes. 
 To explore in greater detail why E111 neutralized infection in a genotype-
dependent manner, we determined the crystal structures of an E111 single chain variable 
fragment (scFv) in complex with DIII of 16007 and the E111 Fab fragment in complex 
with DIII from West Pac-74. E111 bound to a previously uncharacterized epitope 
centered on the CC' loop of DIII, which should not be exposed on the virion according to 
existing flavivirus atomic models; our structural data defining the CC' loop epitope of 
E111 was supported by extensive mutagenesis and binding analyses. While E111 showed 
a higher affinity and longer half-life of binding to DIII of 16007 (genotype 2) compared 
to DIII from several other DENV-1 genotypes by surface plasmon resonance, this did not 
explain the disparity in neutralization potency for viruses from all five genotypes. 
Mutation at position 345 of West Pac-74 DIII to the corresponding residue in 16007 
resulted in increased E111 binding, but only a small improvement in neutralization 
potency, suggesting that differences in amino acids within the epitope among genotypes 
could not account for the phenotype. However, neutralization of DENV-1 West Pac-74 
with E111 was enhanced by incubating virus-antibody complexes at higher temperature 
or for longer times, whereas this treatment failed to equivalently impact inhibition of 
strain 16007 by E111. Our experiments suggest that the conformational ensemble of 
DENV virion structures differs in a genotype-dependent manner, which impacts the 
neutralizing activity of antibodies that recognize nominally cryptic epitopes. 
 
5.5 Future Directions: Complex DENV virion structures.  
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The structural biology of flaviviruses has been characterized extensively. Crystal 
structures of the soluble ectodomain of TBEV 20, WNV 21, Japanese Encephalitis virus 
(JEV) 22, and the four DENV serotypes 23–26 have been determined. Additionally, There 
are currently several atomic models of DENV virions by cryo-EM: the mature virion 27, 
the immature virion at low 28 and neutral pH 29, DENV-2 bound by 1A1D-2 Fab 
fragments 15, and the virion bound to the attachment factor DC-SIGN 30, in addition to 
multiple models of WNV 17–19,31,32, of the immature YFV 33, and that of TBEV subviral 
particles 34.   
Despite the bounty of information characterizing flavivirus structures, results 
from our lab and others suggests there remain additional virus conformations affecting 
pathogenesis. Our results show that E111 binds to the CC’ loop of DENV-1, which is not 
accessible for antibody binding in the current virion structures. Currently, there are no 
structures of DENV-1. However, we do not expect that DENV-1 virions adopt a radically 
different structure from those of DENV-2, as those of WNV and DENV-2 are quite 
similar for both immature and mature virions. Our collaborators are attempting to 
determine the structure of E111 in complex with DENV-1, as well as that of DV2-104, 
which binds the analogous DENV-2 DIII CC’ loop epitope 35, using cryo-EM. As we 
predict that E106 bivalently binds single virions, ultrastructural studies of the intact IgG 
or F(ab)2 fragments are needed to confirm this. 
While attempts to crystallize entire flaviviruses has met with limited success (36 
and unpublished results, B. Thompson, M.S. Diamond, and D.H. Fremont), utilization of 
a combination of cryo-EM, cryo-electron tomography, single particle reconstruction, and 
crystallography may overcome limitations of these techniques in isolation 37. Partially 
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mature particles are an example where a combinatorial approach is needed. The flavivirus 
maturation process is inefficient, especially for DENV 38–41. A recent study used cryo-
electron tomography to characterize partially mature, or mosaic, DENV-2 particles that 
displayed regions similar to mature and immature particles 42. However, cryo-ET does 
not provide atomic details, and due to the heterogeneity of the virion population, 
crystallography and cryo-EM are inadequate. Integration of these techniques should 
provide an opportunity to evaluate the atomic details of flavivirus structures of complex 
populations.  
 
5.6 Future Directions: Genotype-dependent conformational ensembles. 
 The antibody E111 shows disparate neutralization of DENV-1 strains 
representing the genotypes of this serotype. Our results support the conclusion that potent 
neutralization depends on genotype-dependent exposure of the CC’ loop epitope. This 
suggests that these viruses exist in differing conformational ensembles that exposes the 
CC’ loop at differing frequencies. However, questions remain concerning the biological 
function and consequences of these differing ensembles.  
Firstly, what are the determinants of the virus conformation with respect to 
epitope exposure? Examination of the DIII sequences from strain 16007 and West Pac-
74, reveal there are two sites of variation: position 339 and 345. Affinity and half-life 
measurements of E111 binding to soluble DIII mutants did show differences in the 
interaction kinetics. However, mutational analysis showed that exchange of amino acids 
within the E111 epitope among these strains could not explain the differential inhibitory 
activity of the antibody. This suggests that there are determinants outside of the epitope 
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that determine the rate of exposure for the CC’ loop. Our collaborators at the NIH (T. 
Pierson and K. Dowd) have begun to investigate the contributions of the additional sites 
of variation in the structural proteins in controlling different ensemble conformations.  
The second question pertaining to these alternate virus conformations asks what 
are the functional consequences of differing conformational ensembles? It is interesting 
to speculate that viruses using different conformational ensembles may have differing 
properties related to pathogenesis, tropism, neutralization, and virion stability. There are 
numerous reports in the literature that note differences in the virology between the 
different DENV serotypes, and even DENV genotypes. Correlations between clinical 
manifestations and the infecting DENV serotype (43 summary in Table 1) have been 
observed. Though, the mechanisms behind such differences are unknown. For the 
DENV-2 serotype, the Asian genotype is generally considered to be more virulent than 
the American genotype 44,45. A humanized mouse model of DENV-2 disease, showed 
disease phenotypes differed based upon the genotype of infection 46. And while a receptor 
for DENV has not been identified, there is evidence for differences in usage of 
attachment factors and receptors 47. Finally, unpublished results from T. Pierson and K. 
Dowd, show differences in virus stability between the DENV-1 strains 16007 and West 
Pac-74 RVPs.  
This is not to say that theses conformational ensembles contribute to all of these 
properties, only to suggest that these conformations remain uncharacterized in terms of 
DENV virology. 
 
5.7 Future Directions: DENV diagnostics and vaccines. 
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 Development of DENV diagnostics. Serologic diagnosis of DENV can be used 
after viremia is no longer detectable.  Diagnostic assays have been developed to identify 
the infecting DENV serotype based upon reactivity with monoclonal antibodies 48. An 
important consideration for DENV diagnosis using serology is the presence of cross-
reactive antibodies, due to previous infection or immunization with a related flavivirus 49. 
While the AB loop and the A-strand epitopes are conserved between the DENV 
serotypes, the DIII-LR and CC’ loop epitopes are not conserved. Previously, we 
successfully transferred the analogous WNV DIII-LR to DENV-2 DIII-LR in an attempt 
to examine the contribution of this epitope in neutralization 50. A similar approach could 
be taken to remove the AB and A-strand epitopes to develop a DIII epitope-based 
diagnostic reagent for polyclonal antibodies. Removal of these epitopes could abolish 
cross-reactivity with other flaviviruses and aid in the detection of the strongly 
neutralizing type-specific response. 
 DENV vaccine evaluation and development. Our data suggests that the ensemble 
of conformations of the DENV virion structure differ in a genotype-dependent manner 
and that these conformations affect the potency of antibody-mediated neutralization. 
Indeed, we observed that antibodies against the highly accessible DIII lateral ridge shows 
a time- and temperature-dependent increase in neutralization potency of different DENV-
1 genoypes (K. Dowd and T. Pierson, unpublished results).  
Selection of DENV strains that sample a greater diversity of conformations as 
vaccine candidates could broaden the repertoire of neutralizing antibodies against DENV. 
Such strains could better expose and present the spectrum of epitopes available, and 
thereby induce a more diverse neutralizing antibody repertoire. Alternatively, the use of 
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DENV strains or formulations with a limited structural ensemble could focus the 
neutralizing antibody response on specific epitopes whose accessibility is independent of 
time and temperature, and thus, more effective at neutralizing a diverse range of strains, 
regardless of particle conformation. Our work suggests that further empirical studies are 
necessary to assess directly how virion ensembles affect immunogenicity as well as 
pathogenesis. Finally, the conformational diversity of DENV strains used for evaluation 
of polyclonal serum could affect the interpretation of its neutralizing potential; for 
example, the choice of a DENV strain that cycles through limited structural 
conformations at 37oC for neutralization assays could underestimate the quality of the 
inhibitory activity of the antibody response in human serum.  
 
5.8 Future Directions: Antiviral Therapy of DENV 
 DENV is estimated to cause approximately 50 million infections annually 51. 
While there are several vaccines currently in clinical trials, none have been approved for 
use in humans to prevent or ameliorate disease. A major hurdle in vaccine development 
against DENV is inducing a neutralizing response to all four DENV serotypes due to the 
risk of ADE. There are also no specific treatments for DENV disease, and symptoms are 
treated in a supportive fashion.  
 Small molecule inhibitors. Research into DENV virology and immunity has 
received more attention and money in the last decade than ever before 
(www.niaid.nih.gov).  With the increased awareness of DENV has come an explosion in 
the number of researchers working to understand the viruses and the disease it causes. A 
detailed understanding of the viral lifecycle in during mammalian infection has revealed 
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multiple targets for anti-DENV therapies 52. Studies investigating the inhibiting DENV 
entry and fusion have shown effective inhibition using peptide mimetics of the stem loop 
regions of the E protein 53–55.  Another compound was shown to prevent viral fusion from 
a broad spectrum of enveloped viruses 56. Targeting viral replication and assembly with 
siRNA or shRNA has also shown efficacy in vitro 57–59. 
 Antibody therapeutics of flavivirus infections. Another source of therapeutics for 
the treatment of DENV infections is antibodies. Antibodies have been approved for the 
treatment of multiples diseases, as well as for viral infections 60–62. There are limited 
examples of antibody therapy for flavivirus infections, and most involve pooled 
convalescent serum for WNV infections in transplant patients 63–65. Humanization of 
WNV E16 (MGAWN1) has completed Phase II clinical trials for the treatment of WNV 
infection (www.clinicaltrials.gov). However, antibodies against multiple flaviviruses, 
including DENV, have been shown to protect after virus infection in animal models 
5,14,35,66–70. Although these studies have shown a potential for therapeutic treatment of 
flavivirus disease, there is a concern for enhancement of disease, especially for DENV. 
As with vaccination, the risk of ADE from passive immunotherapy poses a major 
challenge to its implementation. One approach to avoiding Fc-γ receptor-mediated 
enhancement is to make aglycosylated MAbs which will not engage these cellular 
receptors 70.  
 Challenges remain for developing and evaluating potential antiviral therapies for 
DENV. In the absence of a protective vaccine, pursuit of antiviral therapies could prove 
to be a worthwhile endeavor. 
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Abstract
Antibody protection against flaviviruses is associated with the development of neutralizing antibodies against the viral
envelope (E) protein. Prior studies with West Nile virus (WNV) identified therapeutic mouse and human monoclonal
antibodies (MAbs) that recognized epitopes on domain III (DIII) of the E protein. To identify an analogous panel of
neutralizing antibodies against DENV type-1 (DENV-1), we immunized mice with a genotype 2 strain of DENV-1 virus and
generated 79 new MAbs, 16 of which strongly inhibited infection by the homologous virus and localized to DIII. Surprisingly,
only two MAbs, DENV1-E105 and DENV1-E106, retained strong binding and neutralizing activity against all five DENV-1
genotypes. In an immunocompromised mouse model of infection, DENV1-E105 and DENV1-E106 exhibited therapeutic
activity even when administered as a single dose four days after inoculation with a heterologous genotype 4 strain of DENV-
1. Using epitope mapping and X-ray crystallographic analyses, we localized the neutralizing determinants for the strongly
inhibitory MAbs to distinct regions on DIII. Interestingly, sequence variation in DIII alone failed to explain disparities in
neutralizing potential of MAbs among different genotypes. Overall, our experiments define a complex structural epitope on
DIII of DENV-1 that can be recognized by protective antibodies with therapeutic potential.
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Introduction
Dengue virus (DENV) is a member of the Flaviviridae family and is
related to the viruses that cause yellow fever, and the Japanese, St.
Louis, and the West Nile encephalitides [1]. DENV infection after
mosquito inoculation causes a spectrum of clinical disease ranging
from a self-limited febrile illness (DF) to a life threatening
hemorrhagic and capillary leak syndrome (Dengue Hemorrhagic
Fever (DHF)/Dengue Shock Syndrome (DSS)). Globally, there is
significant diversity among DENV strains, including four distinct
serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) that differ at
the amino acid level in the viral envelope proteins by 25 to 40 percent.
There is additional complexity within a given DENV serotype, as
genotypes vary further by up to ,6% and 3% at the nucleotide and
amino acid levels, respectively [2,3]. At present, no approved antiviral
treatment or vaccine is available, and therapy is supportive. DENV
causes an estimated 25 to 100 million infections and 250,000 cases of
DHF/DSS per year worldwide, with 2.5 billion people at risk [4,5].
DENV is an enveloped virus with a single-stranded, positive-
sense RNA genome [6]. The 10.7 kilobase genome is translated as
a single polyprotein, which is cleaved into three structural proteins
(C, prM/M, E) and seven nonstructural (NS) proteins (NS1,
NS2A, NS2B, NS3, NS4A, NS4B, NS5). The mature DENV
virion has a well-organized outer protein shell, a lipid membrane
bilayer, and a less-defined inner nucleocapsid core [7,8]. The
ectodomains of DENV E proteins are assembled as dimers with
each subunit comprised of three discrete domains [9–11]. Domain
I (DI) is a central, eight-stranded b-barrel, which contains a single
N-linked glycosylation site in most DENV strains. Domain II (DII)
is a long, finger-like protrusion from DI and contains a second
N-linked glycan that binds to DC-SIGN [12–15] and the highly
conserved fusion peptide at its distal end. Domain III (DIII), which
adopts an immunoglobulin-like fold, has been argued to contain
a cell surface receptor recognition site [16–19]. Exposure to mildly
acidic conditions in the trans-Golgi secretory pathway pro-
motes virus maturation through a structural rearrangement of
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the flavivirus E proteins and cleavage of prM to M by a furin-like
protease [20,21]. Mature DENV virions are covered by 90 anti-
parallel E protein homodimers, which are arranged flat along the
surface with quasi-icosahedral symmetry.
Many flavivirus neutralizing antibodies recognize the structural
E protein (reviewed in [22]). Serotype-specific MAbs against
DENV reportedly have the greatest neutralizing activity [23,24]
although some sub-complex specific MAbs, which recognize some
but not all DENV serotypes, also are inhibitory [25–27].
Protection in animals by antibodies correlates generally with the
degree of neutralizing activity in vitro [24,28–31]. Several type-
specific strongly neutralizing antibodies against individual flavivi-
ruses (e.g., West Nile virus (WNV), Japanese encephalitis virus
(JEV), DENV-2, DENV-4, and yellow fever virus (YFV)) have
been localized to epitopes in DI and DIII [26,29,32–42]. Based on
their potency of neutralization and protection in vivo, anti-WNV
humanized or human MAbs are in clinical development as
candidate therapeutics (reviewed in [43]). Although type-specific
neutralizing MAbs against DENV-1 have been characterized
[44,45], few have been mapped to specific amino acids or
structural determinants. To date, only two neutralizing IgM
against DENV-1 were mapped by neutralization escape selection
to amino acids E279 and E293, which lie outside of DIII [46].
To develop neutralizing MAbs against DENV-1 with possible
clinical potential, mice were infected with a genotype 2 strain of a
DENV-1 virus, and boosted with recombinant protein of the
homologous virus. 79 new MAbs against DENV-1 were generated:
15 of these were DIII-specific IgG and strongly neutralized the
homologous DENV-1 strain. Of these, 9 were serotype-specific, 5
were sub-complex-specific, and only 1 MAb cross-reacted with all
4 serotypes of DENV. Several MAbs failed to neutralize at least
one DENV-1 strain of a distinct genotype, suggesting that
antibody recognition of the neutralizing epitopes on DIII varied
among genotypes.
As a first step towards generating antibody therapeutics against
DENV-1, we evaluated the protective capacity of these MAbs in an
immunocompromised IFN-abR2/26IFN-cR2/2 (AG129) mouse
infection model with a heterologous DENV-1 genotype 4 strain.
Among the strongly neutralizing antibodies tested, only four were
highly protective. Two MAbs, DENV1-E105 and DENV1-E106,
which neutralized all genotypes, were therapeutically active even
when administered as a single dose four days after infection. These
studies define the complexity of epitopes on DIII of DENV-1 that




Previous studies with WNV and DENV-2 demonstrated that
MAbs against DIII of the E protein protect against infection of cells
[26,27,29,32,35,41] and, in the case of WNV, in animals [29]. To
date, few DENV-1 MAbs have been characterized functionally or
mapped structurally. To develop neutralizing MAbs, mice were
infected with the 16007 (genotype 2) prototype strain of DENV-1
and in some cases, boosted with recombinant DIII from the
homologous DENV-1 strain. Initial immunization studies were
performed with wild type BALB/c mice as done previously with
WNV [29]. Because low neutralizing titers (,1/100) were achieved,
likely because of poor replication of DENV-1, we switched to an
immunodeficient (IFN-abR2/2) strain in the C57BL/6 back-
ground. After screening more than 3,000 hybridoma clones as part
of five independent fusions, we isolated and cloned 79 new MAbs
that recognized cells infected with DENV-1 (Table S1).
All MAbs were initially tested semi-quantitatively for neutral-
ization of the homologous DENV-1 strain by a single endpoint
plaque reduction assay in Vero or BHK21-15 cells using neat
hybridoma supernatant (,10 mg/ml). Of the MAbs generated, 18
showed no inhibitory activity (,15% neutralization), 45 had
modest inhibitory activity (15–75% neutralization) and 16 were
strongly inhibitory (.95% neutralizing). All MAbs were screened
for E protein domain recognition using yeast that expressed
DENV-1 DI-II or DIII on their surface (Table S1): 14 bound to
yeast expressing DI-DII, 53 recognized DIII, and the remaining
12 did not bind either DI-DII or DIII, indicating they recognized
epitopes that are not present on the truncated yeast-expressed
forms of DENV-1 E protein. All MAbs were tested for cross-
reactivity using cells infected with different serotypes of DENV or
WNV. Five of the fourteen DI-DII-specific MAbs and 26 of the 53
DIII-specific MAbs cross-reacted with other serotypes of DENV.
Only 3 of the 78 MAbs bound all DENV serotypes and WNV.
One of the neutralizing MAbs, DENV1-E50, was of the IgM
isotype and not evaluated further here.
Characterization of strongly neutralizing MAbs against
DENV-1
Studies with neutralizing mouse MAbs against DENV-2 defined
a type-specific epitope on the lateral ridge of DIII (DIII-LR) and
an adjacent more conserved b-strand termed the sub-complex-
specific DIII A-strand epitope [25–27,41]. As our single endpoint
titer neutralization experiments showed that all 15 inhibitory IgG
MAbs localized to DIII of DENV-1, we analyzed their reactivity
patterns with other strains. We found that 9 of the 15 neutralizing
IgG MAbs were serotype-specific and showed no cross-reactivity
to DENV-2, DENV-3, DENV-4 or WNV-infected cells. Five
MAbs were sub-complex specific and bound some but not all
DENV serotypes. Only one MAb, DENV1-E102, cross-reacted
with all DENV serotypes but not with WNV-infected cells
(Table 1).
Genotype-specific reactivity of anti-DENV-1 MAbs
As variation exists in the genetic composition of viruses within a
given DENV serotype, an intra-serotype genotype classification
system was developed [2,3], with a given genotype of a serotype
Author Summary
Dengue virus (DENV) is a mosquito-transmitted virus that
infects 25 to 100 million humans annually and can progress
to a life-threatening hemorrhagic fever and shock syn-
drome. Currently, no vaccines or specific therapies are
available. Prior studies identified a highly neutralizing
monoclonal antibody (MAb) against West Nile virus, a
related flavivirus, as a candidate therapy for humans. In this
study, we generated 79 new MAbs against the DENV type 1
(DENV-1) serotype, 16 of which strongly inhibited infection
in cell culture. Using structural and molecular approaches,
the binding sites of these inhibitory MAbs were localized to
distinct regions on domain III of the DENV-1 envelope
protein. We tested the protective capacity of all of the
neutralizing MAbs in mice against infection by a strain of
DENV-1 from a distinct genotype. Only two of the MAbs,
DENV1-E105 and DENV1-E106, showed efficacy in a post-
exposure treatment model, and these antibodies efficiently
neutralized all five DENV-1 genotypes. Collectively, our
studies define a complex structural binding site on domain
III of the envelope protein for MAbs with therapeutic
potential against DENV-1.
Therapeutic MAb Neutralization of DENV-1
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having no more than 6% nucleotide sequence divergence in the E
gene [47]. To address whether the neutralizing MAbs were
affected by the variation within the serotype, we tested reactivity
and neutralizing potential against individual strains that encom-
pass the five distinct DENV-1 genotypes: Asian genotype 1 (strain
TVP-2130), Thai genotype 2 (strain 16007), Malaysian genotype 3
(TVP-5175), South Pacific genotype 4 (strain West-Pac 74), and
American/African genotype 5 (strain 3146 SL).
(a) Binding to different DENV-1 genotypes. To determine
whether antibodies recognized different genotypes of DENV-1,
we infected Raji-DC-SIGN-R or C6/36 cells (depending on
permissiveness) with strains of the five different genotypes of
DENV-1. Infected cells were incubated with hybridoma super-
natants and analyzed by flow cytometry. All neutralizing MAbs
tested efficiently recognized genotypes 1, 2, 4, and 5. However, a
few of the MAbs (DENV1-E100, DENV1-E104, and DENV1-
E111) showed reduced binding to cells infected with the genotype
3 strain (Table 2). In contrast, other DIII-specific non-
neutralizing MAbs (e.g., DENV1-E91) showed reduced binding
to several of the heterologous DENV-1 genotypes (Fig 1).
(b) Neutralizing potential ofMAbs against different DENV-
1 genotypes. Although most MAbs retained binding to cells
infected with many of the genotypes, we questioned whether this
translated into efficient cross-genotypic neutralization. A recent
study of neutralization escape mutants with human MAbs against
WNV showed that retention of binding did not necessarily sustain
neutralizing activity [48]. To evaluate this, we assessed semi-
quantitatively the inhibitory activity of hybridoma supernatants of
15 neutralizing MAbs against all five genotypes by a standard
plaque reduction assay with 102 PFU of virus in Vero or BHK21-15
cells, depending on the strain (Table 3). Only 8 of 15 hybridoma
supernatants neutralized strains from all five genotypes by greater
than 90%, with three MAbs (DENV1-E103, DENV1-E105, and
DENV1-E106) showing 100% neutralization of all genotypes.
Several MAbs showed reduced neutralizing potential for individual
genotypes even at the relatively high (,10 mg/ml) concentration of
MAb used in the assay. For example, 9, 12, 12, and 14 MAbs
neutralized infection by DENV genotypes 1, 3, 4, and 5,
respectively. This was especially surprising for the genotype 1
strain as no appreciable reduction in binding to infected cells was
observed (Table 2). As an example, DENV1-E104 showed
relatively normal binding to the genotype 1 strain yet showed a
92% loss in neutralization activity. Some MAbs (DENV1-E100 and
DENV1-E111), which had decreased binding to genotype 3
infected cells, also showed reduced inhibitory activity. Others
(e.g., DENV1-E104) sustained normal inhibitory activity despite
attenuated binding to fixed, permeabilized cells. Although more
studies are necessary, this could reflect an epitope that is more
sensitive to fixation in the context of recognition of specific
genotypes.
To more rigorously characterize the neutralizing potency, we
purified MAbs and assessed their inhibitory activity against the
homologous genotype 2 (16007) strain in cell culture by
performing a dose-response curve and determining the concen-
tration of MAb (PRNT50, expressed here as ng/ml of antibody)
that blocked plaque formation by 50% (Table 4). For the
homologous genotype 2 16007 strain, 8 of 15 MAbs potently
neutralized infection with PRNT50 values below 5 ng/ml. This
value is significant as it is lower than that observed with our most
inhibitory anti-WNV MAb (E16), which functions successfully as a
post-exposure therapeutic agent [29,49,50]. Six other MAbs also
showed strong inhibitory activity with PRNT50 values against
16007 of between 10 and 70 ng/ml. Only one MAb, E104 showed
modest activity with a PRNT50 value of ,600 ng/ml.
Given our findings of genotype variation with respect to single
endpoint neutralization using hybridoma supernatants, we repeat-
Table 1. Binding of MAbs to cells infected with other DENV serotypes.
MAb Neutralization Specificity Binding to virus-infected cellsa
DENV-1 DENV-2 DENV-3 DENV-4
16007 16681 16652 H241
DENV1-E90 Strong Sub-complexb +++ 2 2 +++
DENV1-E95 Strong Type +++ 2 2 2
DENV1-E98 Strong Sub-complex +++ + +++ 2
DENV1-E99 Strong Sub-complex +++ +++ 2 2
DENV1-E100 Strong Type +++ 2 2 2
DENV1-E101 Strong Type +++ 2 2 2
DENV1-E102 Strong Cross-reactive +++ +++ + +++
DENV1-E103 Strong Type +++ 2 2 2
DENV1-E104 Moderate Type +++ 2 2 2
DENV1-E105 Strong Type +++ 2 2 2
DENV1-E106 Strong Sub-complex +++ 2 2 +++
DENV1-E108 Strong Type +++ 2 2 2
DENV1-E111 Strong Type +++ 2 2 2
DENV1-E112 Strong Type +++ 2 2 2
DENV1-E113 Strong Sub-complex +++ +++ 2 +++
Raji-DC-SIGN-R cells were infected with the indicated DENV serotypes and relative binding was determined by flow cytometry based on the mean fluorescence intensity
after staining with MAbs.
a+++, strong binding (40–100%) to infected cells; +, weak binding (15–40%) to infected cells; 2, no appreciable binding detected.
bsub-complex MAbs recognize some but not all DENV serotypes.
doi:10.1371/journal.ppat.1000823.t001
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ed the dose-response curve analysis with a heterologous genotype 4
(West Pac-74) (Table 4). Surprisingly, the neutralizing activity was
markedly decreased for all MAbs against the heterologous DENV-
1 genotype (e.g., 6 to 9600-fold for DENV1-E100 and DENV1-
E113, respectively). Only 2 MAbs, DENV1-E105 and DENV1-
E106, retained strong neutralizing activity (#20 ng/ml) against
the West Pac-74 strain. Seven of 15 MAbs neutralized West-Pac
74 poorly with PRNT50 values greater than 1 mg/ml of antibody.
Thus, the neutralizing efficiency of several DIII-specific anti-
DENV-1 MAbs was significantly altered against strains of a
different DENV-1 genotype.
Crystal structure of DENV-1 DIII and analysis of genotypic
variation
To begin to understand the disparity in inhibitory potential of
the DIII-specific neutralizing MAbs among different genotypes,
we determined the X-ray crystal structure of recombinant DIII of
the 16007 (genotype 2) strain at 2.25-A˚ resolution (Fig 2 and
Table 2. MAb binding to cells infected with different genotypes of DENV-1 virus.
MAb Binding to virusa
Genotype 1 Genotype 2 Genotype 3 Genotype 4 Genotype 5
TVP-2130 16007 TVP-5175 West Pac-74 3146-SL
DENV1-E90 93 98 83 95 95
DENV1-E95 94 98 81 95 95
DENV1-E98 97 98 83 96 97
DENV1-E99 96 98 84 96 97
DENV1-E100 93 98 70 94 95
DENV1-E101 93 98 82 95 96
DENV1-E102 92 98 78 94 94
DENV1-E103 94 98 83 95 95
DENV1-E104 93 98 71 94 92
DENV1-E105 89 98 75 94 95
DENV1-E106 94 98 75 95 95
DENV1-E108 93 98 77 95 94
DENV1-E111 90 98 57 93 92
DENV1-E112 94 98 81 95 95
DENV1-E113 90 98 74 93 93
aDepending on the strain, Raji-DC-SIGN-R or C6/36 cells were infected with different genotypes of DENV-1 viruses. Fixed and permeabilized infected cells were
incubated with the indicated MAbs (10 mg/ml) to determine the binding efficiency by flow cytometry. The data shown are the mean percentage of positive cells and
derived from three independent experiments. Values underlined and italicized are statistically different (P,0.05).
doi:10.1371/journal.ppat.1000823.t002
Figure 1. Binding of MAbs to cells infected with different genotypes of DENV-1. C6/36 insect cells were infected with strains of DENV-1
virus corresponding to all five genotypes. After fixation and permeabilization, MAbs were incubated with infected cells and binding was assessed by
flow cytometry. The data shown are representative histograms from two independent experiments with a neutralizing (DENV1-E106, upper panels)
and non-neutralizing (DENV1-E91, lower panels) MAb.
doi:10.1371/journal.ppat.1000823.g001
Therapeutic MAb Neutralization of DENV-1
PLoS Pathogens | www.plospathogens.org 4 April 2010 | Volume 6 | Issue 4 | e1000823
Table S2). Among the DENV-1 strains that represent the five
different genotypes used in this study, variation in DIII was limited
to nine residues, six of which were conservative substitutions (Fig 2
and Fig 3B). Four of the conservative substitutions (V/I380,
L/V351, T/S339, and D/N341) are predicted to be partially or
completely solvent inaccessible in the isolated DENV-1 DIII
crystal structure and cryoelectron microscopy reconstruction of the
mature virion [51], and thus, should not directly affect antibody
engagement. In contrast, the conservative substitution K/R361
should be accessible due to its location in the DE loop. S/T397,
the remaining conservative substitution is located after the
G-strand in a region that links DIII with the first a-helix of the
stem anchor motif. Of the three non-conservative substitutions,
A/T369 is completely buried and although A/I/V345 is largely
solvent accessible in the DIII crystal structure, it is likely buried in
the virion according to cryoelectron microscopy reconstructions.
The remaining non-conservative substitution (M/V297) occurs in
the N-terminal linker region that connects to DI, which is solvent
accessible in the DIII crystal structure, but less so in the mature
virion structure. In summary, amino acid variation in DIII among
the five different DENV-1 genotypes is modest, with the majority
of changes being solvent inaccessible. Indeed, none of the observed
genotypic variation occurs in residues previously implicated as
critical to the creation of neutralizing antibody epitopes in DENV
or related flaviviruses.
Epitope mapping of DIII neutralizing MAbs
On the basis of studies that mapped DIII-specific MAbs against
WNV and DENV-2 [25–27,29,41], we initially used reverse
genetics to engineer corresponding mutations (S305P, K307E,
E309K, K310E, V324I, T329G, D330G, K361E, E362K,
E384K, K385E, and K393E) on residues of the BC, DE, and
FG loops and the A b-strand (A-strand) of DIII of the genotype 2
Table 3. MAb neutralization of different DENV-1 genotypes.
MAb aPercent Neutralization (%)
Genotype 1 Genotype 2 Genotype 3 Genotype 4 Genotype 5
TVP-2130 16007 TVP-5175 West Pac-74 3146-SL
DENV1-E90 95 100 93 97 100
DENV1-E95 93 100 94 72 93
DENV1-E98 90 100 100 99 100
DENV1-E99 95 100 97 96 100
DENV1-E100 100 100 96 97 99
DENV1-E101 98 100 100 92 100
DENV1-E102 79 100 100 98 100
DENV1-E103 100 100 100 100 100
DENV1-E104 8 96 51 55 48
DENV1-E105 100 100 100 100 100
DENV1-E106 100 100 100 100 100
DENV1-E108 69 100 86 97 95
DENV1-E111 15 100 63 85 91
DENV1-E112 46 100 76 79 94
DENV1-E113 71 100 97 92 100
aNeutralizing activity was determined semi-quantitatively by single endpoint plaque reduction assay on BHK21 or Vero cells with neat hybridoma supernatant cells and
102 PFU of the indicated DENV-1 genotype. The data was derived from at least two independent assays performed in duplicate. Highlighted, italicized values indicate a
genotypic specific reduction in neutralizing potential of a given MAb using neat hybridoma supernatant of greater than 20%.
doi:10.1371/journal.ppat.1000823.t003
Table 4. PRNT50 values of MAbs against a homologous and
heterologous DENV-1 strain.








DENV1-E90 1.961.9 11616241 611
DENV1-E95 1463.1 856164480 612
DENV1-E98 1362.5 7576212 58
DENV1-E99 1163.9 8036116 73
DENV1-E100 2465.0 145642 6
DENV1-E101 0.860.5 10296327 1286
DENV1-E102 1.160.4 5756546 522
DENV1-E103 0.760.3 5426192 774
DENV1-E104 5906105 2306862720 39
DENV1-E105 0.560.09 2069.7 40
DENV1-E106 0.660.3 1367.5 21
DENV1-E108 7069.1 391261930 56
DENV1-E111 3.761.6 1519864905 4107
DENV1-E112 42613 1889163331 450
DENV1-E113 1.360.3 1249868911 9614
Neutralizing activity was determined by plaque reduction assay on BHK21 with
increasing concentrations of purified MAb cells and 102 PFU of the indicated DENV-1
genotype. The data was derived from three independent experiments performed in
duplicate. PRNT50 values were calculated by non-linear regression analysis and SD
indicates the standard deviations. The column on the right was obtained by dividing
the PRNT50 values from West Pac-74 by those of 16007 for a given MAb.
doi:10.1371/journal.ppat.1000823.t004
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(16007) strain, and displayed these variants on the surface of yeast.
All DIII-specific MAbs were screened for loss-of-binding to the
mutants to identify potentially critical recognition residues. Using
this strategy, we localized binding of seven MAbs (DENV1-E100,
DENV1-E101, DENV1-E102, DENV1-E103, DENV1-E104,
DENV1-E105, and DENV1-E106) to individual or combinations
of amino acids on the BC, DE, and FG loops of the lateral ridge of
DIII (Table 5, Fig 3A, B, and C). Analogously, five MAbs
(DENV1-E99, DENV1-E100, DENV1-E104, DENV1-E106, and
DENV1-E113) exhibited reduced binding after mutation of A-
strand (K307, E309, K310, and/or E311) residues (Fig 3D).
Three of the neutralizing MAbs (DENV1-E95, DENV1-E111,
and DENV1-E112), however, showed no appreciable reduction in
binding with analogous mutations in the lateral ridge or A-strand
residues that were identified from DENV-2 yeast screens.
Forward genetic screens subsequently were performed to define
additional residues that affected MAb binding. Error-prone PCR
introduced random point mutations within DIII of DENV-1 E
protein. Yeast were incubated sequentially with an Alexa Fluor 647-
conjugated individual MAb and an Alexa Fluor 488-conjugated
oligoclonal pool of MAbs to eliminate mutants that abolished
surface expression of DIII (see Materials and Methods). Yeast that
selectively lost expression of individual MAb epitopes were
identified, subjected to plasmid recovery, sequenced, and tested
for reactivity by flow cytometry against the remainder of the MAb
panel (Table 5). In total, 21 DIII residues were identified that when
changed resulted in a decrease in yeast staining by one or more
MAbs, with mutations in BC-loop residues most frequently
observed (Fig 3B). Only one of these residues (K/R361) is variable
amongst the five genotypes, an unexpected observation based on the
distinct genotypic specificities of the different MAbs.
The two most protective MAbs in vivo (see below), DENV1-
E105 (type-specific) and DENV1-E106 (sub-complex specific), lost
binding when residues on the BC (G328, T329 and D330), DE
(K361E and E362K), and FG (K385) loops of the DIII-LR region
were altered. Similarly, other protective MAbs (DENV1-E100
and DENV1-E103) also lost binding when residues in the BC
or DE loop were altered. Type-specific MAbs (DENV1-E95,
DENV1-E101, DENV1-E104, DENV1-E108, DENV1-E111, and
DENV1-E112) that inhibited genotype 2 (16007) yet poorly
neutralized the genotype 4 (West Pac-74) strain mapped to
additional sites in DIII. DENV1-E95, DENV1-E104, DENV1-
E108, and DENV1-E112 exhibited reduced binding with
mutations in the G-strand (S390, W391, and K393) (Fig 3E)
whereas DENV1-E101 was affected by changes in the N-terminal
linker (T303) and BC-loop (G328, T329, and D330). Surprisingly,
none of the mutations altered DENV-E111 binding, and forward
genetic screens with this MAb also failed to identify a loss-of-
binding variant (data not shown). DENV1-E104, which showed
the weakest neutralizing activity, localized to residues in the A
(K310 and E311), F (E375), and G (S390 and W391) b-strands.
Because of analogous studies with DENV-2, we anticipated that
sub-complex-specific and cross-reactive MAbs would recognize the
A-strand epitope [25–27]. Indeed, mutation of S305, K307, E309,
K310, and E311 reduced binding of several sub-complex MAbs
(DENV1-E98, DENV1-E99, DENV1-E106, and DENV1-E113)
in our panel. For the cross-reactive neutralizing MAb DENV1-
E102, its epitope localized to residues in the N-terminal linker
region (Y299, V300, and M301) and the BC loop (D330 and P332)
(Fig 3F). Although Y299, M301, and P332 are highly conserved
among strains of different DENV serotypes, V300 is specific for
DENV-1 and D330 is present in DENV-1 and DENV-3; this may
explain why DENV1-E102 fails to neutralize DENV-2 and
DENV-3 efficiently (S. Sukupolvi-Petty, J. Brien, and M.
Diamond, unpublished results).
Despite the extensive epitope mapping data (summarized in
Fig 3B and 4), no structural explanation was readily apparent for
the decrease in neutralization of the genotype 4 West Pac-74 strain
by several antibodies. MAbs that showed markedly depressed
neutralization of West Pac-74 localized to residues that were
instead conserved among DENV-1 genotypes. To begin to address
this, we evaluated whether individual MAbs differentially
recognized DIII from 16007 or West Pac-74 strains when
expressed on yeast; the DIII of these two strain differ by only
two amino acids at positions 339 and 345 in the C strand and C-
C9 loop (Fig 3B). Notably, all neutralizing MAbs equivalently
recognized yeast displaying DIII of 16007 or West Pac-74 over a
range of concentrations (Fig 5A, and data not shown). Thus,
sequences differences in DIII of West Pac-74 and 16007 did not
explain the differential patterns of neutralization. Because of this,
we hypothesized that sequences variation in other domains of the
West Pac-74 E protein could directly alter MAb binding or
perhaps influence the display of DIII on the infectious virion. To
test this, we performed a virion capture ELISA with 16007 and
West Pac-74 viruses and selected MAbs having different
neutralization profiles against the two strains (Fig 5B). DENV1-
E98, which exhibited a ,50-fold reduction in neutralization
showed little difference in binding over several concentrations of
antibody. In contrast, DENV1-E111, which had ,4,000-fold less
neutralizing activity, exhibited a depressed ability to bind West
Pac-74 compared to 16007. Surprisingly, DENV1-E90 and
DENV1-E113, which had ,600 to 9,600-fold differences in
PRNT50 values with West Pac-74 compared to 16007 showed
virtually no variation in binding in the capture ELISA. Thus,
differential neutralization of genotypes 2 and 4 of DENV-1 could
Figure 2. Crystal structure of DENV-1 DIII (strain 16007) and
analysis of genotypic variation. Ribbon diagram of Ig-like fold of
DENV-1 DIII with b-strands and loops labeled accordingly after solution
of the X-ray crystallographic structure at 2.25 A˚ resolution. Amino acid
sequences in DIII that vary among the five different DENV-1 genotypes
are indicated, with solvent inaccessible and accessible residues
depicted in blue and green, respectively.
doi:10.1371/journal.ppat.1000823.g002
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Figure 3. Epitope localization of anti-DENV-1 MAbs. A. Flow cytometry histograms of loss-of-function DIII variants (V324I, T329G, D330G,
K361E, E362K, and E384K) with individual neutralizing MAbs. Representative histograms are shown for the MAbs WNV E16 (negative control), DENV1-
E95, DENV1-101, DENV1-103, and DENV1-106 with the wild type DIII and each of the variants. Data shown are representative of three independent
experiments. B. Sequence alignment of different DENV-1 genotypes and mapping of neutralizing MAbs. The sequence and secondary structure of DIII
from DENV-1 (strain 16007, genotype 2) E protein is aligned with other DENV-1 genotypes (genotype 1, strain TVP-2130; genotype 3, strain TVP 5175;
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be explained by disparate binding to the virion for only a subset of
MAbs. For MAbs like DENV1-E90 and DENV1-E113, the profile
was similar to that observed with escape variants of a human anti-
WNV MAb; in that case, mutations that abolished neutralizing
activity did not appear to affect antibody binding to virus [48].
In vivo protection studies with neutralizing MAbs
Pre-exposure passive transfer of neutralizing MAbs against
WNV, DENV-2, and DENV-4 protects against lethal infection in
wild type and immunodeficient mice [24,29,52–56]. To confirm
that neutralizing anti-DENV-1 MAbs protect in vivo and begin to
explore the possibility for antibody therapy, we evaluated the
efficacy of our panel of inhibitory MAbs against West Pac-74, the
heterologous genotype 4 DENV-1 strain. The heterologous strain
was selected for two reasons: (i) the West Pac-74 strain was the
only DENV-1 isolate in our collection that caused 100% lethality
in an intraperitoneal challenge model in AG129 mice; and (ii) a
possible antibody therapeutic must demonstrate efficacy against
DENV-1 strains of different genotypes.
A single dose (500 mg) of neutralizing MAbs against DENV-1
was administered as prophylaxis one day prior to infection with
106 PFU of West Pac-74. Two MAbs (DENV1-E105 and
DENV1-E106) protected 100% of mice compared to PBS or
irrelevant MAb controls (P,0.0001), which had a 0% survival rate
(Table 6). Three other MAbs (DENV1-E99, DENV1-E100, and
DENV1-E103) exhibited strong yet incomplete protection with 60
to 80% survival rates. However, nine neutralizing MAbs (DENV1-
E90, DENV1-E95, DENV1-E98, DENV1-E101, DENV1-E102,
DENV1-E108, DENV1-E111, DENV1-E112 and DENV1-E113)
protected inefficiently, with an 11 to 38% survival rate. Although
the survival rate was relatively low for these MAbs, the mean time
to death (MTD) was protracted (2366.1 to 4068.6 days)
compared to untreated, infected mice (2063.3 days). One
neutralizing MAb, DENV1-E104 showed no protection against
lethality although a longer MTD was observed. In general, the
protective efficacy in vivo correlated with neutralizing activity
against the West Pac-74 genotype 4 strain. As an example,
DENV1-E105 and DENV1-E106 had low PRNT50 values (13 to
20 ng/ml) for West Pac-74 and protected against infection
whereas DENV1-E104 and DENV1-E112, which protected
poorly, had PRNT50 values (18 to 23 mg/ml) that were almost
1,000-fold different.
To begin to define the therapeutic potential of the highly
protective MAbs (DENV1-E99, DENV1-E103, DENV1-E105,
and DENV1-E106), we administered 5 and 25-fold lower doses
(100 mg and 20 mg) one day prior to IP infection of AG129 mice
with 106 PFU of West Pac-74. The lower doses of DENV1-E99
and DENV1-E103 provided sub-optimal protection against lethal
infection (Fig 6A and B), with only a delay in the MTD observed.
In comparison, ,50% of mice survived West Pac-74 infection
after receiving a single dose of 20 or 100 mg of DENV1-E105
antibody (Fig 6C, P#0.003). More strikingly, a single 20 or
100 mg injection of DENV1-E106 completely protected DENV-1
infected mice (Fig. 6D, P,0.0001). These data suggest that
DENV1-E106 was the most protective MAb in our panel of
neutralizing antibodies against infection by the heterologous
strain, DENV-1 West Pac-74.
Therapeutic studies with neutralizing MAbs
Antibody-based therapeutics against DENV will need to be
administered after infection. To assess the therapeutic efficacy of
strongly neutralizing anti-DENV-1 MAbs, mice were infected with
106 PFU of West Pac-74 and two days after infection, a single
500 mg MAb dose (DENV1-E99, DENV1-E103, DENV1-E105,
or DENV1-E106) was transferred passively by an IP route.
Notably, 500 mg of DENV1-E99 or DENV1-E103 provided no
protection with animals dying at a rate and time similar to
untreated mice (P.0.2). In contrast, DENV1-E105 and DENV1-
E106 protected 75 and 82% (P#0.0001) of mice, respectively,
when administered two days after infection. When a single dose of
DENV1-E105 or DENV1-E106 MAb was given four days after
infection, 20 and 40% (P#0.03) of mice, respectively were
protected from lethal infection (Fig 7A and B).
Given the potency of DENV1-E105 and DENV1-E106 in
protection against the genotype 4 West Pac-74 strain, we per-
formed PRNT50 analysis with strains corresponding to the
remaining genotypes to assess potential clinical utility of these
MAbs. Both DENV1-E105 and DENV1-E106 strongly neutral-
ized infection of all DENV-1 genotypes (Fig 8A and B), with
PRNT50 values ranging from 0.5 to 59.2 ng/ml. Thus, DENV1-
E105 and DENV1-E106 protected AG129 immunocompromised
mice as a pre and post-exposure treatment from infection by a
heterologous DENV-1 genotype and efficiently inhibited all
DENV-1 genotypes in cell culture.
Discussion
One primary goal of this study was to generate a collection of
strongly neutralizing MAbs that would recognize virtually all
DENV-1 strains and protect against infection as post-exposure
therapy. In an attempt to achieve this, we generated a panel of 79
new MAbs against DENV-1 E protein. Although neutralizing
antibodies can be generated against all three domains of the
flavivirus E protein [29,32,42,46,52,55,57,58], we mapped the
epitopes of the MAbs with the greatest inhibitory activity primarily
to epitopes on DIII, analogous to that observed with MAbs against
DENV-2 [25–27,41]. One surprising finding that has not been
reported previously was the disparate neutralizing activity and
protective potential of individual MAbs against different DENV-1
genotypes. In comparative studies with strains from genotype 2
and genotype 4, virtually all MAbs showed reduced (from 6 to
9,600-fold) PRNT50 values against the heterologous genotype.
Because of this, few (5 of 15) MAbs protected as pre-exposure
prophylaxis against infection by the heterologous DENV-1
genotype in AG129 mice, and only two (DENV1-E105 and
DENV1-E106) showed utility as post-exposure therapy.
Although many DENV strains can cause a similar debilitating
febrile illness in humans, there is significant genetic variation (25 to
40% amino acid difference for serotypes and up to 3% variation
among genotypes within a serotype) and phenotypic difference
in virulence among individual strains of specific serotypes and
genotype 4, strain Western Pacific-74; genotype 5, strain 3146 Sri Lanka). The secondary structure of DENV-1 E DIII residues 294 to 395 from the strains
that had not been crystallized was predicted by DSSP [112] using the 16007 strain coordinates. Black blocks highlight residues of genotypic variation.
The results of the yeast surface-display epitope mapping (see Table 5) are denoted underneath in red to indicate the number of neutralizing MAbs in
our panel that lose binding when a specific amino acid is changed. Colored boxes correspond to specific neutralizing antibody and structural recognition
determinants: N-terminal region, light purple; lateral ridge (BC, DE, and FG loops), dark purple; A-strand, cyan; and F- and G-strand, green. C–F.
Localization of neutralizing epitopes on DENV-1 DIII as determined by yeast surface display. Structure of DENV-1 DIII (strain 16007) with amino acid
residues marked in blue that significantly affect binding of neutralizing MAbs (C) DENV1-E106, (D) DENV1-E99, (E) DENV1-E95, and (F) DENV1-E102.
doi:10.1371/journal.ppat.1000823.g003
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genotypes [59–63]. Previous studies identified the lateral ridge and
A-strand epitopes in DIII as targets of strongly neutralizing type-
specific and sub-complex-specific neutralizing MAbs against
DENV-2 and DENV-3 [26,27,41,64–67] and the fusion loop in
DII as a recognition site for many cross-reactive neutralizing
DENV MAbs [58,68,69]. In comparison, the serotype-specific
5H2 neutralizing MAb against DENV-4 localized to the loop
between the G and H b-strand in DI [42]. Prior to our study, little
was known as to how neutralizing antibodies recognized DENV-1.
Although neutralizing anti-DENV-1 MAbs have been generated
[44,45], few were localized to specific amino acids or structural
domains. Two neutralizing IgM against DENV-1 were mapped by
neutralization escape selection to amino acids E279 and E293, at
the hinges between DI and DII or DI and DIII, respectively [46].
While our experiments establish that highly neutralizing antibodies
recognize determinants in DIII of DENV-1, we do not rule out the
existence of other epitopes in distinct regions. Rather, the panel of
MAbs that we obtained may be skewed by the immunization
protocol (boosting with recombinant DIII), primary screen, and
genetic background of the animals, which influences the B cell
repertoire. Indeed, for WNV we have recently identified strongly
neutralizing and fusion-blocking human MAbs that poorly
recognize recombinant forms of the E protein and map to the
DI-DII hinge and dimer contact regions [48].
This is the first study that describes a post-exposure therapeutic
effect of a MAb against any DENV strain in any animal model. In
particular, DENV1-E105 and DENV1-E106, which neutralized
all five DENV-1 genotypes showed efficacy when administered
two or four days after infection of highly immunocompromised
AG129 mice. In contrast, three other neutralizing MAbs (DENV1-
E99, DENV1-E100, and DENV1-103) failed to protect when
added a few days after infection even though they functioned as
pre-exposure prophylaxis. Although prior studies demonstrated
that anti-E MAbs protect against DENV infection in rodents and
non-human primates [42,55,56,70,71], none have reported
efficacy when added after infection. It is noteworthy that the
two MAbs with the most neutralizing PRNT50 values were the
ones with greatest therapeutic efficacy, suggesting, at least for
strongly neutralizing MAbs of a given class, a correlation between
in vitro and in vivo activity. It is unclear why therapeutic anti-
DENV MAbs have not been previously described. Several post-
exposure therapeutic MAbs or polyclonal antibody preparations
against WNV, JEV, YFV, and tick-borne encephalitis virus have
been reported [29,30,53,57,72–77], with some entering human
clinical trials [43]. One speculation is that because viremia
associated with DENV infection is several log greater than WNV
[78–80], a condition of viral antigen excess occurs more rapidly in
circulation leading to fewer antibody molecules binding to a given
DENV virion. As neutralization is determined in part by the
stoichiometry of antibody binding [81,82], only MAbs that can
block infection at low fractional occupancy may be capable of
neutralizing in vivo.
MAb-based therapeutics against DENV could be complicated
by antibody-dependent enhancement of infection (ADE). Sub-
neutralizing concentrations of antibody augment infection of Fc-c
receptor-expressing cells possibly by enhancing the efficiency of
virus attachment or entry [83,84]. Thus, the administration of
virus-specific MAbs could adversely impact the outcome of DENV
infection. In non-human primates, passive transfer of sub-
neutralizing concentrations of monoclonal or polyclonal antibody
increased viremia although no change in disease status was
observed [85,86]. Based on the possibility of ADE, MAb
therapeutics against DENV in humans would appear to have
considerable regulatory hurdles. However, recent studies with
amino acid substitutions or deletions in the Fc region of
recombinant anti-flavivirus antibodies prevented ADE in vitro
and in vivo [86–88]. As such, studies are underway to engineer
mutations into the Fc region of a humanized version of DENV1-
E106 that abolishes the possibility of enhancement by abrogating
binding to Fc-c receptors.
Amino acid contact residues of neutralizing MAbs that react
with DENV-2 or DENV-3 have been defined by analyzing
neutralization escape mutants [40], chimeric DENV variants [89],
site-specific DENV-2 mutants [68,90], peptide mapping
[65,91,92], yeast surface display of variant E proteins [25,26,66],
mutant recombinant proteins [27,41,67], and by co-crystallogra-
phy of recombinant DENV proteins and Fab fragments of
neutralizing MAbs [25]. Here, we used genetic strategies to
generate mutant DIII of DENV-1 on yeast to map antibody
recognition residues. The validity of the yeast surface display
mapping for identifying critical contact residues has been
confirmed by crystallographic studies that resolved the structural
interface between WNV and DENV2 DIII Fab fragments [25,93]
as well as DII-fusion loop specific Fab recognition [94]. For
neutralizing type-specific DENV-2 MAbs that mapped to specific
amino acid residues in DIII, the majority localized to residues in
the BC and FG loops within the lateral ridge [26,41]. Our yeast
mapping experiments confirm that the lateral ridge and A-strand
on DIII are also recognized by strongly neutralizing anti-DENV-1
antibodies.
The detailed mapping of neutralizing anti-DENV-1 MAbs
identified two additional regions on DIII that comprised protective
epitope(s): (a) DENV1-E102 and DENV1-E113, which react with
Figure 4. Summary of neutralizing antibody and structural
recognition determinants on DENV-1 DIII. Data from yeast surface
display (Table 5) and sequence alignment (Fig 3B) were mapped onto
the crystal structure of DENV-1 DIII to visualize the composite epitopes
of different neutralizing MAbs. Recognition sites include N-terminal
region, light purple; lateral ridge (BC, DE, and FG loops), dark purple; A-
strand, cyan; and F- and G-strand, green.
doi:10.1371/journal.ppat.1000823.g004
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Figure 5. Binding of MAbs to DIII or virions of 16007 and West Pac-74. A. MAb binding to DIII of 16007 or West Pac-74 on yeast. Flow
cytometry histograms of DIII of 16007 or West Pac-74 (different at residues 339 and 345) with neutralizing MAbs. Data shown are representative of
two independent experiments. B. A capture ELISA was used to detect binding of MAbs to 16007 and West Pac-74 virions. Microtiter plates were
coated with the indicated MAbs, incubated with 26105 PFU of 16007 or West Pac-74 at room temperature, and with biotinylated anti-E MAbs. The
data is an average of several separate experiments performed in duplicate, and error bars indicate standard deviation.
doi:10.1371/journal.ppat.1000823.g005
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multiple DENV serotypes, showed an almost complete loss-of-
binding with mutation of residues (Y299, V300, and M301) in the
N-terminal linker region. This result is analogous to that described
for neutralizing DENV-2 MAbs where the mutation M301G
abolished reactivity of five complex-specific and seven serotype-
specific MAbs [27,41]. The binding of the N-terminal linker by
MAbs against WNV has been speculated to contribute to
neutralization by inhibiting the significant rotation of DIII during
the dimer to trimer transition [93]. (b) DENV1-E95, DENV1-E98,
DENV1-E104, DENV1-E108, and DENV1-E112 exhibited loss
of binding when residues (S390, W391, and K393) in the G-strand
were changed. As the G-strand of the DIII is solvent accessible on
the surface of the DENV virion [7], it is structurally feasible that
recognition of this region by MAbs will inhibit infection. Indeed, in
experiments that assessed the reactivity of a panel of complex-
specific neutralizing MAbs against DENV-2 and DENV-3 DIII,
mutation of G-strand residues also reduced binding [27,67].
Additionally, X-ray crystallography studies identified residues
K388 and N390 in the G-strand of DENV-2 as contacts for the
neutralizing sub-complex-specific MAb 1A1D-2 [25]. These
studies suggest that DIII is a complex antigen that is recognized
by neutralizing MAbs that localize to one of four overlapping
regions: the N-terminal linker, A-strand, lateral ridge loops, and
G-strand. What remains uncertain is whether binding to specific
determinants on DIII influences the mechanism of antibody
neutralization of DENV.
Although our most strongly neutralizing MAbs localized to DIII
of DENV-1, these antibodies were derived from immunodeficient
mice, which may not necessarily reflect the neutralizing antibody
response in humans. The antibody repertoire against DENV-1 or
other serotypes in humans remains unknown, as B cell profiling at
the epitope level has not been performed. Nonetheless, recent
studies suggest that the humoral response against flaviviruses in
humans may be directed away from DIII neutralizing epitopes
[53,54,95]. DIII-specific antibodies comprised only a small
fraction of the total antibody in DENV immune sera [96,97];
whether these antibodies contribute to DENV neutralization in
vivo remains controversial. Because highly neutralizing antibodies
against DIII of DENV-1, DENV-2, and DENV-3 map to the
lateral ridge and A-strand epitopes [26,27,41,67], DIII-based
vaccines [98–101] that skew the humoral response have the
potential to elicit highly protective responses.
One intriguing finding was the disparate neutralizing activity of
individual MAbs against different DENV-1 genotypes. Infection
with one DENV serotype is believed to confer long-term immunity
against strains of the homologous but not heterologous DENV
serotypes. Based on this, we assumed it would be straightforward
to generate DIII-specific therapeutic MAbs that neutralized all five
genotypes within the DENV-1 serotype. Indeed, there are limited
amino acid changes in DIII among DENV-1 genotypes with a
maximum difference of seven amino acids, with genotype 5 the
most diverse although the changes are largely conserved and reside
in solvent inaccessible regions. Nonetheless, several MAbs in the
panel exhibited markedly depressed neutralizing activity against
the heterologous West Pac-74 strain. This was perplexing given
that the 16007 and West Pac-74 strains differ in DIII by two
amino acids, which were not coincident with our epitope mapping
data: a TRS change at residue 339 in the C-strand and an ARV
change at residue 345 in the C-C9 loop. Indeed, in comparative
binding assays with 16007 and West Pac-74 DIII on yeast, no
obvious difference in binding at saturating concentrations of MAb
was observed. When studies were repeated with selected MAbs in
a virus capture ELISA, one MAb (DENV1-E111) with disparate
neutralizing potential showed reduced binding to West Pac-74, but
others (DENV1-E90 and DENV1-E113) did not. This was
corroborated in surface plasmon resonance studies, which showed
an ,10-fold decrease in the KD of binding of DENV1-E111
for West Pac-74 DIII (K. Austin, M. Diamond, D. Fremont,
unpublished results). Although further structural studies are
warranted, we propose four hypotheses to explain these results:
(a) similar to findings with a recently characterized human anti-
WNV MAb [48], mutations that abrogate neutralizing activity do
not always reduce measurable antibody binding to the virion; (b)
because of sequence variation outside of DIII, the E protein of
different DENV-1 genotypes may pack differently on the virion.
Some components of an epitope for a given MAb may be
differentially exposed on virions of distinct genotype; (c) individual
loss-of-function mutations identified by yeast display do not
necessarily represent the complete footprint on DIII of bound
antibody, as mutation of other residues may have allosteric effects;
or (d) neutralizing anti-DENV-1 MAbs in our panel may have
additional amino acid contacts outside of DIII that vary among
the DENV-1 genotypes. Notably, we did not observe detectable
binding of any the DIII-specific neutralizing MAbs to a DI-DII
protein displayed on yeast (data not shown). Structural studies with
Fab-E protein or Fab-virion complexes will be required to address
these possibilities.
Regardless of the mechanism, our results suggest that antibodies
against one DENV genotype may have decreased inhibitory
potency against a heterologous genotype within the same serotype.
Table 6. In vivo protection of AG129 mice from West Pac-74




(mg/mouse) Survival MTDa 6 SD P valueb
No MAb 0 0/12 2063
WNV E16 500 0/5 1862 NS
DENV1-E90 500 2/9 3767 ,0.0001
DENV1-E95 500 2/10 36611 ,0.0001
DENV1-E98 500 2/8 34614 0.002
DENV1-E99 500 6/8 5263 ,0.0001
DENV1-E100 500 6/10 35617 ,0.0001
DENV1-E101 500 3/8 34612 0.0005
DENV1-E102 500 1/9 2366 0.03
DENV1-E103 500 7/10 29614 ,0.0001
DENV1-E104 500 0/8 2668 0.03
DENV1-E105 500 8/8 NA ,0.0001
DENV1-E106 500 10/10 NA ,0.0001
DENV1-E108 500 2/8 4069 ,0.0001
DENV1-E111 500 2/8 2868 0.001
DENV1-E112 500 1/8 25611 0.03
DENV1-E113 500 1/8 34611 0.001
Mice were administered with 500 mg of indicated MAbs one day before
infection with 106 PFU of West Pac-74 by an IP route. Mice were monitored for
survival for 60 days after infection. NS, not statistically different from PBS
control.
aMean time to death (MTD) 6 standard deviations (SD) refers to the mean time
to death of the animals that succumbed to fatal infection. NA, indicates that no
animals died in the presence of this MAb, and thus, the value was not
calculated.
bP values were calculated using the log rank test of the Kaplan Meier survival
curve by comparing the no antibody treated and antibody treated mice.
doi:10.1371/journal.ppat.1000823.t006
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This has potential implications for assessing the breadth
of the protective efficacy of tetravalent DENV vaccines, which
are in advanced clinical trials. In addition to evaluating
protection against other serotypes, it may be critical to assess
whether antibody responses against the vaccine strain of a




Vero, BHK21-15 and Raji-DC-SIGN-R cells were cultured in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
10% fetal bovine serum (FBS) (Omega Scientific) and antibiotics
(penicillin G and streptomycin) at 37uC in a 5% CO2 incubator.
Figure 6. Dose response of protective efficacy MAbs in mice infected with DENV-1. AG129 mice were passively transferred saline or 20,
100, or 500 mg of (A) DENV1-E99, (B) DENV1-E103, (C) DENV1-E105, and (D) DENV1-E106 MAbs one day before infection with 106 PFU of West Pac-74
(genotype 4) by an IP route. Mice were monitored for survival for 60 days after infection. The survival curves were constructed from data of two
independent experiments. The number of animals for each antibody dose ranged from 5 to 10 per group.
doi:10.1371/journal.ppat.1000823.g006
Figure 7. Therapeutic efficacy of strongly neutralizing antibodies in mice after DENV-1 infection. Mice were administered saline or a
single 500 mg dose of DENV1-E105 or DENV1-E106 MAbs at day (A) 2 or (B) 4 after infection with 106 PFU of West Pac-74 (genotype 4) by an IP route.
Mice were monitored for survival for 60 days after infection. The number of animals for each antibody ranged from 10 to 11 per group.
doi:10.1371/journal.ppat.1000823.g007
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Strains from all five genotypes of DENV-1 included: TVP-2130
(genotype 1), 16007 (genotype 2), TVP-5175 (genotype 3), Western
Pacific-74 (genotype 4) and 3146 Sri Lanka (genotype 5). TVP-
2130 and TVP-5175 were obtained from Dr. Robert Tesh and the
World Reference Center for Emerging Viruses and Arboviruses
(University of Texas Medical Branch, Galveston, TX). Western
Pacific-74 (West Pac-74) and the 3146 Sri Lanka strain were
obtained from Drs. Stephen Whitehead (NIAID, NIH, Bethesda,
MD) and Rebeca Rico-Hesse (Southwest Foundation for Biomed-
ical Research, San Antonio, Texas), respectively. Strains corre-
sponding to other DENV serotypes were also used: 16681 (DENV-
2), 16652 (DENV-3), and H241 (DENV-4). All viruses were
amplified in C6/36 Aedes albopictus cells according to previously
described protocols [26].
Generation, purification, and labeling of anti-DENV-1
MAbs
MAbs were generated essentially as described [29] after
performing several independent splenocyte-myeloma fusions. To
generate anti-DENV-1 MAbs, IFN-abR2/2 C57BL/6 mice were
infected with 105 PFU of DENV-1 strain 16007 (genotype 2) via
an intraperitoneal route and re-challenged two weeks later with
the same strain. Mice with serum having the highest neutralizing
titer (.1/1500) were immunized with purified DIII (50 mg, strain
16007) in PBS as a final intravenous boost. Three days later
splenocytes were fused to P3X63Ag8.53 myeloma cells [102].
MAbs were subcloned by limiting dilution, isotyped (Pierce Rapid
ELISA Kit), and purified using protein A affinity chromatography
(Invitrogen). For library sorting experiments, MAbs were labeled
with Alexa Fluor 647 or Alexa Fluor 488, using a MAb labeling kit
(Molecular Probes) according to the manufacturer’s instructions.
In vitro neutralization assay
Plaque reduction neutralization titer (PRNT) assays were
performed with the indicated DENV-1 strains with MAbs or
serum on BHK21-15 cells as described previously [26,80].
PRNT50 values were determined using non-linear regression
analysis (Graph Pad Prism4).
Cloning and expression of DIII of DENV-1 E protein
A cDNA encoding DENV-1 DIII (strain 16007, residues 293 to
400) of the 16007 strain was amplified from viral RNA by reverse
transcriptase and high-fidelity Platinum Taq polymerase chain
reaction (PCR) according to the manufacturer’s instructions
(Invitrogen). The PCR product was cloned into the pET21a
bacterial expression plasmid (EMD Biosciences) using flanking
NdeI and XhoI restriction sites, sequenced, and then expressed in
BL21 Codon Plus (Stratagene) E. coli. Inclusion bodies containing
insoluble aggregates were denatured in the presence of 6 M
guanidine hydrochloride and 20 mM b-mercaptoethanol and
refolded in the presence of 400 mM L-arginine, 100 mM Tris-
base (pH 8.0), 2 mM EDTA, 0.2 mM phenylmethylsulfonyl
fluoride, and 5 and 0.5 mM reduced and oxidized glutathione,
respectively. Refolded protein was separated from aggregates on a
Superdex 75 or 200, 16/60 size exclusion column using fast-
protein liquid chromatography (GE Healthcare).
X-ray crystallographic structure determination of DV1 DIII
DENV-1 DIII was crystallized by vapor diffusion in hanging
drops at 20uC at a concentration of 14 mg/ml. The drop
contained equal parts protein and well solution composed of
0.1 M imidazole-HCl at pH 7.5, 0.2 M lithium sulfate, and 30%
(w/v) polyethylene glycol 3000. Crystals were cryoprotected after a
soak in well solution containing 15% glycerol before rapid cooling
in a nitrogen gas stream. Data was collected at ALS beamline 4.2.2
(Lawrence Berkeley Laboratories, Berkeley, CA) at 293u K and at
a wavelength of 1.29 A˚ using a CCD detector. The data were
processed and scaled in HKL-3000 [103]. Crystallographic
phasing was obtained by molecular replacement using the
program Phaser [104] and the corresponding DIII fragment from
DV2 (PDB accession 1OAN) as a search model. The resulting
atomic model was iteratively built in O [105] and refined in
REFMAC [106]. The final model with one DENV1 DIII
monomer per asymmetric unit has been refined to 2.25A˚
resolution and contains 103 amino acids (residues 296 to 399 of
DIII) and 53 water molecules. The DENV1 DIII domain is similar
in structure to that reported for the post-fusion DENV-1 E
ectodomain trimer (3G7T) [11] with a root-mean-square differ-
ence of 1.6 A˚ between Ca atom positions for equivalent core
residues 296 through 394 [107]. The coordinates and diffraction
data have been deposited in the RCSB with accession number
3IRC.
Domain mapping by yeast surface display
The DNA fragments encoding amino acid residues 1 to 293
(DI-DII) and 294 to 409 (DIII) of DENV-1 E protein were
amplified from the DENV-1 strain 16007 or West Pac-74 by RT-
PCR with BamHI and XhoI sites added at the 59 and 39 end,
respectively. The PCR products were cloned as downstream
fusions to Aga2 and Xpress epitope tag genes in the yeast surface
display vector pYD1 (Invitrogen), under the control of an
Figure 8. PRNT50 analysis of different DENV-1 genotypes by
DENV1-E105 and DENV1-E106. Increasing concentrations of
purified (A) DENV1-E106 and (B) DENV1-E105 were mixed with 102
PFU of DENV-1 strains corresponding to all five genotypes and
neutralization was assessed by a standard PRNT assay in BHK or Vero
cells (depending on the strain). PRNT50 values were calculated after
regression analysis using statistical software. The graph is representa-
tives of at least two independent experiments performed in duplicate.
doi:10.1371/journal.ppat.1000823.g008
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upstream GAL1 promoter. These constructs were transformed
into Saccharomyces cerevisiae strain EBY100 [108,109] using S.c.
EasyComp Transformation Kit (Invitrogen) to generate yeast that
expressed DENV-1 DI-DII or DIII. Individual yeast colonies were
grown to logarithmic phase at 30uC in tryptophan-free yeast
media containing 2% glucose. Fusion protein expression was
induced on the surface by growing yeast for additional 48 hrs in
tryptophan-free media containing 2% galactose at 20uC. Yeast
cells were washed with PBS supplemented with BSA (1 mg/ml)
and incubated with 50 ml of neat culture supernatant or purified
MAbs at a concentration of 25 mg/ml. After a 30 minute
incubation on ice, yeast were washed in PBS with BSA and then
incubated with a goat anti-mouse IgG secondary antibody
conjugated to Alexa Fluor 647 (Molecular Probes). After fixation
with 1% paraformaldehyde in PBS, yeast cells were analyzed on a
FACSArray flow cytometer (Becton-Dickinson) using FloJo
software.
Yeast library construction and screening
To generate a library of DENV-1 DIII variants on yeast,
mutation was accomplished by error-prone PCR, using a
GeneMorph II random mutagenesis kit (Stratagene). The library
was ligated into the pYD1 vector and transformed into XL2-Blue
ultracompetent cells (Stratagene). The colonies were pooled and
transformed into yeast cells as described above. In some instances,
additional site-specific mutations were engineered into DENV-1
DIII by a reverse genetic approach using the Quick Change II
Mutagenesis Kit (Stratagene).
For individual MAbs, the DENV-1 DIII mutant library was
screened according to a previously described protocol [29]. To
identify yeast that had selectively lost binding to a given MAb, the
library was stained with an individual Alexa Fluor 647 conjugated
MAb for 30 min on ice. To control for surface expression of
appropriately folded DIII of DENV-1, yeast cells were subse-
quently stained for 30 min on ice with an Alexa Fluor 488-
conjugated pool of DIII-specific MAbs (DENV1-E90, DENV1-
E95, DENV1-E99, DENV1- DENV1-E111, DENV1-E112, and
DENV1-E113), and then processed by flow cytometry, The
population that was single MAb negative but pool oligoclonal
MAb positive was selected and sorted. After four to five rounds of
sorting, yeast were plated and individual colonies were tested for
binding to individual MAbs by flow cytometry. For clones that had
lost binding to the desired MAb of interest, the plasmid was
recovered using a Zymoprep yeast miniprep kit (Zymo Research),
transformed into XL1-Blue competent E. Coli (Stratagene),
purified using a QIAprep spin miniprep kit (Qiagen), and
sequenced.
Immunostaining of DENV-infected cells
For the study of binding of DENV-1 MAbs to different DENV
strains, Raji-DC-SIGN-R or C6/36 cells were infected with
different DENV strains at a multiplicity of infection (MOI)
of 1. Depending on the DENV-1 strain, Raji-DC-SIGN-R cells
were harvested at 48 or 96 hours and C6/36 cells were
harvested at day 7 after infection. Cells were washed, fixed in
PBS with 4% paraformaldehyde, and permeabilized in Hanks’
balanced salt solution (HBSS) supplemented with 10 mM
HEPES (pH 7.3), 0.1% (w/v) saponin (Sigma), and 0.02%
NaN3. The cells were then incubated with MAbs for 30 minutes
on ice, washed and incubated subsequently with an Alexa Fluor
647-conjugated goat anti-mouse IgG (Molecular Probes). After
30 minutes, cells were washed and fixed in PBS with 1%
paraformaldehyde and analyzed by flow cytometry. To test
whether DENV-1 MAbs cross-reacted with more distantly related
flaviviruses, infection and staining experiments were performed
with WNV (strain 3000.0259) and Raji-DC-SIGN-R cells as
described previously [52].
DENV-1 virus capture ELISA
The capture ELISA for DENV-1 was based on a published
assay for WNV with modifications [48]. Briefly, anti-DENV-1
MAbs were coated at indicated concentrations on MaxiSorp
(Nunc) polystyrene 96-well microtiter plates in a sodium carbonate
(pH 9.3) buffer. Plates were washed three times in ELISA wash
buffer (PBS with 0.02% Tween 20) and blocked for 1 hour at
37uC with ELISA block buffer (PBS, 2% bovine serum albumin,
and 0.02% Tween 20). DENV-1 virions (2.5 to 5.06105 PFU of
strain 16007 or West Pac-74) diluted in DMEM with 10% heat-
inactivated FBS were captured on plates coated with anti-DENV-
1 MAbs for 2 hours at room temperature. Plates were rinsed five
times in wash buffer and then incubated with biotinylated 4G2
(1 mg/ml, respectively diluted in ELISA block buffer), which
recognizes the fusion loop peptide in DII, for 1 hour at room
temperature. Plates were washed again five times and then
sequentially incubated with 2 mg/ml of horseradish peroxidase-
conjugated streptavidin (Vector Laboratories) and tetramethyl-
benzidine substrate (Dako). The reaction was stopped with the
addition of 2 N H2SO4 to the medium, and emission (450 nm) was
read using an iMark microplate reader (Bio-Rad).
Mouse experiments
All mouse studies were approved and performed according to
the guidelines of the Washington University School of Medicine
Animal Safety Committee. IFN-abR2/2 6 cR2/2 mice on the
129 Sv background (AG129 mice) were a gift from Dr. Skip Virgin
(Washington University School of Medicine) and bred in a
pathogen-free barrier facility. In prophylaxis experiments, AG129
mice were administered a single dose of individual MAbs one day
before infection. Subsequently, mice were challenged with West
Pac-74 (genotype 4, 106 PFU) by an IP route and morbidity and
mortality were monitored for 60 days. In post-exposure therapeu-
tic experiments, a single 500 mg dose of MAb dose was
administered by IP injection two or four days after infection with
106 PFU of West Pac-74.
Mapping of mutations onto the DENV-1 DIII crystal
structure
Figures were prepared using the atomic coordinates of DENV-1
DIII (RCSB accession number 3IRC) using the programs
CCP4MG [110]. The alignment of DENV-1 DIII from different
genotypes was created with the program ALSCRIPT [111].
Statistical analysis
All data were analyzed using Prism software (GraphPad
software). For survival analysis, Kaplan-Meier survival curves
were analyzed by log-rank test. For neutralization assays an
unpaired student’s T-test was used to determine significance.
Supporting Information
Table S1 Profile of DENV-1 MAbs
Found at: doi:10.1371/journal.ppat.1000823.s001 (0.06 MB
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DENV1-E106 is a monoclonal antibody (MAb) with strong neutralizing activity against all five DENV-1 geno-
types and therapeutic activity in mice. Here, we evaluated the potential for DENV-1 to escape neutralization
by DENV1-E106. A single mutation in domain III of the envelope protein (T329A) emerged, which conferred
resistance to DENV1-E106. However, the T329A variant virus had differing phenotypes in vitro and in vivo
with attenuation in cell culture yet increased infectivity in Aedes aegypti mosquitoes. Mice infected with
this T329A variant still were protected against lethal infection by DENV1-E106 even though much of the neu-
tralizing activity was lost. This study reveals the complex dynamics of neutralization escape of an inhibitory
MAb against DENV, and suggests that evaluation of therapeutic MAbs requires detailed investigation in rele-
vant hosts.
© 2012 Elsevier Inc. All rights reserved.
Introduction
Dengue virus (DENV) infection after mosquito inoculation causes
clinical disease ranging from a self-limiting febrile illness (Dengue
Fever, DF) to a life threatening hemorrhagic and capillary leak syndrome
(Dengue Hemorrhagic Fever (DHF)/Dengue Shock Syndrome (DSS)).
DENV is the most prevalent mosquito-transmitted viral disease and
causes an estimated 50 to 100 million infections and 250,000 cases of
DHF/DSS per year worldwide, with 2.5 billion people at risk (Halstead,
1988; Monath, 1994). Globally, there is significant diversity among
DENV strains, including four serotypes (DENV-1, DENV-2, DENV-3, and
DENV-4) that differ at the amino acid level by 25 to 40% andmultiple ge-
notypes within a serotype that vary by up to ~6% (Holmes and Twiddy,
2003; Rico-Hesse, 1990). At present, no approved antiviral treatment
or vaccine is available, and therapy remains supportive.
The potential of passive immunotherapy for flavivirus infection has
prompted the development and evaluation of several neutralizing
human or humanized monoclonal antibodies (MAbs) against West
Nile, Japanese encephalitis, and Dengue viruses (Balsitis et al., 2009;
Beltramello et al., 2010; Goncalvez et al., 2008; Gould et al., 2005;
Schieffelin et al., 2010; Sultana et al., 2009; Throsby et al., 2006). Re-
cently, we described a panel of inhibitory DENV-1-specific MAbs, of
which only four were highly protective in an IFNαβR−/−×IFNγR−/−
AG129 mouse model of DENV-1 infection (Shrestha et al., 2010).
One of these MAbs, DENV1-E106, strongly neutralized all five DENV-
1 genotypes in cell culture and was active therapeutically even when
administered as a single dose four days after infection in mice. Map-
ping studies by yeast display suggested that DENV1-E106 recognizes
a composite epitope on the A-strand and lateral ridge of domain III
(DIII) of the envelope (E) protein. As flaviviruses have an error-
prone RNA polymerase, replication can result in rapid viral evolution.
Thus, the potential for emergence of resistant variants is a significant
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concern for antibody-based therapeutics, especially for DENV, in
which humans play a requisite role in the natural transmission cycle.
In this study, we selected for neutralization escape mutations
of DENV1-E106. A single mutation in DIII of the E protein
(T329A) was identified that conferred resistance to DENV1-E106.
This T329A variant virus had differing phenotypes in vitro and in
vivo with attenuation in cell culture yet paradoxically enhanced
infectivity in mosquitoes. Moreover, mice infected with this
Fig. 1. Phenotype of the DENV-1 T329A neutralization escape variant. A. Neutralization curves with DENV1-E106 and the parent 16007 DENV-1 strain (genotype 2), the heterolo-
gous West-Pac-74 DENV-1 strain (genotype 4), and the T329A West-Pac-74 DENV-1 strain derived directly from passage in cell culture. The data are representative of three inde-
pendent experiments performed in duplicate on BHK21-15 cells. B–C. Yield of wild type and T329A West-Pac-74 DENV-1 from supernatants of BHK21-15 cells after infection at
different input MOI in the (B) absence or (C) presence of DENV1-E106. The data are the average of three independent experiments performed in duplicate and asterisks indicate
differences that are statistically significant. Dashed lines indicate the limit of detection of the assay. D–E. Confirmation of resistant phenotype with wild type and mutant DENV-1
RVP. Genetically engineered DENV-1 RVP displaying the structural proteins of (D) West-Pac-74 or (E) 16007 with or without a single amino acid substitution (T329A) were incu-
bated with increasing concentrations of DENV1-E106. F. Neutralization curves of DENV1-E106 with wild type or T329A West-Pac-74 DENV-1 strains derived by site-directed sub-
stitution into an infectious cDNA clone. The data are representative of two independent experiments performed in duplicate on BHK21-15 cells. G–I. Genetically engineered DENV-1
RVP (strain West-Pac-74) with single mutations (G) K90R in prM or (H) V83L in E or both mutations (I) K90R+V83L were incubated with increasing concentrations of DENV1-
E106 and analyzed by flow cytometry. For D, E, and G–I, representative data of experiments performed on Raji-DCSIGNR cells is shown. Error bars represent the standard error
of the mean of duplicate infections.
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T329A variant nonetheless were protected against lethality by
DENV1-E106. This study reveals the complex dynamics of escape
of a strongly neutralizing MAb against DENV in mice and
mosquitoes.
Results
Selection of a neutralization escape variant in cell culture
DENV1-E106 is an inhibitory sub-complex specific MAb that neu-
tralized infection of strains corresponding to all five DENV-1 geno-
types and improved clinical outcome in mice when administered as
a single dose four days after infection with the West-Pac-74 (geno-
type 4) strain of DENV-1 (Shrestha et al., 2010). Given its broad-
spectrum antiviral activity against all DENV-1 genotypes and possible
therapeutic potential, we questioned whether resistance would occur
under selective pressure during the course of treatment. Prior map-
ping studies identified putative recognition sites for DENV1-E106
MAb in the A-strand (K310) and lateral ridge of DIII (G328, T329,
D330, P325, K361, E362, P364, and K385), as mutations in these resi-
dues reduced binding to DIII when expressed on the surface of yeast
(Shrestha et al., 2010). To begin to identify key functional residues
on DIII that engaged DENV1-E106, we selected for neutralization es-
cape mutants in cell culture. We used DENV-1 West-Pac-74, a geno-
type 4 strain, since it was more resistant (12-fold, Pb0.01, Fig. 1A)
to DENV1-E106 compared to the genotype 2 strain 16007, and thus
might be easier to recover escape variants. After three sequential pas-
sages of DENV-1 strain West-Pac-74 in BHK21-15 cells in the pres-
ence of 10 μg/ml of MAb, a resistant virus emerged that no longer
was efficiently neutralized (EC50 of 7860 ng/ml of escape variant ver-
sus 16 ng/ml of wild type, P=0.005, Fig. 1A); nonetheless, as high
concentrations of MAb did inhibit infection, the escape mutant must
still bind DENV1-E106, albeit with markedly reduced affinity.
To determine the mutations that conferred the neutralization es-
cape phenotype, viral RNA sequenceswere obtained from 30 indepen-
dent plaque-purified escape variants and compared to the wild type
DENV-1 sequence derived from virus propagated in parallel in the ab-
sence of MAb selection. All (30 of 30) escape variants contained only a
single-nucleotide change (T to A) encoding a T329Amutation in the E
protein, as no other changeswere identified. To understand the signif-
icance of the T329A change, we assessed the growth kinetics of wild
type and escape variant (T329A) viruses in the absence or presence
of 10 μg/ml DENV1-E106 MAb in BHK21-15 cells. Notably, in the ab-
sence of antibody, T329A DENV-1 grew less well as evidenced by a re-
duced percentage of infected cells and lower (up to 70-fold, Pb0.001)
viral titers at 48 h over a broad range (0.01 to 5) of multiplicities of in-
fection (MOI) (Fig. 1B, and data not shown). However, in the presence
of MAb, while virtually no virus was recovered in the supernatants of
cells infectedwithwild type virus at 48 h, T329A virus was obtained at
several different MOI (Fig. 1C). As additional confirmation, we gener-
ated a T329A mutant virus using two different reverse-genetic strate-
gies. First, DENV-1 RVP (Ansarah-Sobrinho et al., 2008; Dowd et al.,
2011) corresponding to West-Pac-74 or 16007 strains were engi-
neered with or without a single amino acid mutation at T329A, pro-
duced in HEK293T cells, and analyzed for MAb neutralization.
Whereas DENV1-E99 MAb (which maps to residues E309, K310, and
E311 on the A-strand of DIII (Shrestha et al., 2010)) neutralized both
wild-type and T329A RVP equivalently (data not shown), DENV1-
E106 failed to efficiently neutralize the T329A mutant in either the
West-Pac-74 or 16007 backgrounds (Figs. 1D and E). As a final confir-
mation, we introduced the T329A substitution into an infectious cDNA
clone of DENV-1 West-Pac-74 (Whitehead et al., 2003). As expected,
the EC50 of the fully infectious T329A variant generated by reverse ge-
netics showed similar resistance to DENV1-E106 MAb (Fig. 1F) but
retained sensitivity to neutralization by DENV1-E99 (data not
shown). Overall, our results suggest that while the infectivity of wild
type DENV-1 was strongly inhibited by DENV1-E106 MAb, similar
viral titers were observed for the T329A escape variant in the presence
or absence of antibody. However, the T329A mutant virus still was at-
tenuated in BHK21-15 cells compared to wild type virus.
Stability of T329A DENV-1 variant in cell culture and mosquitoes
To further characterize the attenuated phenotype of the T329A
DENV-1 variant in cell culture, we performed multi-step growth ki-
netics in mammalian (BHK21-15) and insect (C6/36) cells. Notably,
in both cell types a 9 to 26-fold reduction in viral yield compared to
wild type virus was observed after infection over a period of 72 to
96 h (Figs. 2A and B). To assess whether the T329A mutation was sta-
ble in BHK21-15 and C6/36 cells, virus was harvested from the super-
natant of the respective cell types at the end of the time course and
used for PRNT assays with DENV1-E106 MAb. No evidence of func-
tional reversion was observed, as virus harvested from BHK21-15 or
C6/36 cells infected with the T329A variant retained its resistant phe-
notype (Figs. 2C and D). Consistent with this, sequencing of RNA from
virus-containing supernatants at 96 h revealed no reversion at amino
acid position 329 of the E protein (data not shown).
Given the growth defect of T329A DENV-1 in C6/36 Aedes albopic-
tus cells, we assessed its infectivity and stability in Aedes aegyptimos-
quitoes. Initially, we confirmed the presence of DENV-1 RNA in the
Fig. 2. Growth analysis and stability of DENV-1 T329A neutralization escape variant. A–B. Multi-step growth curves of wild type or T329A West-Pac-74 DENV-1 in (A) BHK21-15 or
(B) C6/36 cells. Cells were infected at an MOI of 0.01 and supernatants were harvested at 24-hour intervals for titration by plaque assay. The data are the average of three indepen-
dent experiments performed in duplicate and asterisks indicate differences that are statistically significant. C–D. Supernatants were harvested at 96 h from wild type or T329A
DENV-1 infected (C) BHK21-15 or (D) C6/36 cells and used for PRNT analysis to assess stability of the escape mutation in cell culture. The data are representative of two indepen-
dent experiments performed in duplicate on BHK21-15 cells.
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midgut after blood meal infection with 3×106 PFU of wild type or
T329A DENV-1 (West-Pac-74 strain) by harvesting at mosquitoes at
1 h after feeding, homogenizing tissues, and analyzing viral RNA by
RT-PCR; notably, no difference in initial infection with wild type or
T329A DENV-1 was observed (Table 1, and data not shown). Remark-
ably, the T329A virus showed greater infectivity (22% for T329A and
0% for wild-type) of mosquitoes after a 14-day extrinsic incubation
period. Sequencing of viral RNA recovered from the whole body of
infected mosquitoes at 14 days post-infection revealed a low (7%)
rate of reversion to wild type virus. Thus, the T329A DENV-1 neutral-
ization escape variant efficiently infected the relevant arthropod vec-
tor and did not rapidly revert to the wild type sequence during a
typical (14 day) period of replication in mosquitoes.
Phenotype of T329A DENV-1 in mice
Given that the growth defect of T329A DENV-1 in C6/36 cells did
not correlate with the phenotype in mosquitoes, we hypothesized
that although it was attenuated in BHK21-15 cells, it nonetheless
might still retain virulence in mice; this would suggest that replica-
tion dynamics in some tissue culture cell lines might not reliably pre-
dict phenotypes in animals. To test this, we performed a dose–
response analysis using a stringent intracranial challenge model of
DENV-1 West-Pac-74 in AG129 mice; this model was used because
previously we had observed a dose-dependent change in the mean
survival time of infected mice (Shrestha et al., 2010). Somewhat sur-
prisingly, no difference in overall survival rate or average survival
time was detected between wild type and T329A DENV-1 (West-
Pac-74 strain) after intracranial infection with 101, 102, or 103 PFU
of virus (Figs. 3A, B, and C, P>0.5). Because the intracranial challenge
route bypasses infectivity requirements in peripheral organs, we also
tested for attenuation after intraperitoneal challenge. Using a higher
105 PFU dose, which is required to achieve 100% lethality of the par-
ent DENV-1 West-Pac-74 strain over the course of 3 to 5 weeks
(Shrestha et al., 2010), we now observed mild attenuation of T329A
DENV-1 (Fig. 3D) as reflected by a decreased lethality rate (77% ver-
sus 100%, Pb0.02) and increased mean survival time (27.1±2.8 ver-
sus 35.3±2.8 days, Pb0.05).
Because of the shift of the survival curve, we speculated that in the
absence of DENV1-E106 MAb pressure, within a few days, T329A
DENV-1 might revert to the more virulent A329T parent virus. To
evaluate this, we repeated the intraperitoneal challenge experiments
with the wild type and T329A DENV-1 in the presence of 500 μg of
DENV1-E106 that was administered one day prior to infection. As an-
ticipated, the wild type DENV-1 showed no virulence in the presence
of DENV1-E106 MAb. However, and somewhat unexpectedly, the
T329A DENV-1 variant also showed no virulence when DENV1-E106
MAb was administered (Fig. 3D), suggesting that either reversion of
the escape virus occurred (and this revertant was blocked by
DENV1-E106) or that the low-level of neutralizing activity of the
DENV1-E106 MAb against the T329A virus (EC50 of 7860 ng/ml, see
Fig. 1A) was sufficient to limit virulence in this model. To address
this, we recovered infectious virus from the brains of moribund
mice infected with T329A DENV-1 and obtained viral RNA sequences
directly after RT-PCR amplification of viral RNA of brain homogenates
or after plaque purification. Remarkably, all viral RNA sequences
retained the T329A mutation in the E protein, with no other specific
changes in the E protein identified. Consistent with this, 12 indepen-
dent plaque-purified viruses from brain homogenates retained resis-
tance to DENV1-E106 by plaque reduction neutralization assay
(data not shown). Thus, although the T329A virus was attenuated
and relatively resistant to DENV1-E106 MAb in mice, in vivo reversion
did not occur frequently and DENV1-E106 MAb could still inhibit the
virulence of the escape virus.
Table 1
Infection and reversion of DENV-1 T329A in Aedes aegypti.
0 to 1 h post infection 14 days post infection 14 days post infection
Virus Number positive (%) Number infected (%) Number revertants (%)
T329A 10/10 (100) 15/69 (22) 1/15 (7)
Wild type 10/10 (100) 0/47 (0) ND
P-value NS 0.0003 ND
Aedes aegypti mosquitoes were fed orally wild type (3.1×106 PFU/ml) or T329A (2.6×106 PFU/ml) DENV-1 in a 1:1 blood to virus ratio. Engorged mosquitoes were harvested im-
mediately (within 1 h) after feeding and screened for presence of DENV RNA or held for a 14-day extrinsic incubation period, after which bodies were harvested for viral RNA se-
quencing as described in the Materials and methods. The results are pooled from independent experiments, and the proportions infected were compared by Fisher's exact test. ND
indicates not determined, as mosquitoes were not infected with the wild type parent DENV-1 West-Pac-74 strain under these conditions. NS indicates no significant difference.
Fig. 3. Phenotype of T329A DENV-1 in AG129 mice. A–C. AG129 mice were infected via an intracranial route with (A) 101, (B) 102, or (C) 103 PFU of wild type or T329AWest-Pac-74
DENV-1 and followed for survival. The number of animals for each dose ranged from 5 to 6 per group. No differences were statistically significant. D. AG129 mice were untreated or
pre-treated with 500 μg of DENV1-E106 prior to infection with wild type or T329A West-Pac-74 DENV-1. The number of animals for each antibody ranged from 10 to 18 per group.
Statistically significant differences are described in the text.
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Selection of DENV1-E106 MAb escape virus in vivo
As the T329A DENV-1 cell culture derived escape variant retained
sensitivity to DENV1-E106 MAb in vivo, we subsequently assessed
the potential for emergence of resistant variants directly by recover-
ing viruses from mice infected with wild type virus during MAb
treatment. Ten AG129 mice were infected with 105 PFU of wild
type DENV-1 West-Pac-74 and treated with a single 500 μg dose of
DENV1-E106 MAb on day two post-infection. Whereas 8 of 10
mice showed complete protection with no evidence of clinical dis-
ease, two mice developed signs of infection by day 21 including leth-
argy and weight loss. Brain homogenates were recovered from these
animals as well as control mice infected with wild type or T329A
mutant DENV-1 West-Pac-74 in the absence of DENV1-E106 treat-
ment. Viral RNA was obtained from plaque picks from brain homog-
enates corresponding to the mice receiving wild type virus
+DENV1-E106 MAb, or receiving wild type or T329A mutant virus
without MAb treatment, and the structural genes were sequenced
in their entirety (Table 2). Notably, none of the plaque isolates
from DENV1-E106-treated ill mice contained the T329A escape mu-
tation. Instead, 22 of the 24 plaque picks isolated from mice receiv-
ing DENV1-E106 treatment had viral RNA sequences containing
conservative mutations in prM (K90R) and DII of the E protein
(V83L); despite the presence of these mutations, bulk brain tissue
homogenates and all plaque isolates remained sensitive to neutrali-
zation by DENV1-E106, and substitution of the V83L, K90R, or
V83L+K90R mutations into DENV-1 West-Pac RVP also failed to
confer resistance (Figs. 1G–I). Thus, while treatment failure with
DENV1-E106 MAb was possible and resulted in mutation from the
wild type virus, surprisingly, this was not associated with neutraliza-
tion escape.
Discussion
Antibody-based therapy is currently being explored as a platform
for pre- and/or post-exposure treatment of flavivirus infections
(Diamond, 2009). For DENV in particular, theoretical concerns re-
garding exacerbation of acute disease and increasing the likelihood
of DHF/DSS through the induction of antibody-dependent enhance-
ment of infection (ADE) have been minimized by modification of se-
quences in the Fc region to eliminate binding to Fc-γ and complement
receptors (Balsitis et al., 2010; Beltramello et al., 2010). Nonetheless,
for DENV, where humans are an integral part of the natural cycle, the
emergence of resistance and transmission of variants to mosquitoes
could rapidly render costly therapeutic antibodies ineffective. To ex-
plore this question, we evaluated the potential for resistance of our
most potently and broadly neutralizing MAb against DENV-1.
Although selection of neutralization escape variants in cell culture
occurred, we recovered only one mutant (T329A) from 30 different
plaque-purified viruses in the course of two independent experi-
ments. Resistance can occur via selection of a pre-existing mutant
subpopulation or through the emergence of variant viruses during
prolonged treatment (Margeridon-Thermet and Shafer, 2010).
Given that a single mutation with the same nucleotide change was
observed in all independent plaque variants, it seems likely that the
T329A variant existed as a small subpopulation within the original
viral stock. The T329A variant was attenuated in culture in BHK21-
15 mammalian and C6/36 insect cells, with decreased replication in
single- and multi-step growth analyses. Somewhat surprisingly, this
attenuated phenotype was not observed in A. aegypti mosquitoes
after feeding by blood meal; instead, and for reasons that remain
unclear, the T329A variant showed a higher level of infectivity com-
pared to the neutralization sensitive parent strain. We confirmed
that feeding mosquitoes ingested the wild type and T329A mutant
virus equivalently by harvesting tissues immediately after blood
meal, and assaying viral RNA by RT-PCR. A related disparity between
infectivity in C6/36 cells and A. aegypti mosquitoes was recently de-
scribed with DENV-2 engineered with mutations in the adjacent FG
loop (residues 382 to 385) on DIII (Erb et al., 2010); in that study,
however, an opposing phenotype was described, as mutant DENV-2
replicated efficiently in insect cells but was compromised in mosqui-
toes fed blood meals or inoculated by intrathoracic injection. The low-
level (in our case, 0%) infectivity rate with DENV-1 West-Pac-74 wild
type virus after oral feeding of a blood meal has been reported previ-
ously in A. aegypti mosquitoes (Whitehead et al., 2003). The virus-
host cell interactions that mediate midgut infection of A. aegypti by
DENV remain poorly understood, and wide variation in infectivity
has been observed among DENV serotypes (Gubler et al., 1979) and
genotypes within a given serotype (Armstrong and Rico-Hesse,
2001, 2003). Since the T329Amutation was selected based on its abil-
ity to escape MAb neutralization and maps to a region of DIII that has
been postulated to participate in virus attachment to host cells
(Bhardwaj et al., 2001; Chu et al., 2005; Lee et al., 2006; Zhang et
al., 2010), this residue could have functional significance in mediating
midgut infection of mosquitoes. Although this particular observation
was unexpected, it was reproducible, consistent with known varia-
tion in DENV strain infectivity of mosquitoes, and warrants further
investigation.
The central finding derived from the mosquito experiments, how-
ever, is that in most insects the T329A mutation was not purified dur-
ing the extrinsic phase of replication. Analogously, T329A DENV-1
showed no change in virulence after intracranial infection of mice
and only a modest attenuation after intraperitoneal infection, without
evidence of reversion. Thus, and somewhat surprisingly, analysis of
attenuation of variant viruses in cell culture did not directly predict
their behavior in insects or animals. In addition to understanding
the significance of cell culture selected escape mutants of therapeutic
antibodies, this finding may be relevant for characterization of live
flavivirus vaccines that contain attenuating mutations, whose pheno-
type is initially selected based on altered replication in cell culture.
Prior experiments with WNV and the highly therapeutic MAb E16
identified an escape mutant (K307E) that was completely resistant to
neutralization in vitro even at high MAb concentrations, and this cor-
related with a failure to protect in vivo after passive antibody transfer
and infection with an in vitro-derived escape variant (Zhang et al.,
2009). In comparison, even though the T329A variant was ~500-
Table 2
Virus mutations isolated from in vivo passage in AG129 mice.
Wild type virus, No MAb T329A virus, No MAb Wild type virus DENV1-E106 MAb
K90R (prM) 0/8a (0)b 0/8 (0) 22/24 (92)
V83L (Envelope) 0/8 (0) 0/8 (0) 23/24 (96)
E202K (Envelope) 4/8 (50) 8/8 (100) 12/24 (50)
T329A (Envelope) 0/8 (0) 8/8 (100) 0/24 (0)
AG129 mice were infected with 105 PFU of wild type DENV-1 West-Pac-74 or T329A mutant virus by an intraperitoneal route. Two days later, some of the mice receiving wild type
viruses were administered a single 500 μg dose of DENV1-E106 by an intraperitoneal route. Brain homogenates were collected from all mice at 21 days and processed for viral RNA
sequencing (see Materials and methods).
a Indicates # isolates with mutation/total # of isolates.
b Indicates the mutation frequency.
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fold less sensitive to the neutralizing activity of DENV1-E106 MAb in
cell culture and could cause lethal infection in AG129 mice in the ab-
sence of antibody without reversion, its pathogenesis still was inhib-
ited when mice were pretreated with DENV1-E106 MAb. Although
further study is warranted, this could reflect the residual neutralizing
activity that DENV1-E106 MAb has for DENV-1 T329A (EC50 of ~8 μg/
ml) or an enhanced protection that is conferred by the effector func-
tions of the Fc region of antibodies. We also were unable to select for a
bona fide escape mutation in vivo in the presence of DENV1-E106
MAb, even though treatment failure occurred; these results are anal-
ogous to studies with WNV E16 MAb in which escape mutants in vivo
were not identified during the acute course of infection; rather sus-
tained treatment over months was required before emergence of an
escape variant was observed (Zhang et al., 2009). Binding of the com-
plement component C1q can reduce the stoichiometric threshold for
antibody-mediated neutralization and improve the potency of anti-
bodies 5 to 20-fold, depending on the isotype (Mehlhop et al.,
2009), and activating Fc-γ receptors can enhance protection against
flaviviruses in vivo (Chung et al., 2006, 2007; Oliphant et al., 2005;
Schlesinger et al., 1993; Vogt et al., 2011) through enhanced phagocy-
tosis or antibody-dependent cellular cytotoxicity. Future testing of
aglycosyl variants of DENV1-E106 MAb that lack the ability to bind
C1q or Fc-γ receptors (Tao and Morrison, 1989) with wild type and
T329A West-Pac-74 viruses will help to define whether antibody ef-
fector functions explain the residual protective activity in vivo against
the T329A escape variant and the failure to select treatment-resistant
variants.
In summary, whereas a single neutralization escape variant was
selected rapidly in cell culture, distinct phenotypes with this virus
were observed in vivo in mosquitoes andmice. Emergence of resistant
variants could occur with single MAb therapeutics against DENV dur-
ing an epidemic if introduction into the mosquito vector does not pu-
rify the mutation. Alternatively, the use of combinations of
neutralizing MAbs that recognize distinct epitopes could limit the
rapid development of resistance.
Materials and methods
Cells, virus and mice
The Dengue virus type-1 strain (West-Pac-74, genotype 4) was
obtained from Dr. Stephen Whitehead (NIAID, NIH, Bethesda, MD)
and amplified in C6/36 A. albopictus cells according to previously de-
scribed protocols (Shrestha et al., 2010). BHK21-15 cells were cul-
tured in Dulbecco's Modified Eagle Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) (Omega Scientific) and antibiotics
(penicillin G and streptomycin) at 37 °C in a humidified 5% CO2 incu-
bator. BHK21-15 cells were used to determine DENV-1 West-Pac-74
stock titer by standard plaque assay (Shrestha et al., 2010).
IFNαβR−/−×IFNγR−/− mice on the 129 Sv background (AG129
mice) were a gift from Dr. Skip Virgin (Washington University School
of Medicine) and bred in a pathogen-free barrier facility. All mouse
studies were carried out in strict accordance with the recommenda-
tions in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved by the Insti-
tutional Animal Care and Use Committee at the Washington Universi-
ty School of Medicine (Assurance Number: A3381-01).
Selection of the T329A neutralization escape mutant in cell culture
To select a variant that escaped neutralization by DENV1-E106 MAb,
the genotype 4 DENV-1 strain West-Pac-74 (4×105 PFU) was incubated
with 10 μg/ml of DENV1-E106 for 1 h at room temperature in DMEM
supplemented with 10% FBS. The mixture was added to BHK21-15 cells
in a six-well plate and incubated for 2 h at 37 °C. Wells were washed
three times, fresh DMEM medium containing 10 μg/ml of DENV1-E106
MAb was added, and cells were incubated at 37 °C for 96 h. Supernatant
was harvested, mixed with 20 μg/ml of fresh DENV1-E106 mAb, and the
selection process was repeated for two additional passages. After the
third passage under MAb selection, supernatants were titrated for resis-
tant viruses by performing a plaque reduction neutralization test
(PRNT)50 assay in BHK21-15 cells in the presence of DENV1-E106
MAb. After confirmation of an escape phenotype, plaques formed under
DENV1-E106 MAb selection were visualized using a neutral red overlay.
Plaque-purified virus was recovered, amplified under MAb selection
(10 μg/ml) in BHK21-15 cells for three days at 37 °C, and supernatants
were stored aliquotted at −80 °C. Infected BHK21-15 cells were trypsi-
nized from wells, washed, and total cellular RNA was isolated using an
RNeasy kit (Qiagen). The E gene was amplified by reverse-transcription
of the viral RNA and cDNA synthesis using the Superscript III One-Step
RT-PCR System (Invitrogen) with the following DENV-1 forward and
reverse primers: 840F: 5′-TGCCATAGGAACATCCATCA-3′ or 850F: 5′-
ACATCCATCACCCAGAAAGG-3′; 1436F: 5′-TGACCGACTACGGAGCTCTT-
3′; 1655R: 3′-TGCTTCTTTGCATGAGCTGT-5′; 2416R: 3′-TGACAAAAATGC-
CACTTCCA-5′, and 2519R: 3′-CTCTTTGGGGAGTCAGCTTG-5′. Direct
sequencing of the gel-purified PCR products was compared to the
sequence of the laboratory stock DENV-1 West-Pac-74 strain that was
passaged and plaque-purified in parallel in the absence of MAb
selection.
In vivo selection of escape mutant
In an attempt to generate a neutralization escape virus in vivo,
AG129 mice were infected with 105 PFU of wild type DENV-1 West-
Pac-74 by an intraperitoneal route. Two days later, mice were admin-
istered a single dose of 500 μg of DENV1-E106 by an intraperitoneal
route and monitored for morbidity for 60 days. Ill-appearing mice
were euthanized, and brain tissues were divided for virus titration
in the presence or absence of DENV1-E106 and extraction of total
RNA. To isolate potential escape mutants, virus from brain homoge-
nates was plaque purified as described previously (Sukupolvi-Petty
et al., 2010). Viral RNA was extracted from brain tissue by using an
RNeasy mini kit (Qiagen) and sequenced as described above along
with an additional forward primer in the capsid gene: 69F: 5′
AGGGTCGACCGTCTTTCAAT-3′ to obtain complete structural gene se-
quences. Viral RNA was extracted from viral supernatants of plaque-
purified isolates using the QIAamp Viral RNA kit (Qiagen) and
sequenced.
DENV-1 infectious cDNA clone and mutant generation
The DENV-1 West-Pac-74 infectious cDNA clone pRS424DEN1WP
(Puri et al., 2000; Whitehead et al., 2003) (gift of S. Whitehead, Be-
thesda. MD) was used to create wild type and mutant infectious
DENV-1. The T329A single amino acid substitution was introduced
into pRS424DEN1WP by site directed mutagenesis. Wild type and
mutant plasmids were grown in competent BD1528 bacteria at
room temperature and recovered using standard molecular biology
techniques. Plasmids were linearized, treated with proteinase K,
extracted twice with phenol and chloroform, and precipitated with
ethanol at −20 °C overnight. DNA was used as a template for in
vitro DNA-dependent RNA transcription with the AmpliScribe T7 kit
(Epicenter) with the addition of m7G(5′)ppp(5′)A cap analog (New
England BioLabs). Transcription reactions were run at 37 °C for 5 h
and the reaction was then electroporated (3 pulses at 850 V, 25 μF,
∞Ω) into BHK21-15 cells. Cells were added to a T75 tissue culture
flask in DMEM with 10% FBS and observed for the onset of cytopathic
effects (CPE). Once CPE were observed, virus-containing supernatant
was collected, cellular debris pelleted, and supernatant aliquots fro-
zen at −80 °C. The cells remaining in the T75 flask were harvested
and used as a source of viral RNA to confirm that the desired sequence
was retained.
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DENV-1 neutralization assay with reporter virus particles
DENV-1 reporter virus particles (RVP) are pseudo-infectious vi-
rions produced by genetic complementation of a WNV sub-genomic
replicon with the DENV structural genes in trans. Wild type and mu-
tant (T329A (E gene), K90R (prM gene), and V83L (E gene)) DENV-
1 RVP were generated as described previously (Ansarah-Sobrinho et
al., 2008; Dowd et al., 2011); a plasmid expressing the wild type or
mutant C-prM-E genes of DENV-1 (strains West-Pac-74 or 16007)
was cotransfected into 293T cells with a plasmid encoding a WNV
replicon expressing GFP. The C-prM-E plasmid of DENV-1 West-Pac-
74 or 16007 was mutated using the QuikChange site directed muta-
genesis kit (Stratagene) to introduce amino acid substitutions. Super-
natants containing RVP were harvested 72 h after transfection,
filtered through a 0.2 μm filter, and stored aliquotted at −80 °C.
RVP were incubated with serial dilutions of MAb under conditions
of antibody excess at 37 °C for 1 h. Subsequently, MAb-RVP mixtures
were added to Raji-DCSIGNR cells, which stably express the DC-
SIGNR attachment factor (Davis et al., 2006), and were incubated at
37 °C for 48 h. Infected cells were assayed for GFP expression using
a FACSCalibur flow cytometer (Becton Dickinson).
Phenotype of neutralization escape mutant viruses
Cell culture
The neutralizing activity of DENV1-E106 was determined by using
a plaque reduction neutralization test in BHK21-15 cells as described
previously (Shrestha et al., 2010). Additionally, single- and multi-step
growth curve analysis was performed in BHK21-15 or C6/36 cells
with wild type and mutant DENV-1 at different MOI (5, 1, 0.1, 0.01,
or 0.001) in the presence or absence of 25 μg/ml DENV1-E106 MAb.
Two hours later, free virus was removed and cells were grown in
the presence or absence of 25 μg/ml DENV1-E106 MAb at 37 °C.
Two days later, supernatants were harvested, and virus production
was determined by plaque assay in BHK21-15 cells.
Mice
To determine the virulence of T329A escape viruses, AG129 mice
were infected with wild type or mutant virus at 101, 102 or 103 PFU
by intracranial infection or 105 PFU by intraperitoneal infection.
Mice were monitored for morbidity and mortality for 60 days. Brain
tissues were harvested when mice were moribund and stored at
−80 °C. To assess whether DENV1-E106 MAb could protect mice
after infection with the T329A escape virus, AG129 mice were admin-
istered single dose of 500 μg/mouse antibody one day before intra-
peritoneal infection with 105 PFU of wild type and mutant virus.
Mosquito infection
A. aegyptimosquitoes (Rexville D strain) were provided by Dr. Ken
Olson (Colorado State University) and reared according to standard
procedures. Adult females were fed a mixture of defibrinated goose
blood and either wild type or T329A DENV-1 in a 1:1 blood:virus
ratio. ATP was added to the bloodmeal at a final concentration of
2 mM. Undiluted titers of the wild type and mutant viruses were
3.1×106 PFU/ml and 2.6×106 PFU/ml, respectively. After feeding,
mosquitoes were anesthetized, and engorged females separated into
cartons and held for a 14-day extrinsic incubation period (EIP) at
28 °C, 70 to 80% relative humidity, and a 16:8 photoperiod. In sepa-
rate experiments, mosquitoes were fed a blood meal using the same
virus stocks, and harvested within 1 h of feeding.
Viral RNA sequencing from mosquitoes
Whole mosquito bodies were collected, homogenized in RLT lysis
buffer, and RNA was extracted using RNeasy kits (Qiagen, Valencia
CA). Samples were screened for DENV-1 infection using a OneStep
RT-PCR Kit (Qiagen, Valencia CA) and primers that amplified a 500
nucleotide region in domain III of the envelope (E) gene (1546F: 5′-
ATCATGGCTCGTCCACAAAC-3′ and 2045R: 5′-GCTCCGCTTCAATGTT-
GACT-3′). This region contains the single nucleotide polymorphism
that differentiates the wild type and mutant viruses. RT-PCR reactions
from positive mosquitoes were purified using either QIAquick PCR
purification kits (Qiagen, Valencia CA) or StrataPrep PCR purification
kits (Stratagene, La Jolla CA). Amplicons were sequenced using a
primer annealing 149 bases upstream (1771F: 5′-TGCAGGACACCT-
GAAATGCAG-3′) of the single nucleotide polymorphism (Genewiz,
South Plainsfield NJ). Sequence chromatograms were analyzed to as-
sess reversion to the wild type sequence using the PERL script
PolySNP (Hall and Little, 2007).
Statistical analysis
All data were analyzed using Prism software (GraphPad software).
For survival analysis, Kaplan–Meier survival curves were analyzed by
log-rank test. For growth kinetics and neutralizing titers an unpaired
T-test or analysis of variance was used to determine significance.
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Dengue virus (DENV) is the most prevalent insect-transmitted viral disease in humans globally, and
currently no specific therapy or vaccine is available. Protection against DENV and other related flaviviruses is
associated with the development of antibodies against the viral envelope (E) protein. Although prior studies
have characterized the neutralizing activity of monoclonal antibodies (MAbs) against DENV type 2 (DENV-2),
none have compared simultaneously the inhibitory activity against a genetically diverse range of strains in vitro,
the protective capacity in animals, and the localization of epitopes. Here, with the goal of identifying MAbs that
can serve as postexposure therapy, we investigated in detail the functional activity of a large panel of new
anti-DENV-2 mouse MAbs. Binding sites were mapped by yeast surface display and neutralization escape, cell
culture inhibition assays were performed with homologous and heterologous strains, and prophylactic and
therapeutic activity was evaluated with two mouse models. Protective MAbs localized to epitopes on the lateral
ridge of domain I (DI), the dimer interface, lateral ridge, and fusion loop of DII, and the lateral ridge, C-C
loop, and A strand of DIII. Several MAbs inefficiently inhibited at least one DENV-2 strain of a distinct
genotype, suggesting that recognition of neutralizing epitopes varies with strain diversity. Moreover, antibody
potency generally correlated with a narrowed genotype and serotype specificity. Five MAbs functioned effi-
ciently as postexposure therapy when administered as a single dose, even 3 days after intracranial infection of
BALB/c mice. Overall, these studies define the structural and functional complexity of antibodies against
DENV-2 with protective potential.
Dengue virus (DENV), a member of the Flaviviridae family
of RNA viruses, is related to several other human pathogens of
global concern, including yellow fever and tick-borne, West
Nile, and Japanese encephalitis viruses. DENV infection in
humans occurs after Aedes aegypti or Aedes albopictus mosquito
inoculation and results in clinical disease, ranging from a fe-
brile illness (dengue fever [DF]) to a life-threatening hemor-
rhagic and capillary leak syndrome (dengue hemorrhagic fever
[DHF]/dengue shock syndrome [DSS]). Globally, there is sig-
nificant diversity among DENV strains, including four distinct
serotypes (DENV type 1 [DENV-1], DENV-2, DENV-3, and
DENV-4) that differ at the amino acid level by 25 to 40%.
Additional complexity occurs within each serotype, as geno-
types vary from one another by up to 3% at the amino acid
level (21, 49). No approved antiviral treatment is currently
available, and several candidate tetravalent vaccines remain in
clinical development (reviewed in reference 11). Because of
the increased geographic range of its mosquito vectors, urban-
ization, and international travel, DENV continues to spread
worldwide and now causes an estimated 50 to 100 million
infections and 250,000 to 500,000 cases of DHF/DSS per year,
with 2.5 billion people at risk (68).
DENV is an enveloped icosahedral virus with a single-
stranded, positive-polarity RNA genome. The 10.7-kb genome is
translated as a single polyprotein, which is cleaved into three
structural proteins (capsid [C], premembrane/membrane [prM/
M], and envelope [E]) and seven nonstructural (NS) proteins
(NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) by host and
viral proteases. The mature DENV virion is 500 Å in diam-
eter, with a highly organized outer protein shell, a 50-Å lipid
membrane bilayer, and a nucleocapsid core (26). Mature
DENV virions are covered by 90 anti-parallel E protein ho-
modimers, arranged flat along the surface with quasi-icosahe-
dral symmetry. The immature virion, which lacks cleavage of
the prM protein, has a rough surface with 60 spikes each
composed of three prM-E heterodimers (7, 73). Exposure to
mildly acidic conditions in the trans-Golgi network promotes
virus maturation through a structural rearrangement of the
* Corresponding author. Mailing address: Departments of Medi-
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flavivirus E proteins and cleavage of prM to M by a furin-like
protease (29, 66, 69, 70). The ectodomain of DENV E protein
is comprised of three discrete domains (34–36, 39). Domain I
(DI) is a central, eight-stranded -barrel, which contains a
single N-linked glycan in most DENV strains. DII is a long,
finger-like protrusion from DI, with the highly conserved fu-
sion peptide at its distal end and a second N-linked glycan that
recognizes DC-SIGN (37, 38, 46, 59). DIII, which adopts an
immunoglobulin-like fold, has been suggested to contain cell
surface receptor recognition sites (5, 64, 71). Several groups
have recently defined contact residues for type-specific, sub-
complex-specific, and cross-reactive monoclonal antibodies
(MAbs) that recognize DIII of DENV-2 (16, 17, 31, 47, 57, 61).
Type-specific MAbs with neutralizing activity against DENV-2
localized to the BC, DE, and FG loops on the lateral ridge of
DIII, whereas subcomplex-specific MAbs recognized an adja-
cent epitope centered on the connecting A strand of DIII at
residues K305, K307, and K310.
To date, no study has compared the in vitro inhibitory
activity of MAbs in cells against a genetically diverse range
of DENV-2 strains and their protective capacity in animals.
Here, we had the goal of generating strongly neutralizing
MAbs that would recognize virtually all DENV-2 strains and
function as a possible postexposure therapy. Twenty-four new
anti-DENV-2 mouse MAbs were generated with moderate or
strong neutralizing activity against the homologous virus in cell
culture assays. Binding sites were mapped for the majority of
these by yeast surface display, identifying distinct epitopes in
regions in DI (lateral ridge), DII (dimer interface, lateral
ridge, and fusion loop), and DIII (lateral ridge, C-C loop,
and A strand). Several MAbs failed to neutralize efficiently
at least one DENV-2 strain of a distinct genotype, suggesting
that antibody recognition of neutralizing epitopes varies
among DENV-2 genotypes.
To begin to assess the utility of this new panel of inhibitory
MAbs as possible therapeutics against DENV-2, we evaluated
their protective capacity in a stringent intracranial challenge
model in BALB/c mice. Among the 16 neutralizing MAbs
tested in mice, most were protective when given as prophylaxis.
Seven of these had postexposure therapeutic activity when
administered as a single dose by intraperitoneal route even 3
days after intracranial infection. For the MAbs with the great-
est therapeutic potential, protection was confirmed with an
antibody-enhanced vascular leakage mouse model (2, 72) of
DENV-2 infection.
MATERIALS AND METHODS
Cells and viruses. BHK21 and HEK-293T cells were cultured in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) (Omega Scientific) and antibiotics (penicillin G and streptomycin). Raji-
DC-SIGN-R cells were cultured in RPMI-1640 medium supplemented with 10%
FBS and antibiotics. DENV-2 strains used in this study included 16681 (South-
east Asian genotype), C0477 (Southeast Asian genotype), New Guinea C (NGC)
(Southeast Asian genotype), D2S10 (Southeast Asian genotype), ArA6894 (In-
dian genotype), IQT2913 (American genotype), and PM33974 (West African
genotype). DENV strains from other serotypes were obtained from colleagues
(A. de Silva, University of North Carolina, and R. Tesh, University of Texas
Medical Branch) and included 16007 (DENV-1), 16652 (DENV-3), and 1036
(DENV-4). All viruses were propagated in C6/36 Aedes albopictus cells according
to described protocols (57).
E gene sequencing. The virus nucleotides from positions 616 to 2578 were
amplified by reverse transcription (RT)-PCR using a high-fidelity polymerase
and RNA extracted directly from infected C6/36 cells. Each amplicon was se-
quenced on both strands by conventional capillary sequencing on an Applied
Biosystems 310 genetic analyzer using previously reported primers (28). The
resulting sequence reads were assembled, and the E gene sequences aligned
using the Lasergene suite (DNASTAR).
Generation, purification, and labeling of anti-DENV-2 MAbs. To generate
anti-DENV-2 MAbs, alpha/beta interferon receptor-deficient (IFN-/R/)
C57BL/6 mice were infected with 105 PFU of a mixture (1:1) of DENV-2 strains
16681 and NGC via an intraperitoneal route and rechallenged 2 weeks later with
the same strains. Mice with serum showing the highest binding titer to Raji-DC-
SIGN-R cells infected with DENV-2 strain 16681 (1:10,000) were immunized
with purified DIII (50 g, strain 16681 [31]) in phosphate-buffered saline (PBS)
as a final intravenous boost. Three days later, splenocytes were fused to
P3X63Ag8.6.5.3 myeloma cells using polyethylene glycol 1500 (20). Hybridomas
producing anti-DENV-2 MAbs were subcloned by limiting dilution, isotyped
using an enzyme-linked immunosorbent assay (ELISA) kit (Southern Biotech)
and purified by protein A or protein G immunoaffinity chromatography. For
in vivo studies, MAbs were purified by a second size exclusion chromatogra-
phy step and then concentrated using a Centricon centrifugal concentrator
(Millipore). For some experiments, MAbs were labeled directly with Alexa
Fluor 647 or Alexa Fluor 488 (Invitrogen) according to the manufacturer’s
instructions.
In vitro neutralization assays. Three virus neutralization assays were used. (i)
Plaque reduction neutralization titer (PRNT) assays were performed with the
different DENV-2 strains and MAbs on BHK21 cells as described previously (10,
57). Fifty-percent PRNT (PRNT50) values were determined using nonlinear
regression analysis and expressed as nanograms per milliliter of antibody. (ii) To
assay whether MAbs inhibited at a pre- or postattachment step, a PRNT assay
was performed with the following modifications. In the postattachment assay,
after cells and solutions were prechilled to 4°C, 102 PFU of DENV-2 was added
to cells and viral adsorption was allowed for 1 h at 4°C. Wells were washed thrice
with cold media to remove unbound virus, and MAb was added at the specified
concentrations. Virus-antibody complexes were allowed to form for 1 h at 4°C
and then were washed three times with cold media. Cells were warmed to 37°C,
and the PRNT assay was completed. For the preattachment assay, a PRNT assay
with all cells and solutions at 4°C, in which MAb DENV-2 were mixed for 1 h at
4°C or 37°C prior to addition to cells, was performed. (iii) DENV-2 reporter virus
particles (RVPs) were produced as described previously (1). Briefly, HEK-293T
cells were transfected with plasmids encoding DENV-2 strain 16681 C-prM-E
and a West Nile virus (WNV) replicon to generate DENV-2 RVPs. In some
experiments, the C-prM-E plasmid was mutated using the QuikChange site-
directed mutagenesis kit (Stratagene) to introduce amino acid substitutions in
the E gene. Neutralization assays were performed as described previously (1, 45),
and infection was measured by flow cytometry at 48 h after infection. The 50%
effective dose (EC50) of each antibody was calculated using nonlinear regression
analysis.
Domain and fine epitope mapping by yeast surface display. The DNA frag-
ments encoding amino acid residues 1 to 292 (DI-DII) and 293 to 409 (DIII) of
the DENV-2 E protein were amplified from DENV-2 strain 16681 by RT-PCR
with KpnI and XhoI or BamHI and XhoI sites added at the 5 or 3 end,
respectively. The PCR product was cloned as a downstream fusion to Aga2 and
Xpress epitope tag genes in the yeast surface display vector pYD1 (Invitrogen)
and transformed into Saccharomyces cerevisiae strain EBY100 (Invitrogen) to
generate yeast that expressed DENV-2 DI-DII or DIII as described previously
(42, 57).
To generate random variant libraries, DENV-2 DI-DII or DIII was mutated
by error-prone PCR, using the GeneMorph II random mutagenesis kit (Strat-
agene). The libraries were ligated into the pYD1 vector and transformed into
XL2-Blue ultracompetent Escherichia coli cells (Stratagene). The colonies were
pooled and transformed into yeast. For mapping of each individual MAb, the
relevant DENV-2 DI-DII or DENV-2 DIII library was screened according to a
previously described protocol (42, 57). For individual clones that lost binding to
the desired MAb, the mutant pYD1-DV2 DI-DII or DIII plasmids were recov-
ered, transformed into XL1-Blue-competent cells (Stratagene), purified using a
QIAprep spin miniprep kit (Qiagen), and sequenced. In some cases, variants
with multiple mutations were isolated. To determine which mutation conferred
the phenotype, single mutations were engineered using a QuikChange II mu-
tagenesis kit (Stratagene).
Immunostaining of DENV-infected cells. To assess binding of DENV-2 MAbs
to different DENV strains, Raji-DC-SIGN-R cells were infected at a multiplicity
of infection (MOI) of 0.5 or 1. Depending on the strain, Raji-DC-SIGN-R cells
were harvested 48, 72, or 96 h after infection. Cells were washed, fixed in PBS
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with 1% paraformaldehyde, permeabilized, incubated with MAbs, and processed
by flow cytometry as described previously (53).
Generation of MAb-resistant virus escape mutants. DENV-2 (16681 strain,
5  105 PFU) was incubated with 25 g/ml of MAb DV2-48 or DV2-67 for 1 h
at 37°C in DMEM. The mixture was added to 5  105 BHK21 cells in a 6-well
plate. After infection for 2 h at 37°C, wells were washed thrice with DMEM, and
fresh media containing 25 g/ml of MAb were added. Virus growth under
antibody selection proceeded for 72 h at 37°C. At each passage, half of the
supernatant was mixed 1:1 with 50 g/ml of MAb for 1 h. The remaining half was
stored at 80°C. After three to six passages under MAb selection, virus-con-
taining supernatants were tested by plaque reduction assay for escape from
neutralization of DV2-48 or DV2-67. After the escape phenotype was confirmed,
an aliquot of the supernatant was used for a BHK21 cell plaque assay under MAb
selection. Plaque-purified virus was amplified further under MAb selection (25
g/ml) overnight at 37°C. BHK21 cells were scraped from wells, and total cellular
RNA was isolated using an RNeasy kit (Qiagen). cDNA was amplified with
random hexamers as well as primer DENV-2 3756R (5-TCAAGAGTAGTCC
AGCTGCAAA-3) using a Superscript III first-strand synthesis system for RT-
PCR (Invitrogen) and served as a template for PCR amplification using forward
(609F, 5-GCAGAATGAGCCAGAAGACAT-3) and reverse (2784R, 5-TGC
TTTGCCCCATGTTTTC-3) primers. Amplicons were sequenced, and the neu-
tralization escape mutant sequence was compared to that of the parent virus
stock that was passaged in parallel in the absence of MAb selection.
Mouse experiments. All mouse studies were approved and performed accord-
ing to the guidelines of the Washington University School of Medicine Animal
Safety Committee or the University of California, Berkeley Animal Safety Com-
mittee. IFN-/R/ mice on the C57BL/6 background were a gift of Jonathan
Sprent (The Scripps Research Institute). The IFN-/R/  R/ mice on a
129 Sv background (AG129) have been described previously (52). BALB/c mice
were purchased commercially (Jackson Laboratories). All mice were housed in
pathogen-free barrier facilities. In prophylaxis experiments, mice were adminis-
tered a single dose of individual MAbs via an intraperitoneal route 1 day before
infection. BALB/c and AG129 mice were challenged with DENV-2 NGC (South-
east Asian genotype, 6  104 PFU) intracranially or DENV-2 D2S10 (Southeast
Asian genotype, 105 PFU) intravenously, respectively, and mortality was moni-
tored. In postexposure therapeutic experiments, a single dose of MAb was
administered by intraperitoneal injection 2 or 3 days after infection.
Statistical analysis. All data were analyzed using Prism software (GraphPad
Prism, San Diego, CA). Kaplan-Meier survival curves were analyzed by the log
rank test. For neutralization assays, an unpaired Student t test was used to
determine significance.
Nucleotide sequence accession numbers. Two new E gene sequences, C0477
and ArA6894, were deposited in GenBank with accession numbers HM234641
and HM234642.
RESULTS
Generation of MAbs against DENV-2. Previous experiments
identified type- and subcomplex-specific MAbs of DENV-2
that neutralized infection in cell culture and localized to DIII
of the E protein (16, 17, 57). However, these studies did not
assess the in vivo efficacy of these antibodies nor evaluate their
ability to neutralize a diversity of DENV-2 strains. As a first
step toward generating antibody therapeutics that protect
against genetically diverse DENV-2 strains, we generated a
larger panel of DENV-2-specific MAbs by infecting mice with
a mixture of 16681 (Southeast Asian genotype) and NGC
(Southeast Asian genotype) DENV-2 strains and boosting with
homologous virus or recombinant DIII. After screening
more than 3,000 hybridoma clones as part of four indepen-
dent fusions, 57 new MAbs that recognized cells infected
with DENV-2 were isolated (see Table S1 in the supplemen-
tal material).
All MAbs were tested by ELISA for binding to recombinant
E protein or Western blot immunoreactivity against DENV-2-
infected cell lysates and for binding to permeabilized BHK21
cells propagating a subgenomic replicon that expressed only
the nonstructural proteins (41). We identified 33 new MAbs
that recognized E protein and 21 that recognized nonstructural
proteins; the remaining MAbs (DV2-16, DV2-34, and DV2-
47) recognized DENV-2-infected cells but could not be as-
signed to a specific protein, as they failed to bind to purified
recombinant proteins by ELISA or Western blot analysis (data
not shown).
MAbs that recognized the DENV-2 E protein were tested
semiquantitatively for neutralization of DENV-2 16681 by
single endpoint plaque reduction assay using undiluted hy-
bridoma supernatant. Of the 33 MAbs that mapped to the E
protein, 7 showed no neutralization activity (0% neutraliza-
tion), 2 had modest inhibitory activity (50 to 90% neutral-
ization), and 24 were strongly neutralizing (	90% neutral-
ization). MAbs also were screened for E protein domain
recognition using yeast that expressed DENV-2 DI-DII, DIII,
or the entire ectodomain of E (DI-DII-DIII) on their surface
(see Table S1 in the supplemental material): 13 bound to yeast
expressing DI-DII and 17 recognized DIII on yeast. A total of
13 of the DI-DII-specific MAbs and 11 of the DIII-specific
MAbs showed strong inhibitory activity.
Cross-reactivity with other serotypes. To begin to determine
the breadth of the inhibitory potential of the MAbs, we as-
sessed cross-reactivity of binding using Raji-DC-SIGN-R cells
infected with different serotypes of DENV. Three DI-DII-
specific (DV2-29, DV2-30, and DV2-52) and one DIII-specific
(DV2-77) strongly neutralizing MAb cross-reacted with all
other serotypes of DENV, with some recognizing distantly
related flaviviruses (e.g., WNV). Additionally, two DI-DII spe-
cific (DV2-40 and DV2-53) and two DIII-specific (DV2-76 and
DV2-94) neutralizing MAbs were subcomplex-specific and rec-
ognized a subset of DENV serotypes. Eight DI-DII-specific
and eight DIII-specific strongly neutralizing MAbs were type
specific and reacted only with DENV-2-infected cells (see Ta-
ble S1 in the supplemental material).
Genotype-specific neutralization. Globally, there is diversity
among DENV strains, including distinct serotypes (DENV-1,
-2, -3, and -4) that differ at the amino acid level by 25 to 40%,
and variation within each serotype, with genotypes varying by
in vitro and in vivo phenotypes (21, 49). We examined the
neutralizing potential of anti-DENV-2 MAbs against individ-
ual strains that corresponded to heterologous DENV-2 geno-
types: ArA6894 (Indian genotype), IQT2913 (American geno-
type), and PM33974 (West African genotype). We initially
assessed the inhibitory activity of neat hybridoma supernatants
of the 24 neutralizing MAbs by a standard plaque reduction
assay. With the exception of DV2-67, all MAbs showed strong
neutralization activity (75% or greater) against the Indian and
American genotypes (data not shown). Nonetheless, we observed
decreased neutralization activity by several MAbs against the
West African genotype (PM33974). This virus strain is classified
as a sylvatic DENV that is transmitted primarily between non-
human primates and mosquitoes; viruses belonging to this ge-
notype have not been associated with outbreaks of severe dis-
ease in humans (48).
Although the semiquantitative neutralization results were
informative, we expanded on them by purifying 18 MAbs and
performing a dose-response analysis to define the concentra-
tion of MAb that blocked plaque formation by 50% (the
PRNT50, here expressed as ng/ml of antibody) (Table 1). In
addition to strains corresponding to the homologous and het-
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erologous genotypes mentioned above, we performed experi-
ments with a low-passage Southeast Asian genotype strain
(C0477) and with NGC, as this Southeast Asian strain was used
for immunization and therapeutic studies in vivo (see below).
In general, DIII-specific MAbs showed higher neutralization
activity against the homologous strain (16681) than DI-DII-
specific MAbs, with most (6 of 8 MAbs) having PRNT50 values
below 200 ng/ml. Neutralization levels of other strains (C0477
and NGC) of the homologous Southeast Asian genotype strains
were generally comparable, with some exceptions: DV2-58 and
DV2-77 showed stronger (6- to 12-fold) inhibitory potential
against C0477, DV2-106 had stronger (11- to 14-fold) neutral-
izing activity against NGC and C0477, and DV2-73 was less
potent (9- to 30-fold) against NGC and C0477.
In the analysis of neutralization of heterologous DENV-2
genotypes, most MAbs, with the exception of DV2-36, DV2-
40, DV2-48, and DV2-58, neutralized the Indian genotype
strain (ArA6894) efficiently (PRNT50 below 600 ng/ml). Some-
what surprisingly, DV2-46 neutralized ArA6894 to a greater
extent (5- to 16-fold) than the homologous Southeast Asian
genotype strains against which it was raised. A subset of the
strongly neutralizing MAbs (DV2-30, DV2-44, DV2-58, DV2-
76, DV2-87, DV2-96, DV2-104, and DV2-106) was tested for
neutralization of strains corresponding to the American and
West African genotypes (Fig. 1 and Table 1). With the excep-
tion of DV2-58, the remainder of the MAbs strongly neutral-
ized infection by the American genotype strain (IQT2913),
with PRNT50 values less than 150 ng/ml. Remarkably, DV2-
106 had 	60-fold greater neutralizing activity against IQT2913
than any of the strains of the Southeast Asian genotype.
However, several MAbs (DV2-30, DV2-87, DV2-96, and
DV2-106) inhibited infection of the West African genotype
strain (PM33974) less efficiently (up to 25-fold-lower neu-
tralization potency) than other genotypes.
Epitope mapping of neutralizing MAbs using yeast display.
To understand in greater detail the disparity in inhibitory po-
tential of the neutralizing MAbs, we mapped the amino acid
residues required for MAb binding using yeast surface display
(Table 2). Two approaches were used. (i) For forward genetics,
a library of DI-DII and DIII variants of strain 16681 was
generated using random mutagenesis for flow cytometry-based
screens to identify residues that comprise MAb epitopes. (ii)
For reverse genetics, based on prior studies that mapped DIII-
specific neutralizing MAbs against DENV-2 (16, 17, 31, 57),
mutations were engineered (S300T, K307E, V309K, K310E,
D329G, G330D, K361E, E383R, P384N, and K393R) on res-
idues of the BC, DE, and FG loops and the A -strand (A
strand) of DIII of DENV-2 strain 16681, and these variants
also were displayed on the surface of yeast.
(i) DI-DII-specific MAbs. The highly conserved fusion loop
in DII has been identified as a recognition site for moderately
and weakly neutralizing cross-reactive MAbs (7, 8, 15, 43, 58).
Consistent with this, four of our DI-DII-specific neutralizing
MAbs localized to sites within this loop of DII (Fig. 2A and
Table 2). Mutation of W101, G106, or L107 reduced binding of
cross-reactive (DV2-29)-, complex (DV2-30 and DV2-52)-,
and subcomplex (DV2-36)-specific neutralizing MAbs. The
yeast display screening of variant DI-DII also identified the
dimer interface on DII as a second epitope for neutralizing
DENV-2 MAbs. Binding of MAbs DV2-30, DV2-40, DV2-44,
DV2-46, and DV2-58 was reduced or abolished by mutations
at residue K88, Q233, or H244. We also identified by yeast
surface display one type-specific neutralizing MAb (DV2-51)
that mapped to a site in DI at residue E184.
(ii) DIII-specific MAbs. The amino acid residues K305,
K307, and K310 on the A strand of DIII have been defined as
recognition sites for some subcomplex- and type-specific MAbs
(17, 57). In agreement with this, several of the newly generated
TABLE 1. MAb neutralization of homologous and heterologous DENV-2 strainsa
MAb Domain
PRNT50b
16681 NGC C0477 ArA6894 IQT2913 PM33974
DV2-29 DI-DII 852 182 1,189 154 NT NT
DV2-30 DI-DII 190 500 500 321 71 996
DV2-36 DI-DII 1,212 	5,000 	5,000 614 NT NT
DV2-40 DI-DII 869 4,500 	5,000 1,204 NT NT
DV2-44 DI-DII 204 280 324 91 13 231
DV2-46 DI-DII 2,069 1,500 634 126 NT NT
DV2-48 DI-DII 731 267 1,440 1,254 NT NT
DV2-51 DI-DII 1,176 936 	5,000 419 NT NT
DV2-52 DI-DII 876 491 296 204 NT NT
DV2-58 DI-DII 2,467 	5,000 200 653 	5,000 2,351
DV2-70 DIII 168 214 133 375 NT NT
DV2-73 DIII 92 2,800 827 453 NT NT
DV2-76 DIII 29 185 303 92 9 72
DV2-77 DIII 200 311 32 280 NT NT
DV2-87 DIII 76 200 111 232 11 486
DV2-96 DIII 67 106 34 69 146 1,648
DV2-104 DIII 76 228 79 320 81 232
DV2-106 DIII 311 60 79 192 1 2,061
a Neutralizing activity was determined by plaque reduction assay on BHK21 cells with increasing concentrations of purified MAbs and 102 PFU of the indicated
DENV-2 genotype (16681, Southeast Asian; NGC, Southeast Asian; C0477, Southeast Asian; ArA6894, Indian; IQT2913, American; and PM33974, West African). The
data were derived from two or three independent experiments performed in duplicate.
b PRNT50 values were calculated by nonlinear regression analysis and are expressed as ng/ml of antibody. NT, not tested.
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DIII-specific neutralizing MAbs localized to residues along the
A strand (Fig. 2B and Table 2). The subcomplex-specific neu-
tralizing MAb DV2-76 showed moderately reduced binding
after mutation of the A-strand residue K310. Both type-specific
(DV2-70, DV2-96, and DV2-106) and subcomplex-specific
(DV2-76) MAbs were affected by residue changes at positions
K305 and K307, which lie at the junction of the N-terminal
linker and the A-strand regions. Several MAbs (DV2-70, DV2-
76, and DV2-96) also lost binding when residue V309
was changed. Although the type-specific neutralizing MAbs
DV2-70 and DV2-96 map to residues in the conserved A
strand (K305, K307, or V309) in a manner analogous to that
of the subcomplex-specific MAbs, they were distinguished
FIG. 1. MAb neutralization of different DENV-2 genotypes. In-
creasing concentrations of purified DV2-87 (A), DV2-96 (B), and
DV2-106 (C) were mixed with 102 PFU of DENV-2 strains corre-
sponding to all four genotypes, and neutralization was assessed by a
standard PRNT assay in BHK21 cells. Graphs were generated after
regression analysis using statistical software. The data are representa-
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by an additional recognition site in the BC loop at position
E327. Thus, some type-specific neutralizing MAbs recognize
an epitope comprised of amino acids in the N-terminal
linker, BC loop, and A strand (Fig. 2C), whereas subcom-
plex neutralizing MAbs localize more directly to amino ac-
ids on the A strand.
The amino acid residues E383 and P384 in the FG loop were
previously identified as binding sites for type-specific neutral-
izing DENV-2 MAbs that mapped to the DIII-lateral-ridge
epitope (16, 57). Surprisingly, none of the newly generated
strongly neutralizing MAbs lost binding when these residues
were changed. Instead, two groups of type-specific neutralizing
MAbs that recognized distinct regions were identified in this
study. DV2-70, DV2-96, and DV2-106 bound to sites along the
lateral ridge of DIII, including the N-terminal linker, the BC
loop, the top region of the A strand, and a residue in the G
strand. A second group of neutralizing MAbs (DV2-73,
DV2-77, DV2-87, and DV2-104) showed loss of binding,
with mutations in three residues that have not been de-
scribed previously as sites for neutralizing antibody recog-
nition (Fig. 2D). The P336 residue is found at the junction
of the BC loop and the C strand and is conserved among all
DENV serotypes. M340 and H346 are located in the C
strand and C-C loop, respectively, and are unique to the
DENV-2 serotype.
Epitope mapping of MAbs using neutralization escape and
reverse genetics. As two MAbs (DV2-48 and DV2-67) recog-
nized a determinant on DENV-2 that was not present on
yeast-displayed forms of E, we generated neutralization escape
mutants to define their epitopes. After sequential virus passage
on BHK21 cells under DV2-48 or DV2-67 selection, these
MAbs lost the ability to neutralize DENV-2 infection (Fig.
3A). To identify the mutations that conferred the escape phe-
notype, the viral sequence from plaque-purified escape vari-
ants was compared to that for virus passaged in parallel in the
absence of MAb selection. All (4 of 4) sequences from the
DV2-48 escape variants contained the same single nucleotide
change encoding a G177D mutation in the E protein. In con-
trast, of the DV2-67 escape variants that were sequenced,
three contained a single mutation (M196V), and one contained
two amino acid changes (K291R and K307R).
To establish which amino acid substitutions conferred the
FIG. 2. Epitope mapping of anti-DENV-2 MAbs on the E protein. (A) Localization of neutralizing epitopes on DENV-2 DI-DII as determined
by yeast surface display. Structure of DENV-2 DI-DII (strain 16681), with amino acid residues that significantly affect binding of indicated
neutralizing MAbs marked. (B to D) Localization of neutralizing epitopes on DENV-2 DIII as determined by yeast surface display. Structure of
DENV-2 DIII (strain 16681), with amino acid residues that affect binding of representative neutralizing MAbs marked in orange. (B) DV2-76
(A strand); (C) DV2-106 (lateral ridge); (D) DV2-104 (C-C loop).
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neutralization escape phenotypes, we utilized a reverse-genet-
ics approach. DENV-2 reporter virus particles (RVPs; strain
16681) composed of E proteins encoding single amino acid
mutations were produced and analyzed for MAb neutralization
(1). Whereas DV2-96 neutralized the wild type and G177D,
K307R, and K291R variants equivalently, RVPs composed of E
proteins with the G177D mutation were resistant to neutraliza-
tion by DV2-48, even at concentrations of 60 g/ml of MAb
(Fig. 3B). Correspondingly, K307R RVPs were resistant to
neutralization by DV2-67, whereas K291R RVPs remained
sensitive and behaved similarly to wild-type RVPs (Fig. 3C).
Interestingly, M196V RVPs resulted in altered neutralization
curves for DV2-67, DV2-96, and several other MAbs compared
to wild-type RVP, suggesting a global change in E protein struc-
ture or arrangement (Fig. 3C and D and data not shown). We
subsequently mapped the residues that conferred neutralization
escape onto the DENV-2 E crystal structures (34, 35). G177D is
solvent-accessible in DI and localizes in proximity to the E184D
epitope identified for DV2-51 (Fig. 2A), whereas K307R maps to
the middle of the A strand of DIII.
Structural analysis of genotypic variation of DENV-2 E pro-
tein. Amino acid sequences of the ectodomain of the E protein
of six DENV-2 strains were aligned, representing strains of the
Southeast Asian, American, Indian, and West African geno-
types (see Fig. S1 and S2 in the supplemental material), with 33
sites of variation observed. PM33974, a sylvatic strain of the
West African genotype, showed great sequence diversity com-
pared to the consensus DENV-2 sequence, with 14 and 3
amino acid differences in DI-DII and DIII, respectively. The
IQT2913 strain of the American genotype also had significant
variation, with nine amino acid changes detected. The other
genotypes had limited diversity in the E protein, ranging from
two to five changes for strains of the Southeast Asian and
Indian genotypes. Sequence alignment with other DENV se-
rotypes or flaviviruses (e.g., WNV) revealed that 16 of the sites
of genetic variation among the genotypes were unique to the
DENV-2 serotype, with six of them occurring only in the syl-
vatic strain.
There are 12 conservative substitutions and 13 nonconser-
vative substitutions within DI and DII among the genotypes of
DENV-2 (see Fig. S1 in the supplemental material). Of the
conservative substitutions, four are solvent exposed or located
along the dimer interface (I/M6, S/T81, V/I129, and S/L247),
whereas eight are buried and likely contribute to domain sta-
bilization and structure (Y/F59, K/R93, I/V139, I/V141,
I/V162, I/V164, V/I181, and L/I277) (Fig. 4A). We identified
11 nonconservative substitutions that are solvent exposed and
two nonconservative substitutions that are proximal to the viral
membrane. Nine of the 11 nonconservative substitutions
occur in DII, with the e strand alone containing four solvent-
accessible genotypic variants (T/R120, K/L122, N/K124, and
K/E126). The remaining variation in DII was in the b strand
FIG. 3. Characterization of neutralization escape mutants. (A) A neutralization assay was performed with selected escape variants (G177D or
K307R) after plaque purification. These escape variants were obtained after three to six passages of DENV-2 (strain 16681) under selection with
either DV2-48 or DV2-67 on BHK21 cells. Note that the G177D and K307R variants are resistant to DV2-48 and DV2-67, respectively. Data are
representative of two independent experiments performed in duplicate. (B to D) Confirmation of resistant phenotype with DENV-2 RVPs.
Mutated RVPs (G177D, K291R, K307R, or M196V) were used to confirm that single amino acid substitutions in the E protein reduce or eliminate
neutralization by the selecting MAb (DV2-48 [B]; DV2-67 [C]; and DV2-96 [DR] control DIII MAb). In each series, the reduced neutralizing
capacity of the indicated MAb is compared to the neutralizing capacity of wild-type DENV-2 RVP generated in parallel. The data are
representative of two or three separate experiments performed in triplicate. Error bars indicate standard error within a single experiment. Lines
represent curve fits generated by nonlinear regression analysis. For panel C, diluted hybridoma supernatant was used instead of purified antibody.
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(E/D/A71) and the ef (N/K/V83), fg (N/D/S203), hi (T/K226),
and jk (S/L274) loops. The remaining solvent-exposed residues
that varied were present in DI at amino acid positions 149
(H/N) and 171 (T/A); however, residue 149 is likely shielded by
the conserved N-linked glycan at asparagine 153. T/K236 and
T/M280 are nonconservative substitutions in DII that localize
proximal to the lipid bilayer of the virion.
Alignment of the DIII amino acid sequences revealed eight
sites of variation among the DENV-2 genotypes (see Fig. S2 in
the supplemental material). Using the pseudo-atomic model
of the mature DENV-2 virion (26), we assessed the solvent
accessibility of these variable amino acids. For four of
the residues that had conservative substitutions (V/I308,
I/V322, K/R345, and I/V365) in the A strand, B strand, C-C
loop, and E strand, the amino acid side chains are predicted to
be partially or completely solvent inaccessible (Fig. 4B). Sim-
ilarly, two of the nonconservative substitutions (A/V382) at the
junction of the FG loop and in the C-C loop (H/Y346) appear
buried in the mature virus. In contrast, the nonconservative
substitution D/G330 is located at the apex of the BC loop and
is fully solvent accessible. Consistent with this, changes in this
residue were associated with altered MAb (DV2-70 and DV2-
106) binding and genotype-specific neutralization. The final
nonconservative substitution (N/D390) in the G strand appears
solvent accessible but did not alter the function of any of the
MAbs in this study. Although substitutions in the C-C or FG
loops at residues 345, 346, or 382 are not surface exposed in the
structure of the mature DENV-2 virion, they may become
surface accessible as part of the ensemble of transitional states
(31), which likely reflect “breathing” of the virion. This may
explain why substitutions at position H346 reduced binding of
several type-specific neutralizing antibodies (DV2-73, DV2-77,
DV2-87, and DV2-104).
Prophylaxis in mice. To define the relationship between
neutralization in cell culture and protection in vivo and to
explore the possibility for antibody therapy, we evaluated the
efficacy of inhibitory MAbs against DENV-2 NGC in BALB/c
mice. This mouse model was selected because (i) NGC effi-
ciently causes lethal infection in BALB/c mice after an intra-
cranial challenge (12, 54); (ii) large numbers of BALB/c mice
can be obtained commercially, facilitating comparison of many
MAbs in a short period of time; and (iii) although intracranial
DENV infection of BALB/c does not recapitulate pathogene-
sis in humans, it is a stringent protection model, as small
amounts of MAb cross the blood-brain barrier and accumulate
in the central nervous system (22).
A single dose (500 g) of 16 different neutralizing MAbs was
administered as prophylaxis 1 day prior to intracranial infec-
tion with 6  104 PFU of DENV-2 NGC. With the exception
of DV2-36, all neutralizing MAbs showed significant protec-
tion against lethal DENV-2 NGC infection at a 500-g dose
(Table 3). Among those tested, 11 of 16 (DV2-30, DV2-44,
DV2-46, DV2-48, DV2-52, DV2-58, DV2-76, DV2-77, DV2-
87, DV2-96, and DV2-104) enhanced survival rates beyond
77%. Four of sixteen neutralizing MAbs (DV2-29, DV2-51,
DV2-70, and DV2-106) protected less efficiently yet signifi-
cantly, with survival rates of 37 to 63% (P  0.02).
To begin to gauge in vivo potency, we administered 5- and
25-fold-lower doses (100 g and 20 g) 1 day prior to intra-
cranial infection of BALB/c mice with DENV-2 NGC (Table
3). The 20-g dose of DV2-30 provided little protection
against lethal infection, with no difference in average survival
FIG. 4. Structural analysis of genotypic variation. (A) Diagram of DI-DII (top, top view; bottom, bottom view) showing sequence variation of
different DENV-2 genotypes. Amino acid sequences that differ among DENV-2 genotypes are indicated, with solvent-accessible or -inaccessible
residues depicted in green and cyan, respectively. (B) Ribbon diagram of DENV-2 DIII with -strands and loops labeled accordingly from
published X-ray crystallographic structure. Amino acid sequences that vary among the different DENV-2 genotypes are indicated, with solvent-
inaccessible and -accessible residues depicted in blue and green, respectively. Magenta coloring indicates residues that are not predicted to be
solvent accessible in the mature virion based on cryo-electron microscopic reconstruction (26) but may be accessible during other stages of the virus
life cycle.
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times observed. In comparison, 40 to 60% of mice survived
infection after receiving a single dose of 20 g of any of seven
different MAbs (DV2-44, DV2-52, DV2-58, DV2-76, DV2-87,
DV2-96, and DV2-104).
Epidemiological data and cell culture experiments have
suggested that poorly neutralizing cross-reactive anti-
DENV antibodies contribute to severe disease in humans by
an antibody-dependent enhancement (ADE) of infection
mechanism (reviewed in reference 19). Recently, a disease
model of ADE of DENV infection that causes a vascular
leakage syndrome was developed in AG129 immunocompro-
mised mice (2, 72): passive transfer of anti-DENV antibodies
enhanced disease after infection with a mouse-adapted
DENV-2 Southeast Asian genotype strain (D2S10). To further
define the protective activity of anti-DENV-2 MAbs in vivo, we
selected three of the promising MAbs from the BALB/c stud-
ies and evaluated their activity in this ADE disease model.
Fifty micrograms of MAb (DV2-44, DV2-76, or DV2-104) or
PBS was administered concurrently with enhancing concentra-
tions of either anti-flavivirus MAb 4G2 (which recognizes the
highly conserved fusion loop in DII) or polyclonal anti-
DENV-1 cross-reactive immune serum. One day later, mice
were infected with a sublethal dose (105 PFU) of DENV-2
D2S10 by an intravenous route. Mice receiving 4G2 or
DENV-1 immune sera and PBS or an isotype control MAb
succumbed to lethal DENV infection within 5 days (Table 4
and data not shown). Among mice treated with anti-DENV-2
MAbs (DV2-44, DV2-76, or DV2-104), only one mouse, a
recipient of DV2-76, demonstrated any sign of morbidity. All
other animals receiving neutralizing DENV-2 MAbs remained
healthy throughout the experiment.
Therapeutic activity of neutralizing MAbs in mice. To
assess the potential therapeutic efficacy of neutralizing anti-
DENV-2 MAbs, BALB/c mice were infected intracranially
with DENV-2 NGC, and 2 days later, a single 500-g dose of
TABLE 3. Pre- and postexposure protection of BALB/c mice from




1 day before infection
PBS control 0 0/31
WNV-E16 500 0/9 NS
DV2-29 500 5/8 
0.0001
DV2-30 500 5/5 
0.0001
DV2-30 100 5/5 
0.0001
DV2-30 20 0/5 NS
DV2-36 500 2/5 NS
DV2-44 500 5/5 
0.0001
DV2-44 100 5/5 
0.0001
DV2-44 20 3/5 0.005
DV2-46 500 7/9 
0.0001
DV2-46 100 4/5 0.0002
DV2-48 500 4/5 
0.0001
DV2-48 100 2/5 0.03
DV2-51 500 3/8 0.02
DV2-52 500 5/5 
0.0001
DV2-52 100 4/5 0.0004
DV2-52 20 3/5 0.0004
DV2-58 500 9/10 
0.0001
DV2-58 100 5/5 
0.0001
DV2-58 20 2/5 0.007
DV2-70 500 5/9 
0.0001
DV2-76 500 9/10 
0.0001
DV2-76 100 3/5 0.005
DV2-76 20 3/5 0.005
DV2-77 500 9/10 
0.0001
DV2-87 500 5/5 
0.0001
DV2-87 100 3/5 0.007
DV2-87 20 2/5 NS
DV2-96 500 8/9 
0.0001
DV2-96 100 4/4 
0.0001
DV2-96 20 3/5 0.0004
DV2-104 500 4/5 0.0006
DV2-104 100 3/5 0.004
DV2-104 20 2/5 NS
DV2-106 500 3/5 0.001
Therapeutic studies administered
at day 2 after infection
PBS 0/22
DV2-30 500 4/5 0.002
DV2-44 500 4/5 0.007
DV2-46 500 8/12 
0.0001
DV2-52 500 7/11 
0.0001
DV2-58 500 4/5 0.004
DV2-76 500 4/5 0.007
DV2-77 500 9/13 
0.0001
DV2-87 500 4/5 0.004
DV2-96 500 4/5 0.004
DV2-104 500 4/5 0.007
DV2-106 500 3/5 0.04
Therapeutic studies administered
at day 3 after infection
PBS 0/10
DV2-30 500 3/12 0.03
DV2-44 500 10/11 
0.0001
DV2-58 500 5/12 0.04
DV2-76 500 6/11 
0.0001
DV2-87 500 4/12 0.04
DV2-96 500 9/12 
0.0001
DV2-104 500 10/12 
0.0001
a Three-week-old BALB/c mice were infected with 6  104 PFU of DENV-2
NGC by an intracranial route. At day 1, day 2, or day 3, a single dose of the
indicated MAbs was administered via an intraperitoneal route. Mice were mon-
itored for survival for 21 days after infection. Of note, intracranial DENV
infection of BALB/c mice is a highly stringent protection model, as low concen-
trations (0.1% of serum levels) of MAb cross the blood-brain barrier and
accumulate in the central nervous system (22).
b Survival refers to the number of animals surviving compared to the total
number infected over a period of 21 days.
c P values were calculated using the log rank test of the Kaplan-Meier survival
curve by comparing the no-antibody and antibody-treated mice. NS represents
values that were not statistically different (P 	 0.05).
TABLE 4. Prophylaxis of neutralizing MAbs against antibody-




























IgG2a (20 g; nonenhancing) PBS 5/5 
0.003
NMS (nonenhancing) PBS 5/5 
0.003
a Six- to eight-week-old AG129 mice were administered by an intraperitoneal
route either 25 l of anti-DENV-1 98J polyclonal immune or naı¨ve mouse serum
(NMS) in 200 l PBS, or 20 g of the flavivirus cross-reactive fusion loop MAb
4G2 or an isotype control IgG2a MAb. Immediately after, mice were given 50 g
of the indicated anti-DENV-2 MAb. Twenty-four hours after antibody transfer,
mice were infected with 105 PFU of DENV-2 D2S10 intravenously. Morbidity
and mortality were measured for 10 days.
b The antibody-enhanced mortality measured between days 0 and 10 is due to
a vascular leakage syndrome, as previously described (2, 72).
c The P value was calculated using the log rank analysis of a Kaplan-Meier
survival curve compared to mice treated with PBS.
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MAb (DV2-30, DV2-44, DV2-46, DV2-58, DV2-76, DV2-77,
DV2-87, DV2-96, DV2-104, and DV2-106) was administered
by an intraperitoneal route (Table 3). Treatment with any of
nine different MAbs (DV2-30, DV2-44, DV2-46, DV2-58,
DV2-76, DV2-77, DV2-87, DV2-96, and DV2-104) protected
80% of mice (P 0.0007). When a single dose was given 3 days
after intracranial infection, seven of the MAbs again protected
significantly (P  0.03), with four (DV2-44, DV2-76, DV2-96,
and DV2-104) showing survival rates between 55 and 91%.
For most MAbs, there was a correlation between neutraliz-
ing activity against DENV-2 NGC in BHK21 cells and thera-
peutic efficacy in vivo in mice. As an example, the DIII-specific
MAbs DV2-76 and DV2-96 had PRNT50 values of 100 to 200
ng/ml against DENV-2 NGC (Table 1). In contrast, for the
DI-DII-specific MAbs DV2-46 and DV2-58, protective activity
was associated with relatively poor intrinsic neutralizing activ-
ity (PRNT50 of 1.5 to 7.2 g/ml) against DENV-2 NGC. Thus,
relative neutralization potency in BHK21 cells did not neces-
sarily predict the protective efficacy of MAbs in vivo in this
model.
Strongly protective MAbs inhibit infection at a postattach-
ment step. Antibody neutralization may occur by inhibiting
receptor attachment, internalization, and/or endosomal fusion
(44). To begin to identify mechanistic correlates of protection,
we performed pre- and postattachment neutralization assays
(23, 63) with several of the therapeutic MAbs (DV2-44, DV2-
58, DV2-76, DV2-77, DV2-87, and DV2-104). For comparison,
we also tested DV2-29, a DII fusion loop-specific MAb with
more-limited activity in vivo, as a control. A saturating (50-g/
ml) concentration of MAb was incubated with DENV-2 (strain
16681) before or after virus binding to a monolayer of BHK21
cells, and infection was measured by a plaque reduction assay.
As expected, all MAbs neutralized DENV-2 infection when
premixed with virus at 37°C (Fig. 5A). However, DV2-29
showed reduced inhibitory activity when the preincubation
step was performed at 4°C (Fig. 5B). Temperature sensitivity
of MAb neutralization was observed previously with MAbs
that recognize the A strand of DIII and may be due to a
requirement for dynamic motion on the virion surface to en-
hance epitope accessibility (31). All MAbs with therapeutic
activity in vivo potently inhibited DENV-2 infection when
added after virus adsorption to the cell surface (Fig. 5C),
indicating that at least part of their neutralizing activity was
at a postattachment step of the viral life cycle, similar to that
observed for highly therapeutic anti-WNV MAbs (60, 63).
This included several MAbs (DV2-73, DV2-77, and DV2-
87) that mapped to the C strand and C-C loop epitope on
DIII. As expected, DV2-29, which neutralized inefficiently
after a 4°C preincubation, failed to inhibit in the postattach-
ment assay.
DISCUSSION
In a prior study, we localized the epitopes of 14 type-,
subcomplex-, and complex-specific MAbs that reacted with
DENV-2, had different inhibitory properties against a single
DENV-2 strain in cell culture, and localized to DIII of the E
protein (57). Despite acquiring a detailed understanding of the
structural basis of neutralization by DIII-specific MAbs against
DENV, these studies did not assess the in vitro inhibitory
activity in cells against a genetically diverse range of DENV-2
strains or their protective capacity in animals. Moreover, in our
original study and those by others (16, 17), evaluation in vivo
was not performed, which is essential for identifying MAbs
FIG. 5. Strongly neutralizing DENV-2 MAbs inhibit at a postat-
tachment stage. To determine whether the MAbs neutralize DENV-2
infection after cellular attachment, BHK21 cells were prechilled and
102 PFU of DENV-2 (strain 16681) was added to each well for 1 h at
4°C. (C) After extensive washing at 4°C, saturating concentrations of
the MAbs (50 g/ml) were added for 1 h at 4°C, and then the neu-
tralization assay was completed. In comparison, a standard preincuba-
tion neutralization test with all steps performed at 37°C (A) or 4°C
(B) is shown for reference. (A and B) In this case, virus and MAb are
incubated together for 1 h at 37°C or 4°C, prior to addition to cells.
Data shown are the average of three independent experiments, with
error bars representing standard deviation. Asterisks indicate statisti-
cally significant differences. Note that DV2-29 loses some of its neu-
tralization potency when preincubated at 4°C compared to 37°C.
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with therapeutic activity as possible treatment against DENV-2
infection in humans.
Neutralizing antibodies against DENV-2 were generated
against all three domains of the E protein, consistent with
previous studies of other flaviviruses (3, 4, 14, 15, 27, 42, 43, 50,
53, 58). We observed disparate neutralizing activity of individ-
ual MAbs against strains corresponding to different DENV-2
genotypes, results analogous to those of studies of DENV-1
and DENV-3 (53, 65). In comparative studies of strains from
all DENV-2 genotypes, many MAbs showed reduced inhibi-
tory potency values against heterologous genotypes. This het-
erogeneity in neutralizing activity for different DENV-2 geno-
types is likely explained by the 3% amino acid variation
between individual genotypes, with up to 7% of the amino
acids being variable across the four genotypes of DENV-2.
Alternatively, variable neutralization could reflect genotype- or
strain-specific differences in virus maturation, which can affect
epitope accessibility (40).
Previous studies identified the lateral ridge and A-strand
epitopes in DIII as targets of type- and subcomplex-specific
MAbs against DENV-2 with strongly neutralizing activity (16,
17, 30, 33, 47, 57, 61) and the fusion loop in DII as a recogni-
tion site for cross-reactive MAbs with weaker inhibitory activ-
ity (8, 9, 15). Our report expands on the mapping of inhibitory
anti-DENV MAbs by identifying epitopes in the C strand and
C-C loop of DIII, within DI, and at the interfaces of adjacent
E protein dimers on DII. The discovery of type-specific neu-
tralizing MAbs against DENV-2 in DI (DV2-48 and DV2-51 at
residues G177 and E184, respectively) is consistent with an
earlier report that localized a protective DENV-4-specific
chimpanzee MAb (5H2) to amino acid K174 in DI (27). Sim-
ilarly, neutralizing MAbs that map to sites along the dimer
interface have been identified for other flaviviruses (8, 32,
43, 63). Because some of these MAbs inhibited virus fusion
in a liposome assay in vitro (56, 63), this class of antibodies
may neutralize efficiently by disrupting the pH-dependent E
protein structural transitions required for membrane fusion.
This study is the first to examine the genotypic variation of
DENV-2 in the context of antibody neutralization. Genotypic
variation was observed at 25 different amino acid sites in DI
and DII. The diversity clustered in DII with twice the fre-
quency of variation per residue compared to DI or DIII. The
majority of changes were nonconservative and on solvent-ac-
cessible surfaces, suggesting that DII may accommodate more
variability and contribute significantly to antigenic variation.
However, and as seen previously with DENV-1 MAbs in DIII
(53), the mapping of neutralizing MAbs in DI and DII did not
correspond directly to the residues of genotypic variation. The
sylvatic West African strain had more genotypic variation than
any other, with a total of 17 substitutions, 15 of which were
unique among the DENV genotypes. As sylvatic strains circu-
late between nonhuman primates and arboreal mosquitoes of
the Aedes genus (62), they are not under the same evolutionary
constraints that bottleneck variation between human DENV
strains and Aedes aegypti mosquitoes. Thus, sylvatic strains may
accumulate substitutions that would normally disrupt transmis-
sion of human strains.
For DIII of DENV-2, genotypic variation was limited to
eight amino acids. Two surface-accessible residues (positions
330 and 390) had nonconservative substitutions among differ-
ent DENV-2 genotypes. The G3D change at position 330 in
the sylvatic West African strain was associated with the de-
creased neutralizing potential of DV2-106, which showed re-
duced binding to the same variant when displayed on yeast. In
contrast, changes at position 390 did not affect binding of any
of the neutralizing MAbs in this study. This amino acid is a
known contact residue for the subcomplex neutralizing MAb
1A1D-2 (31), but it is unknown whether variation at this po-
sition affects neutralization of strains of the American geno-
type (e.g., IQT2913). Changes at amino acid 390, however,
have been associated with altered virulence, as a D3N change
in Mexican strains of the American genotype caused a small
plaque phenotype and decreased virulence in mice (51). Sub-
stitutions in the C-C loop of DIII at positions 345 and 346 are
not surface exposed, based on the DENV-2 mature virion
structure, but may be accessible in transition states (31). How-
ever, MAbs that mapped to the C strand and C-C loop did not
show significant temperature sensitivity of neutralization, sug-
gesting that this epitope is accessible on a significant fraction of
DENV-2 virions. Genotypic variation in this region is signifi-
cant because it could affect binding of type-specific neutralizing
MAbs (DV2-73, DV2-77, DV2-87, and DV2-104) that map to
this epitope. Indeed, neutralization of the C0477 strain, which
contained an H3Y substitution at position 346, was associated
with the decreased neutralizing potential of DV2-73.
Although the plaque reduction neutralizing activity for
DIII-specific MAbs correlated with in vivo protective activ-
ity, this relationship was less clear for DI-DII MAbs, which
generally neutralized less well but, in several cases, still
retained efficacy in vivo. DV2-46 and DV2-58, which had
relatively poor neutralizing activity against DENV-2 NGC in
BHK21 cells, still had significant postexposure therapeutic
activity in the intracranial BALB/c mice challenge model.
This poor correlation between neutralizing activity in vitro
and protection in vivo is analogous to that observed in
DENV-2 vaccine trials in which prechallenge neutralization
titers did not predict protection in nonhuman primates (55).
The PRNT assay with BHK21 cells, while a convenient
method to measure inhibitory antibodies in vitro, by itself,
does not provide a complete picture of protection in vivo, at
least for MAbs that bind outside DIII.
Our experiments describe a postexposure therapeutic effect
by several MAbs that map to distinct epitopes in DI-DII (DV2-
30, DV2-44, and DV2-58) and DIII (DV2-76, DV2-77, DV2-
87, DV2-96, and DV2-104) on DENV-2. While prior studies
have demonstrated that, as prophylaxis, anti-E MAbs protect
rodents and nonhuman primates against DENV infection (6,
24, 25, 27, 58), few reported MAbs have efficacy when added
after infection. Until recently, the concept of MAb therapy
against DENV seemed implausible due to the concern for
ADE. As subneutralizing concentrations of antibody augment
infection of Fc receptor-expressing cells likely by enhancing
the efficiency of virus entry (13, 18), administration of virus-
specific MAbs could adversely impact the outcome of DENV
infection. However, we reported recently that highly neutral-
izing DIII-specific anti-DENV-1 MAbs had therapeutic activ-
ity in AG129 mice even when administered as a single dose 4
days after infection (53). Additionally, DII-specific fusion loop
MAbs that were modified to eliminate Fc receptor interac-
tions and ADE also functioned as postexposure therapy
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against the D2S10 strain of DENV-2, which causes a fatal
vascular leakage syndrome in AG129 mice (2). In our studies
using the D2S10 strain and AG129 mice, three neutralizing
MAbs (DV2-44, DV2-76, and DV2-104) functioned efficiently
as prophylaxis to prevent antibody-dependent enhanced dis-
ease.
In summary, our results suggest that antibodies raised
against one genotype within the DENV-2 serotype may have
decreased inhibitory potency against heterologous genotypes.
Given that this paradigm also appears true for DENV-1 (53)
and DENV-3 (65), it may be critical to assess whether poly-
clonal antibody responses generated against vaccine strains,
which are inherently attenuated compared to natural infection,
neutralize strains of the more divergent heterologous geno-
types within a serotype in a durable manner (67).
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Supplementary Figure 1. Sequence alignment of different DENV-2 genotypes and 
mapping of neutralizing MAbs in DI-DII. The sequence and secondary structure of DI-
DII from DENV-2 (strain 16681, Southeast Asian genotype) E protein is aligned with 
other DENV-2 genotypes (Southeast Asian genotype, strain NGC and strain C0477; 
Indian genotype, strain Ara6895; American genotype, strain IQT2913; West African 
(sylvatic) genotype, strain PM33974). The secondary structure of DENV-2 E from the 
strains that have not been crystallized was predicted by DSSP (38) using the 16681 strain 
coordinates, and are labeled above the alignment. Black blocks highlight residues of 
genotypic variation. Colored boxes correspond to specific neutralizing antibody and 
structural recognition determinants according to mapped epitopes by yeast surface 
display. DI-DII epitopes: DII lateral ridge, orange; Fusion loop, green; DI linker region, 
magenta; and DII dimer interface, blue. 
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Supplementary Figure 2. Sequence alignment of different DENV-2 genotypes and 
mapping of neutralizing MAbs in DIII. The sequence and secondary structure of DIII 
from DENV-2 (strain 16681, Southeast Asian genotype) E protein is aligned with other 
DENV-2 genotypes as described in Fig 6. Black blocks highlight residues of genotypic 
variation. Colored boxes correspond to specific neutralizing antibody and structural 
recognition determinants according to mapped epitopes by yeast surface display. DIII 
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Dengue viruses (DENV) comprise a family of related positive-strand RNA viruses that infect up to 100
million people annually. Currently, there is no approved vaccine or therapy to prevent infection or diminish
disease severity. Protection against DENV is associated with the development of neutralizing antibodies that
recognize the viral envelope (E) protein. Here, with the goal of identifying monoclonal antibodies (MAbs) that
can function as postexposure therapy, we generated a panel of 82 new MAbs against DENV-3, including 24
highly neutralizing MAbs. Using yeast surface display, we localized the epitopes of the most strongly neutral-
izing MAbs to the lateral ridge of domain III (DIII) of the DENV type 3 (DENV-3) E protein. While several
MAbs functioned prophylactically to prevent DENV-3-induced lethality in a stringent intracranial-challenge
model of mice, only three MAbs exhibited therapeutic activity against a homologous strain when administered
2 days after infection. Remarkably, no MAb in our panel protected prophylactically against challenge by a
strain from a heterologous DENV-3 genotype. Consistent with this, no single MAb neutralized efficiently the
nine different DENV-3 strains used in this study, likely because of the sequence variation in DIII within and
between genotypes. Our studies suggest that strain diversity may limit the efficacy of MAb therapy or tetravalent
vaccines against DENV, as neutralization potency generally correlated with a narrowed genotype specificity.
Dengue viruses (DENV) cause the most common arthro-
pod-borne viral infection in humans worldwide, with 50 mil-
lion to 100 million people infected annually and 2.5 billion
people at risk (13, 61). Infection by four closely related but
serologically distinct viruses of the Flavivirus genus (DENV
serotypes 1, 2, 3, and 4 [DENV-1 to -4, respectively]) cause
dengue fever (DF), an acute, self-limiting, yet severe, febrile
illness, or dengue hemorrhagic fever and dengue shock syn-
drome (DHF/DSS), a potentially fatal syndrome characterized
by vascular leakage and a bleeding diathesis. Specific treatment
or prevention of dengue disease is supportive, as there is no
approved antiviral therapy or vaccine available.
DENV has an 11-kb, single-stranded, positive-sense RNA
genome that is translated into a polyprotein and is cleaved
posttranslationally into three structural (envelope [E], pre/
membrane [prM], and capsid [C]) and seven nonstructural
(NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) proteins.
The three structural proteins encapsidate a single infectious
RNA of the DENV genome, whereas the nonstructural pro-
teins have key enzymatic or regulatory functions that promote
replication. Additionally, several DENV proteins are multi-
functional and modulate cell-intrinsic and cell-extrinsic host
immune responses (10).
Most flavivirus-neutralizing antibodies recognize the struc-
tural E protein (reviewed in reference 40). Based on X-ray
crystallographic analysis (32, 33), the DENV E protein is di-
vided into three domains: domain I (DI), which is an
8-stranded -barrel, domain II (DII), which consists of 12
-strands, and domain III (DIII), which adopts an immuno-
globulin-like fold. Mature DENV virions are covered by 90
antiparallel E protein homodimers, arranged flat along the
surface of the virus with quasi-icosahedral symmetry (25).
Studies with mouse monoclonal antibodies (MAbs) against
DENV-1 and DENV-2 have shown that highly neutralizing
anti-DENV antibodies are serotype specific and recognize pri-
marily the lateral-ridge epitope on DIII (15, 49, 53). Addition-
ally, subcomplex-specific MAbs, which recognize some but not
all DENV serotypes, recognize a distinct, adjacent epitope on
the A -strand of DIII and also may be inhibitory (16, 28, 42,
53, 56). Complex-specific or flavivirus cross-reactive MAbs rec-
ognize epitopes in both DII and DIII and are generally less
strongly neutralizing (8, 53).
Beyond having genetic complexity (the E proteins of the
four distinct serotypes are 72 to 80% identical at the amino
acid level), viruses of each serotype can be further divided into
closely related genotypes (43, 44, 57). DENV-3 is divided into
4 or 5 distinct genotypes (depending on the study), with up to
4% amino acid variation between genotypes and up to 2%
amino acid variation within a genotype (26, 58, 62). The indi-
vidual genotypes of DENV-3 are separated temporally and
geographically (1), with genotype I (gI) strains located in In-
donesia, gII strains in Thailand, and gIII strains in Sri Lanka
and the Americas. Few examples of strains of gIV and gV exist
from samples isolated after 1980 (26, 62). Infection with one
* Corresponding author. Mailing address: Departments of Medi-
cine, Molecular Microbiology, and Pathology and Immunology, Wash-
ington University School of Medicine, 660 South Euclid Ave., Box
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† Supplemental material for this article may be found at http://jvi
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DENV serotype is believed to confer long-term durable im-
munity against strains of the homologous but not heterologous
DENV serotypes due to the specificity of neutralizing antibod-
ies and protective CD8 T cells (45). Indeed, epidemiological
studies suggest that a preexisting cross-reactive antibody (7,
24) and/or T cells (34, 35, 64) can enhance the risk of DHF/
DSS during challenge with a distinct DENV serotype. None-
theless, few reports have examined how intergenotypic or even
strain variation within a serotype affects the protective efficacy
of neutralizing antibodies. This concept is important because
the development of tetravalent DENV vaccines with attenu-
ated prototype strains assumes that neutralizing antibody re-
sponses, which are lower during vaccination than during nat-
ural infection, will protect completely against all genotypes
within a given serotype (60). However, a recent study showed
markedly disparate neutralizing activities and levels of protec-
tion of individual anti-DENV-1 MAbs against different
DENV-1 genotypes (49).
Herein, we developed a panel of 82 new DENV-3 MAbs and
examined their cross-reactivities, epitope specificities, neutral-
ization potential at the genotype level in cell culture, and
protective capacities in vivo. The majority of strongly neutral-
izing MAbs in this panel mapped to specific sites in DIII of the
E protein. Remarkably, because of the scale of the sequence
variation of DENV-3 strains, most of the protective antibodies
showed significant strain specificity in their functional profiles.
MATERIALS AND METHODS
Viruses and cells. The following DENV-3 strains were used in this study:
16652 (gI, from R. Kinney, Centers for Disease Control and Prevention), H87
(gI, from R. Tesh, University of Texas Medical Branch), UNC3043 and
UNC3044 (gI, from A. de Silva, University of North Carolina), UNC3046 and
UNC3049 (gII, from A. de Silva), UNC3006 and UNC3018 (gIII, from A. de
Silva), and UNC3050 (gIV, from A. de Silva). Strains representing other DENV
serotypes also were tested: 16007 (DENV-1), 16681 (DENV-2), and H241
(DENV-4) (53). All DENV isolates were propagated in C6/36 Aedes albopictus
cells as described previously (11). Vero T144 cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 5% fetal bovine serum
albumin (FBS), nonessential amino acids (NEAA), sodium pyruvate, and 100
IU/ml of penicillin and streptomycin. Raji-DC-SIGN cells were generated by
electroporating Raji cells with a plasmid (pUNO; Invivogen) that encodes hu-
man DC-SIGN-1A and a blasticidin selection marker. Single-cell clones were
isolated after blasticidin (5 g/ml) selection, and cell surface expression was
confirmed by flow cytometry with an anti-DC-SIGN MAb (DCN46; BD Phar-
mingen). Raji-DC-SIGN cells were maintained in RPMI 1640 supplemented
with 10% FBS, NEAA, sodium pyruvate, penicillin, and streptomycin.
Cloning and expression of DENV-3 E protein and domains. cDNA encoding
the ectodomain (amino acid residues 1 to 407) and DIII (amino acid residues 291
to 407) of the E protein of DENV-3 strain 16652 were amplified from viral RNA
isolated from infected C6/36 cells using Superscript III and Platinum HiFi Taq
polymerase according to the manufacturer’s instructions (Invitrogen). The PCR
product was cloned into the pET21a bacterial expression plasmid (EMD Bio-
sciences) using flanking NdeI and XhoI restriction sites, sequenced, and then
expressed in BL21 Codon Plus (Stratagene) Escherichia coli by autoinduction
(51). Two independent QuikChange (Stratagene) reactions were completed to
generate the D328G or P330G mutation within DIII from DENV-3 strain 16652.
Inclusion bodies containing insoluble aggregates were denatured in the presence
of 6 M guanidine hydrochloride and 20 mM -mercaptoethanol and refolded in
the presence of 400 mM L-arginine, 100 mM Tris base (pH 8.0), 2 mM EDTA,
0.2 mM phenylmethylsulfonyl fluoride, and 5 mM reduced and 0.5 mM oxidized
glutathione. Refolded protein was separated from aggregates on a Superdex 200
size exclusion column using fast-protein liquid chromatography (GE Health-
care). The DENV-3 E protein ectodomain (amino acid residues 1 to 395, strain
16652) was cloned downstream of a honeybee melittin signal peptide (amino acid
residues 1 to 21) into a baculovirus expression vector (pFastBac; Invitrogen)
using BamHI and XhoI cloning sites. Recombinant baculoviruses were propa-
gated in SF9 insect cells in Grace’s medium under serum-free conditions.
Generation and purification of anti-DENV-3 MAbs. Anti-DENV-3 MAbs
were generated as part of six independent splenocyte-myeloma fusions as de-
scribed previously (37). For the first three fusions, which produced MAbs
DENV-3–E1 to DENV-3–E43, C57BL/6 mice were immunized and boosted
iteratively with 25 g of recombinant DENV-3 E protein and DIII. For the
remaining fusions, DENV-3–E49 to DENV-3–E98 MAbs were generated after
infection of alpha/beta interferon receptor-negative (IFN-/R/) C57BL/6
mice with 104 PFU of DENV-3 (strain 16652, gI) by an intraperitoneal route and
rechallenge 3 weeks later with the same strain, route, and dose. Three weeks
after secondary challenge, mice were boosted subcutaneously with 20 g
DENV-3 DIII (16652) mixed with alum (100 l) and 10 g CpG1826 (IDT) in
a final volume of 200 l per mouse. Mice were bled, and those with sera having
plaque reduction neutralization titers (PRNT) of 1/1,000 or greater were se-
lected. Mice received a final boost with 20 g of purified DIII in phosphate-
buffered saline (PBS) intravenously. Three days later, splenocytes were fused to
P3X63Ag8.53 myeloma cells (19). MAbs were subcloned by limiting dilution,
isotyped (Southern Biotech), and purified using protein A or G affinity chroma-
tography (Invitrogen).
In vitro neutralization assay. Because several of the DENV-3 strains do not
form visible plaques on BHK21-15 or Vero cells, focus-forming assays (47) were
used to measure the neutralizing titers of MAbs against DENV-3 isolates. Four-
fold serial dilutions of MAb (5 g/ml to 2.5 ng/ml) were mixed with 100
focus-forming units (FFU) of virus, incubated at 37°C for 1 h, and added to Vero
T144 monolayers in 24-well plates for 1 h at 37°C to allow virus adsorption.
Medium was removed, and cells were overlaid with 1% methylcellulose mixed
with DMEM containing 5% FBS and incubated for 4 days. Monolayers were
washed thrice with PBS to remove methylcellulose, fixed with 1% paraformal-
dehyde in PBS for 10 min at room temperature, rinsed, and permeabilized in
Perm Wash (PBS, 0.1% saponin, and 0.1% BSA). Infected cell foci were stained
by incubating cells with the flavivirus-cross-reactive, chimeric, human West Nile
virus (WNV) MAb E18 (1 g/ml) (39) for 1 h at 37°C and then washed three
times with Perm Wash. Foci were detected after the cells were incubated with a
1:2,000 dilution of horseradish peroxidase-conjugated goat anti-human IgG
(Sigma) for 1 h. After three washes with Perm Wash, staining was visualized by
addition of TrueBlue detection reagent (KPL) and terminated by rinsing mono-
layers in water. Infected foci were enumerated by counting cells in wells using a
Nikon dissecting microscope with a 10 objective lens.
Flow cytometry analysis of DENV-infected cells. To assess MAb reactivity with
heterologous DENV serotypes, Raji-DC-SIGN or C6/36 cells (depending on the
strain) were infected with individual strains at a multiplicity of infection (MOI)
of 1 and harvested 3 or 8 days later, respectively. Cells were washed in PBS, fixed
with 1% paraformaldehyde, permeabilized, and incubated sequentially with 20
g/ml MAb and 4 g/ml Alexa-647-conjugated goat anti-mouse IgG (Invitrogen)
for 30 min on ice. After a final wash, cells were processed on a FACSArray flow
cytometer (Becton Dickinson) and analyzed using FlowJo software v8 (Treestar).
Domain mapping by yeast surface display. A cDNA fragment encoding DIII
(amino acid residues 293 to 409) was amplified from the DENV-3 strains 16652
(gI), UNC3043 (gI), UNC3049 (gII), UNC3006 (gIII), and UNC3050 (gIV) by
reverse transcription) (RT-PCR using Superscript III reverse transcriptase and
Platinum HiFi Taq DNA polymerase with BamHI and XhoI sites added at the 5
and 3 ends, respectively. Cloning, transformation, and expression were per-
formed as described previously (37, 53), with one exception: yeast synthetic
dropout medium (Sigma) was used in place of Casamino Acids. Saccharomyces
cerevisiae cells were stained after sequential incubation with 50 l of purified (20
g/ml) MAb and Alexa-647 goat anti-mouse IgG secondary antibody (4 g/ml),
each for 30 min. Yeast cells were processed by flow cytometry without perme-
abilization and analyzed as described above.
Generation of a yeast expressing DIII variants. Site-specific mutations were
engineered into a DENV-3 strain 16652 DIII yeast expression plasmid by a
reverse genetics approach using the QuikChange II mutagenesis kit (Stratagene).
Point mutations were generated at amino acid positions 301, 302, 303, 328, and
329 to define potential variation in MAb binding to the different genotypes
within the DENV-3 serotype. Mutations at amino acid residues 305, 306, 308,
309, 325, 330, 340, 384, 386, and 389 in the A strand, BC and FG loops, and G
strand were generated based on previously described epitopes for WNV,
DENV-1, and DENV-2 (15, 16, 28, 37, 42, 49, 53). Surface expression of indi-
vidual DENV-3 DIII variants was confirmed by flow cytometry after they were
stained with two nonneutralizing MAbs, DENV-3–E1 and DENV-3–E8.
Mouse protection experiments. All mouse studies were approved and per-
formed according to the guidelines of the Washington University School of
Medicine Animal Safety Committee. IFN-/R/  IFN-	R/ mice on the
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129 Sv background (AG129 mice) were a gift from H. Virgin (Washington
University School of Medicine) and bred in a pathogen-free barrier facility. For
protection experiments, mouse-adapted strains of DENV-3 16652 (gI) and
UNC3050 (gIV) were used. Adapted strains were generated by passaging virus
between AG129 mice (after intracranial [i.c.] infection) and C6/36 insect cells,
with DENV-3 16652 passaged twice and DENV-3 UNC3050 thrice in this man-
ner. In prophylaxis experiments, AG129 mice were administered a single dose of
individual MAbs (500 g via the intraperitoneal [i.p.] route) 1 day before infec-
tion. Subsequently, mice were challenged with DENV-3 strain 16652 (gI, 5  103
PFU) or UNC3050 (gIV, 1  105 PFU) by the i.c. route, and mortality was
monitored for 50 days. In postexposure therapeutic experiments, a single dose
(500 g) of MAb was administered by i.p. injection 2 days after i.c. infection with
5  103 PFU of strain 16652.
Mapping of mutations onto the DENV-3 DIII structure. Figures were pre-
pared using the atomic coordinates of DENV-3 DIII (RCSB protein data bank
accession number 1UZG) with the program PyMOL (www.pymol.org). The
alignment of DENV-3 DIII from different genotypes was created with the pro-
gram ALSCRIPT (3).
Bioinformatic analysis. Nine hundred ninety-five full-length DENV-3 E pro-
tein amino acid sequences were downloaded from the Virus Variation database
(NCBI) and aligned using MUSCLE (http://www.drive5.com/muscle). Sequences
were manually trimmed to include only DIII sequences (amino acid residues 295
to 408). Duplicate sequences were removed by DuplicatesFinder (bioinfotutlets-
.blogspot.com), resulting in 139 unique DENV-3 DIII sequences. The locations
and percentages of amino acid variation were completed by calculating percent
identity at each amino acid position. The solvent-accessible surface area was
determined using GETAREA (12).
Statistical analysis. Data were analyzed for statistical significance using Prism
software (GraphPad Software). For survival analysis, Kaplan-Meier survival
curves were analyzed by the log rank test. For neutralization assays, an unpaired
Student t test was used. Focus reduction neutralization titers (FRNT) that
resulted in 50% inhibition (50% effective concentration [EC50]) were determined
using nonlinear-regression analysis.
RESULTS
Generation of MAbs. Studies from several decades ago
showed that polyclonal sera directed against the E protein can
protect against lethal flavivirus challenge in animals (6, 41).
More recent experiments with WNV, DENV-1, and DENV-2
(4, 15, 16, 37, 46, 49, 53) have suggested that DIII of the E
protein is a key target for strongly neutralizing MAbs, although
the human B cell repertoire may be directed away from this
region (38, 55, 59). To gain insight into the structural specific-
ities of protective MAbs that recognize the DENV-3 E protein,
we performed six independent myeloma-B cell fusions and
generated 82 new mouse MAbs after screening 4,300 primary
wells. Three fusions were performed after BALB/c mice were
immunized with recombinant DENV-3 E protein (strain
16652) generated in insect cells, resulting in 33 MAbs (see
Table S1 in the supplemental material). Because these MAbs
had poorly neutralizing activities, we modified the immuniza-
tion protocol and instead infected IFN-/R/ C57BL/6 mice
with strain 16652; the immunodeficient mice supported in-
creased DENV-3 replication compared to that in wild-type
mice, which are relatively nonpermissive for infection (48).
Infection was followed by virus rechallenge and boosting with
DIII of the homologous strain; this augmented neutralizing
polyclonal antibody titers substantially (data not shown). By
this approach, 49 additional anti-DENV-3 MAbs were gener-
ated (see Table S1 in the supplemental material).
All MAbs were initially characterized for neutralizing activ-
ity, isotype, epitope recognition, and cross-reactivity. MAbs
were initially tested semiquantitatively for neutralization of the
homologous DENV-3 strain by a single-endpoint plaque re-
duction assay using Vero cells and neat hybridoma supernatant
(10 g/ml). Of the MAbs generated, 32 showed no inhibitory
activity (
15% neutralization), 28 had modest inhibitory ac-
tivity (15 to 90% neutralization), and 22 were strongly inhibi-
tory (90% neutralizing) (see Table S1 in the supplemental
material); one of the MAbs (DENV-3–E83) was not tested
because we were unable to isolate an individual subclone.
Subsequently, MAbs were screened for E protein domain rec-
ognition using yeast cells expressing DENV-3 DI-DII or DIII
on their surfaces (see Table S1 in the supplemental material).
MAbs in the sequences of DENV-3–E2 to DENV-3–E37, with
the exception of DENV-3–E8 and DENV-3–E22, bound yeast
expressing DENV-3 DI-DII (data not shown). Mapping
studies using DIII of the homologous strain 16652 identified
28 DIII-specific MAbs. Notably, 16 MAbs (DENV-3–E52,
DENV-3–E58, DENV-3–E70, DENV-3–E72, DENV-3–
E75, DENV-3–E76, DENV-3–E81, DENV-3–E82, DENV-
3–E85, DENV-3–E87, DENV-3–E88, DENV-3–E89, DENV-3–
E92, DENV-3–E93, DENV-3–E94, and DENV-3–E96) failed to
bind yeast cells expressing DI-DII or DIII on their surfaces yet
recognized fixed and permeabilized SF9 insect cells infected with
a baculovirus that expressed the ectodomain of DENV-3 E pro-
tein (data not shown) and, thus, were defined as E protein spe-
cific. The remaining six MAbs were either IgM and not analyzed
further or were tested by Western blotting of DENV-3-infected
cell lysates under nonreducing conditions and failed to produce a
signal, leaving their antigen specificity undetermined.
All MAbs were tested for cross-reactivity using cells infected
with WNV or different serotypes of DENV (Fig. 1 and see
Table S1 in the supplemental material). Twenty-three of the 54
FIG. 1. Defining the serotype cross-reactivities of anti-DENV-3
MAbs by flow cytometry. MAbs DENV-3–E77, DENV-3–E61,
DENV-3–E3, DENV-3–E55, and DENV-3–E47 were added to fixed,
permeabilized, uninfected Raji-DC-SIGN cells (filled histograms) and
cells infected (dashed-line histograms) with strains corresponding to
different DENV serotypes (DENV-1 [strain 16007], DENV-2 [strain
16681], DENV-3 [strain 16652], and DENV-4 [strain H241]). Results
are representative of 4 independent experiments. MAb reactivity was
determined by the loss of binding to infected cells, as judged by a
decrease (shift to the left) in the mean fluorescent intensity of staining.
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FIG. 2. Genetic variation among DENV-3 genotypes within DIII. (A) Sequence alignment of nine different DENV-3 strains. The sequence of
DIII from DENV-3 strains of different genotypes (gI, strains H87, 16652, UNC3043, and UNC3044; gII, strains UNC3046 and UNC3049; gIII,
strains UNC3006 and UNC3018; and gIV, strain UNC3050) were aligned. The secondary structures of DENV-3 E DIII residues 291 to 401 from
the strains that have not been crystallized were predicted by DSSP (22) using the H87 strain coordinates. Black blocks highlight residues of
genotypic variation. Colored boxes correspond to specific neutralizing antibody and structural recognition determinants according to epitopes
mapped by yeast surface display (Table 5). The results of the yeast surface display epitope mapping are denoted underneath in red to indicate the
number of neutralizing MAbs in our panel that lose binding when a specific amino acid is changed. Green or cyan circles denote solvent-accessible
or inaccessible amino acids, respectively, in the mature dengue virion at sites of variation between any DENV-3 strains. (B) C6/36 cells infected
with the indicated DENV-3 strains were fixed, permeabilized, and incubated with the indicated MAbs (20 g/ml). Uninfected (filled histogram)
and infected (dashed-line histograms) cells after exposure to DENV-3 16652 (gI), DENV-3 UNC3044 (gI), DENV-3 UNC3046 (gII), DENV-3
UNC3018 (gIII), and DENV-3 UNC3050 (gIV) are shown. Results are representative of four independent experiments.
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DI-DII-specific MAbs and 4 of the 25 DIII-specific MAbs were
subcomplex or complex specific and bound to some or all of
the other serotypes of DENV. Only 3 (DENV-3–E31, DENV-
3–E32, and DENV-3–E33) of the 82 MAbs in our panel were
completely cross-reactive and bound all DENV serotypes and
WNV. DENV-3–E11 and DENV-3–E15 displayed an unusual
reactivity pattern and recognized DENV-1, DENV-3, and
WNV but not DENV-2 or DENV-4.
Characterization of strongly neutralizing MAbs against
DENV-3. Twenty-one of the 23 MAbs that neutralized infec-
tion at a level of greater than 50% in the single-endpoint
plaque reduction neutralizing tests were purified and used for
all remaining functional and epitope mapping experiments.
MAb DENV-3–E66 was isotyped as an IgM antibody and not
examined further in this study. MAb DENV-3–E55 produced
poor antibody yields and, thus, was used only for some in vitro
experiments. Of the 21 strongly neutralizing MAbs, 3, 15, 1, 1,
and 1 were isotyped as IgG1, IgG2a, IgG2b, IgG2c, and IgG3,
respectively (see Table S1 in the supplemental material). The
variation in IgG2 isotypes (IgG2a and IgG2c) is due to allo-
typic differences between BALB/c and C57BL/6 mice (29).
Twenty of the 23 neutralizing MAbs mapped to DENV-3 DIII,
as determined by recognition of yeast cells that expressed DIII
of strain 16652 on their surfaces.
Genotype-specific reactivities of anti-DENV-3 MAbs. To
further evaluate the specificity of these neutralizing MAbs
against a range of genetically diverse DENV-3 isolates, we
infected C6/36 cells with nine different DENV-3 virus strains
that represented four DENV-3 genotypes (Fig. 2A and B and
data not shown). This allowed us to determine whether epitope
recognition by these MAbs was strain or genotype specific.
Four gI strains (16652, H87, UNC3043, UNC3044), two gII
strains (UNC3046, UNC3049), two gIII strains (UNC3006,
UNC3018), and one gIV strain (UNC3050) were used for this
analysis. Remarkably, among the neutralizing MAbs, only
DENV-3–E61 recognized all nine DENV-3 strains equiva-
lently (Table 1). Nine MAbs bound to cells infected only with
gI and gII strains, whereas two MAbs recognize cells infected
with gI, gII, and gIII strains. DENV-3–E62 was unique in its
ability to recognize cells infected with gI, gII, and gIV viruses.
In comparison, a nonneutralizing MAb (DENV-3–E8) that
mapped to DIII reacted with cells infected with all DENV-3
strains regardless of genotype.
Neutralizing potential of MAbs against different DENV-3
genotypes. Given the variation in binding of our panel of MAbs
to insect cells infected with different DENV-3 genotypes, we
assessed their ability to neutralize infection more quantita-
tively. All DENV-3 MAbs that had strong neutralizing activity
in the single-endpoint PRNT assay (see Table S1 in the sup-
plemental material) were tested over a range of concentrations
to establish an EC50 using one DENV-3 strain from each
genotype. In these experiments, a focus-forming reduction as-
say (to determine FRNT) was substituted for a classical PRNT
assay, as many of the low-passage-number DENV-3 strains
TABLE 1. MAb binding to C6/36 insect cells infected with strains representing different DENV-3 genotypesa
MAb Specificity Genotyperecognition




















DENV-3–E47 Type Varies 113 36 36 1 24 52 35 0 166
DENV-3–E48 Type I, II 113 117 100 104 104 79 25 0 8
DENV-3–E49 Type I, II 107 118 90 103 107 98 3 0 1
DENV-3–E50 Type I, II 113 118 95 104 107 101 2 0 0
DENV-3–E51 Type I, II, III, IV 112 119 100 104 106 100 69 11 111
DENV-3–E52 Type Varies 11 7 0 0 1 0 0 0 0
DENV-3–E53 Type I, II, III 114 77 68 86 94 78 73 36 32
DENV-3–E54 Type I, II 101 118 82 99 105 81 1 0 4
DENV-3–E56 Type Varies 104 83 2 5 70 54 6 0 1
DENV-3–E57 Type I, II 99 118 87 103 107 93 9 0 2
DENV-3–E58 Type Varies 103 5 1 0 11 26 5 0 5
DENV-3–E59 Type I, II 100 119 76 104 108 84 7 0 4
DENV-3–E60 Type I, II 95 118 73 102 106 78 1 0 1
DENV-3–E62 Type I, II, IV 88 118 80 102 107 80 33 0 118
DENV-3–E63 Type I, II 115 119 100 102 106 98 0 0 ND
DENV-3–E64 Type Varies 100 20 4 0 0 9 1 0 8
DENV-3–E67 Type I, II 97 118 69 101 105 69 1 0 1
DENV-3–E55 Subcomplex I, II, III 102 117 91 103 106 86 87 115 1
DENV-3–E61 Subcomplex I, II, III, IV 97 119 72 104 107 70 66 116 64
DENV-3–E77 Complex I, II, III 109 117 99 103 104 82 109 114 ND
Poorly neutralizing
DENV-3–E97 Type I, III 98 112 91 96 103 26 89 103 ND
DENV-3–E8 Type I, II, III, IV 101 100 100 100 100 100 100 100 100
DENV-3–E84 Type I, II, III 102 112 93 97 103 24 88 106 ND
DENV-3–E98 Complex I, III 88 84 68 84 23 10 39 71 ND
a C6/36 cells were infected with the indicated DENV-3 strains and stained with MAbs (20 g/ml). Data are the averages of results from three to four independent
experiments and are normalized to values for percentage-positive cells based on staining with the control MAb DENV-3–E8. Boldface indicates that the level of binding
of a given MAb was from 0 to 25% of the control value, and underlining indicates that the level of binding was from 26 to 50% of the control value. Note that values
that exceed 100% represent MAbs that likely have a higher avidity for a given strain than were indicated by detection by DENV-3–E8. ND, not done.
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failed to consistently cause plaques in BHK21 or Vero cell
monolayers. Notably, no single MAb efficiently neutralized
strains corresponding to all four DENV-3 genotypes (Fig. 3A
and Table 2). One MAb, DENV-3–E51, strongly neutralized
(EC50  514 ng/ml) viruses from three of the DENV-3 geno-
types (gI, gII, and gIII). Seven MAbs efficiently neutralized two
of the four genotypes, whereas, and somewhat surprisingly, 10
MAbs neutralized only the strain that was used for immuniza-
tion to generate the panel of MAbs (16652, gI). When the
levels of cell binding and inhibitory activities of all of the
neutralizing MAbs were compared across genotypes, we ob-
served a largely direct relationship between preservation of
binding to a given genotype and neutralizing activity (see Table
S2 in the supplemental material).
Neutralizing potential of MAbs against different gI DENV-3
strains. Because of the unanticipated extent of genotype-spe-
cific neutralization, we evaluated whether the MAbs efficiently
inhibited three additional DENV-3 strains (H87, UNC3043,
and UNC3044) of gI that vary within DIII by 1.5% at the
amino acid level (Fig. 3B and Table 3). These gI viruses vary at
three amino acid positions in DIII: 302, 303, and 391 (Fig. 2A).
DENV-3–E47 neutralized only strain 16652, whereas DENV-
3–E60 and DENV-3–E62 neutralized two of the four gI vi-
ruses. Four MAbs (DENV-3–E49, DENV-3–E50, DENV-3–
E54, and DENV-3–E57) inhibited the four gI viruses, albeit to
various degrees, whereas three MAbs (DENV-3–E51, DENV-
3–E59, and DENV-3–E61) strongly neutralized all four gI
strains.
Epitope mapping of DIII-neutralizing MAbs. Given the dif-
ferences in genotype-specific inhibition by several DIII-specific
MAbs, we mapped binding determinants using yeast surface
display to gain structural insight into the basis for differential
neutralization. Initial studies were performed with 23 of our
DIII-specific MAbs and four DIII variants (UNC3043,
UNC3049, UNC3006, UNC3050) corresponding to the differ-
ent DENV-3 genotypes (Table 4). There are 11 amino acid
positions within DENV-3 DIII that vary between genotypes:
positions 301, 302, 303, 322, 329, 340, 368, 380, 383, 386, and
391, most of which are surface exposed (underlined) (Fig. 2A).
The greatest diversity overall between genotypes occurs within
the N-terminal linker of DIII at positions 301, 302 and 303. Of the
five poorly neutralizing MAbs, two (DENV-3–E8 and DENV-
3–E98) bound to DIII from all four genotypes, whereas three
(DENV-3–E1, DENV-3–E84, DENV-3–E97) recognized DIII
from gI, gII, and gIII viruses. Unlike with staining of infected,
fixed, and permeabilized C6/36 cells, two neutralizing MAbs
(DENV-3–E77 and DENV-3–E61) recognized DIII from all
four genotypes on yeast. Two neutralizing MAbs (DENV-3–
E51 and DENV-3–E57) recognized DIII from three gI, gII,
and gIV strains, whereas eight neutralizing MAbs (DENV-3–
E49, DENV-3–E50, DENV-3–E54, DENV-3–E59, DENV-3–
E60, DENV-3–E62, DENV-3–E63, and DENV-3–E67) recog-
FIG. 3. Neutralization of DENV-3 strains. (A) MAb neutralization of different genotypes of DENV-3. Neutralization of different DENV-3
genotypes (16652, gI; UNC3046, gII; UNC3018, gIII; and UNC3050, gIV) by MAbs DENV-3–E47 (left), DENV-3–E51 (middle), and DENV-
3–E60 (right). Increasing concentrations of purified MAbs were mixed with 102 PFU of the indicated DENV-3 strains, corresponding to all
genotypes, and inhibition was assessed by an FRNT assay in Vero cells. Graphs were generated after regression analysis using Prism statistical
software. The data are representative of at least four independent experiments. (B) MAb neutralization of different gI strains. Neutralization of
different gI DENV-3 strains (16652, H87, UNC3043, and UNC3044) by MAbs DENV-3–E47 (left), DENV-3–E51 (middle), and DENV-3–E49
(right). Increasing concentrations of purified MAbs were mixed with 102 PFU of the indicated gI DENV-3 strains, and neutralization was assessed
by an FRNT assay in Vero cells. Graphs were generated after regression analysis using Prism software. The data are representative of at least four
independent experiments.
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nized DIII of gI and gII strains only. Six neutralizing MAbs
(DENV-3–E47, DENV-3–E48, DENV-3–E53, DENV-3–E56,
DENV-3–E58, DENV-3–E64), however, bound to yeast ex-
pressing DIII from only the 16652 strain. Although binding to
DIII on yeast generated from heterologous DENV-3 strains
did not always correlate with data from infected cells, it
more directly predicted neutralizing activity. For example,
DENV-3–E48, which failed to neutralize gII viruses, bound
insect cells infected with gII viruses but not yeast cells ex-
pressing gII DIII. Consistent with this, DENV-3–E47,
DENV-3–E48, DENV-3–E51, DENV-3–E53, and DENV-
3–E62 bound insect cells but failed to recognize yeast-dis-
played DIII or neutralize the infection of a given individual
genotype (Table 4).
On the basis of studies that mapped DIII-specific MAbs
against WNV, DENV-1, and DENV-2 (15, 16, 28, 37, 49, 53),
we engineered mutations (L301T, S302N, S303A, V305G,
TABLE 2. MAb neutralization of different DENV-3 genotypesa
MAb Specificity Domainlocation
EC50 for:
gI 16652 gII UNC3046 gIII UNC3018 gIV UNC3050
DENV-3–E47 Type DIII 110 5,000 5,000 4,600
DENV-3–E48 Type DIII 500 5,000 5,000 5,000
DENV-3–E49 Type DIII 8 4 20,000 20,000
DENV-3–E50 Type DIII 24 5,000 5,000 20,000
DENV-3–E51 Type DIII 20 25 514 5,000
DENV-3–E52 Type E 3,739 ND ND ND
DENV-3–E53 Type DIII 38 457 5,000 20,000
DENV-3–E54 Type DIII 9 5,000 1,982 20,000
DENV-3–E56 Type DIII 2 20,000 4,700 20,000
DENV-3–E57 Type DIII 6 
1.0 5,000 20,000
DENV-3–E58 Type DIII 20 20,000 20,000 20,000
DENV-3–E59 Type DIII 42 3 5,000 20,000
DENV-3–E60 Type DIII 90 67 20,000 3,586
DENV-3–E62 Type DIII 9 162 5,000 5,000
DENV-3–E63 Type DIII 33 ND 20,000 20,000
DENV-3–E64 Type DIII 4 20,000 20,000 20,000
DENV-3–E67 Type DIII 5 383 20,000 20,000
DENV-3–E55 Subcomplex DIII 5,000 5,000 1,980 5,000
DENV-3–E61 Subcomplex DIII 281 5,000 99 3,084
a The assay to determine focus reduction neutralization titers (FRNT) was performed on Vero cells after incubating 102 PFU of strains of the indicated DENV-3
genotype with increasing concentrations of purified MAbs. All EC50 values are indicated in ng/ml. Values are the averages of results from three to five independent
experiments performed in duplicate. EC50 values were calculated by nonlinear-regression analysis. ND, not done.
TABLE 3. MAb neutralization of DENV-3 genotype I virusesa
MAb
EC50 for:
gI 16652 gI H87 gI UNC3044 gI UNC3043
DENV-3–E47 109 20,000 20,000 20,000
DENV-3–E49 4 113 2,478 1,229
DENV-3–E50 24 16 1,136 522
DENV-3–E51 20 41 218 242
DENV-3–E54 9 49 3,121 2,570
DENV-3–E57 6 19 1,013 1,079
DENV-3–E59 42 71 112 3
DENV-3–E60 2 160 20,000 20,000
DENV-3–E61 281 853 54 95
DENV-3–E62 9 43 20,000 20,000
a FRNT analysis was performed on Vero cells with increasing concentrations
of purified MAbs and 102 PFU of the indicated DENV-3 gI strain. All EC50
values are indicated in ng/ml. Values are the averages of results from three to five
independent experiments performed in duplicate.
TABLE 4. Binding of DENV-3 MAbs to yeast cells expressing
DIIIs of different DENV genotypesa
MAb












DENV-3–E47 137 13 40 18 12
DENV-3–E48 131 67 7 3 11
DENV-3–E49 138 54 75 6 17
DENV-3–E50 136 66 77 12 11
DENV-3–E51 125 60 62 2 57
DENV-3–E53 123 13 20 13 1
DENV-3–E54 131 36 67 3 1
DENV-3–E56 124 1 37 1 1
DENV-3–E57 133 61 66 30 74
DENV-3–E58 119 1 2 1 1
DENV-3–E59 123 67 57 2 65
DENV-3–E60 132 47 57 2 29
DENV-3–E62 124 32 58 2 27
DENV-3–E63 120 29 51 2 36
DENV-3–E64 110 1 2 1 1
DENV-3–E67 131 37 88 42 1
DENV-3–E61 117 62 53 82 69
DENV-3–E77 130 106 94 133 94
Poorly neutralizing
DENV-3–E1 115 105 110 114 1
DENV-3–E8 100 93 92 95 86
DENV-3–E84 106 79 58 99 0.3
DENV-3–E97 114 86 65 107 6
DENV-3–E98 105 78 65 95 90
WNV E111 56 57 45 83 85
a Staining of yeast cells expressing DENV-3 DIIIs from different genotypes
after incubation with 20 g/ml of MAb. Data are the averages of results from
four independent experiments and are normalized to the percentage of cells that
were positive after staining with the poorly neutralizing MAb DENV-3–E8.
Boldface indicates that the level of binding of a given MAb was from 0 to 25%
of the control value, and underlining indicates that the level of binding was from
26 to 50% of the control value.
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L306G, K308E, E309K, K325E, D328G, D328N, A329G,
A329T, A329V, P330G, G340N, A384Q, L385A, K386E,
K386N, I387A, W389G, and W391A) on residues of the N-
terminal linker, BC and FG loops, and the A and G -strands
of DIII from strain 16652 (gI) and displayed these variants on
the surfaces of yeast cells. DIII-specific MAbs were screened
for loss of binding to the mutants to identify potentially critical
recognition residues (Fig. 4A and Table 5). Using this strategy,
we localized the epitopes of the different classes of neutralizing
MAbs against DENV-3. For example, the complex-specific
MAb DENV-3–E77 showed loss of binding when residues in
the A strand (L306), BC loop (A329 and P330), and G strand
(L385) were altered. For subcomplex-specific MAbs (e.g.,
DENV-3–E61), changes in the A strand (L306, K308, E309)
and G strand (L385 and W389) diminished or abolished bind-
ing. For the strongly inhibitory type-specific MAbs (e.g.,
DENV-3–E54), substitutions in the BC loop (D328, A329, and
P330) abrogated binding to DIII on yeast (Fig. 5A). Due to the
large number of MAbs that lost binding to the D328G or
P330G DIII mutant when DIII was displayed on yeast cells, we
independently confirmed this phenotype by performing bind-
ing assays with wild-type DIII or a mutant (D328G or P330G),
recombinant, bacterially expressed DIII (Fig. 4B). With the
exception of DENV-3–E77, all MAbs showed binding patterns
similar to those of mutants containing the D328G and P330G
mutations when DIII was displayed on the surfaces of yeast
cells or as a recombinant protein in an enzyme-linked immu-
nosorbent assay.
Structural analysis of genotypic variation. Based on the
DENV-3 strains used in this study, there are 11 sites of geno-
typic variation in DENV-3 DIII, four of which are conservative
and seven are nonconservative (Fig. 2A and 5B). Four sites of
variation in DIII are not predicted to be solvent accessible in
the mature virion structure; they are located in the B strand
(V/I322), C-C loop (G/V340), E strand (E/D368), and C-
terminal linker to the stem anchor region (R/K391). In con-
trast, the N-terminal linker contains three sites of variation, all
of which are nonconservative and solvent exposed (L/T/S301,
N/S/G302, T/A/S303). The BC loop and FG loop contain three
sites of nonconservative, solvent-accessible variation (A/V329
FIG. 4. Epitope localization of anti-DENV-3 MAbs to DIII of the E protein. Yeast expressing wild-type E protein and DIII point mutation
(S302N, L306G, E309K, D328G, W389A) strains of DENV-3 were incubated with the indicated DENV-3 (DV3) MAbs and analyzed by flow
cytometry. Histograms are shown for the MAbs WNV E16 (negative control), DENV-3–E8, DENV-3–E61, DENV-3–E77, and DENV-3–E47, with
yeast variants. (B) ELISA with plate-bound wild-type, D328G, or P330G DENV-3 DIII protein expressed in bacteria after detection by DENV-3
MAbs. Values are the averages of results from two independent experiments performed in duplicate. O.D. 450 nm, optical density at 450 nm;
wE111, a cross-reactive MAb against WNV that binds all DENV serotypes and was used as a control.
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and I/T380 [BC loop] and K/N383 [FG loop]). The final site of
variation is solvent accessible and conservative in the G strand
(K/R386). Of note, intragenotypic variation is observed at po-
sitions 302, 303, and 391 within the gI strains, position 368
within the gII strains, and position 329 within the gIII strains.
Because of the variation in the intragenotypic neutralization
pattern (Table 3), we evaluated the overall amino acid varia-
tion among DENV-3 strains independently of genotype. To
determine the conservation of amino acid residues within DIII,
we aligned all available DENV-3 envelope sequences in the
NCBI database. Sequences were trimmed and duplicates elim-
inated, and the resulting 139 unique DENV-3 DIII sequences
were analyzed for conservation at each amino acid position.
Using this approach, we independently confirmed variation at
positions 301, 302, 303, 329, 380, 383, 386, and 391 (Fig. 5C and
Table S3 in the supplemental material). Three additional sites
(345, 360, and 377) of amino acid variation were identified and
mapped on the DENV-3 DIII structure. Residue 360 (DE
loop) is the sole solvent-accessible amino acid, as residues 345
(C-C loop) and 377 (F strand) are not accessible on the
mature virion.
In vivo protection against homologous and heterologous
DENV-3 challenge. Preexposure passive transfer of neutraliz-
ing MAbs against DENV-1, DENV-2, and DENV-4 protects
against infection in mice (2, 21, 49, 54). To confirm that neu-
tralizing anti-DENV-3 MAbs protect in vivo, we developed a
lethal infection model for the homologous DENV-3 16652
strain. This was not straightforward, as DENV-3 strains repli-
cate poorly in wild-type and immunodeficient mice. To our
knowledge, only one mouse-passaged strain (H87, gI) has been
reported to cause subtotal lethality in mice after intracranial
inoculation (9). To generate a more virulent mouse-adapted
strain, DENV-3 16652 was passaged twice between IFN-/
R/  IFN-	R/ AG129 mice after intracranial infection
with C6/36 insect cells. The resultant isolate caused 100%
lethality in AG129 mice after i.c. infection (Fig. 6). Although
this DENV-3 challenge model does not recapitulate human
DENV disease, it serves as a stringent assay to define highly
protective antibodies because lower concentrations of MAb
cross the blood-brain barrier and accumulate in the central
nervous system (20).
A single 500-g dose of a control anti-WNV MAb (E16,
IgG2b) 1 day prior to infection had no effect, as expected, with
6% survival (1 of 18 mice) and a mean time to death (MTD) of
14 days (Table 6 and Fig. 6A). Three MAbs (DENV-3–E47,
DENV-3–E48, DENV-3–E52) showed little, if any protection
in this model. For DENV-3–E47, this was quite surprising as
the neutralization potency was strong, with EC50 values of
110 ng/ml against the parent strain (Table 2). Due to the
disparity between the EC50 values and protection, the neutral-
ization potential of DENV-3–E47, DENV-3–E48, and DENV-
3–E52 was confirmed using the mouse-adapted 16652 strain;
notably, no difference in EC50 value from that for the parental
virus was observed (data not shown). In comparison, 13 MAbs
protected significantly, and these were separated into two
(moderate- and high-level) groups. DENV-3–E49, DENV-3–
E51, DENV-3–E53, DENV-3–E54, DENV-3–E58, DENV-3–
E61, DENV-3–E62, and DENV-3–E64 protected between 20
and 40% (P 
 0.05) of AG129 mice, whereas DENV-3–E50,
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E63 protected between 60 and 83% (P 
 0.005) of animals
from lethal infection. Surprisingly, and in contrast to that seen
with WNV, DENV-1, and DENV-2 (37, 39, 49, 52), we ob-
served no clear relationship between neutralizing potency in
vitro and protective activity in vivo.
Based on the prophylaxis studies, the four most protective
MAbs (DENV-3–E48, DENV-3–E57, DENV-3–E59, and
DENV-3–E63) were selected for evaluation in a postexposure
therapeutic model. A single 500-g dose of MAb was trans-
ferred passively 2 days after i.c. infection with DENV-3 16652,
and survival was monitored. Two MAbs (DENV-3–E57 and
DENV-3–E63) showed an 75% survival (P 
 0.001) rate in
this model (Fig. 6B and Table 7). To determine the possible
utility of our protective MAbs as a therapeutic against genet-
ically diverse DENV-3 strains, we developed a heterologous
DENV-3 challenge model by generating a mouse-adapted
UNC3050 (gIV) strain after passaging it between AG129 mice
and C6/36 cells. AG129 mice were passively transferred a sin-
gle 500-g dose of DENV-3–E47, DENV-3–E60, and DENV-
3–E61, the three MAbs that showed modest cross-neutraliza-
tion of UNC3050 in cell culture, prior to i.c. challenge with 105
PFU (Fig. 6C). However, none of the three MAbs protected
against the adapted heterologous UNC3050 virus in this strin-
gent challenge model.
DISCUSSION
In two recent studies, we evaluated large panels of MAbs
against DENV-1 and DENV-2 for their neutralizing activity,
epitope-specific binding patterns, and in vivo protective capac-
ity (49, 52). Several strongly neutralizing MAbs failed to inhibit
infection of DENV-1 strains of a heterologous genotype, sug-
gesting that variable antibody neutralization may be due to the
limited amino acid dissimilarity that occurs within a DENV
serotype. For studies with DENV-2, we identified a similar
trend, as 4 of 18 strongly neutralizing MAbs failed to inhibit in
vitro infection of a heterologous genotype. These data sug-
gested that it may be important to assess whether antibody
responses generated against an individual strain of a given
serotype neutralize infection by heterologous genotypes effec-
tively. As this concept had implications for DENV vaccine
development and evaluation, here, we assessed the cross-geno-
type neutralizing and protective activities of an extensive panel of
newly generated anti-DENV-3 MAbs. Twenty-four of the 82
MAbs strongly neutralized the homologous virus strain (DENV-3
16652), and 20 of these mapped to epitopes in DIII of the E
protein. Remarkably, only two of the neutralizing MAbs effi-
ciently recognized cells infected with all four DENV-3 genotypes,
with many showing reduced binding to multiple genotypes. None
of the strongly inhibitory MAbs efficiently neutralized all
DENV-3 isolates used in this study, and the majority inhibited
only strains classified as gI and gII. Although we identified MAbs
with similar functional characteristics within the panels of MAbs
against DENV-1 and DENV-2 (49, 52), the extent of the geno-
type-specific neutralization was greatest for the DENV-3 panel.
Consistent with this, several MAbs were highly protective in mice
as prophylaxis or postexposure therapy in an i.c.-challenge model
of homologous (gI) DENV-3 infection, yet none of the tested
MAbs protected against infection by a heterologous (gIV)
DENV-3 strain.
Although there is significant genetic variation throughout
the genomes of strains of the DENV-3 serotype, the diversity
is greatest within the E protein (5, 23, 26, 57), the target of the
majority of neutralizing MAbs. The DENV-3 serotype is seg-
FIG. 5. Structural analysis of the effects of sequence diversity in DIII on the neutralization of DENV-3. (A) Localization of neutralizing
epitopes on DENV-3 DIII as determined by yeast surface display. Ribbon diagrams of the DENV-3 DIII structure (Protein Database identifier
1UZG) (33) are shown with amino acid residues that affect the binding of neutralizing MAbs colored as follows: blue, residues involved in
neutralization by complex-specific neutralizing MAbs; magenta and blue, residues involved in neutralization by subcomplex-specific MAbs; and
orange and blue, residues that alter binding of type-specific neutralizing MAbs. K386 mutants sometimes reduced the binding of type-specific
MAbs and, thus, are grouped with the subcomplex MAbs in this figure. The disulfide bond between positions 300 and 331 is highlighted in yellow.
(B) Ribbon diagram of DENV-3 DIII showing amino acid sequences that vary among the different DENV-3 genotypes, with solvent-inaccessible
and -accessible residues depicted in cyan and green, respectively. (C) Ribbon diagram of DENV-3 DIII showing amino acid variation of DIII from
all 139 available unique DENV-3 strain sequences, with solvent-inaccessible and -accessible residues depicted in cyan and green, respectively.
VOL. 84, 2010 MAb NEUTRALIZATION OF DENV-3 GENOTYPES 10639
 o
n
 June 7, 2012 by W






regated into four different genotypes, with gI, gII, and gIII
causing the majority of contemporary human infections (1).
Within the DENV-3 serotype, one area of genetic variation
among natural viral isolates is in the E protein along the
lateral-ridge epitope of DIII (58). This region, which includes
amino acids in the N-terminal linker and BC loop, has been
identified as a key recognition site for MAbs that potently
neutralize the infection of other flaviviruses, including WNV
(4, 37, 46), DENV-1 (49), DENV-2 (15, 53), tick-borne en-
cephalitis virus (50), and Japanese encephalitis virus (14, 63).
FIG. 6. Prophylactic and therapeutic efficacy of strongly neutralizing antibodies in mice after DENV-3 infection. (A) Mice were administered
a single 500-g dose of the indicated MAbs via the i.p. route 1 day prior to infection and then i.c. infected with 5  103 PFU of the mouse-adapted
DENV-3 strain 16652 and monitored over 60 days for survival. The left and right panels show MAbs with different levels of protection. (B) The
therapeutic efficacy of the strongly protective neutralizing antibodies was tested by administering a single 500-g dose of MAb i.p. 2 days after
infection with 5  103 PFU i.c. (C) Mice were administered a single 500-g dose of the indicated MAb via an i.p. route 1 day prior to i.c. infection
with 105 PFU of the mouse-adapted DENV-3 UNC3050 strain and monitored over 30 days for survival. The survival analysis represents the results
from two to six independent experiments with at least 4 mice per group.
TABLE 6. Preexposure prophylaxis with neutralizing MAbs against













a SD P valueb
DENV-3–E47 0 7 7 0 15 4.4 0.1
DENV-3–E48 4 11 21 33 18 8.6 
0.0005
DENV-3–E49 2 3 5 40 24 5.1 
0.001
DENV-3–E50 9 6 15 60 23 6.6 
0.0001
DENV-3–E51 1 4 5 20 23 3.2 
0.0005
DENV-3–E52 0 5 5 0 12 4.7 0.5
DENV-3–E53 2 3 5 40 22 5.9 
0.001
DENV-3–E54 9 6 15 46 13 9.6 0.1
DENV-3–E56 2 2 4 50 18 1.4 
0.005
DENV-3–E57 5 3 8 63 23 5.0 
0.0001
DENV-3–E58 1 3 4 25 18 9.2 
0.05
DENV-3–E59 10 2 12 83 14 4.9 
0.0001
DENV-3–E60 3 2 5 60 13 8.5 
0.01
DENV-3–E61 8 6 17 47 17 6.8 
0.0001
DENV-3–E62 2 3 5 40 19 8.2 
0.01
DENV-3–E63 7 2 9 78 10 1.4 
0.005
DENV-3–E64 2 3 5 40 23 2.1 
0.0005
DENV-3–E67 4 2 6 67 21 2.8 
0.005
WNV E16 1 17 18 6 14 3.3
a MTD, mean time to death.
b P values were calculated using the log rank test by comparing values for the
negative-control MAb (WNV E16) and antibody-treated mice.
c Four- to 5-week-old AG129 mice were passively administered 500 g of the
indicated MAbs 1 day before infection with 5  103 PFU of strain 16652 by an
i.c. route. Mice were monitored for survival for 60 days after infection.
TABLE 7. Postexposure therapy with neutralizing MAbs after













a SD P valueb
WNV E16 0 12 12 0 14 3.4
DENV-3–E48 0 7 7 0 19 9.7 0.1
DENV-3–E57 8 3 11 73 14 4.0 
0.001
DENV-3–E59 3 7 10 30 14 5.6 0.1
DENV-3–E63 10 3 13 77 20 1.5 
0.0001
a MTD, mean time to death.
b P values were calculated using the log rank test by comparing values for the
negative-control MAb and antibody-treated mice.
c Four -to 5-week-old AG129 mice were administered 500 g of the indicated
MAbs 2 days after infection with 5  103 PFU of strain 16652 by the i.c. route.
Mice were monitored for survival for 60 days after infection.
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The lateral-ridge epitope on DENV-3 DIII was the dominant
site of recognition for the majority of the strongly neutralizing
mouse MAbs in our study and also for two mouse MAbs
reported by others (58). With analysis of 82 new MAbs, our
experiments confirm and extend the results of recent studies
which characterized five anti-DENV-3 MAbs, including two
type-specific neutralizing antibodies and one subcomplex-spe-
cific neutralizing antibody (58). Consistent with their results
and the structural variation of DIII among strains at positions
along the lateral-ridge epitope, none of our strongly type-
specific MAbs efficiently recognized and inhibited DENV-3
from all four genotypes. In comparison, only one subcomplex-
specific MAb (14A4) from the prior study, which recognized a
residue (K308) in the A-strand epitope, neutralized all four
genotypes, albeit with rather modest EC50 values ranging from
0.25 to 2.2 g/ml, values that were 100- to 1,000-fold less
potent than many of the MAbs described in our study.
Two of the subcomplex-specific neutralizing MAbs (DENV-
3–E61 and DENV-3–E77) described here localized to addi-
tional amino acids, 306 and 385, on the A and G -strands of
DIII. These regions were described as recognition sites for
other subcomplex- or complex-specific neutralizing MAbs
against DENV (16, 27, 30, 31, 42, 53, 56). It is interesting to
note that these two MAbs, despite binding multiple DENV
serotypes, still failed to neutralize efficiently all of the geno-
types within the DENV-3 serotype. Thus, future evaluation of
therapeutic anti-DENV MAbs should consider efficacy testing
against all genotypes within a DENV serotype, even if the
MAb retains the ability to bind and neutralize heterologous
DENV serotypes.
To evaluate the protective activity of the neutralizing MAbs,
we developed two new lethal-challenge mouse models using
homologous gI and heterologous gIV strains. This model,
which does not reflect DENV-3 pathogenesis in humans, none-
theless is particularly stringent for protection, as immunocom-
promised AG129 mice are challenged by an i.c. route and only
a small fraction (0.1%) of IgG crosses the blood-brain bar-
rier in rodents during flavivirus infection (36). This challenge
route was necessary, as virtually all DENV-3 isolates replicated
poorly in mice after peripheral (subcutaneous, intraperitoneal,
or intravenous) inoculation. Our challenge model is similar to
one that was used recently to monitor the effect of protective
polyclonal antibodies against DENV-3 after DNA plasmid vac-
cination (9). Against the homologous DENV-3 genotype, two
of our neutralizing MAbs significantly protected when they
were used as pre- or postexposure therapy, the latter even 2
days after i.c. challenge. However, neither of the most protec-
tive MAbs (DENV-3–E57 or DENV-3–E63) had activity
against the gIV strain, even as prophylaxis. These results are
analogous to what was observed with several strongly neutral-
izing anti-DENV-1 MAbs generated against a genotype 2 iso-
late, which failed to protect against challenge by a heterolo-
gous genotype 4 strain (49).
Our functional studies with anti-DENV-3 MAbs potentially
have implications for evaluating candidate tetravalent DENV
vaccines. It is widely believed that a successful DENV vaccine
requires a robust and durable neutralizing antibody response
against all four serotypes (60). This is essential because sub-
neutralizing antibody responses against any single serotype
could, in theory, facilitate antibody-dependent enhancement
and enhanced disease severity upon infection with a natural
isolate (17). Our data with MAbs against DENV-3, along with
recent and earlier studies on DENV-1 (49) and DENV-2 (18),
demonstrate variable neutralization among strains of a given
serotype, likely because of the sequence diversity of the E
protein between genotypes. A key question is whether the
genetic diversity across DENV strains in nature will affect the
neutralization potential observed during vaccine trials in
the context of a polyclonal response, especially with the less
robust or durable neutralizing antibody responses that occur
after immunization with attenuated strains or recombinant
proteins. As neutralizing activity in polyclonal antibody re-
sponses in humans appears to be serotype specific (59), there
is at least a possibility of incomplete neutralization of specific
genotypes within a serotype, especially over time as immunity
wanes. Thus, it may be important to evaluate candidate vac-
cines for neutralizing antibody responses against an array of
viruses within a serotype encompassing genotypic variation to
confirm the efficacy and breadth of a protective antibody re-
sponse.
Our results suggest that the lateral-ridge epitope of DIII of
the flavivirus E protein is a target for strongly neutralizing
antibodies produced, but sequence variation within that
epitope can limit the breadth of activity of antibodies that
target that region. Moreover, the potency of antibody neutral-
ization generally correlated with narrowed genotype specific-
ity. The identification of key target determinants for antibody
protection against all DENV serotypes and genotypes ulti-
mately may allow the generation of epitope-based diagnostic
reagents that can better predict the qualitative, quantitative,
and functional profiles of polyclonal antibody responses within
humans during natural infection or after vaccination.
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West Nile virus (WNV) is a neurotropic flavivirus that is now a primary cause of epidemic encephalitis in
North America. Studies of mice have demonstrated that the humoral immune response against WNV limits
primary infection and protects against a secondary challenge. The most-potent neutralizing mouse monoclonal
antibodies (MAbs) recognize an epitope on the lateral ridge of domain III (DIII-lr) of the envelope (E) protein.
However, studies with serum from human patients show that antibodies against the DIII-lr epitope comprise,
at best, a minor component of the human anti-WNV antibody response. Herein, we characterize in detail two
WNV-specific human MAbs, CR4348 and CR4354, that were isolated from B-cell populations of convalescent
patients. These MAbs strongly neutralize WNV infection of cultured cells, protect mice against lethal infection
in vivo, and yet poorly recognize recombinant forms of the E protein. Instead, CR4348 and CR4354 bind
determinants on intact WNV virions and subviral particles in a pH-sensitive manner, and neutralization is
altered by mutations at the dimer interface in domain II and the hinge between domains I and II, respectively.
CR4348 and CR4354 human MAbs neutralize infection at a postattachment step in the viral life cycle, likely
by inhibiting acid-induced fusion within the endosome.
West Nile encephalitis virus (WNV) is a positive-polarity,
single-stranded RNA virus of the genus Flavivirus within the
family Flaviviridae. Other members of this genus that cause
significant human disease include dengue virus (DENV), St.
Louis encephalitis virus, Japanese encephalitis virus (JEV),
yellow fever virus, and tick-borne encephalitis virus (TBEV).
Flaviviruses are translated as a single polypeptide, which is
then cleaved by host and viral proteases into three structural
(capsid [C], premembrane [prM], and envelope [E]) and seven
nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and
NS5) proteins (reviewed in references 42 and 43).
WNV cycles in nature between several species of birds and
Culex mosquitoes, with humans and other mammals as dead-
end hosts (25, 62). Infection causes syndromes ranging from a
mild febrile illness to severe encephalitis and death (13, 72).
WNV has spread globally and causes outbreaks with thousands
of severe human cases annually in the United States. An age of
greater than 55 years, a compromised immune status, and a
CC532 genotype have been associated with more-severe dis-
ease (15, 20). There is currently no approved vaccine or ther-
apy for WNV infection.
The mature WNV virion has a 500-Å diameter and con-
sists of a single RNA genome surrounded by the capsid pro-
tein, a lipid bilayer, and a shell of the prM/M and E proteins
(31, 55). X-ray crystallography studies have elucidated the
three-domain structure of the flavivirus E protein (30, 48, 50,
58, 67). Domain I (DI) is a central, eight-stranded -barrel,
which contains the only N-linked glycosylation site in WNV E.
Domain II (DII) is a long, finger-like protrusion from DI and
contains the highly conserved fusion peptide at its distal end.
Domain III (DIII) adopts an immunoglobulin-like fold at the
opposite end of DI and is believed to contain a site for receptor
attachment (6, 8, 40).
Within an infected cell, progeny WNV are assembled ini-
tially as immature particles. In immature virions, three pairs of
E and prM interact as trimers and form 60 spiked projections
with icosahedral symmetry (85, 86). Exposure to mildly acidic
conditions in the trans-Golgi secretory pathway promotes virus
maturation through a structural rearrangement of the E pro-
teins and cleavage of prM to M by a furin-like protease (41,
83). Mature WNV virions are covered by 90 antiparallel E
protein homodimers, which are arranged flat along the surface
in a herringbone pattern with quasi-icosahedral symmetry (55).
Upon binding to poorly characterized cell surface receptors,
internalization of WNV is believed to occur through receptor-
mediated, clathrin-dependent endocytosis (1, 79, 80). After
trafficking to Rab5- and/or Rab7-positive endosomes (38, 79),
the mildly acidic pH within the lumen of the endosome induces
structural alterations in the flavivirus E protein (7, 49), which
includes changes in its oligomeric state (7, 49, 77). During this
process, also known as type II fusion, the hydrophobic peptide
on the fusion loop of DII of the E protein inserts into the
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ington University School of Medicine, 660 South Euclid Ave., Box
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endosomal membrane, thus physically joining the host and
viral membranes, which allows the infectious RNA genome to
enter the cytoplasm (32, 33).
Humoral immunity is an essential component of the protec-
tive host response against flaviviruses including WNV (re-
viewed in references 64 and 68). Studies by several groups have
shown that the neutralization of WNV can occur after anti-
bodies bind to a series of discrete epitopes on all three domains
of the E protein (3, 12, 22, 59, 61, 71). To date, the most
potently neutralizing monoclonal antibodies (MAbs) localize
to an epitope on the lateral ridge of DIII (DIII-lr). One well-
characterized strongly neutralizing mouse MAb, E16, blocks
infection primarily at a postattachment step (57) and requires
the engagement of only a fraction of its epitopes on the surface
of the virion (66). Studies of the human antibody response to
WNV infection reveal that, in contrast to mice, antibodies that
bind the DIII-lr epitope comprise a minor component of the
neutralizing humoral response in most individuals (60).
In this study, we characterized two strongly neutralizing
novel human MAbs (CR4348 and CR4354) that were selected
from an antibody phage display library constructed from B
cells of subjects that survived WNV infection (78). We dem-
onstrate that both MAbs are WNV specific, bind weakly to
recombinant or yeast surface-displayed E proteins, exhibit pH-
sensitive binding to viral particles, and protect against lethal
infection in mice. Our experiments suggest that these human
MAbs map to distinct epitopes and neutralize infection at a
postattachment stage, likely by inhibiting the acid-catalyzed
viral fusion step.
MATERIALS AND METHODS
Preparation of virus, subviral particles, and pyrene-labeled virus. WNV strain
3000.0259, which was isolated in New York in 2000 (16), was used to generate
stocks of passage 2 (4.2  107 PFU/ml) and passage 3 (2.0  107 PFU/ml) virus
after propagation in C6/36 Aedes albopictus cells. The propagations of wild-type
and mutant WNV from the New York 1999 (NY99ic) infectious clone (5) are
detailed below. WNV subviral particles (SVP) were generated after transfection
of BHK21-15 cells with a pcDNA3.1 plasmid expressing premembrane (prM)
and envelope (E) genes (36) from the NY99 WNV strain using FuGENE HD
(Roche) according to the manufacturer’s instructions. Supernatants containing
SVP were collected 48 h after transfection, filtered through a 0.2-m filter, and
stored aliquoted at 80°C.
Labeling of WNV with the fluorescent probe pyrene was performed essentially
as described previously for alphaviruses (73, 81). Briefly, BHK21-15 cells cul-
tured in the presence of 15 g/ml of 16-(1-pyrenyl)-hexadecanoic acid (Invitro-
gen) were infected with WNV at an multiplicity of infection of 4. At 24 h
postinfection, the medium was harvested and clarified by low-speed centrifuga-
tion, and pyrene-labeled WNV particles were pelleted by ultracentrifugation in
a Beckman type 19 rotor for 15 h at 48,500  g at 4°C. The virus particles were
further purified on an Optiprep (Axis-Shield) density (15 to 55%, wt/vol) gradi-
ent by ultracentrifugation in a Beckman SW41 rotor for 18 h at 100,000  g at
4°C. The infectious titer was determined by 50% tissue culture infective dose
analysis, and the protein concentration was measured by micro-Lowry analysis.
MAbs. Unless otherwise specified, all antibodies used were protein A purified
and of the human immunoglobulin G1 (IgG1) subclass. Humanized E16 (Hu-
E16) was generated from a mouse MAb after genetic engineering as described
previously (59). CR4348, CR4354, and CR4293 (anti-prM) were selected from
single-chain variable-fragment (scFv) phage display libraries constructed from
peripheral blood lymphocytes isolated from three human patients who survived
neuroinvasive WNV disease (78). Construction of the libraries, selections with
the libraries, and reformatting of scFv phage into full-length IgG1 molecules was
previously described in detail (78). WNV E24 (mouse IgG2a) localizes to the
DIII-lr epitope (59) and was purified by protein A affinity chromatography.
Control non-WNV reactive anti-fluorescein isothiocyanate and anti-DENV1 E50
human IgG1 were gifts of S. Johnson (Macrogenics, Rockville, MD).
Neutralization assays. (i) PRNT. In many experiments, the neutralizing activ-
ity of MAbs was determined using a 50% plaque reduction neutralization test
(PRNT50) analysis. Briefly, serially diluted MAbs were mixed 1:1 with 102 PFU
of WNV in Dulbecco’s modified Eagle medium (DMEM) containing 10% fetal
bovine serum (FBS) (Omega Scientific) and incubated for 1 h at 37°C. The
WNV-MAb mixture was then added to individual wells of a six-well tissue culture
plate in duplicate or triplicate with either Vero or BHK21-15 cells. Viral adsorp-
tion proceeded for one hour at 37°C, followed by an overlay with 1% low-melt
agarose (SeaPlaque) in -modified Eagle medium and 4% FBS. After solidifi-
cation, plaques were visualized 3 to 4 days later following fixation with 2 ml of
10% formaldehyde, removal of agarose plugs, and staining with 1% (wt/vol)
crystal violet in 20% (vol/vol) ethanol. Plaques were counted and then normal-
ized to the average of data from six control wells in which WNV was mixed with
DMEM containing 10% FBS and no antibody.
(ii) Pre- and postattachment neutralization assays. To assay for postattach-
ment neutralization, a PRNT assay was completed essentially as described above
with the following modifications. All solutions and Vero cells were prechilled to
4°C, and 102 PFU of WNV were then added to each well of cells, and viral
adsorption was allowed for 1 h at 4°C. Wells were then washed three times with
medium, and MAb at the specified concentrations was added. Virion-antibody
complexes were allowed to form for 1 h at 4°C, followed by three washes with
chilled medium. Cells were then warmed to 37°C, and the PRNT was completed
as described above. In parallel, a PRNT with all cells and solutions at 4°C was
performed in which MAb and WNV were mixed for 1 h at 4°C prior to addition
to cells (preattachment assay).
(iii) RVP assay. WNV and mutant reporter virus particles (RVP) were gen-
erated as described previously (65, 66). Separate plasmids expressing the wild-
type prM-E genes and the capsid (C) gene of WNV were transfected into a BHK
cell that stably propagates a WNV replicon expressing green fluorescent protein.
In some experiments, the prM-E plasmid was mutated using the QuikChange
site-directed mutagenesis kit (Stratagene) to introduce specific amino acid sub-
stitutions. In other experiments, RVP were produced from 293T cells at various
stages of maturation (immature, partially mature, or fully mature) according to
previously published protocols (56). Supernatants containing RVP were har-
vested 48 h after transfection, filtered through a 0.2-m filter, and stored ali-
quoted at 80°C. RVP were incubated with serial dilutions of MAb under
conditions of antibody excess at room temperature (RT) for 1 h. Subsequently,
MAb-RVP mixtures were added to Raji-DCSIGNR cells, which stably express
the DC-SIGNR attachment factor (14), and were incubated at 37°C for 48 h.
Infected cells were assayed for green fluorescent protein expression using a BD
FACSArray flow cytometer. Alternatively, human CD32A (Fc-	RIIA)-express-
ing K562 cells were used to assay for antibody-dependent enhancement of in-
fection.
Yeast surface display of WNV E proteins. The generation of Saccharomyces
cerevisiae cells that express the WNV E protein ectodomain (amino acid residues
1 to 415) or DIII (residues 296 to 415) was described previously (59). Yeast cells
expressing WNV E or DIII were washed in a solution containing phosphate-
buffered saline (PBS), 2% bovine serum albumin, and 0.025% NaN3; incubated
with primary MAbs (50 g/ml) for 30 min on ice; washed three times; mixed with
a 1:500 dilution of Alexa Fluor 647-conjugated goat anti-human antibody (Mo-
lecular Probes); washed again; and processed using a BD FACSArray flow
cytometer.
Antigen capture and solid-phase ELISA. Nunc MaxiSorp polystyrene 96-well
plates were coated either overnight at 4°C with murine DIII-lr MAb (10 g/ml)
or for 1 h at 37°C with the soluble recombinant WNV E protein ectodomain (10
g/ml), generated as described previously (57), in a pH 9.3 carbonate buffer.
Plates were washed three times in enzyme-linked immunosorbent assay (ELISA)
wash buffer (PBS with 0.02% Tween 20) and blocked for 1 h at 37°C with ELISA
block buffer (PBS, 2% bovine serum albumin, and 0.02% Tween 20). SVP or
WNV infectious virions (wild type or mutant) were captured on plates coated
with murine DIII-lr MAb for 1 h at RT. Subsequently, plates were rinsed five
times in wash buffer and then incubated with anti-WNV or control human IgG1
(10 g/ml in block buffer) in triplicate for 1 h at RT. Plates were washed five
times and then incubated with biotinylated rabbit anti-human IgG antibody
(1:1250 dilution; Southern Biotech) for 1 h at RT in blocking buffer. Plates were
washed again five times and then sequentially incubated with 2 g/ml of horse-
radish peroxidase-conjugated streptavidin (Vector Laboratories) and tetrameth-
ylbenzidine substrate (Dako). The reaction was stopped with the addition of 2 N
H2SO4 to the medium, and emission (450 nm) was read using an iMark micro-
plate reader (Bio-Rad). In the pH-dependent ELISA, plates were washed four
times with wash buffer and once with the indicated pH buffer (150 mM NaCl,
0.05% Tween 20, and 50 mM MES [morpholineethanesulfonic acid] [pH 6.0]) or
wash buffer (pH 7.4) after trapping of SVP. The plate was incubated for 30 min
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at RT with the indicated pH buffer and then washed five times in wash buffer
followed by normal completion of the capture ELISA protocol.
Western blots. The recombinant WNV E protein, SVP, or infectious WNV
was diluted in 2 sodium dodecyl sulfate loading buffer with or without -mer-
captoethanol (5%, vol/vol) and incubated at RT or 95°C for 10 min as indicated.
Samples were loaded into wells of a NuPAGE (Invitrogen) 4 to 12% Bis-Tris-
gradient gel and electrophoresed. Protein was transferred onto a polyvinylidene
difluoride transfer membrane using the iBlot system (Invitrogen). Membranes
were rinsed in PBS–0.05% Tween 20 (wash buffer) with gentle shaking for 10 min
at RT and then blocked overnight with block buffer (5% dry milk in wash buffer)
with shaking at RT. After five 10-min washes, membranes were stained with
primary human MAb (1 g/ml diluted in block buffer with normal goat serum
added at a 1:250 dilution) for 1 h at RT. After five additional washes, membranes
were incubated with horseradish peroxidase-conjugated goat anti-human anti-
body (diluted 1:5,000 in block buffer; Sigma) for 1 h. Membranes were then
washed five times for 10 min in wash buffer and developed using ECL reagent
(Amersham).
Generation of neutralization escape mutants. WNV was incubated with 25
g/ml of CR4348 or CR4354 for 1 h at RT in DMEM. The mixture was added
to Vero cells in a six-well plate at a multiplicity of infection of 1. After infection
for 2 h at 37°C, wells were washed three times with DMEM, and fresh medium
containing 25 g/ml of MAb was added. Virus growth under antibody selection
was allowed for 48 h at 37°C. At each passage, half of the supernatant was mixed
1:1 with 50 g/ml of MAb for 1 h. The remaining half of the supernatant was
aliquoted and stored at 80°C. After three passages under MAb selection,
virus-containing supernatants were tested by PRNT for escape from neutraliza-
tion by CR4348 or CR4354. After confirmation of the escape phenotype, an
aliquot of the supernatant was used in a Vero cell plaque assay under MAb
selection. Plaques were visualized by overlaying with neutral red, and sterile glass
Pasteur pipettes were used to isolate resistant virus from single plaques. Plaque-
purified virus was amplified under MAb selection (25 g/ml) overnight at 37°C.
Vero cells were scraped from wells, and total cellular RNA was isolated using an
RNeasy kit (Qiagen). cDNA was amplified using a reverse primer (2501R [5
-
TGCCGGCTGATGTCTATGG-3
]) in the WNV NS1 gene and served as a
template for PCR amplification of the prM and E genes using forward (454F
[5
-AGCGTAGGAGCAGTTACCC-3
]) and reverse (2501R) primers. The prM
and E genes were then directly sequenced from gel-purified PCR products, and
the neutralization escape mutant sequence was compared to the sequence of the
laboratory stock WNV that was passaged and plaque purified in parallel in the
absence of MAb selection.
WNV infectious cDNA clone and mutant generation. The two-plasmid WNV-
NY99 cDNA clone (36) was used to create wild-type and mutant infectious
WNV. Single amino acid substitutions were introduced into plasmid pWNAB by
site-directed mutagenesis. Wild-type and mutant plasmid pWNAB (encoding
nucleotides 1 to 2495 of the WNV genome) and wild-type plasmid pWNCG
(encoding nucleotides 2495 to 11029) were grown in SURE-2 supercompetent
Escherichia coli cells (Stratagene) at RT. Each plasmid was digested with XbaI
and NgoMIV restriction endonucleases, and the resultant 5.2- and 8-kb frag-
ments of pWNAB and pWNCG, respectively, were gel purified and ligated with
T4 DNA ligase (Invitrogen) at 4°C overnight. The reaction mixtures were then
heat inactivated, digested with XbaI to linearize the DNA, treated with protein-
ase K, extracted twice with phenol and chloroform, and precipitated with ethanol
at 20°C overnight. All DNA was used as a template for in vitro DNA-depen-
dent RNA transcription with the AmpliScribe T7 kit (Epicentre) with the addi-
tion of an m7G(5
)ppp(5
)A cap analog (New England Biolabs). Transcription
reactions were run at 37°C for 5 h, and the reaction mixture was then electro-
porated (three pulses at 850 V, 25 F, and ) into BHK21-15 cells. Cells were
added to a T75 tissue culture flask in DMEM with 10% FBS and observed for the
onset of cytopathic effects. Once cytopathic effects were observed, the virus-
containing supernatant was collected, cellular debris was pelleted, and superna-
tant aliquots were frozen at 80°C. The cells remaining in the T75 flask were
harvested and used as a source of viral RNA to confirm that the desired mutant
sequence was retained.
Structural analysis. The coordinates for the WNV E protein (RCSB accession
number 2HG0) were divided by domains and fit onto the cryo-electron mi-
croscopy structure for mature DENV (RCSB accession number 1K4R) using
CCP4MG to create a model of the WNV E protein dimer. Distances were
calculated and figures were prepared using PyMol (http://www.pymol.org).
Mouse experiments. Mouse studies were approved and performed according
to the guidelines of the Washington University School of Medicine Animal
Safety Committee. Three- to four-week-old outbred NIH Swiss mice (Harlan)
were infected by intraperitoneal injection with WNV-NY99ic diluted in Hanks’
balanced salt solution containing 1% heat-inactivated FBS. For antibody pro-
tection studies, 1 day prior to infection, mice were treated by intraperitoneal
injection with 50 g of the indicated MAb or vehicle control diluted in 100 l
PBS. Mice were monitored daily for 21 days for mortality and were euthanized
when moribund. In some experiments, passive transfer of MAbs was performed
with 5-week-old C57BL/6 mice (Jackson Laboratories) as described previously
(59).
Fusion assay. The fusion of pyrene-labeled WNV with liposomes was moni-
tored continuously in a Fluorolog 3-22 fluorometer (BFi Optilas) at excitation
and emission wavelengths of 345 nm and 475 nm, respectively. Liposomes (large
unilamellar vesicles with a diameter of200 nm) were prepared by a freeze-thaw
extrusion procedure as described previously (73). Liposomes consisted of a
mixture of phosphatidylcholine from egg yolk, phosphatidylethanolamine pre-
pared by the transphosphatidylation of egg phosphatidylcholine, and cholesterol
in a molar ratio of 1:1:2. The lipids were obtained from Avanti Polar Lipids. The
concentration of phospholipids was determined by phosphate analysis.
Pyrene-labeled WNV (1.24 g of total viral protein) and liposomes (final
concentration, 200 M phospholipid) were mixed in a final volume of 665 l in
a solution containing 5 mM HEPES, 150 mM NaCl, and 0.1 mM EDTA (pH 7.4)
with continuous stirring in a temperature-controlled cuvette at 37°C. At 0 s, the
medium was acidified by the addition of 35 l of a solution containing 0.1 MES
and 0.2 M acetic acid, which was pretitrated with NaOH to achieve the final
desired pH. The fusion scale was calibrated such that 0% fusion corresponded to
the initial excimer fluorescence value. The 100% value was obtained through the
addition of 35 l 0.4 M octaethyleneglycol monododecyl ether (Fluka Chemie
AG) to achieve an infinite dilution of the probe. The extent of fusion was
determined 60 s after acidification. To determine the influence of the MAbs on
membrane fusion, pyrene-labeled WNV was incubated with different concentra-
tions of MAbs for 1 h at RT prior to mixing with liposomes.
Statistical analysis. All data were analyzed using Prism software (GraphPad,
San Diego, CA). Kaplan-Meier survival curves were analyzed by the log-rank
test. For neutralization assays, an unpaired Student’s t test was used to determine
significance. For ELISA data, a paired Student’s t test was used to determine
significance.
RESULTS
Characterization of strongly neutralizing human MAbs.
Previous studies that mapped the epitope specificity of inhib-
itory antibodies in convalescent-phase human serum samples
suggested that only a fraction of WNV-infected patients de-
veloped antibodies against the strongly neutralizing epitope on
DIII-lr of the E protein (60). Consistent with this, few DIII-
specific human MAbs were isolated from phage display scFv
libraries from infected patients (78), and none were selected
from very large libraries of pooled sera from uninfected donors
(22). As human convalescent-phase serum retains strong neu-
tralizing activity, we hypothesized that antibodies with distinct
specificities must contribute to the inhibitory activity.
Antibody-phage display libraries constructed from periph-
eral blood lymphocytes of three convalescent patients after
WNV infection were screened for reactivity on WNV antigen
as described previously (78). All selected monoclonal phages
specifically bound a preparation of inactivated WNV and im-
mobilized prM-E-containing SVP. SVP, in addition to contain-
ing prM/M proteins, display 60 E protein homodimers in a
lipid bilayer (18), whereas virions have 90 E protein ho-
modimers in a distinct icosahedral arrangement (39, 55). Two
MAbs, CR4348 and CR4354, which demonstrated strong neu-
tralizing activity in pilot functional assays, tested negative for
binding to the recombinant E protein by ELISA (data not
shown); in contrast, other neutralizing human MAbs that were
identified in the screen and previously characterized (e.g.,
CR4374) (60, 78) readily bound the recombinant E protein.
In both the PRNT and WNV RVP assay, CR4348 (PRNT50 
536 ng/ml; RVP 50% effective concentration [EC50]  146
ng/ml) and CR4354 (PRNT50  88 ng/ml; RVP EC50  26
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ng/ml) inhibited infection strongly albeit slightly less than that
achieved with a humanized version of a therapeutic WNV
type-specific mouse MAb, E16 (Hu-E16), that maps to the
DIII-lr epitope (59) (Fig. 1A and B). CR4348 and CR4354
appeared to be distinct from Hu-E16, as they did not efficiently
recognize the ectodomain of the E protein when expressed as
a purified protein or displayed on the surface of yeast cells
(Fig. 2A and B). These neutralizing human MAbs also effi-
ciently neutralized variant WNV RVP composed of E proteins
encoding a T332K mutation that abrogates the neutralization
of virtually all DIII-lr MAbs (Fig. 1C) (3, 59). Additionally,
both human MAbs likely do not recognize linear epitopes, as
they did not identify prM, M, or E by Western blotting under
reducing or nonreducing conditions (Fig. 2C).
Because CR4348 and CR4354 neutralized WNV but did not
appear to recognize the recombinant E protein, we speculated
that they might inhibit infection by binding to an epitope on
prM that was not be detected by Western blotting. To test this,
we took advantage of a series of WNV RVP preparations that
differ with respect to the efficiencies of the maturation process;
similar preparations were used previously to define the differ-
ential neutralizing activity of anti-WNV MAbs generated in
mice (56). WNV RVP were produced as fully mature (in cells
overexpressing the furin protease), partially and heteroge-
neously mature (standard conditions), or largely immature (in
the presence of NH4Cl, which inhibits furin cleavage) particles.
These three types of RVP differ in their content of prM,
ranging from virtually none (mature) to 95% (immature).
CR4348 and CR4354 neutralized prM-containing or -absent
particles equivalently (Fig. 3), eliminating the pr peptide as
part of the epitope for either MAb.
An alternative possibility was that CR4348 and CR4354 do
not bind a viral protein but instead inhibit WNV infection by
binding a host cell surface receptor and blocking attachment
and/or entry. However, if the neutralizing MAbs CR4348 and
CR4354 recognized a structural protein on the virion, they
should enhance infection in Fc-	 receptor-expressing cells
when the stoichiometry of binding falls below the neutraliza-
tion threshold (51, 66). The addition of subneutralizing con-
centrations of CR4348 and CR4354 to K562 cells that display
human CD32 (Fc-	RIIA) enhanced infection in a manner that
was analogous to that observed with Hu-E16 (Fig. 1D). This
experiment suggests that CR4348 and CR4354 recognized a
protein on the surface of the infectious virion.
To corroborate these findings, we used a capture ELISA to
measure the direct binding of CR4348 and CR4354 to SVP and
infectious WNV virions. Notably, CR4348 and CR4354 bound
to both SVP and infectious virus (P  0.002) (Fig. 2D). How-
ever, CR4348 and CR4354 did not bind to DENV particles,
consistent with their inability to neutralize these viruses in a
plaque reduction assay (data not shown). Thus, biochemical
and functional analyses suggested that CR4348 and CR4354
neutralize WNV by virtue of their ability to bind an epitope on
one of the viral structural proteins (M or E) that requires a
specific oligomeric arrangement present on virions or SVP.
Neutralization by CR4348 and CR4354 occurs primarily at
a postattachment step. Antibody neutralization of enveloped
viruses may occur by inhibiting receptor attachment, internal-
FIG. 1. Neutralization and enhancement of human MAbs. (A) PRNT50. Hu-E16, CR4348, CR4354, and an isotype control MAb (DENV1-
E50) were tested for neutralization activity by standard PRNT on BHK21-15 cells. The data shown are combined results of data for two
independent experiments performed in triplicate. The data are normalized to data from six control wells in each experiment with no MAb. (B and
C) RVP neutralization assay. Hu-E16, CR4348, and CR4354 were incubated with RVP prior to infection of Raji-DCSIGNR cells. RVP were
prepared normally (B) or with the T332K mutation in the E protein (C), which abrogates neutralization by virtually all DIII-lr MAbs. Data shown
are representative of data from three independent experiments performed in duplicate. Error bars represent standard deviations, and lines
represent curve fits generated by nonlinear regression analysis. (D) Hu-E16, CR4348, and CR4354 were tested for their abilities to enhance WNV
RVP infection of human CD32 (Fc-	RIIA)-expressing K562 cells. Data shown are representative of data from at least two experiments performed
in triplicate. Error bars represent standard deviations.
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FIG. 2. Binding of human MAbs to recombinant protein, SVP, and virions. (A) Yeast display assay. The WNV E protein ectodomain (Ecto-E)
(amino acids 1 to 415) (left) or DIII alone (amino acids 296 to 415) (right) was expressed on the surface of yeast cells; stained with CR4348 (dotted
lines), CR4354 (dashed lines), Hu-E16 (solid lines), or irrelevant human IgG1 (filled area) MAbs; and detected by flow cytometry. Data from one
representative experiment of three are shown. (B) ELISA. The ectodomain (amino acids 1 to 415) of the E protein was adsorbed onto microtiter
plates for 1 h at 37°C or overnight at 4°C. After blocking, wells were incubated with the indicated MAbs, and ELISA was performed as detailed
in Materials and Methods. Data shown are representative of data from three experiments performed in triplicate, with error bars representing
standard deviations. Abs, absorbance. (C) Western blot. The recombinant E protein ectodomain (39 kDa), SVP (glycosylated full-length E
protein) (44 kDa), or WNV virus (unglycosylated full-length E protein) (43 kDa) was assessed for binding by the indicated human MAbs to
the E or prM (15-kDa) protein. Samples were prepared in sodium dodecyl sulfate sample buffer with or without heating to 95°C and with or
without 5% (vol/vol) -mercaptoethanol (-ME). (D) A capture ELISA was used to detect binding of MAbs to WNV SVP (left) and virions (right).
Microtiter plates were coated with murine E16, incubated with SVP or virus, and detected with the indicated human IgG1 MAbs. Dashed lines
indicate the background of the assay with an isotype control MAb.
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ization, and/or endosomal fusion (63, 88). To determine the
stage of the viral entry pathway at which CR4348 and CR4354
inhibit infection, we performed pre- and postattachment neu-
tralization assays (11, 29, 57). CR4348 and CR4354 were in-
cubated with WNV before or after virus binding to a mono-
layer of Vero cells, and infection was measured by a plaque
reduction assay. As expected, CR4348 and CR4354 efficiently
neutralized infection when premixed with virus (Fig. 4A). Both
MAbs also inhibited WNV infection when added after virus
adsorption to the cell surface, indicating that at least part of
their neutralizing activity was at a postattachment step of the
viral life cycle. When added after attachment, CR4354 was
FIG. 3. Effect of virus maturation state on neutralization by CR4348 and CR4354. CR4348 (left) and CR4354 (right) were incubated with MAbs
prior to infection of Raji-DCSIGNR cells. RVP were prepared normally (mixture of mature, immature, and partially mature particles), in the
presence of NH4Cl (immature), or in cells overexpressing furin protease (mature) to create virions of different maturation states. These virions
were incubated with MAbs prior to infection of Raji-DCSIGNR cells. Data shown are combined results from three independent experiments
performed in duplicate.
FIG. 4. Mechanism of WNV neutralization by CR4348 and CR4354. (A) Pre- and postattachment inhibition assays. To determine whether the
MAbs neutralize WNV infection after cellular attachment, Vero cells were prechilled to 4°C, and 102 PFU of WNV were added to each well for
1 h at 4°C. After extensive washing at 4°C, the MAbs were added for 1 h at 4°C, and the PRNT protocol was then completed (dashed lines) (Post).
In comparison, a standard preincubation PRNT with all steps performed at 4°C is shown for reference. In this case, virus and MAb were incubated
together for 1 h at 4°C, prior to addition to cells (solid lines) (Pre). Data shown are representative of data from three experiments performed in
duplicate, with error bars representing standard deviations. (B) pH sensitivity of MAb binding to SVP. The capture ELISA protocol was modified
such that the pH was changed (pH 6.0 or 7.4) for 30 min immediately before captured SVP were detected by the indicated human IgG1 MAbs.
Data from one representative experiment of three performed in triplicate are shown, with error bars representing standard deviations. Dashed lines
indicate the background of the assay with an isotype control MAb. Abs, absorbance. (C and D) Fusion of pyrene-labeled WNV with liposomes.
(C) Pyrene-labeled WNV was incubated with or without 50 nM of the indicated MAbs for 1 h at room temperature prior to mixing with liposomes
and acidification at pH 6.3. Fusion was measured online, as described in Materials and Methods. Representative fusion data for at least three
independent experiments are shown. Curve a, no antibody; curve b, 50 nM isotype-matched control; curve c, 50 nM CR4348; curve d, 50 nM
CR4354. (D) Extent of WNV fusion with increasing concentrations of antibody. The extent of fusion was determined at 60 s upon acidification
and is shown as a percentage of the control (no antibody) (pH 6.3). White bars, isotype-matched control MAb; dark gray bars, CR4348; light gray
bars, CR4354. Representative fusion data for at least three independent experiments are shown.
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more potent than CR4348 in neutralizing infection. Impor-
tantly, no pre- or postattachment neutralization was detected
with a nonbinding isotype control, and a largely postattach-
ment pattern of inhibition was seen with Hu-E16 (Fig. 4A), as
observed previously (57).
pH sensitivity of CR4348 and CR4354 binding. The expo-
sure of flavivirus virions or SVP to acidic pH in solution or in
the endosome prompts a rapid structural rearrangement (7, 19,
49, 77). Given that CR4348 and CR4354 preferentially recog-
nize epitopes present on virions and SVP but not on recombi-
nant E proteins (Fig. 2), we hypothesized that changes in the
oligomeric arrangement of E that are associated with shifts in
pH might alter immunoreactivity. To test this, we used our
SVP capture ELISA, exposing particles to different pH (pH 6.0
or 7.4) conditions for 30 min prior to pH normalization (pH
7.4) and incubation with MAbs. Notably, our control neutral-
izing MAb, Hu-E16, did not show pH-sensitive binding (Fig.
4B). In contrast, the exposure of SVP to pH 6.0, which should
promote E protein rearrangement and irreversible trimer for-
mation, significantly reduced the levels of binding of both
CR4348 and CR4354 (P  0.003).
CR4348 and CR4354 inhibit WNV fusion. Since both
CR4348 and CR4354 have the capacity to neutralize WNV
infection at a postattachment step, we investigated whether
these MAbs would also affect WNV fusion. To evaluate this,
we utilized a model liposome fusion assay with pyrene-labeled
virus that was previously used to monitor the fusion dynamics
of TBEV (9, 19, 75–77). Briefly, pyrene-labeled WNV was
preincubated with different concentrations of MAbs for 1 h at
RT and then mixed with liposomes at 37°C. Fusion was trig-
gered by the acidification of the mixture to pH 6.3, which is the
optimal pH for WNV fusion (B. Moesker, J. Wilschut, and J.
Smit, unpublished observations). In the absence of antibodies
or in the presence of 50 nM (7.5 g/ml) of a nonbinding
control MAb, fusion was essentially complete within seconds
upon acidification. In contrast, preincubation of the virus with
CR4348 or CR4354 potently inhibited fusion activity (Fig. 4C).
Both MAbs reduced the extent of fusion in a dose-dependent
manner (Fig. 4D). CR4354 inhibited fusion at concentrations
of 1 nM (0.15 g/ml) and above, whereas for CR4348, a min-
imal concentration of 10 nM (1.5 g/ml) was required. This
difference in potency was also reflected in the maximum level
of fusion inhibition at saturating antibody concentrations.
CR4354 and CR4348 neutralized 85% and 65% of the
virus particles, respectively (Fig. 4D). Thus, in the model lipo-
some assay, CR4348 and CR4354 can block the low-pH-cata-
lyzed fusion of the majority of WNV virions; this supports the
idea that these MAbs act at a postattachment step. Nonethe-
less, even under conditions of saturating antibody concentra-
tions, a fraction of the virus particles resists complete inhibi-
tion by these MAbs, although the rate of fusion of the residual
fractions is substantially lower than that in the absence of
antibody.
Generation of neutralization escape mutants. Because
CR4348 and CR4354 recognized a determinant on the WNV
virion or SVP, which is not readily apparent on recombinant or
yeast-displayed forms of E, we generated neutralization escape
mutants to further define their epitopes. After three sequential
virus passages on Vero cells under CR4348 or CR4354 selec-
tion (25 g/ml), WNV was no longer neutralized by these
MAbs in plaque reduction assays (Fig. 5A). To determine the
mutations that conferred the escape phenotype, RNA se-
quences obtained from plaque-purified escape variants were
compared to the wild-type WNV sequence derived from virus
passaged in parallel in the absence of antibody selection. All
(five of five) sequences from CR4348 escape variants con-
tained the same single-nucleotide change encoding a T208I
mutation in the E protein; in addition, two of the five se-
quences also had an independent H246Y mutation in the E
protein. In contrast, all (15 of 15) CR4354 escape variants
contained a single-nucleotide mutation, encoding a K136E mu-
tation in the E protein; no other nucleotide changes were
observed in any of the CR4354 variants.
To establish that these amino acid substitutions conferred
the neutralization escape phenotypes observed, we utilized two
reverse-genetic systems. First, RVP with single amino acid
mutations were generated and analyzed for MAb neutraliza-
tion. Whereas Hu-E16 neutralized all mutant and wild-type
RVP equivalently, the T208I and K136E RVP were not effi-
ciently neutralized by CR4348 and CR4354, respectively, even
at concentrations of 15 g/ml of MAb (Fig. 5B). H246Y RVP
were neutralized by CR4348 but only at the highest doses of
antibody tested; the concentration at which 50% inhibition
(EC50) occurred was increased by 31-fold (P  0.02) com-
pared to that of wild-type RVP (Fig. 1B).
As an independent confirmation, we introduced these substi-
tutions into a wild-type, infectious New York 1999 WNV cDNA
clone (NY99ic) (5) to generate mutant viruses. Analogous results
were obtained with all genetically engineered mutant WNV and
MAbs using a plaque reduction assay on BHK21-15 cells (Fig.
5C). Thus, results of experiments with RVP and infectious cDNA
clones confirmed the sequencing results and suggest that CR4348
and CR4354 likely bind distinct epitopes on the WNV E protein.
To directly determine the contributions of these amino acids to
MAb binding, we used mutated NY99ic WNV in a capture
ELISA (Fig. 5D). As expected, Hu-E16 recognized all three vari-
ant viruses. CR4354 failed to bind to WNV with a K136E muta-
tion but did recognize the other viruses, establishing that a change
in K136 confers a loss-of-binding phenotype. In contrast, no de-
crease in the level of CR4348 binding was observed for the single
T208I or H246Y variant or a double T208I H246Y variant (data
not shown). Thus, these two individual mutations, which strongly
impact CR4348 neutralization, do not alter MAb binding in the
capture ELISA.
To gain a better understanding of why CR4348 and CR4354
recognized intact virions or subviral particles but not recombinant
E proteins, we mapped the residues that conferred escape from
MAb neutralization onto the existing WNV E protein crystal
structures (30, 58). K136, T208, and H246 are all solvent-acces-
sible residues (Fig. 6A). K136 is located at the end of DI adjacent
to the hinge between DI and DII. This hinge rotates 20° to 30°
during structural rearrangements of the E protein associated with
low-pH-induced viral fusion in late endosomes (7, 49). The flex-
ibility of the DI-DII hinge may be less dynamic on an icosahedral
virion or SVP than the soluble recombinant protein, possibly
explaining the differential reactivity of the CR4354 epitope. In
contrast, the conformationally sensitive nature of CR4348 binding
may be due to a preferential reactivity with WNV E protein
dimers. T208 and H246 are present in DII and, although relatively
distant (43 Å) within an individual E protein monomer, are
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separated by19 Å across the dimer interface, which is within the
spatial limits of an antibody footprint (Fig. 6B). It is important
that in contrast to the TBEV and DENV E proteins, which
readily form dimers in solution, the soluble WNV E protein is
largely monomeric (30, 58). Consistent with the mapping and
binding data that suggest that the two human MAbs recognize
distinct epitopes, CR4348 efficiently neutralized the K136E WNV
variant, and CR4354 inhibited infection of the T208I and H246P
variants (data not shown).
Given these mapping data, we hypothesized that CR4348
might recognize oligomeric forms of the E protein that are not
prevalent in our purified recombinant preparation. As men-
tioned above, ELISA plates coated with the WNV E protein
overnight at 4°C showed no immunoreactivity with either
CR4348 or CR4354 (Fig. 2B). However, coating plates with the
E protein at 37°C resulted in a modest yet significant signal by
CR4348, possibly due to oligomeric interactions between E
proteins that occur more favorably at a higher temperature,
prior to adsorption (Fig. 2B).
Phenotype of WNV variants in cell culture. Comparisons of
E protein amino acid sequences of WNV isolates that varied
geographically and temporally showed that T208 and H246
were completely conserved. K136 was completely conserved
among lineage 1 WNV isolates but varied in the less-virulent
lineage 2 and 3 strains, with alanine and serine substitutions,
respectively (data not shown). To evaluate whether the muta-
tions associated with the neutralization escape of CR4348 and
CR4354 were functionally important for virus replication and
FIG. 5. Characterization of neutralization escape mutants. (A) PRNT performed in duplicate with virus after three passages under selection
of either CR4348 (left) or CR4354 (right) on Vero cells. A reduced neutralization capacity was observed compared to that of Hu-E16. (B and C)
Confirmation of a resistant phenotype with reverse-genetic RVP or infectious cDNA clone assays. Mutated RVP (B) and infectious WNV (C) were
used to confirm that single amino acid substitutions of T208I (left), H246Y (middle), and K136E (right) in the E protein could reduce or eliminate
neutralization by the selecting MAb. In each series of experiments, the reduced neutralizing capacity of the indicated human MAb was compared
to the neutralizing capacity of Hu-E16, which maps to a distinct epitope on the DIII-lr. The data are combined data from two or three separate
experiments performed in duplicate or triplicate. Error bars indicate standard deviations. Lines represent curve fits generated by nonlinear
regression analysis. (D) A capture ELISA was used to detect the binding of MAbs to mutated (K136E, T208I, and H246Y) WNV virions.
Microtiter plates were coated with murine DIII-lr MAb, incubated with mutated virus, and detected with the indicated human IgG1 MAbs. Dashed
lines indicate the background of the assay with an isotype control human MAb. The data are representative of data from three separate
experiments performed in triplicate. Error bars indicate standard deviations. Abs, absorbance.
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affected viral virulence, growth analyses using BHK21-15 cells
was performed. The plaque morphologies of the three mutant
viruses (K136E, T208I, and H246Y) in BHK21-15 cells was
compared to that of wild-type WNV strain New York 1999.
The wild type and K136E and T208I variants had similar large-
plaque morphologies, whereas the H246Y mutant had a small-
plaque phenotype (data not shown).
In vivo protection studies. Passive transfer of neutralizing
MAbs against WNV confers protection against disease in mice
(22, 59, 61, 69, 78) and hamsters (53, 54). To evaluate the
potency of human MAbs, protection studies were performed
using wild-type C57BL/6 mice after infection with WNV-
NY99ic. Analogous to results with Hu-E16 (59), prophylaxis
with low (1.4 and 0.4 g, respectively) doses of CR4348 and
FIG. 6. Structural mapping of MAb epitopes. (A) WNV E protein dimer, with K136 (CR4354) in blue and T208 and H246 (CR4348) in
magenta. (B) Close-up view of the WNV E DII dimer interface, with the CR4348 epitope highlighted in magenta. (C) Surface display model of
the WNV E DI-DII hinge region with epitope recognition sites of CR4354 and the corresponding WNV residues of other antiflavivirus MAbs
(E113, 503, NARMA3, B2, and 4B6C-2) listed in Table 4. Note that residue 136 is labeled CR4354 but is also part of the 503 epitope, and residue
126 is labeled B2 but is also part of the 503 and 4B6C-2 epitopes.
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CR4354 completely protected mice against lethal WNV en-
cephalitis (Table 1). No protective effect was observed in these
or other previously reported studies (17, 59, 78) using isotype
control antibodies.
To characterize the protective activity of the more potent of
the two neutralizing MAbs, CR4354, in greater detail, infec-
tion studies with wild-type and K136E escape variant WNV
were repeated using highly susceptible 3- to 4-week-old NIH
Swiss mice (Table 2); this strain was selected because WNV
morbidity and mortality show a linear virus dose dependence
(4). Consistent with the cell culture plaque morphology data,
the lethalities of wild-type and K136E WNV-NY99ic were not
different, with 50% lethal dose values of 0.28 and 0.24 PFU,
respectively (P 0.8). Sequencing of viral RNA from brains of
mice infected with wild-type or K136E variant WNV-NY99ic
revealed no amino acid changes: WNV in the brain after in-
fection with wild-type and mutant viruses contained K and E
residues at position 136, respectively (data not shown). To
confirm the neutralization escape phenotype, mice were pre-
treated with 50 g (100 times the minimum protective dose
in C57BL/6 mice) of CR4354 MAb 1 day prior to infection with
3  101 PFU of wild-type or K136E variant WNV-NY99ic.
CR4354 protected 94% (15 of 16) of mice from wild-type
NY99ic challenge, whereas only 19% (3 of 16) of mice chal-
lenged with K136E-NY99ic survived despite CR4354 prophy-
laxis. In contrast, Hu-E16 protected nearly all mice after in-
fection with either the wild type or K136E-NY99ic.
Collectively, these data confirm the highly protective activity of
CR4354 in vivo and the CR4354 escape phenotype of the
K136E mutation.
DISCUSSION
Previous studies suggested that antibodies that map to the
DIII-lr epitope do not account for the majority of neutralizing
activity in serum from human patients or horses (60, 70). In
this study, we characterized the functional properties of two
neutralizing human MAbs, CR4348 and CR4354, that recog-
nize distinct epitopes. Both MAbs inhibit WNV infection in
vitro and in vivo but did not recognize closely or distantly
related flaviviruses, including St. Louis encephalitis virus or
DENV (M. Throsby, M. Vogt, and M. Diamond, unpublished
results). Biochemical studies demonstrate that these MAbs
have similar but not identical profiles: they bind to conforma-
tionally sensitive epitopes on E proteins displayed on virions or
SVP in a pH-sensitive manner but recognize recombinant E
proteins in solution or displayed on the surface of yeast poorly,
if at all. Functional experiments suggest that both human
MAbs neutralize infection primarily at a postattachment stage
in the viral life cycle, specifically through the inhibition of viral
fusion with the endosomal membrane.
The CR4354 recognition site was established by neutraliza-
tion escape and reverse-genetic experiments and localized to
the DI-DII hinge interface at residue K136. This hinge is highly
flexible, as the angle between DI and DII on DENV E rotates
27° during the transition from the immature to the mature
state after the furin-mediated cleavage of prM (87). The hinge
then rotates back 30° during the prefusion-to-postfusion do-
main rearrangement (7, 49). Two X-ray crystal structures of
similarly prepared WNV E proteins also have distinct DI-DII
hinge angles, differing by 5° (30, 58). This inherent flexibility of
the DI-DII hinge could explain the lack of CR4354 binding to
soluble and yeast surface-displayed E, as these recombinant E
proteins may not display the native hinge that is found on
virions or SVP. Indeed, the exposure of SVP to acidic condi-
tions that alter the DI-DII hinge angle significantly reduced
the level of binding of CR4354.
Although the characteristics of CR4354 appear relatively
unique among anti-WNV MAbs, several other antiflavivirus
neutralizing MAbs that localize to this region have been de-
scribed (Table 3). The anti-WNV MAb that maps closest to
this region is mouse MAb E113, which binds a determinant
along the DI-DII hinge interface at residues E49 and K208
(Fig. 6C). E113 is protective in vitro (EC50 of 0.25 g/ml)
and in vivo, but unlike CR4354, E113 binds recombinant and
yeast-displayed E proteins efficiently (61). The importance of
this epitope for antibody neutralization is reflected by the
characterization of several DI-DII-inhibitory antiflavivirus
MAbs. Notably, MAbs (503, NARMA3, and B2) that recog-
nize the DI-DII hinge are strongly inhibitory against the closely
TABLE 1. Effect of MAb pretreatment on survival of
C57BL/6 miceb
MAb Dose (g) No. of survivors/total no. of mice % Survival P value
a
PBS 4/20 20
CR4348 14 4/4 100 0.01
CR4348 4.2 5/5 100 0.01
CR4348 1.4 5/5 100 0.01
CR4348 0.42 3/5 60 0.13
CR4348 0.14 3/5 60 0.10
CR4348 0.042 2/5 40 0.31
CR4348 0.014 1/5 20 0.70
CR4354 14 5/5 100 0.01
CR4354 4.2 5/5 100 0.01
CR4354 1.4 5/5 100 0.01
CR4354 0.42 5/5 100 0.01
CR4354 0.14 4/5 80 0.02
CR4354 0.042 2/5 40 0.21
CR4354 0.014 1/5 20 0.57
a P values were determined using the log-rank test and are compared to the
PBS controls.
b C57BL/6 mice were pretreated with the indicated dose of human MAb at
day 1 by intraperitoneal injection. On day 0, mice were infected with WNV by
the subcutaneous route and monitored for survival.
TABLE 2. Effect of the K136E substitution on MAb protection of
NIH Swiss miceb
MAb NY99ic WNV No. of survivors/total no. of mice % Survival P value
a
PBS Wild type 4/16 25
Hu-E16 Wild type 16/16 100 0.0001
CR4354 Wild type 15/16 94 0.0001
PBS K136E 1/16 6
Hu-E16 K136E 15/16 94 0.0001
CR4354 K136E 3/16 19 0.37
a P values were determined using the log-rank test and compared to the PBS
controls for each virus.
b NIH Swiss mice were pretreated with 50 g of human MAb (Hu-E16 or
CR4354) at day 1. On day 0, mice were infected with 3  101 PFU/mouse of
wild-type NY99ic or K136E-NY99ic virus and monitored for survival.
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related JEV, which is a member of the same serogroup as
WNV (21, 27, 35, 52).
Neutralization escape experiments suggested that T208 and
H246 are recognition sites near the DII dimer interface for
MAb CR4348. The importance of these residues for neutral-
ization was confirmed using reverse-genetic approaches by in-
troducing these mutations into WNV RVP and the infectious
cDNA clone. Although the mutation of these two residues
abolished neutralization, they did not prevent MAb CR4348
binding in capture ELISAs, suggesting that other amino acids
that were not revealed in our selection experiments contribute
to the epitope. While T208 and H246 lie spatially far apart
(43 Å) within the E monomer, likely beyond the footprint of
the antibody paratope, they reside significantly closer (19 Å)
across the dimer interface. Thus, CR4348 may recognize an
epitope that is sensitive to the oligomeric state of the E pro-
tein. Consistent with this, CR4348 does not stably bind WNV
E on yeast cells or in the solid phase when adsorbed at a low
temperature (4°C). However, when WNV E was adsorbed onto
microtiter plates at 37°C, we reproducibly observed modest
levels of binding. Furthermore, CR4348 binds poorly to SVP
that have been exposed to mildly acidic solutions; a decrease in
pH induces a structural rearrangement in flavivirus E proteins,
resulting in dimer dissociation and trimer formation (7, 49).
The CR4348 MAb epitope is structurally and functionally
unique among characterized anti-WNV MAbs. Although
CR4348 recognizes residues at the DII dimer interface that are
proximal to mouse anti-WNV E MAb E100 (61), the two differ
in several respects: E100 maps more distal from DI at residue
H263, only modestly neutralizes WNV in cell culture (EC50 
10 g/ml), recognizes both soluble and yeast forms of E, and
shows a quite limited protective efficacy against lethal WNV
infection in mice. However, a DII dimer interface MAb with
more-similar properties for the distantly related flavivirus
TBEV has been described (Table 4). MAb A5 (26) maps to
residue E207 along the dimer interface (45), is strongly neu-
tralizing in culture (26), and partially blocks TBEV fusion in a
pyrene excimer liposome fusion assay (74). Moreover, the
binding of at least some cross-reactive neutralizing flavivirus
MAbs (e.g., 4G2 and 6B6C-1) that map to the fusion peptide
in DII are also affected by mutations of residues (E231) along
a dimer interface (10). One speculation as to why so few MAbs
with these functional properties have been described is that
they may not be identified with screens or immunization pro-
tocols using recombinant E proteins.
One limitation to mapping analyses by neutralization es-
cape, which may be important for MAbs that show a loss of
function with mutations in a flexible hinge, is the inability to
exclude a distal binding site that is modulated allosterically by
the hinge. A lack of binding to yeast or soluble E could reflect
that these recombinant forms of E are truncated at amino acid
415 and lack the C-terminal stem-anchor and transmembrane
regions. The lack of an identification of an escape mutant in
the highly conserved C-terminal regions could be due to a poor
viability of these variants. Unfortunately, because these MAbs
bind poorly to recombinant E proteins, cocrystallography (44,
57), nuclear magnetic resonance (82), or saturation mutagen-
esis (23, 24, 46) approaches to identify the structural epitope
are not possible. Instead, cryo-electron microscopy studies with
Fab-virion complexes (31, 44) are planned to confirm the lo-
cation of the epitope on the virion. Such experiments will be
especially important for MAbs like CR4348, which shows a loss
of neutralization but not binding with mutations at the DII
dimer interface.
We previously described E16, a strongly neutralizing WNV-
specific mouse MAb that maps to the DIII-lr of the E protein
(59) and inhibits infection by blocking viral membrane fusion
in endosomes (B. Thompson, B. Moesker, J. Wilschut, J. Smit,
TABLE 3. Flavivirus MAbs that localize to the DI-DII hinge interface
MAb Virus Epitope(s) Immunogen(s) Source ofMAb
Neutralizationa
Reference(s)
In vitro In vivo
CR4354 WNV K136 Natural infection Human   78, this paper
E113 WNV E49, K280 Infectious virus 
recombinant E protein
Mouse   61
503 JEV S275, K136, I126 Infectious virus Mouse   34, 35, 52
NARMA3 JEV Q52 Infectious virus Mouse  ND 27, 37





Purified virus Mouse   28, 47
a , greater than 90% inhibition via any in vitro assay or capable of 90% protection in any lethal in vivo model; , any significant in vitro neutralization or in vivo
protective capacity; ND, not determined.
TABLE 4. Flavivirus MAbs that localize to the DII dimer interface
MAb Virus Epitope(s) Immunogen(s) Source of MAb
Neutralizationa
Reference(s)
In vitro In vivo
CR4348 WNV T208, H246 Natural infection Human   78, this study
E100 WNV H263 Infectious virus  purified E Mouse   61
A5 TBEV E207 Solubilized virus Mouse  ND 26, 45
a , greater than 90% inhibition via any in vitro assay or capable of 90% protection in any lethal in vivo model; , any significant in vitro neutralization or in vivo
protective capacity; ND, not determined.
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M. Diamond, and D. Fremont, unpublished data). Although
CR4348 and CR4354 also strongly neutralize infection and
affect a postattachment step in the viral life cycle, they likely
inhibit WNV by a mechanism distinct from that of E16.
CR4354 appeared to inhibit infection almost equivalently
when it was added before or after attachment. In contrast,
CR4348 and E16 showed somewhat enhanced neutralizing ac-
tivity when added prior to attachment. Moreover, in the lipo-
somal model system, E16 completely blocked fusion at differ-
ent pH values ranging from pH 6.3 to 5.0, consistent with
ELISA and surface plasmon resonance data showing pH-inde-
pendent binding of E16 to SVP (Thompson et al., unpub-
lished). In contrast, CR4354 and CR4348 do not completely
block low-pH-induced fusion of the virus with liposomes, with
some residual fusion activity observed. This residual fusogenic
activity in the setting of saturating concentrations of CR4354
and CR4348 may be due to heterogeneity among the WNV
virions. Indeed, we also observed a small resistant fraction of
virions in classical PRNT50 analyses under conditions of anti-
body saturation, with 10% and 20% of the virus remaining
infectious in the presence of high concentrations of CR4354
and CR4348, respectively (Fig. 1A). At present, the molecular
basis for the differences in residual infectivity or fusogenic
activity of the two experimental systems under conditions of an
excess of CR4354 and CR4348 remains uncertain. The residual
nonneutralized fractions, however, are not likely related to the
maturation stage of the virus (56), since mature and partially
immature WNV RVP are neutralized equivalently by these
MAbs. More-detailed analyses of antibody-virion structures
and the precise pH dependency of the inhibition are planned
to further define the mechanisms of neutralization.
For WNV and other flaviviruses, passive immunotherapy
has been shown to protect small animals against lethal infec-
tion even when administered several days after infection (22,
59, 68). As recent studies suggested that resistance to mono-
therapy with MAb E16 can occur in vivo (84), the use of
combinations of neutralizing MAbs that recognize distinct
epitopes may be advantageous, as was demonstrated previously
for a therapeutic antibody cocktail against rabies virus (2). The
characterization of potently neutralizing MAbs like CR4348
and CR4354 that map to distinct regions and inhibit virus by
different mechanisms suggests that this may be feasible.
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Previous studies have established that an epitope on the lateral ridge of domain III (DIII-lr) of West Nile
virus (WNV) envelope (E) protein is recognized by strongly neutralizing type-specific antibodies. In contrast,
an epitope against the fusion loop in domain II (DII-fl) is recognized by flavivirus cross-reactive antibodies
with less neutralizing potential. Using gain- and loss-of-function E proteins and wild-type and variant WNV
reporter virus particles, we evaluated the expression pattern and activity of antibodies against the DIII-lr and
DII-fl epitopes in mouse and human serum after WNV infection. In mice, immunoglobulin M (IgM) antibodies
to the DIII-lr epitope were detected at low levels at day 6 after infection. However, compared to IgG responses
against other epitopes in DI and DII, which were readily detected at day 8, the development of IgG against
DIII-lr epitope was delayed and did not appear consistently until day 15. This late time point is notable since
almost all death after WNV infection in mice occurs by day 12. Nonetheless, at later time points, DIII-lr
antibodies accumulated and comprised a significant fraction of the DIII-specific IgG response. In sera from
infected humans, DIII-lr antibodies were detected at low levels and did not correlate with clinical outcome. In
contrast, antibodies to the DII-fl were detected in all human serum samples and encompassed a significant
percentage of the anti-E protein response. Our experiments suggest that the highly neutralizing DIII-lr IgG
antibodies have little significant role in primary infection and that the antibody response of humans may be
skewed toward the induction of cross-reactive, less-neutralizing antibodies.
West Nile virus (WNV) is a neurotropic, positive-sense
RNA virus that has become endemic to North America (28).
WNV is a member of the Flaviviridae family of viruses, along
with other important human pathogens such as dengue virus
(DENV), Japanese encephalitis virus, tick-borne encephalitis
virus, and yellow fever virus. Although most cases of WNV
infection are asymptomatic, it can cause severe encephalitis
and death in immunocompromised or elderly individuals (39).
At present, treatment is supportive, with no specific therapy or
vaccine available for human use.
The WNV genome encodes three structural (capsid [C],
premembrane/membrane [prM/M], and envelope [E]) and
seven nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B,
and NS5) proteins. The E proteins of flaviviruses, including
WNV, have three domains and form head-to-tail homodimers
on the surface of the mature virion (27, 38). Domain I (DI) is
the central structural domain and consists of a 10-stranded
-barrel. Domain II (DII) is formed from two extended loops
that project from DI. At the end of DII is a highly conserved
loop, amino acid residues 98 to 110, that has been implicated
in the acid catalyzed type II fusion event (1, 9, 35). DIII,
located on the opposite side of DI, adopts a seven-stranded
immunoglobulin-like fold and has been implicated in cellular
attachment (8, 12, 14). Short, flexible linker regions connect
the domains and allow for the conformational changes associ-
ated with virus maturation and fusion (60).
Neutralizing antibodies are essential for the control of WNV
infection in vivo (6, 16–18, 20, 44, 45). Specific amino acid
residues have been defined that are critical for the binding of
DII- and DIII-specific neutralizing monoclonal antibodies
(MAbs) against WNV (4, 10, 44, 50). Using X-ray crystallog-
raphy, the structure of a strongly neutralizing DIII-specific
MAb, E16, was determined in complex with DIII (42). The
binding epitope consisted of four discontinuous loops along
the lateral ridge of DIII (DIII-lr). Introduction of mutations at
the core residues of the DIII-lr epitope (residues S306, K307,
T330, and T332) reduced or abrogated binding of not only E16
but also all other DIII-specific, strongly neutralizing MAbs (4,
44, 50). The fusion loop within DII elicits cross-reactive anti-
bodies with relatively weak inhibitory activity; recent mapping
studies have defined the core residues of this epitope as W101,
G106, and L107 (13, 19, 45, 51). Whereas DIII-lr MAbs neu-
tralize potently in all cells tested, DII-fl MAbs inhibit to a
lesser degree and not on all cell types. Accordingly, MAbs
against the DII-fl were less effective than DIII-lr MAbs at
preventing or treating WNV infection in vivo (20, 45).
Study of the epitope specificity of the humoral response
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during the course of flavivirus infection has begun to explain
the protective capacity of antibodies in vivo. In serum from
convalescent horses, the levels of DIII-lr antibodies were low,
but in some cases correlated with neutralizing activity (49).
However, a recent report that evaluated 138 human MAbs
derived from three convalescent WNV-infected patients
showed that 92% of the E-specific MAbs were non-neutraliz-
ing and reacted with regions outside of DIII (52). Consistent
with this, immune serum from DENV-infected patients
showed reduced binding to tick-borne encephalitis virus sub-
viral particles that contained mutations in DII at position L107
in the fusion loop (51). These latter experiments suggest that
the human immune response may be directed away from gen-
erating antibodies to the highly protective DIII-lr epitope. In
this report, using gain- and loss-of-function E protein variants,
we evaluated the kinetics of development DIII-lr and DII-fl
antibodies in mice and compared this to serum from humans
after WNV infection. Our experiments suggest that induction
of the highly neutralizing DIII-lr immunoglobulin G (IgG)
antibodies is delayed in mice and variable in humans after
WNV infection. Moreover, in humans, antibody responses ap-
pear to be skewed toward the induction of less-neutralizing
DII-fl-specific antibodies.
MATERIALS AND METHODS
Cloning and protein expression. The WNV E ectodomain (residues 1 to 404)
and DIII (residues 296 to 404) of the New York 1999 strain were amplified from
an infectious cDNA clone (5) by high-fidelity Platinum Taq PCR (Invitrogen).
The PCR product was cloned into the pET21a bacterial expression plasmid
(EMD Biosciences, San Diego, CA) using flanking NdeI and XhoI restriction
sites. The mutations K307E and T330I were introduced into the DIII construct
iteratively, and the mutation W101R was introduced into the E ectodomain by
using a QuikChange mutagenesis kit (Stratagene, La Jolla, CA) according to the
manufacturer’s instructions. All mutations were confirmed by bidirectional se-
quencing.
The generation of a WNV-DENV2 DIII chimera was accomplished by trans-
planting the WNV DIII-lr epitope onto the DENV2 DIII backbone. Amino acid
exchange was informed by X-ray crystal structures of WNV-E (41), DENV-2 E
(34), and the E16-WNV DIII complex (42). To construct the WNV-DENV2
DIII chimeric protein, we swapped all four segments of WNV DIII that are
directly contacted by the E16 Fab, as defined by interactions within a 4-Å
distance (42). Specifically, we transposed residues that compose the N-terminal
linker (WNV positions 303 to 308), BC loop (positions 330 to 334), DE loop
(positions 363 to 370), and the FG loop (positions 388 to 391). Two of the sixteen
directly contacted DIII residues are conserved between WNV and DENV2 (Tyr
302 and Gly 331). We also included 8 WNV residues (303, 304, 334, 363, 364, 369,
370, and 388) that flank the E16 epitope to increase the chances of mimicking the
wild-type loop conformations and provide chemical similarity to the neighboring
regions. To transplant the WNV DIII-lr epitope, we used in vitro oligonucleotide
assembly PCR (21). A series of overlapping primers (Table 1) that encoded for
a WNV-DENV2 DIII chimera with flanking NdeI and XhoI restriction sites was
designed by using the program DNAWorks (http://helixweb.nih.gov/dnaworks).
The resultant PCR fragment was digested and cloned into the pET21a vector.
All constructs were expressed in Escherichia coli and purified by using an
oxidative refolding protocol as described previously (44). Briefly, the cDNA
plasmids were transformed into BL21 Codon Plus E. coli cells (Stratagene),
grown in Luria broth, and protein expression was induced for 4 h with 1 mM
IPTG (isopropyl--D-thiogalactopyranoside) at 37°C. Inclusion bodies contain-
ing insoluble aggregates were denatured in the presence of 6 M guanidine
hydrochloride and 20 mM -mercaptoethanol and refolded in the presence of
400 mM L-arginine, 100 mM Tris-base (pH 8.0), 2 mM EDTA, 0.2 mM phenyl-
methylsulfonyl fluoride, and 5 and 0.5 mM reduced and oxidized glutathione,
respectively. Refolded protein was separated from aggregates on a Superdex 75
or 200, 16/60 size-exclusion column using fast-protein liquid chromatography
(GE Healthcare, Piscataway, NJ).
Protein characterization. Recombinant proteins (DIII, WNV-DENV2 DIII
chimera, E ectodomain, and E ectodomain W101R) were confirmed as appro-
priately folded and disulfide bonded in the following manner: (i) elution as a
monodispersed peak at the appropriate size on a gel filtration column (data not
shown); (ii) immunoreactivity with all expected MAbs based on parallel yeast
surface display studies with DIII and E protein mutants and chimera (Fig. 1B and
4A; also data not shown); (iii) mass spectrometry at the W. M. Keck Facility
(Yale University, New Haven, CT)—for the wild-type DIII and WNV-DENV2
DIII chimera average molecular weights of 11,723 and 13,258, respectively, were
measured, a finding consistent with disulfide bond formation; (iv) circular di-
chroism spectroscopy; and (v) crystallographic analysis.
The circular dichroism spectroscopy was recorded on a Jasco J-720 spectropo-
larimeter after all proteins were buffer exchanged into a solution with 20 mM
NaF and 10 mM sodium phosphate (pH 7.0). Measurements were taken in the
far-UV region (180 to 260 nm) in a quartz cell with a path length of 0.01 cm.
Protein secondary structure was calculated by using the CONTINLL or CDSSTR
software (available at http://lamar.colostate.edu/sreeram/CDPro). The loss-of-
function (K307E/T330I) and gain-of-function (WNV-DV2 DIII chimera) pro-
teins were within 2.9% of -strand and 0.4% -helix compositions of wild-type
WNV DIII or DV2 DIII. Variation for all DIII proteins was less than 5% for
-strand and 4% for -helix from the DSSP (for definition of secondary structure
of proteins given a set of three-dimensional coordinates) values calculated from
the X-ray crystal structures. Wild-type and W101R E proteins had the same
calculated circular dichroism values for both -helix and -strand structure
content. The variation for these was less than 5% for -strand and 6.4% for
-helix from the DSSP values calculated from the X-ray crystal structure. The
crystallographic analysis was performed for E. coli-derived wild-type WNV DIII
and E proteins (42; data not shown).
SPR. Surface plasmon resonance (SPR) experiments were performed on a
BIAcore2000 (Biacore) at 25°C with 150 mM NaCl, 3 mM EDTA, 15 mM
HEPES (pH 7.5), and 0.005% (vol/vol) Tween 20 as the flow buffer. Antibody
was coupled to Biacore CM5 chips after sequential treatment with 0.2 M N-ethyl-
N-(dimethylaminopropyl)carbodi-imide (EDC) and 50 N-hydroxysuccinimide
ester for 7 min, E16 or E9 anti-WNV MAbs (44) dissolved in 20 mM sodium
citrate (pH 4.5), and 1 M ethanolamine-HCl (pH 8.0). Baselines were stabilized
after three injections of 0.1% sodium dodecyl sulfate in flow buffer for 1 min
each. Flow rates of 80 l/min with WNV DIII or WNV-DENV2 DIII chimera
were used during analysis. Injection of 20 mM glycine (pH 3.0) was used to
regenerate the chip after each injection. Each experiment was performed in
triplicate and the koff and kon values were obtained by global curve fitting of the
Langmuir model in the program Clamp (http://www.cores.utah.edu/interaction
/clamp.html).
Mouse experiments. Mouse studies were approved and performed according
to the guidelines of the Washington University School of Medicine Animal
Safety Committee. Eight-week-old wild-type C57BL/6 mice were purchased
commercially (Jackson Laboratories, Bar Harbor, ME) and inoculated with 102
PFU of WNV subcutaneously via the footpad after anesthetization with xylazine
and ketamine. Sera were collected from groups of mice at different times after
infection, heat inactivated at 56°C for 30 min, and stored as aliquots at 80°C.
Human serum collection and human MAbs. Serum was obtained from con-
valescent patients who were participating in a longitudinal study of WNV infec-
tion 4 to 6 months after the onset of symptoms (ranging from fever to neuroin-
TABLE 1. Primers used to generate the WNV-DENV2 DIII-lr
chimeric protein
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vasive disease). The Research Ethics Board at McMaster University approved
this human trial. The human MAbs against WNV were obtained from three
convalescent patients by using phage display screening and were previously
described (52).
Serologic analysis. Endpoint titers for mouse and human serum were deter-
mined by using a WNV protein enzyme-linked immunosorbent assay (ELISA) as
described previously (32), with the following modifications. To measure DIII-lr-
specific antibodies, two separate ELISAs with a loss-of-function (DIII-K307E/
T330I) or gain-of-function (WNV-DENV2 DIII chimera) protein were per-
formed.
For the ELISA with a loss-of-function DIII, wild-type DIII or DIII-K307E/
T330I was diluted to 5 g/ml in 0.1 M sodium carbonate buffer (pH 9.3) and
adsorbed on 96-well Maxi-Sorp microtiter plates (Nalge Nunc, Rochester, NY)
overnight at 4°C. After blocking with phosphate-buffered saline (PBS), 2% bo-
vine serum albumin (BSA), and 0.05% Tween 20 (PBS-BT) for 1 h at 37°C,
fourfold serial dilutions of serum in PBS-BT were incubated for 1 h at room
temperature. Plates were washed with PBS plus 0.05% Tween 20 and incubated
with either biotin-conjugated goat anti-mouse IgG or IgM (1 g/ml; Sigma-
Aldrich) or biotin-conjugated goat anti-human IgG (0.3 g/ml; Sigma-Aldrich)
for 1 h at room temperature. After being washed, all plates were incubated with
streptavidin-horseradish peroxidase (2 g/ml; Zymed) for 1 h at room temper-
ature and developed with tetramethylbenzidine substrate (Dako, Carpinteria,
CA). After the addition of 1 N H2SO4, the optical density at 450 nm was
measured and adjusted for background by subtracting the optical density at 450
nm of blocked control wells. Best-fit lines were calculated, and endpoint titers
were determined as three standard deviation units above the background signal
by using GraphPad Prism 4 (GraphPad Software, Inc., San Diego, CA). The level
of DII-fl MAbs was measured in an identical manner using the wild-type E
protein and a W101R mutant E. In all cases, a MAb, E9, or a previously defined
serum sample was used to control for site density of the proteins as well as
plate-to-plate variation.
For the ELISA with a gain-of-function WNV-DENV2 DIII chimera, E111, a
DIII-specific flavivirus cross-reactive mouse IgG2a (45) was diluted to 10 g/ml
in sodium carbonate buffer and adsorbed overnight at 4°C. After blocking,
DENV2 DIII, WNV-DENV2 DIII chimera, or BSA (10 g/ml) was incubated
for 1 h at room temperature. Subsequently, plates were incubated with fourfold
serial dilutions of human serum, biotin-conjugated goat anti-human IgG, and
streptavidin-horseradish peroxidase. Plates were developed, and titers were de-
termined as described above.
WNV RVP and neutralization assays. Neutralization assays were performed
according to a previously described protocol (46) using wild-type and mutant
WNV reporter virus particles (RVP). Briefly, WNV RVP were produced by
transfection of BHK21 cells that stably propagate a green fluorescent protein-
expressing lineage II WNV replicon (46) with DNA plasmids encoding the
wild-type or mutant (T332K) structural genes of WNV New York 1999 as
described previously (46). RVP were harvested at 48 h after transfection, filtered
through a 0.22-m-pore-size filter, and frozen in aliquots at 80°C.
Neutralization assays were performed with the B-lymphoblastoid cell line Raji
that stably expresses the C-type lectin and the WNV attachment ligand,
DC-SIGNR (Raji-R) (47). To measure neutralization potential of the mouse and
human serum samples, WNV RVP stocks were diluted and incubated with nine
threefold dilutions in duplicate of heat-inactivated serum for 60 min at room
temperature (in a 200-l volume). For the human MAb dose-response experi-
ment, 19 twofold dilutions of antibody in triplicate were performed. Antibody-
RVP complexes were then added to preplated cells (5  104 cells per well of
96-well plate in a 300-l total volume). Infection was measured by flow cytometry
at 48 h postinfection. At least 5  104 events were collected at each point. The
50% effective concentration (EC50) of each serum preparation was predicted by
nonlinear regression analysis using a variable slope (GraphPad Prism 4).
Yeast expression and staining. Yeast expressing wild-type DIII or variants
were generated and stained as described previously (44). Briefly, human MAbs
were diluted to 50 g/ml in PBS plus 1 mg of BSA/ml (PBS-BSA) and then
incubated on ice for 30 min. The cells were washed three times with PBS-BSA
and incubated with a 1/500 dilution of goat anti-human IgG conjugated to Alexa
Fluor 647 (Invitrogen) for 30 min on ice. Yeast cells were analyzed with a Becton
Dickinson FACSCalibur flow cytometer.
RESULTS
Mouse antibody response against DIII-lr epitope. Previous
studies have defined epitopes on the DIII-lr and the DII-fl of
WNV E protein that elicit type-specific and cross-reactive neu-
tralizing MAbs, respectively (4, 10, 13, 44, 45, 50, 59). Although
MAbs mapping to the DIII-lr have potent inhibitory capacity
in passive transfer prophylaxis and therapeutic models in vivo
(37, 44), their function during the course of natural infection
remains uncertain. Indeed, a recent study demonstrated that
the antibody response to this epitope in single serum samples
from acutely infected horses was variable, with some animals
having little antibody that recognized the DIII-lr epitope (49).
To determine the kinetics of the antibody response against the
DIII-lr neutralizing epitope in mice, we developed an ELISA
using loss-of-function and gain-of-function DIII variants.
Initially, a loss-of-function variant was generated with WNV
DIII incorporating mutations at K307E and T330I (Fig. 1).
These residues were identified as critical amino acid contacts
for DIII-lr neutralizing MAbs using yeast surface display map-
ping (44), X-ray crystallography (42), sequencing of neutral-
ization escape mutants (4, 10), and site-specific substitutions
(50). Mutation of these two residues in tandem eliminated
binding of 10 potently neutralizing DIII-specific MAbs without
reducing the binding of 10 other non-neutralizing DIII-specific
MAbs (Fig. 1B). As an independent test, we engineered a
gain-of-function WNV-DENV2 DIII chimera in which the E16
FIG. 1. Expression of loss- and gain-of-function of DIII variant proteins. (A) Sodium dodecyl sulfate–10% polyacrylamide gel electrophoresis
showing the recombinant E proteins after purification. (B) ELISA comparing binding of MAbs to either the wild-type or K307E/T330I mutant
protein. (C) Ribbon diagram of the WNV E DIII protein. The 23 residues that were transferred to the DENV2 DIII backbone are shown in blue,
and the two residues mutated, K307 and T330, are shown in magenta.
11830 OLIPHANT ET AL. J. VIROL.
MAb neutralizing epitope (corresponding to amino acid resi-
dues in the N-terminal linker, BC, DE, and FG loops of DIII
as defined by X-ray crystallography) (42) was transplanted in
its entirety onto the DENV2 DIII (Fig. 1C). Among the 23
amino acids that were swapped, 8 residues (303, 304, 334, 363,
364, 369, 370, and 388) that are not directly involved in E16
binding were also transferred to maintain conformational sta-
bility. The loss- and gain-of-function DIII proteins folded as
expected and had wild-type disulfide binding and secondary
structure elements as judged by circular dichroism, mass spec-
trometry, and size exclusion chromatography (see Materials
and Methods). To establish the immunoreactivity of the chi-
meric protein, we compared binding of a WNV-specific neu-
tralizing DIII-lr MAb (E16) and WNV-specific poorly neutral-
izing DIII MAb (E9) that maps outside of the DIII-lr epitope
near residue H396 (44). An SPR assay demonstrated that E16
bound both wild-type and chimeric DIII with comparable af-
finity (4.4 nM versus 9.8 nM). As predicted, E9 bound the
wild-type DIII (240 nM) but not the WNV-DENV2 DIII chi-
mera (Table 2). Neither E16 nor E9 demonstrated appreciable
binding to wild-type DENV2 DIII when assayed in parallel
(data not shown).
Studies with mice lacking soluble IgM have established that
the early WNV-specific IgM response is critical for limiting
virus dissemination to the central nervous system (17). WNV-
specific IgM is routinely detected beginning at day 4, whereas
WNV-specific IgG does not appear until day 8 after infection
(16, 32). To examine the contribution of the DIII-lr epitope to
the neutralizing response, we analyzed by ELISA the WNV-
specific antibody reactivity over time (days 6, 8, 10, 15, 20, 30,
and 90 after mouse infection) with the wild-type, loss-of-func-
tion (DIII-K307E/T330I), and gain-of-function (WNV-
DENV2 DIII chimera) proteins. In addition, at day 30 a group
of mice was boosted with 104 PFU WNV, and sera were ana-
lyzed 7 days later to assess an early memory response to the
DIII-lr epitope. To maintain proper conformation of the
WNV-DENV2 chimera in the solid phase, it was necessary to
capture the protein with a mouse IgG MAb, E111; thus, anal-
ysis of mouse antibodies with this variant was limited to WNV-
specific IgM. In each case, antibody reactivity was compared to
an internal control protein for the particular assay (loss-of-
function assay, wild-type WNV DIII; gain-of-function assay,
wild-type DENV2 DIII).
Consistent with previous findings (16, 32), IgM that recog-
nized WNV E ectodomain peaked 8 days after infection and
then declined rapidly (Fig. 2A). In contrast, the DIII-specific
IgM response was relatively constant and significantly lower
than the E titer throughout the time course and comprised 10
to 25% of the overall WNV-specific IgM response. Interest-
ingly, low levels (endpoint titers of 1/40) of IgM antibody
bound to DIII in naive serum, likely reflecting the reactivity of
natural IgM to WNV, analogous to results observed for vesic-
ular stomatitis, lymphocytic choriomeningitis, and influenza
viruses (3, 43). When the levels of IgM were compared be-
FIG. 2. Detection of IgM against DIII-lr in mouse serum. (A) Levels of IgM antibody against purified WNV E and DIII as determined by
ELISA. P values were determined by using an unpaired, two-tailed t test (*, P  0.05; **, P  0.01). (B) Levels of IgM against the wild-type and
K307E/T330I mutant WNV DIII proteins. P values were determined by using an unpaired, two-tailed t test (NS, difference was not statistically
significant; *, P  0.05; **, P  0.01). (C) Levels of IgM that react with WNV-DENV2 DIII chimera. The means and standard deviations of at
least five mice per time point are shown. Dashed lines indicate the limit of detection for each assay. Due to limiting quantities of serum to perform
assays in independent replicates, the limit of sensitivity in panel C is slightly lower (threefold) than in panels A and B.
TABLE 2. Binding affinities of WNV MAbs to wild-type and WNV-DENV2 DIII-lr proteins
MAb
Mean binding affinitya 	 SD
WNV DIII WNV-DENV2 DIII-lr
ka (M1 s1  104) kd (s1  103) KD (nM) ka (M1 s1  104) kd (s1  103) KD (nM)
E16 5.3 	 2.8 0.5 	 0.03 9.8 	 3.2 11 	 1.6 0.5 	 0.002 4.4 	 0.6
E9 4.5 	 2.1 10.6 	 0.04 240 	 50 0 0 0
a Affinities were measured by SPR, and the results are the average of three independent experiments.
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tween WNV DIII and DIII-K307E/T330I, a significant differ-
ence of 65% (P  0.05) existed between the two proteins at
all time points except with the naive serum (Fig. 2B). As an
independent confirmation, the IgM-specific ELISA was re-
peated with the WNV-DENV2 DIII chimera and DENV2
DIII. A consistent and comparable IgM titer was measured
against the WNV-DENV2 DIII chimera but not DENV2 DIII
(Fig. 2C). These experiments suggest that in mice WNV-spe-
cific IgM recognizes the DIII-lr epitope at early time points
after infection.
As observed previously in mice (16, 32), IgG that recognized
WNV E ectodomain was initially detected at 8 days after in-
fection and then increased rapidly over time. Somewhat sur-
prisingly, DIII-specific IgG was not detected consistently until
day 10, since only 20% (one of five) day 8 samples were pos-
itive (Fig. 3A). The E-specific IgG titer peaked at day 20 after
infection, whereas the DIII-specific titer continued to rise
through day 90. At days 15 and 20, the DIII-specific antibodies
made up 10% of the WNV E-specific IgG response, whereas
by day 30 the fraction rose to 25% of the total. When the
levels of IgG that reacted with WNV DIII and DIII-K307E/
T330I were compared, a statistically significant difference was
observed beginning at day 20 (P
 0.01), although a noticeable
trend was present at day 15 (P  0.06) (Fig. 3B). At day 10,
there was no significant difference in IgG reactivity with WNV
DIII and DIII-K307E/T330I (P  0.6), suggesting that the
development of DIII-lr IgG was delayed. This difference was
not due to variable adsorption of DIII and DIII-K307E/T330I
since the E9 MAb, which maps outside of the DIII-lr epitope,
recognized both proteins equivalently (P  0.7) (Fig. 3C).
Antibody response against DII-fl epitope. The fusion loop
on DII of flavivirus E proteins elicits flavivirus cross-reactive
antibodies that have less neutralizing activity than antibodies
that recognize the DIII-lr epitope (13, 45, 51). This is likely
because this epitope is buried or at least partially hidden on the
mature virion (51). To determine the kinetics of the antibody
response against the DII-fl epitope in mice, we again utilized a
loss-of-function protein ELISA. Using a yeast surface display
assay, prior mutational analysis revealed a complete loss of
binding 34 of 40 DII-fusion loop specific MAbs with the single
mutation, W101R (45). A loss-of-function W101R WNV E
protein was generated recombinantly (Fig. 1A). This loss-of-
function variant folded correctly and had wild-type disulfide
binding and secondary structure elements as judged by circular
dichroism and size exclusion chromatography (see Materials
and Methods). Initial analysis with wild-type and W101R E
proteins confirmed the loss-of-binding phenotype of DII-fl
MAbs (Fig. 4A). Subsequently, mouse serum was tested for
reactivity with these proteins. Notably, there was no significant
difference in the IgM titers at days 6 and 8 (P  0.6) and only
a slight, albeit significant, difference at day 10 (P 
 0.05) (Fig.
4B). In contrast to what was observed with DIII-lr antibodies,
no significant differences in the IgG response were observed
with wild-type and W101R E proteins, although a trend was
observed at day 30 and after boosting (P  0.07) (Fig. 4C).
Again, these differences were not due to adsorption variability
between wild-type and W101R E proteins (P  0.2) (Fig. 4D).
Epitope-specific antibody responses in human patient se-
rum. The kinetic experiments suggested that DII-fl antibodies
comprised a much smaller fraction of the WNV-specific anti-
body response in C57BL/6 mice than the DIII-lr antibodies.
Moreover, in the early phases of infection, DIII-lr antibodies
were present in the IgM but not the IgG fraction. We next
assessed the epitope specificity of WNV-antibody response
from sera from convalescent human patients that had experi-
enced distinct clinical phenotypes after WNV infection: sub-
clinical (cases identified by blood donation), mild febrile illness
(West Nile fever), meningitis, or encephalitis. Earlier studies
with seven subclinical human samples that used a competitive
ELISA with a Fab fragment of a DIII-lr antibody suggested
that at least some individuals developed DIII-lr-specific anti-
bodies (44). A total of 35 human serum samples, including 5 of
the earlier samples, were tested by ELISA for reactivity with
the wild-type DIII, K307E/T330I DIII, WNV-DENV2 DIII
chimera, wild-type E ectodomain, and the W101R variant (Ta-
ble 3). A total of 30 of 35 samples were taken between 4 and
FIG. 3. Detection of IgG against DIII-lr in mouse serum. (A) Levels of IgG against purified WNV E and DIII as determined by ELISA. Mice
that were challenged with 104 PFU of WNV on day 30 and harvested 7 days later are labeled as boost. (B) Levels of IgG against the wild-type and
K307E/T330I mutant WNV DIII proteins. P values were determined by using an unpaired, two-tailed t test (NS, difference was not statistically
significant; **, P 0.01). The means and standard deviations of at least five mice per time point are shown. Dashed lines indicate limit of detection
for each assay. (C) Endpoint titer concentrations of an MAb, E9, against the wild-type and K307E/T330I proteins. The means and standard
deviations of 12 independent experiments are shown.
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7 months after infection, whereas 3 of 5 of the subclinical
samples were obtained within 1 month of the presumed infec-
tion. As expected, given the convalescent status of the patients,
the majority of samples contained low titers of IgM to E and
DIII (data not shown), which precluded IgM epitope analysis.
In contrast to inbred mice, which had similar titers between
subjects at each time point, there was substantial variability
(42-fold difference among patient sera) in the E-specific anti-
body titers. DIII-specific antibodies comprised an average of
7.3% (range, 0.6 to 50.5%) of the total IgG antibody response
in convalescent samples, in contrast to the 25% observed 30
days after primary infection in the mouse. An even more pro-
found difference was observed in the DIII-lr antibody re-
sponse. In human convalescent samples the DIII-lr antibodies,
on average, accounted for only 1.6% of the E-specific IgG
response compared to 18% of the response in mice at day 30
after infection. This pattern was observed with both the loss-
and gain-of-function DIII proteins. As an independent confir-
mation of the low frequency of DIII-lr antibodies in serum, we
screened human MAbs that were generated previously from
convalescent WNV patients (52). Only 4 of 51 human MAbs
against WNV E protein were previously shown to bind DIII.
Notably, only 1 of these, CR4374, showed loss-of-binding to a
K307E mutant DIII expressed on the surface of yeast or to the
K307E/T330I recombinant DIII (Fig. 5A and data not shown).
Importantly, this MAb demonstrated the strongest neutralizing
activity of any of the human MAbs. In comparison, CR4299, a
DIII-specific MAb that retained binding to the K307E mutant,
had much weaker inhibitory activity (Fig. 5B). In contrast to
what we observed with mouse serum and in support of the idea
that the DII-fl epitope may be immunodominant in humans
generally (20, 52), a marked reduction in serum antibody bind-
ing was observed with the W101R mutant (P 
 0.001). None-
theless, substantial variability was observed with human sam-
ples: the level of DII-fl antibody varied from 8.8 to 91.0% of
the total E ectodomain-specific response with an overall me-
dian and mean of 65 and 61%, respectively (Table 3).
Antibodies that recognize the DIII-lr and DII-fl epitopes
protect mice and hamsters from lethal WNV infection to var-
ious degrees (20, 37, 44, 45). However, the in vitro correlates of
in vivo protection or severe disease in humans are less clear.
To evaluate whether the epitope specificity and titer of human
serum antibodies correlated with outcome, we compared the
titers of DIII-lr and DII-fl antibodies in convalescent human
serum with the neuroinvasive or non-neuroinvasive clinical
phenotype (Fig. 6). In all cases, including the overall levels of
E, DIII, DIII-lr, and DII-fl specific antibodies, no correlation
between the immunoreactivity of a given E protein and clinical
phenotype was apparent (P  0.4). However, this analysis was
limited by the existence of only a single convalescent-phase
serum sample. It remains possible that correlations could be
made between epitope specificity and clinical outcome with
prospective samples obtained at different stages of the acute
FIG. 4. Detection of DII-fl antibodies in mouse serum. (A) ELISA comparing MAb binding to wild-type and W101R WNV E proteins.
(B) Levels of serum IgM against the wild-type and W101R WNV E proteins. (C) Levels of serum IgG against the wild-type and W101R WNV
E proteins. P values were determined by using an unpaired, two-tailed t test (NS, difference was not statistically significant; *, P 0.05). The means
and standard deviations of at least five mice per time point are shown. Dashed lines indicate limit of detection for each assay. (D) Endpoint titer
concentrations of an MAb, E9, against the wild-type WNV E and W101R proteins. The means and standard deviations of 12 independent
experiments are shown.
VOL. 81, 2007 NEUTRALIZING ANTIBODIES AGAINST WNV IN MICE AND HUMANS 11833
infection. Unfortunately, as of yet no such clinical trials have
been performed with WNV-infected patients.
Contribution of DIII-lr epitope specific responses to neu-
tralizing activity of serum. Antibodies to the DIII-lr epitope
have potent neutralizing activity in vitro and in vivo (4, 44, 50)
and appear to comprise a larger percentage of the antibody
response in mice than in humans. To evaluate their contribu-
tion to the neutralization potential of serum, we utilized a
previously established high-throughput, flow cytometric neu-
tralization assay with WNV RVP (45–47). Because K307E/
T330I RVP showed significantly decreased infectivity (data not
shown), we generated a distinct mutant WNV RVP that con-
tained a single mutation, T332K: these RVP eliminated bind-
ing and neutralization of virtually all DIII-lr-specific MAbs and
yet maintained virus infectivity (4, 50). We compared the neu-
tralization curves and 50% inhibition points (i.e., EC50 values)
of serial dilutions of mouse and human serum on wild-type and
T332K containing RVP. Mouse serum neutralization profiles
showed consistent differences between wild-type and mutant
RVP (Fig. 7A). In contrast, the human serum showed little or
no difference in neutralization of wild-type or T332K RVP
(Fig. 7B and data not shown), even in serum samples that
contained antibodies to the DIII-lr epitope. The fold differ-
ences in the EC50 values (wild type versus mutant) were com-
pared, with significant increases observed at all time points in
the mouse serum compared to the convalescent human serum
(P 
 0.0001) (Fig. 7C). This included day 6, when WNV-
specific IgG is absent and WNV-specific IgM mediates neu-
tralization (17). We also compared the wild-type RVP EC50
values between human and mouse serum (Fig. 7D). Despite
similar E-specific antibody titers as determined by ELISA be-
tween day 30 mouse serum and the human samples (Fig. 3A
and Table 3), the mouse serum, at both days 6 and 30, had
superior neutralizing activity compared to the convalescent
human samples (P 
 0.0001). Taken together, these data sug-
gest that DIII-lr antibodies contribute more significantly to the



















% of total E antibodiesd
E DIII DIII DIII-lr DII-fl
77329 MF 5 mo 1,044 157 18 53 302 15.0 1.7 28.9
77326 MF 4 mo 19,103 1,040 271 80 10,553 5.4 1.4 55.2
77316 MF 5 mo 15,042 1,328 45 37 7,364 8.8 0.3 49.0
77310 MF 6 mo 8,921 402 140 133 4,751 4.5 1.6 53.3
77325 M 4 mo 10,792 273 61 
20 8,485 2.5 0.6 78.6
77323 MF 4 mo 2,345 200 37 
20 1,415 8.5 1.6 60.3
77324 MF 4 mo 6,933 339 256 139 4,455 4.9 3.7 64.3
55301 MF 7 mo 35,983 18,180 25 
20 6,936 50.5 0.1 19.3
55307 MF 6 mo 14,259 237 50 43 9,823 1.7 0.4 68.9
77304 E 6 mo 25,968 193 24 
20 22,422 0.7 0.1 86.3
77307 ME 6 mo 1,856 384 106 72 1,055 20.7 5.7 56.8
55308 ME 7 mo 12,879 1,561 942 1,280 4,268 12.1 7.3 33.1
77306 MF 6 mo 34,557 562 430 72 25,676 1.6 1.2 74.3
77332 ME 4 mo 1,008 44 4 
20 350 4.4 0.4 34.7
55315 MF 5 mo 6,064 167 42 108 3,691 2.8 0.7 60.9
77309 MF 6 mo 4,827 229 248 
20 3,265 4.7 5.1 67.6
77303 ME 6 mo 5,690 246 0 23 4,268 4.3 0.0 75.0
44302 ME 5 mo 6,502 1,019 255 320 2,910 15.7 3.9 44.8
55314 MF 5 mo 2,703 123 0 
20 1,799 4.6 0.0 66.6
77321 MF 5 mo 26,191 267 150 36 2,314 1.0 0.6 8.8
77308 ME 6 mo 3,830 296 5 54 2,255 7.7 0.1 58.9
77315 ME 6 mo 3,187 254 216 56 2,231 8.0 6.8 70.0
77322 MF 5 mo 4,689 219 101 80 3,455 4.7 2.2 73.7
77311 ME 6 mo 21,073 789 531 292 11,890 3.7 2.5 56.4
66301 ME 6 mo 22,534 839 0 33 7,663 3.7 0.0 34.0
77327 MF 4 mo 9,543 572 0 
20 6,926 6.0 0.0 72.6
99301 MF 5 mo 6,322 267 0 51 4,834 4.2 0.0 76.5
77330 MF 5 mo 28,295 169 32 
20 25,761 0.6 0.1 91.0
77320 E 5 mo 6,511 317 0 
20 4,901 4.9 0.0 75.3
77331 MF 5 mo 4,962 117 10 52 3,924 2.4 0.2 79.1
9321234 SC 27 days 16,360 155 16 
20 12,513 0.9 0.1 76.5
9321509 SC 32 days 23,214 185 21 
20 19,388 0.8 0.1 83.5
9321446 SC 34 days 30,559 1,004 427 
20 19,095 3.3 1.4 62.5
9321217 SC 14 days 6,745 249 68 
20 5,053 3.7 1.0 74.9
9321812 SC 152 days 9,598 571 19 
20 5,660 5.9 0.2 59.0
a MF, mild febrile illness; M, meningitis; E, encephalitis; ME, meningoencephalitis; SC, subclinical illness.
b The DIII K307E/T330I antibody endpoint titer was subtracted from the DIII antibody endpoint titer. All comparisons were made using data from the same ELISA
plate.
c The E W101R antibody endpoint titer was subtracted from the E endpoint antibody titer.
d For DIII, the percentage was calculated be dividing the DIII titer by the E titer and multiplying that value by 100. For DIII-lr, the percent DIII-lr (of total anti-E
response) was calculated by dividing the DIII-K307E/T330I titer by the DIII titer and multiplying that value by the percent DIII antibodies. For DII-fl, the percentage
was calculated by dividing the E-W101R titer by the E titer and multiplying that value by 100.
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neutralizing potential of serum in mice than in humans and
that the human antibody response is directed toward less-
neutralizing epitopes.
DISCUSSION
An intact humoral response is critical for the control of
neuroinvasive WNV infection (16, 17, 32, 33). In this report,
we evaluated the kinetics and magnitude of the antibody re-
sponse against two distinct epitopes on the WNV E protein
with discrete functional characteristics. One epitope, DIII-lr, is
recognized by type-specific antibodies with potent neutralizing
and therapeutic activity (4, 42, 44, 50). The other, DII-fl, is
detected by flavivirus cross-reactive antibodies with less neu-
tralizing and protective activity (13, 45). Given the differences
in B-cell V-D-J repertoire and the variation in class II major
histocompatibility complex alleles among different species, it
was not unexpected to see a species-related difference in the
antibody response against the two epitopes. However, several
interesting observations can be made, which may have im-
plications for targeted vaccine development. In mice, DIII-lr
IgM antibodies were detected soon after infection and con-
tributed to the early neutralizing potential of serum. For
unclear reasons, there was a delay in isotype switching of
DIII-lr antibodies to IgG, since these were not reliably mea-
sured until day 15 after infection. Given that the vast ma-
jority of mortality in C57BL/6 mice after WNV infection
occurs between days 8 and 12 (16, 55, 56), DIII-lr IgG
antibodies likely do not contribute to protection against
primary infection. Moreover, in mice, DII-fl antibodies com-
prised a smaller percentage of the total antibody response
compared to DIII-lr antibodies. In humans, only a subset of
individuals generated a significant IgG antibody response
against the DIII-lr epitope. In almost all human cases, a
large fraction of the E-specific antibodies was directed
against the less protective DII-fl epitope.
DIII-lr IgM in mice was observed soon after WNV infection
in mice. Sequence analysis of the V-D-J regions of 10 differ-
ent DIII-lr strongly neutralizing MAbs suggest that some mice
(e.g., BALB/c and C57BL/6) have germ line gene configura-
tions that can produce antibodies recognizing the DIII-lr
epitope (S. Johnson and M. Diamond, unpublished observa-
tions). This could in part explain why neutralizing IgM were
detected soon after infection. At present, it remains unclear
which subset of B cells produce IgM that recognizes the DIII-lr
epitope. CD5 B-1 cells generate natural IgM, are unrespon-
sive to B-cell receptor-mediated growth signals, and instead
FIG. 5. Human MAbs recognize DIII-lr epitope. (A) Flow cytometry histograms of human MAbs binding to yeast expressing wild-type and
mutant DIII. Arrow indicates eliminated or greatly reduced MAb binding. The data are representative of three independent experiments.
(B) Human MAb neutralization curves of WNV RVP on Raji DC-SIGNR cells. Representative curves from three independent experiments are
shown.
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undergo apoptosis upon B-cell receptor cross-linking, whereas
conventional CD5 B-2 cells expand in an antigen-dependent
fashion after B-cell receptor cross-linking and costimulation
(2). Of note, we did not detect DIII-lr antibodies in naive
serum, although we cannot rule out that their presence was
below our limit of detection. More definitive subset depletion
or epitope-based ELISPOT studies are needed to define the
B-cell population that produces the earliest DIII-lr antibody
response in mice.
Despite an early IgM response to the DIII-lr epitope there
was a delay in the isotype switch to IgG of antibodies against
this epitope in mice. The lag was considerable such that DIII-lr
IgG was not consistently measured until between days 10 and
15, a time after which the majority of mortality had occurred in
mice after WNV infection. In contrast, there was no global
delay in IgG responses, since significant WNV E protein anti-
body titers were measured in all infected mice by day 8. Al-
though we cannot yet explain the epitope specific delay in
isotype switching, it could be due to a requirement for germi-
nal center formation in lymphoid tissues. Whereas some IgG
antibodies can be produced in parafollicular zones, others re-
quire T-cell help, specific cytokines, or somatic hypermutation
and are generated exclusively in germinal centers (7, 23). Ex-
periments with signaling lymphocyte activation molecule-asso-
ciated protein-deficient mice, which have impaired germinal
center formation, production of class-switched IgG, and devel-
opment of memory B-cell germinal center formation (15, 26,
58), are in progress to directly address this question.
Although both BALB/c and C57BL/6 mice generate mono-
clonal (44, 50) and polyclonal antibodies that recognized the
DIII-lr epitope, other species, including humans, showed sig-
nificant variability. Accordingly, neutralization profiles with
WNV RVP and mouse serum were affected more significantly
by a mutation at T332K, which abolishes binding and neutral-
ization of DIII-lr antibodies (47). Our evaluation of convales-
cent human serum suggests that only a subset of infected in-
dividuals generate IgG against this DIII-lr epitope, and this
accounted for a relatively small fraction of the neutralizing
antibody response. One possible criticism of our analysis is that
the human serum samples were obtained from individuals in-
fected with heterogeneous WNV isolates, which might not
bind to recombinant proteins derived from the New York 1999
strain of WNV. However, an alignment of all 83 published
WNV isolates in North America between 1999 and 2006
showed virtually no change in amino acid sequences in the
fusion loop or DIII of the E protein (G. Ebel, unpublished
data): only four amino acid changes were seen in any of the
residues of DIII, and each change was observed as a single
mutation in a single strain and occurred at residues Q296,
V364, N394, and H395, which do not engage strongly neutral-
izing MAbs as defined by crystallography (42). Thus, to date,
the type-specific epitope in DIII and cross-reactive epitope in
DII are completely conserved in all North American WNV
isolates.
The apparent lack of immunodominance of the highly pro-
tective DIII-lr epitope in humans is also consistent with two
recent studies that generated human MAbs: only 2% (1 of 51)
and 0% (0 of 5) of unique human single chain antibodies
FIG. 6. Comparison of non-neuroinvasive and neuroinvasive antibody levels for specific E variants. Titers of antibodies against E (A), DIII (B),
DIII-lr (C), and DII-fl (D) were compared among patients with non-neuroinvasive and neuroinvasive WNV disease. Panels B, C, and D show the
percentage of total E antibody titers. P values were determined by using an unpaired, two-tailed t test (NS, difference was not statistically
significant).
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(scFv) generated from immune or nonimmune patient B cells
by phage display reacted with the DIII-lr epitope (20, 52). In
our sample collection, some human sera contained DIII-lr
IgG, whereas others did not. Unfortunately, we could not es-
tablish a correlation between the development of an antibody
response against the DIII-lr epitope and clinical outcome. Al-
though studies with a larger patient cohort are required for
confirmation, our preliminary data suggest that IgG against
this epitope does not contribute significantly to protection
against primary WNV infection. This is similar is to what has
been observed in human immunodeficiency virus infections,
where the level or type of antibodies does not predict disease
progression (53, 61). Alternatively, serum sampling 4 to 6
months after infection may give an incomplete picture of
the function of particular antibodies at a given stage of disease.
Because the majority of human samples in our study were
acquired at a single time point and not as part of a multiple-
time-point prospective study, we cannot ascertain when in
the course of the infections the DIII-lr-specific IgG developed.
Finally, our results with human serum are also consistent with
results obtained with sera from WNV-infected horses: the
equine IgG response to the DIII-lr epitope was also variable
and comprised only a small fraction of the antibodies directed
against DIII (49).
The fusion loop is highly conserved among flaviviruses, and
antibodies against this epitope are in general highly cross-
reactive (13, 19, 45, 51). Earlier studies established that DII-fl
IgG MAbs behaved distinctly from DIII-lr MAbs in infection
assays in cells. In general, they neutralized infection less effi-
ciently in cells lacking Fc- receptors and enhanced infection
across a wide range of antibody concentrations in cells express-
ing Fc- receptors (42, 45). Accordingly, they showed de-
creased efficacy in preventing or treating WNV or DENV
infection in vivo (24, 25, 45). The experiments in the present
study are particularly intriguing since they suggest that DII-fl
antibodies are produced by all humans against WNV and com-
prise a significant fraction of the anti-E protein response.
Moreover, preliminary data with human MAbs isolated from B
cells from secondarily DENV-infected patients indicate that
the majority of E-specific antibodies also map to the DII-fl (C.
Simmons, M. Beltramello, F. Sallusto, M. Diamond, and A.
Lanzavecchia, unpublished results). Based on this, we specu-
late that the cross-reactive DII-fl epitope is immunodominant
in humans.
The experiments with human and horse sera (49) suggest
that some animals do not make significant responses against
the highly protective DIII-lr epitope. Based on passive transfer
studies in rodents, it would be desirable to design vaccines that
elicit high-titer DIII-lr antibodies, which block at a postattach-
ment stage (42). To date, WNV vaccine design has focused on
FIG. 7. Contribution of DIII-lr antibodies to neutralizing activity in mouse and humans serum. (A) Representative neutralization curves for a
day 30 mouse serum sample against the wild-type and T332K RVP. (B) Representative neutralization curve for a convalescent human serum
sample (patient 55308) against the wild-type and T332K RVP. (C) Fold differences in EC50 titers (wild type over T332K mutant) for mouse and
human serum samples. Means and standard deviations are shown for human samples (n  15) and mouse samples (n  5 for each time point).
P values were determined by using an unpaired, two-tailed t test (***, P  0.0001). (D) EC50 titers against wild-type RVP for mouse and human
serum samples. Means and standard deviations are shown. P values were determined as in panel C.
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eliciting a strong neutralizing response against the E protein,
but the epitope specificities of the generated antibodies are
largely unknown (11, 22, 29–31, 36, 40, 48, 54). Complicating
the issue, many of the initial immunization studies have been
performed in mice. Because our studies show that mice gen-
erate distinct antibody responses against specific epitopes,
some caution may be required in applying mouse vaccination
results to humans. Although administration of live attenuated
WNV vaccines to humans and nonhuman primates has in-
duced relatively low-titer WNV-specific neutralizing antibod-
ies that control viremia (36, 48, 57), the epitope specificity of
the response remains unclear. Further study into the naturally
occurring and vaccine-induced antibody repertoire should en-
hance our understanding of the immune correlates of protec-
tion from WNV disease and promote the development of novel
vaccine strategies, which focus on eliciting highly protective
DIII-lr antibodies.
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